dataset_title,description,dbGaP_phs,dbGaP_URL,PI_name,GPA,dataset_doc,dataset_pmid,funding_source,release_date,limitations_for_reuse,assay_method,study_type,primary_disease,participant_count,sample_count,study_links,related_genes,related_diseases,related_terms
A genotype-phenotype study of tumors from patients with inherited    mutations in DNA repair genes,This study investigated the genomic landscape of tumors from patients with inherited mutations in DNA repair genes. The aim of this study was to determine the relationship between locus-specific loss  of heterozygosity (LOH) and genomic signatures of homologous recombination-based DNA repair (HR) deficiency in tumors associated with pathogenic,phs003348.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003348,"Kara N. Maxwell, MD, PhD",Mariam Eljanne,Center for Cancer Training (CCT),37535879,,2024-08-28,GRU,WXS,Clinical Cohort;Cohort;Exome Sequencing;Individual-Level Genomic Data;Sequencing;Tumor vs. Matched-Normal,Neoplasms,39.0,39.0,,BRCA1;BRCA2;ATM;CHEK2;TP53;PALB2;BRIP1;RAD51C;RAD51D,Hereditary Breast and Ovarian Cancer Syndrome;Li Fraumeni Syndrome,"BRCA1- and BRCA2-associated hereditary breast and ovarian cancer; BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC); Breast and ovarian cancer; Familial Breast and Ovarian Cancer Syndrome; Familial Breast/Ovarian Cancer (BRCA1, BRCA2); HBOC Syndrome"
The Somatic Mutational Landscape of Thyroid Cancer in Patients with    Germline PTEN Mutations,"PTEN hamartoma tumor syndrome (PHTS) is associated with a high rate of thyroid cancer and benign thyroid disease, yet nothing is known of the genomic landscape of PHTS-associated thyroid tumors.  In this study, exome sequencing was performed on 58 thyroid tumors (28 cancers, 30 benign nodules) from 19 patients with PHTS, sequenced in",phs003640.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003640,"Charis Eng, MD PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),"No PMID: The Genomic Landscape of Benign and Malignant Thyroid Tumors from Individuals Carrying Germline PTEN Variants is Distinct from Sporadic Thyroid Cancers | Plitt G., Brewer T., Yehia L., Rabinowitz
  L., Griffith C.C., Eng C.",Crile Fellowship at the Cleveland Clinic Genomic Medicine Institute;Ambrose Monell Foundation Cancer Genomic Medicine Fellowship,2024-08-26,DS-CWDN;DS-CWDN-COL-NPU,WXS;Seq_DNA_SNP_MAF_Sum,Case-Control;Exome Sequencing,"Hamartoma Syndrome, Multiple",16.0,68.0,,PTEN;BRAF;BRCA2;RB1;TSHR,Thyroid Neoplasms,BANNAYAN-RILEY-RUVALCABA SYNDROME; BANNAYAN-ZONANA SYNDROME; BBRS; BZS; CD; CS
Molecular Analysis of Alliance A031201 Study,This is the first study examining the relationship between clonal hematopoiesis and clinical outcomes in prostate cancer patients. We used a targeted gene sequencing panel to identify patients in the  A031201 clinical trial with and without clonal hematopoiesis. We found that clonal hematopoiesis did not affect overall or progression free survival,phs003717.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003717,"Catherine C. Coombs, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),36996380,P30CA008748;U10CA180821;U10CA180882;U24CA196171;UG1CA233253;UG1CA233290;UG1CA233180;UG1CA233339;UG1CA233373,2024-08-23,DS-PC,Targeted-Capture,Case Set,Prostatic Neoplasms,957.0,957.0,,DNMT3A;TET2;ASXL1;PPM1D;TP53;CHEK2;SRSF2;SF3B1;JAK2,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
"Botensilimab, an Fc-enhanced Anti-CTLA-4 Antibody, is Effective Against    Tumors Poorly Responsive to Conventional Immunotherapy",This study explores the genomic landscape associated with a novel Fc-engineered anti-CTLA-4 antibody (botensilimab) in advanced solid tumors. We seek to understand if enhancing the Fc-region affinity of anti-CTLA-4 antibodies  can improve anti-tumor efficacy and expand clinical benefit to tumors poorly responsive to conventional immunotherapy. As part of an ongoing,phs003704.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003704,"Dhan Chand, PhD",Joseph Flores-Toro,Office of Data Sharing (ODS),39083809,,2024-08-23,GRU-NPU,RNA-Seq,Clinical Trial;Genotype/Expression;Individual-Level Genomic Data;RNA Sequencing;Tumor,Immunotherapy,70.0,95.0,,CCL5;CD27;CD274;CD276;CD8A;CMKLR1;CXCL10;CXCL9;CXCR6;HLA-DQA1;HLA-DRA;HLA-DRB1;HLA-E;IDO1;IFNG;LAG3;NKG7;PDCD1LG2;PSMB10;STAT1;TIGIT,Colorectal Neoplasms;Ovarian Neoplasms;Sarcoma;Melanoma;Renal Cell Carcinoma;Head and Neck Neoplasms,Sarcoma; CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine
Somatic Mutations in Individual Skin Cells,"Ultraviolet (UV) radiation is the primary cause of melanoma through the acquisition of driver mutations in melanocytes. It also plays a significant role in oncogenesis in other skin cells, such  as keratinocytes. However, the mutational profiles vary widely among different skin cancers, and the early mutational processes in different cell",phs003683.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003683,"A. Hunter Shain, PhD",Justin Benavidez,Division of Cancer Biology (DCB),,R01 CA265786;R01 AR080626;ME210014;Team Science Award;Dermatology Fellows Award;LEO Foundation Region Americas Award;Tracy and Guy Jaquier;P30CA082103;Greg and Anna Brown Family;IDP Professorship Award,2024-08-22,GRU,RNA-Seq;WXS,Cross-Sectional,"Carcinoma, Squamous Cell",16.0,347.0,,TP53;NOTCH1;NOTCH2;NOTCH3;PBRM1;KMT2D;FAT1;AJUBA;CHUK;BRAF;NRAS;RAC1;NF1;PTEN;RASA2;CDKN2A;RB1;ARID2;DDX3X,Melanoma;Melanocyte;Keratinocyte;Fibroblast;Skin Neoplasms,"Skin Neoplasms; Carcinoma, Epidermoid; Carcinoma, Planocellular; Carcinoma, Squamous; Carcinomas, Epidermoid; Carcinomas, Planocellular"
Chromothripsis in Small Cell Lung Carcinoma Associated with Carcinoid    Transformation,"Small cell lung carcinoma (SCLC) is typically associated with tobacco exposure and inactivation of RB1 and TP53 genes. We performed detailed clinicopathologic, genomic, and transcriptomic profiling of an atypical subset  of SCLC in never/light smokers that lacked RB1 and TP53 co-inactivation and found that most cases were associated with chromothripsis &#x02013;",phs003676.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003676,Charles Rudin;Natasha Rekhtman,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2024-08-22,GRU,RNA-Seq;WGS,Case Set;Genotype;RNA Sequencing,"Carcinoma, Small Cell",12.0,29.0,,TP53;RB1,Chromothripsis;Carcinoid Tumor,Carcinoid Tumor; Chromothripsis; Carcinoid; Carcinoid tumor (disease); Carcinoid tumors; Carcinoid tumour
Genomic and Transcriptomic Sequencing of CAR-T-Treated Patients,"Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. Approximately half of patients with refractory large B-cell lymphomas achieve durable responses from CD19-targeting CAR-T treatment; however,  failure mechanisms are identified in only a fraction of cases. Here we use next-generation sequencing technologies to characterize the genomic and",phs002922.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002922,"Marcela Maus, PhD;Catherine J. Wu, MD",,,,"IBM Research;Kite, A Gilead Company",2024-08-22,HMB,OTHER,Cohort,"Lymphoma, B-Cell",58.0,155.0,,,"Immunotherapy, Adoptive",
Evolving Cell States and Oncogenic Drivers during the Progression of    IDH-Mutant Gliomas,"The study aims to understand the changes in cell states during the progression of IDH mutant gliomas. We generated scATAC-seq data from tumor samples of patients with IDH mutant gliomas,  ranging from grade 2 to grade 4, including both IDH mutant oligodendroglioma and IDH mutant astrocytoma samples. Additionally, we have generated",phs003697.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003697,Bradley E. Bernstein,Justin Benavidez,Division of Cancer Biology (DCB),,,2024-08-15,GRU,RNA-Seq;ATAC-seq,Case-Cohort;Single Cell Analysis,Glioma,11.0,15.0,,,,Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia
Lung Cancer Genetic Study Among Asian Never Smokers,"The Lung Cancer Genetic Study Among Asian Never Smokers includes data from four population-based studies conducted among Asian women: the Shanghai Women's Health Study (SWHS), the Hwasun Cancer Epidemiology Study  (HCES1 and HCES2), the Female Lung Cancer Consortium in Asia (FLCCA, including sFLCA), and the Guangzhou Lung Cancer Study (GLCS). Shanghai Women's",phs002366.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002366,"Qiuyin Cai, MD, PhD",,,,U01CA161045,2024-08-13,HMB-PUB-NPU;HMB-PUB;GRU-NPU;DS-LC,WXS;Seq_DNA_SNP_CNV;Array_SNP,Case-Control;Cohort,Lung Neoplasms,8310.0,8369.0,,,,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
"The Genetic Basis of Aggressive Prostate Cancer, The Role of Rare    Variation","In this study, we will apply a multi-staged approach to reveal genes harboring rare variants that are associated with aggressive PCa. Whole-exome sequencing (Aim 1a) of 2,774 aggressive cases and  2,776 non-aggressive cases of European ancestry will be conducted followed by rare variant analysis of single sites and gene burden testing to",phs001524.v3.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001524,Christopher Haiman,,,32853339,"5R01CA196931-02;HHSN268201200008I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease"";HHSN26800080, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2024-08-12,DS-PC;HMB-PUB;DS-CA-NPU-GSO;DS-CA-PUB;GRU;DS-PC-NPU-MDS;MHNSI-MDS;NRUP;DS-PC-MDS;CADM,WXS;Targeted-Capture;Seq_DNA_SNP_CNV,Case Set,Prostatic Neoplasms,21789.0,21898.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
APOLLO-OV: Applied Proteogenomics of High Grade Serous Ovarian Carcinoma,"APOLLO is a proteogenomic study seeking to describe the major genome, transcriptome, proteome and phosphoproteome alterations, subtypes, and molecular predictors of patient outcomes. This study includes 70 high grade serous  ovarian carcinoma tissues from the Gynecologic Cancer Center of Excellence",phs003488.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003488,"George L. Maxwell, MD",Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),38480868,"HU0001-16-2-0006, HU0001-
  19-2-0031, HU0001-20-2-0033,
  HU0001-21-2-0027, HU0001-18-2-0032",2024-08-09,GRU,,Tumor,Ovarian Neoplasms,70.0,70.0,https://www.nature.com/articles/s41698-024-00519-8,,,"Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian"
Genetic Analysis of Skin Cells,"Cutaneous squamous cell carcinoma (cSCC) is a form of skin cancer originating from keratinocytes in the skin. They have high mutation burdens, primarily driven by UV-radiation-induced DNA damage. The order  in which mutations undergo selection during the evolution of cSCC is not known. A subset of cSCCs grow out of benign neoplasms called actinic",phs003282.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003282,A. Hunter Shain,,,38037084,,2024-08-09,GRU,RNA-Seq;Targeted-Capture,Aggregate Genomic Data;Copy Number Variation (CNV);Exome Sequencing;Methods Development;Transcriptome Analysis;Transcriptome Sequencing;Tumor vs. Matched-Normal,DNA Copy Number Variations,16.0,54.0,https://github.com/limin321/stmut,,"Sequence Analysis, RNA",Not Provided
Transfer Learning Associates CAFs with EMT and Inflammation in Tumor    Cells in Human Tumors and Organoid Co-Culture in Pancreatic Ductal    Adenocarcinoma,"This study examined the transcriptional changes induced by cancer associated fibroblasts (CAFs) in pancreatic ductal adenocarcinoma patient-derived tumor organoids. We hypothesized that cancer associated fibroblasts impacted tumor cell transcription to  promote tumorigenic behavior. Using patient-matched cells from 3 patients, we compared the transcriptional profiles of patient-derived organoids in",phs003563.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003563,Elana J. Fertig;Jacquelyn W. Zimmerman;Richard A. Burkhart;Elizabeth M. Jaffee,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),38587552,P01CA247886,2024-08-08,HMB-IRB-NPU,RNA-Seq,Cohort,Pancreatic Neoplasms,3.0,12.0,,VEGFA;ITGB1,Epithelial-Mesenchymal Transition;Inflammation,"Inflammation; Inflammatory Response, Innate; Innate Inflammatory Response; Innate Inflammatory Responses; Cancer of the pancreas; Neoplasia of the pancreas"
Phase II Study of Cryoablation and Post-Progression Immune Checkpoint    Inhibition in Metastatic Melanoma,"Percutaneous cryoablation guided by imaging is a well-established, minimally invasive treatment for oncological conditions. We posited that cryoablation could alter the immune microenvironment by directly influencing the tumor, potentially eliciting  an anti-tumor response in cases resistant to immune checkpoint inhibition (ICI). In this non-randomized phase II single-center study (NCT03290677),",phs003579.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003579,"Nir Hacohen, PhD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),32151777;31899108;31608067;30657859;30388456;25891173;20656228,U54CA224068,2024-08-05,DS-MSC-MDS,RNA-Seq,Case Set;Clinical Trial;Cohort;RNA Sequencing;Single Cell Analysis,Melanoma,15.0,20.0,,CMKLR1;GGH;IL10;MARCKS;MTHFD2;TXK,Immunotherapy;Cryosurgery,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Multi-Omic Profiling of Glioma Patient Tumors and Patient-Derived Model    Systems,"We have created a resource of transcriptomic (RNAseq), genomic (whole-exome seq), and lipidomic (untargeted shotgun) profiling data from over 175 molecularly diverse glioma tumors and derivative models in orthotopic mouse  xenografts and gliomasphere cultures from over 110 unique patient tumor lines. Provided in this dataset are matched bulk RNA and whole-exome",phs003286.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003286,"David A. Nathanson, PhD",Ian Fingerman,Division of Cancer Biology (DCB),37236196,,2024-08-05,GRU-NPU,RNA-Seq;Seq_RNA_Expression;Seq_DNA_CNV_Segments;WXS,Exome Sequencing;Transcriptome Sequencing;Tumor vs. Matched-Normal;Xenograft,Glioblastoma,119.0,461.0,,CDKN2A;TP53,Ferroptosis;Lipidomics;Apoptosis;Glioma,"Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme"
EWS-WT1 Fusion Isoforms Establish Oncogenic Programs and Therapeutic    Vulnerabilities in Desmoplastic Small Round Cell Tumors,Desmoplastic Small Round Cell Tumor (DSRCT) is an aggressive mesenchymal tumor driven by fusions between the disordered domain of the Ewing sarcoma RNA binding protein 1 (EWSR1) and the developmental  transcription factor Wilms tumor 1 (WT1). We used genome-wide chromatin profiling to identify EWSR1-WT1-dependent gene regulatory networks and target,phs003682.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003682,Miguel Rivera,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2024-07-31,HMB,ChIP-Seq,Case Set,Sarcoma,2.0,12.0,,,Neoplasms;Epigenomics,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Single-Cell RNA-Sequencing of Human Prostatectomy Tissue,"The tissue microenvironment in prostate cancer is profoundly altered. How prostate cancer cells and their precursors mediate those changes is unclear, in part due to the inability to longitudinally study  the disease evolution in human tissues. To overcome this limitation, we performed extensive single-cell RNA-sequencing (scRNA-seq) to assess the",phs003480.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003480,Srinivasan Yegnasubramanian,Freddie Pruitt,Center for Cancer Genomics (CCG),37905029,,2024-07-30,HMB-IRB-NPU,RNA-Seq,Single Cell Analysis,Prostatic Neoplasms,7.0,12.0,https://www.biorxiv.org/content/10.1101/2023.09.07.553268v2,MYC,Tumor Microenvironment,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
CPTAC Proteogenomic Study,"Recently, significant progress has been made in characterizing and sequencing the genomic alterations in statistically robust numbers of samples from several types of cancer. For example, The Cancer Genome Atlas  (TCGA), International Cancer Genome Consortium (ICGC) and other similar efforts are identifying genomic alterations associated with specific cancers",phs001287.v19.p6,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001287,,Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),,,2024-07-26,GRU,,Case Set,Neoplasms,7117.0,7117.0,https://proteomics.cancer.gov;https://gdc.cancer.gov/about-gdc/contributed-genomic-data-cancer-research/clinical-proteomic-tumor-analysis-consortium-cptac,,"Adenocarcinoma of Lung;Pancreatic Neoplasms;Glioblastoma;Leukemia, Myeloid, Acute;Carcinoma, Renal Cell;Carcinoma, squamous cell of head and neck;Melanoma;Sarcoma;Lung Neoplasms;Uterine Neoplasms","Lung Neoplasms; Sarcoma; Uterine Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung"
Early Detection of Malignant and Pre-Malignant Peripheral Nerve Tumors    Using Cell-Free DNA Fragmentomics,"Early detection of neurofibromatosis type 1 (NF1) associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, potentially averting deadly outcomes. Here, we describe a cell-free DNA (cfDNA) fragmentomic approach which  distinguishes non-malignant, pre-malignant and malignant forms of NF1 PNST. Using plasma samples from a novel cohort of 101 NF1 patients and 21",phs003712.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003712,"Jack F. Shern, MD;Aadel A. Chaudhuri, MD/PhD;Angela Hirbe, MD/PhD",Abid Al Reza,Center for Cancer Research (CCR),39093127,CTF-2022-04-003;5T32GM007067;1ZIABC011722-04;1ZIABC010801-13;NTAP946745,2024-07-25,GRU-IRB,WGS,Case-Control,Neurofibromatosis 1,122.0,166.0,,NF1,Cell-Free Nucleic Acids,"Molluscum Fibrosum; Multiple non-ossifying fibromatosis; NEUROFIBROMATOSIS TYPE 1; NEUROFIBROMATOSIS, PERIPHERAL TYPE; NEUROFIBROMATOSIS, TYPE I; NEUROFIBROMATOSIS, TYPE I, SOMATIC"
Childhood Cancer Data Initiative (CCDI): Single-Cell Atlas of NF1 Nerve    Sheath Tumors,"The worst outcome of NF1 is the development of the aggressive and highly metastatic malignant peripheral nerve sheath tumors (MPNST), which transform from benign plexiform neurofibroma (PN) and lack effective  treatment. In this study, we performed single-cell RNA sequencing of 63 clinically annotated NF1-associated peripheral nerve sheath tumors, including",phs003519.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003519,Jack Shern,Freddie Pruitt,Center for Cancer Genomics (CCG),36134665;37167059;36130486;34010628,,2024-07-22,GRU,,Longitudinal,Rare Diseases,29.0,55.0,,NF1;CDKN2A;CDKN2B;SUZ12;EED;TP53,"Neoplasms;Pediatrics;Natural History;Neurofibromatosis 1;Neurofibroma, Plexiform;Neurofibrosarcoma",Neurofibromatosis 1; Rare Disease; Blastoma; CA; CA - Cancer; Cancer
"Childhood Cancer Data Initiative (CCDI): Molecular Characterization    across Pediatric Brain Tumors and Other Solid and Hematologic    Malignancies for Research, Diagnostic, and Precision Medicine","This study contains tumor and germline WGS, RNA-Seq, Clinical Panel Sequencing, and other omics and molecular data for patients with pediatric brain tumors and other solid and hematologic malignancies. This  data has been collected from multiple organizations including the multi-institute Children's Brain Tumor Network (CBTN), the Pacific Pediatric",phs002517.v3.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002517,"Adam C. Resnick, PhD;Allison Heath, PhD",Joseph Flores-Toro,Office of Data Sharing (ODS),,,2024-07-22,GRU,WGS;RNA-Seq;miRNA-Seq;WXS;Targeted-Capture,Clinical Cohort;Clinical Genetic Testing;Clinical Trial;Copy Number Variation (CNV);Exome Sequencing;Genotype/Expression;Individual-Level Genomic Data;Longitudinal;Longitudinal Cohort;Multicenter;Observational;Parent-Offspring;Parent-Offspring Trios;Probands;Prospective;RNA Sequencing;Sequencing;Tissue Expression;Tumor;Tumor vs. Matched-Normal;Whole Genome Sequencing,Brain Neoplasms,3937.0,8972.0,https://www.cbtn.org;https://pnoc.us/;https://www.chop.edu/centers-programs/division-genomic-diagnostics;https://portal.kidsfirstdrc.org;https://pedcbioportal.kidsfirstdrc.org/,,Neoplasms;Pediatrics;Whole Genome Sequencing;RNA-Seq,Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour; Neoplasm of Brain; Neoplasm of the Brain
Comprehensive Genomic Characterization of Translocation Renal Cell    Carcinoma,"Xp11 translocation renal cell carcinoma (tRCC) is a rare, female-predominant cancer driven by a fusion between the TFE3 gene on chromosome Xp11.2 and a partner gene on either chrX or  an autosome. It remains unknown what types of rearrangements underlie TFE3 fusions, whether fusions can arise from both the active (chrXa) and",phs003008.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003008,"Srinivas R. Viswanathan, MD, PhD",Heather Basehore,Office of Data Sharing (ODS),,,2024-07-19,HMB,RNA-Seq;WGS,Case Set;RNA Sequencing;Tumor vs. Matched-Normal;Whole Genome Sequencing,Kidney,16.0,61.0,,TFE3;XIST;MITF,,Not Provided
Molecular Characterization of Prostate Cancer Specimens by Bulk and    Single Cell Analysis,"Version 1: We performed single-cell RNA-sequencing (scRNA-seq) of fresh biopsies from metastatic castration resistant prostate cancer. Additionally, where available, we performed matched bulk whole exome sequencing (WXS; tumor and normal  paired) and whole transcriptome sequencing for the same individuals. We also performed bulk whole exome (WXS) and RNA-sequencing (RNA-Seq) from FFPE",phs001988.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001988,"Eliezer M. Van Allen, MD;Atish Choudhury, MD, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,PCF-V Foundation Challenge Award;U01 CA233100;R01 CA227388;U01 CA233100-04;R35 CA253175,2024-07-19,DS-CA-MDS;DS-PC-MDS;GRU,WXS;RNA-Seq;WGS,Randomized Controlled Clinical Trial,Prostatic Neoplasms,58.0,201.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Aberrant Activation of Wound Healing Programs within the Metastatic Niche    Facilitates Lung Colonization by Osteosarcoma Cells,"Lung metastasis is responsible for nearly all deaths caused by osteosarcoma, the most common pediatric bone tumor. How malignant bone cells coerce the lung microenvironment to support metastatic growth is  unclear. This study delineates how osteosarcoma cells educate the lung microenvironment during metastatic progression. Using single-cell",phs003569.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003569,Ryan D. Roberts,Justin Benavidez,Division of Cancer Biology (DCB),38260361,,2024-07-18,GRU-PUB-NPU,RNA-Seq,Case Set,Osteosarcoma,5.0,7.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270231,,Single-Cell Gene Expression Analysis,Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma
Chromatin Landscape of BET Inhibitor-Treated CD8+ T-cells from Chronic    Lymphocytic Leukemia Patients,"The pan-BET (bromodomain and extra-terminal) inhibitor, OPN-51107 (OPN5) was found to alleviate features of T-cell exhaustion in models of chronic lymphocytic leukemia (CLL). To evaluate if OPN5 treatment could relieve  fixed chromatin states associated with terminal T-cell dysfunction, ATAC-sequencing was performed on CLL patient T-cells. Peripheral blood",phs003613.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003613,"Dalia El-Gamal, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2024-07-10,GRU,SRA_supplement;ATAC-seq,Aggregate Genomic Data;Case Set;Epigenetics;Individual-Level Genomic Data;Sequencing,"Leukemia, Lymphocytic, Chronic, B-Cell",5.0,10.0,,,CD8-Positive T-Lymphocytes;Assay for Transposase-Accessible Chromatin Using Sequencing;Bromodomain-Containing Proteins;T-Cell Exhaustion,"B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic"
Childhood Cancer Data Initiative (CCDI): Molecular Characterization    Initiative,"The National Cancer Institute's (NCI) Childhood Cancer Data Initiative (CCDI) focuses on the critical need to collect, analyze, and share data to address the burden of cancer in children, adolescents,  and young adults (AYAs). The Molecular Characterization Initiative (MCI) will further the CCDI's goals by providing access to better diagnostic tests",phs002790.v7.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002790,"Malcolm Smith, MD, PhD",,,37267580,,2024-07-10,GRU,WXS;OTHER,Aggregate Genomic Data;Clinical Diagnostic Testing;Exome Sequencing;Individual-Level Genomic Data;Transcriptome Analysis;Tumor vs. Matched-Normal,Neoplasms,3014.0,8485.0,https://www.cancer.gov/research/areas/childhood/childhood-cancer-data-initiative/data-ecosystem/molecular-characterization,,Childhood;Pediatric;Central Nervous System (SNS);Soft Tissue Sarcomas (STS);Rare cancers,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
ILyAD (Indolent Lymphoma And vitamin D),"Indolent non-Hodgkin lymphomas are incurable diseases, and require intermittent and often morbid and expensive therapy during their prolonged natural history. Lower intensity and better-tolerated, cost-effective treatment strategies are needed for  these patients. Low vitamin D levels at diagnosis of indolent lymphomas are strongly associated with inferior outcomes to treatment. Standard therapy",phs003503.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003503,"Jonathan W. Friedberg, MD, MMSc",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,R01CA214890,2024-07-08,GRU-IRB,WXS;Seq_DNA_SNP_CNV,Clinical Trial;Double-Blind;Exome Sequencing;Placebo-Controlled;Randomized Controlled Clinical Trial,"Lymphoma, Non-Hodgkin",185.0,185.0,,,,Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology; Reticulum-Cell Sarcoma
Tumor detection by analysis of both symmetric- and hemi-methylation of    plasma cell-free DNA,"Aberrant DNA methylation plays a critical role in tumorigenesis. While DNA methylation has been used for cancer detection and classification, DNA hemi-methylation, a novel epigenetic mark has not been analyzed  extensively in cancer epigenomes. Here we report a strand-specific (ss) sequencing method (MeDIP-Seq) for plasma cell free (cf) DNA (sscf-MeDIP-Seq),",phs003462.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003462,Zhiguo Zhang,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2024-07-08,DS-HCC;DS-BT,MeDIP-Seq,Case-Control;Epigenetics;Tumor,Early Detection of Cancer,271.0,271.0,,,Liver Neoplasms;Brain Neoplasms;Healthy Volunteers,Liver Neoplasms; Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour
Identification of High-Risk PHF19 Expressing Cells in Myeloma Single-Cell    Multiomics,"The aim of this study is to identify novel subsets of cells that are associated with progression and response to treatment. In this project, we study the tumor fraction from  49 myeloma patients across stages of progression. Samples were collected from 10 smoldering multiple myeloma (SMM), 22 newly diagnosed multiple",phs003220.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003220,Brian A. Walker,Nathaniel Boyd,Office of Data Sharing (ODS),38755140,,2024-07-08,GRU-NPU,OTHER;WGS,Single Cell Analysis;Tumor,Multiple Myeloma,49.0,186.0,,PHF19;TP53;EZH2;CDKN1B;PBX1,"Single-Cell Analysis;PHF19 protein, human;Whole Genome Sequencing","Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma; Kahler Disease"
Genomic Characterization CS-MATCH-0007 Arm Z1B,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs002180.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002180,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;36853016;37322121,Division of Cancer Treatment and Diagnosis,2024-07-08,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,29.0,29.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,CCND1;CCND2;CCND3,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Genomic Characterization CS-MATCH-0007 Arm C1,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs002177.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002177,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;37322121,Division of Cancer Treatment and Diagnosis,2024-07-08,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,11.0,11.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,MET,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Genomic Characterization CS-MATCH-0007 Arm P,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs002152.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002152,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;37322121,Division of Cancer Treatment and Diagnosis,2024-07-08,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,28.0,28.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,PTEN,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Cancer Moonshot Biobank,"The National Cancer Institute initiated the Cancer Moonshot Biobank to accelerate research through the collection and distribution of biospecimens for key research efforts. The Biobank will engage with over one  thousand cancer patients, being treated with standard-of-care therapies, for longitudinal biospecimen and data collection. Cancer patients will be",phs002192.v3.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002192,"Helen Moore, PhD",,,,,2024-07-03,GRU,Seq_DNA_SNP_CNV,Longitudinal,Neoplasms,248.0,1140.0,https://moonshotbiobank.cancer.gov/,"SLAMF7;CD274;VEGFA;ROS1;PDCD1;ERBB2;EGFR;CTLA-4;BRAF;ALK;Androgen
  R;PMSD4",Colorectal Neoplasms;Lung Neoplasms;Prostatic Neoplasms;Gastric and Esophageal Neoplasms;Melanoma;Multiple Myeloma,Lung Neoplasms; CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine
"Correlative Studies for Protocol #14-C-0059: T Cells Expressing an    Anti-GD2 Chimeric Antigen Receptor in Patients with GD2+ Solid Tumors,    a Collaboration with CIMAC-CIDC",This study is a retrospective correlative analysis of immune cell phenotypes in samples from a Phase I clinical trial (NCT02107963) of GD2 CAR-T cells (GD2-CAR.OX40.28.z.iC9) in children and young adults  with osteosarcoma and neuroblastoma. The study was a 3+3 dose-escalation study with four dose levels (1 x 10(5) transduced T cells/kg; 1 x 106,phs003455.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003455,Rosandra Kaplan;Sneha Ramakrishna,,,,,2024-06-28,GRU-PUB-COL,,Clinical Cohort;Clinical Trial;Marker Discovery;RNA Sequencing;Transcriptome Analysis,Osteosarcoma,15.0,103.0,https://clinicaltrials.gov/study/NCT02107963;https://cdp.cancer.gov/scientific_programs/cimac-cidc.htm,,Neuroblastoma;Neoplasms,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Natural Killer Cell Therapies for Hematologic Malignancies,"The ""Natural Killer Cell Therapies for Hematologic Malignancies"" study is an umbrella repository for data pertaining to multiple related clinical trials that aim to assess NK cell therapies as part  of treatment strategies for a range of hematologic malignancies. Here, data from two trials, NCT03068819 and NCT02782546, are presented. Cytokine",phs002681.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002681,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),35196021;34871371,"P50CA171963;T32GM139799;K12CA167540;U01CA248235;T32HL00708843;R01CA205239;T32HL007088;F30AI16131;Children's Discovery Institute;Intersect Fellowship Program for Computational Scientists and Immunologists;American Society of Hematology Scholar Award;Gabrielle's Angel Foundation Award;St. Louis Children's Hospital Foundation;V Scholar Award V2018-007;Alvin J. Siteman Cancer Center;Young Investigator Award;Pilot Grant;Siteman Investment Program Research Development Award;ImmunityBio, Inc.;P30 CA091842",2024-06-28,DS-HM;NRUP,OTHER,Clinical Trial,Leukemia,36.0,81.0,,,"Killer Cells, Natural",Blood (Leukemia); Blood cancer; Leucocythaemia; Leucocythaemias; Leucocythemia; Leucocythemias
BIRC5 Upregulation Enhances DNMT3A-Mutant T-ALL Cell Survival and    Pathogenesis,"The goal of this study was to determine how patients with T-ALL who have DNA methyltransferase 3 alpha (DNMT3A) mutations develop resistance to therapy. Since DNMT3A is a methyltransferase, we  examined the effect of those mutations on epigenetic regulation using whole genome bisulfite sequencing (WGBS). We also assessed any changes in gene",phs003623.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003623,Grant Challen,Justin Benavidez,Division of Cancer Biology (DCB),,,2024-06-13,DS-CA,RNA-Seq;Bisulfite-Seq,Case Set,"Leukemia-Lymphoma, Adult T-Cell",10.0,10.0,,DNMT3A;BIRC5;STAT3;STAT5,Genomics;Epigenomics;Transcriptomics,ATLL; Adult T Cell Lymphoma/Leukemia; Adult T-Cell Leukemia; Adult T-Cell Leukemia-Lymphoma; Adult T-Cell Leukemia-Lymphomas; Adult T-Cell Leukemias
Structure of the Mucosal and Stool Microbiome in Lynch Syndrome,"The gut microbiota has been associated with colorectal cancer (CRC), but causal alterations preceding CRC have not been elucidated. To prospectively assess microbiome changes prior to colorectal neoplasia, we investigated  samples from 100 Lynch syndrome patients using 16S rRNA gene sequencing of colon biopsies, coupled with metagenomic and metatranscriptomic sequencing",phs002343.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002343,Curtis Huttenhower,Ian Fingerman,Division of Cancer Biology (DCB),32240601,,2024-06-13,GRU,RNA-Seq;WGS,Case Set,Colorectal Neoplasms,100.0,361.0,https://www.ncbi.nlm.nih.gov/bioproject/PRJNA526861/,MHS6;MLH1;MSH2;PMS2,"Colorectal Neoplasms, Hereditary Nonpolyposis","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
NCI Cancer Model Development for the Human Cancer Model Initiative (HCMI),"The Cancer Model Development Center (CMDC) project is part of the Human Cancer Model Initiative (HCMI) and is managed by the Office of Cancer Genomics within the Center for Cancer  Genomics at the National Cancer Institute (NCI). The goal of the HCMI is to generate approximately 1000 novel human ""next generation"" tumor-derived",phs001486.v4.p4,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001486,"Jean Claude Zenklusen, PhD;Jesse S. Boehm, PhD;Keith L. Ligon, MD, PhD;David A. Tuveson, MD, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2024-06-13,GRU,,Longitudinal Cohort,Neoplasms,1117.0,1117.0,https://www.cancer.gov/ccg/research/functional-genomics/hcmi,,"Esophageal Neoplasms;Pancreatic Neoplasms;Neuroblastoma;Wilms Tumor;Osteosarcoma;Sarcoma, Ewing;Rhabdomyosarcoma;Liver Neoplasms;Glioblastoma;Neoplasms, Germ Cell and Embryonal;Medulloblastoma;Glioma;Colorectal Neoplasms;Breast Neoplasms;Lung Neoplasms;Stomach Neoplasms","Esophageal Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasms, Germ Cell and Embryonal; Sarcoma, Ewing; Breast Cancer"
Childhood Cancer Data Initiative (CCDI): Identification and Targeting of    Treatment Resistant Progenitor Populations in T-cell Acute    Lymphoblastic Leukemia,"Our goal with this study was to identify the mechanisms of treatment resistance in T-cell acute lymphoblastic leukemia (ALL) using single-cell genomics. We profiled 40 T-ALL cases from the Children's  Oncology Group AALL0434 clinical trial using CITE-seq/snATAC-seq, capturing a breadth of immunophenotypes, including early T-cell precursor (ETP) and",phs003432.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003432,"David T. Teachey, MD;Kai Tan, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),32813610,,2024-06-12,GRU,RNA-Seq;ATAC-seq,Single Cell Analysis,Pediatrics,43.0,43.0,,S100A4;LGALS1;FAM30A;IGLL1;MEF2C;CTSW;PRDX1;HCST;HSH2D;KLF2;VAMP8;HOPX;CYBA;MT-ND3;ENO1;PEBP1;CD44,Neoplasms;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Blastoma; CA; CA - Cancer; Cancer; MT
Germline Mutations and Developmental Mosaicism Underlying EGFR-Mutant    Lung Cancer,"We designed this study to examine the etiology of multiple lung tumors in EGFR-mutant non-small cell lung cancer patients who undergo surgical resection. Participants were 52-85 years old never or  former smokers, who had at least 2 surgical lung tumor pathology specimens available in the Massachusetts General Hospital biobank, at least one of",phs003379.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003379,"Gad Getz, PhD;Daniel Haber, Md, PhD;Shyamala Maheswaran, PhD",Nathaniel Boyd,Office of Data Sharing (ODS),,HHMI Investigator to Daniel Haber,2024-06-12,GRU,WXS,Case Set;Tumor vs. Matched-Normal,"Carcinoma, Non-Small-Cell Lung",12.0,68.0,,,,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER"
Single-Cell Sequencing Reveals Distinct Microenvironment Cell Types    Associated with Response to High Dose Melphalan and Autologous Stem    Cell Transplant in Multiple Myeloma,"The aim of this study is to understand the transcriptome of microenvironment cells in pre- and post- autologous stem cell transplantation (ASCT) samples between patients with complete response and partial  response to transplant. Here, we studied immune cells from 40 multiple myeloma patients who have undergone ASCT. Samples were collected from 40",phs003219.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003219,Brian Walker,Nathaniel Boyd,Office of Data Sharing (ODS),,,2024-06-06,GRU-NPU,OTHER,Case Set,Multiple Myeloma,40.0,136.0,,,Single-Cell Analysis;Tumor Microenvironment,"Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma; Kahler Disease"
FIGHT-207: Anonymized Genomic Alterations and Clinical Responses,"Background: FIGHT-207 was a phase 2 study of the FGFR1-FGFR3 inhibitor pemigatinib in patients with previously treated, locally advanced/metastatic or unresectable solid tumor malignancies harboring activating fibroblast growth factor receptor  (FGFR) gene alterations. Population information: 107 patients were divided into 3 cohorts: A. FGFR1&#x02013;FGFR3 fusions/rearrangements; n 49 B.",phs003590.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003590,"Jordi Rod&#243;n, MD, PhD;Silvia Damian, MD;Muhammad Furqan, MBBS;Jes&#250;s Garc&#237;a-Donas, MD, PhD;Hiroo Imai, MD, PhD;Antoine Italiano, MD, PhD;Iben Spanggaard, MD, PhD;Makoto Ueno, MD;Tomoya Yokota, MD, PhD;Lipika Goyal, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),38789647,,2024-06-05,HMB-COL,Seq_DNA_SNP_CNV,Interventional;Longitudinal,Antineoplastic Agents,101.0,262.0,,FGFR1;FGFR2;FGFR3;TP53;BAP1,Neoplasms,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Common Deleterious Germline Variants Shape the Urothelial Cancer Genome,"Our study used whole-exome, whole-genome, and RNA sequencing to analyze samples from primary tumors, locally recurrent or metastatic urothelial tumors collected over time, and matched normal urothelium. We described the  molecular landscape of mutational signatures and structural variants in chemotherapy-resistant urothelial cancer. Inclusion Criteria: Patients with",phs001087.v4.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001087,"Bishoy Faltas, MD",Ian Fingerman,Division of Cancer Biology (DCB),"38499531;31278255;27749842;No PMID: The Interplay between Mutagenesis and Extrachromosomal DNA Shapes Urothelial Cancer Evolution | Nguyen DD, Hooper WF, Chu TR, Geiger H, Shelton JM, Shah M, Goldstein ZR, Winterkorn L, Sigouros M, Mahonar J, Moyer J, Wilkes D, Singh RR, Liu W, Sboner A, Tagawa ST, Nanus DM, Nauseef JT, Sternberg CN, Molina AM, Scherr D, Inghirami G, Mosquera JM, Elemento O, Robine N, Faltas BM.","R37CA279737;W81XWH-22-PRCRP-IA;SCC I16-0054;SCC
  I14-0047;The
  Polyethnic-1000 Initiative;KL2TR000458;ASCO-CCF Young Investigator Award",2024-06-05,HMB-MDS,Seq_DNA_SNP_MAF_Ind;AMPLICON;WGS;RNA-Seq;WXS;Seq_DNA_CNV_Segments,Case Set,"Carcinoma, Transitional Cell",174.0,554.0,,,Urinary Bladder Neoplasms;Neoplasm Metastasis,"Neoplasm Metastasis; Urinary Bladder Neoplasms; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm"
"Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor","Immune checkpoint inhibitors (ICIs) are widely used in anti-cancer therapies, but they can cause morbid and potentially fatal immune-related adverse events (irAEs), such as ICI-related myocarditis (irMyocarditis). The pathogenesis of  irMyocarditis and its relationship to anti-tumor immunity remain poorly understood. We sought to define immune responses in heart, tumor, and blood",phs003413.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003413,Alexandra-Chloe Villani,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2024-06-03,GRU,RNA-Seq,Case-Control;RNA Sequencing;Single Cell Analysis;Transcriptome Analysis,Cardiovascular Diseases,69.0,147.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228597,,,"Adverse Cardiac Event; Adverse Cardiac Events; Cardiac Event; Cardiac Event, Adverse; Cardiac Events; Cardiac Events, Adverse"
Phase 2 Study of Pembrolizumab in Combination with Gemcitabine and    Cisplatin as Neoadjuvant Therapy,"The purpose of the clinical trial (NCT02690558) is to evaluate whether adding pembrolizumab (Keytruda) to the combination of gemcitabine and cisplatin will improve shrinkage of the tumor before having a  cystectomy, for people with muscle-invasive bladder cancer (MIBC). Patients from Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and",phs003452.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003452,Matthew Milowsky,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,R01CA241810;Merck Sharp & Dohme LLC,2024-05-30,DS-CA,RNA-Seq;WXS,Case Set,Urinary Bladder Neoplasms,37.0,193.0,,,Immunotherapy;Drug Therapy,"Bladder Cancer; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder; Cancer, Urinary Bladder"
Human Tumor Atlas Network (HTAN),"An NCI-funded Cancer Moonshot initiative to construct 3-dimensional atlases of the dynamic cellular, morphological, and molecular features of human cancers as they evolve from precancerous lesions to advanced disease. Note  for data in CDS: The raw sequencing files for this study are hosted in the NCI's Cancer Data Service (CDS), a data repository under the Cancer",phs002371.v6.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002371,Peter Sorger;Jon Aster;Sandro Santagata;Michael P. Snyder;James Ford;William Greenleaf;Jeremy Goecks;Gordon Mills;George Thomas;Ken S. Lau;Robert Coffey;Martha Shrubsole;Avrum Spira;Steven Dubinett;Kai Tan;Stephen Hunger;Bruce Johnson;Eun-sil (Shelley) Hwang;Carlo Maley;Robert West;Nir Hacohen;Dana Pe'er;Christine Iacobuzio-Donahue;Christopher Amos;Olivier Harismendy;Li Ding;Ryan Fields;William Gillanders;Samuel Achilefu,Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),,,2024-05-22,GRU,,Clinical Diagnostic Testing;Clinical Genetic Testing;Exome Sequencing;GWAS;Individual-Level Genomic Data;Longitudinal;Metastasis;Methylation Sequencing;Multicenter;RNA Sequencing;Sequencing;Single Cell Analysis;Tissue Expression;Transcriptome Analysis;Transcriptome Sequencing;Tumor;Whole Genome Sequencing,Neoplasms,1547.0,4615.0,,,Breast Neoplasms;Lung Neoplasms;Colorectal Neoplasms;Adenomatous Polyposis Coli;Brain Neoplasms;Pancreatic Neoplasms;Skin Neoplasms;Prostatic Neoplasms,Adenomatous Polyposis Coli; Lung Neoplasms; Skin Neoplasms; ADENOMATOUS POLYPOSIS OF THE COLON; APC; APC - Adenomatous Polyposis Coli
Childhood Cancer Data Initiative (CCDI): CCDI Pediatric In Vivo Testing    Program - Leukemia,The goal of this study is to molecularly characterize a large panel of pediatric acute lymphoblastic leukemia (ALL) patient-derived xenografts (PDXs) previously established in immune-deficient mice. These PDXs are utilized  as part of the NCI-funded Pediatric Preclinical In vivo Testing (PIVOT) program to identify novel agents and combinations. Biospecimen data include,phs003164.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003164,"Richard B. Lock, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,NCI CA199000;NHMRC APP1157871,2024-05-21,GRU,,Copy Number Variation (CNV);Exome Sequencing;Repository;RNA Sequencing;Xenograft,Pediatrics,40.0,126.0,https://preclinicalpivot.org/about-pivot/,,"Neoplasms;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Biphenotypic, Acute;Heterografts","Leukemia, Biphenotypic, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; ALL with myeloid markers; AML with lymphoid markers; Acute Biphenotypic Leukemia; Acute Biphenotypic Leukemias"
Light at Night and Prostate Cancer in the Health Professionals Follow-Up    Study,"The Health Professionals Follow-Up Study (HPFS) is a prospective cohort study of men designed to evaluate hypotheses about men's health related to diet and lifestyle to the incidence of serious  illnesses, such as cancer, heart disease, and other vascular diseases. It consisted of 51,529 U.S. male health professionals who were 40-75 years old",phs003538.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003538,Walter C. Willett;Lorelei Mucci,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),37462694;33692100;33627383;33231639;33022699;32530938;32164144;32079915;31026211;30867564;30602500,U01CA167552,2024-05-20,HMB,,Longitudinal;Longitudinal Cohort;Observational;Population;Prospective,Light Pollution,49148.0,0.0,https://www.hsph.harvard.edu/hpfs/;https://www.hsph.harvard.edu/hpfs/publications-using-health-professionals-follow-up-study-data/;https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002460.v1.p1,,Prostatic Neoplasms,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Genetic Underpinnings of Ethnic Disparities in Bone Toxicities Between    Hispanic and Non-Hispanic Children Treated for Acute Lymphoblastic    Leukemia,"Acute lymphoblastic leukemia (ALL) is the most common malignancy among children and young adolescents. More than 90% of children are cured with a combination of multiple chemotherapeutic drugs. Some may  suffer from debilitating toxicities due to the cytotoxic drugs, necessitating pharmacogenetic research to search for genetic markers predictive of",phs002317.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002317,Song Yao;Kara M. Kelly;Qianqian Zhu,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26549586;29090520;33496737,R03 CA223730;Rally Foundation Independent Investigator Award,2024-05-20,GRU-PUB;DS-LEUKLYM,Array_SNP,Genotype/Expression array,"Fractures, Bone",516.0,516.0,,,Osteonecrosis,"Osteonecrosis; Bone Fracture; Bone Fractures; Bone, Broken; Bones, Broken; Broken Bone"
Modelling Multi-Dimensional ClinOmics for Precision Therapy of Children    and Adolescent Young Adults with Relapsed and Refractory Cancer: A    Report from the Center for Cancer Research,"The Center for Cancer Research (CCR), of the intramural NCI undertook a multidimensional clinical genomics study of children and adolescent young adults with relapsed and refractory cancers who were enrolled  on other therapeutic trials to determine the feasibility of a genome guided precision therapy protocol in these patients. Note: NCIPM001blood - This",phs001052.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001052,Javed Khan,Kathleen Calzone,Center for Cancer Research (CCR),25010205;24436047;26994145;34818552,,2024-05-17,GRU,RNA-Seq;WXS;Targeted-Capture,Cohort,Neoplasms,83.0,180.0,https://clinicaltrials.gov/ct2/show/study/NCT01109394,,"Sarcoma;Sarcoma, Ewing;Rhabdomyosarcoma;Wilms Tumor;Desmoplastic Small Round Cell Tumor;Carcinoma, Transitional Cell;Rhabdoid Tumor;Sarcoma, Synovial;Neuroblastoma;Neuroendocrine Tumors","Carcinoma, Transitional Cell; Desmoplastic Small Round Cell Tumor; Neuroendocrine Tumors; Rhabdoid Tumor; Sarcoma; Sarcoma, Ewing"
Systems Analysis of Single-Cell Heterogeneity Underlying Glioma Drug    Resistance,"This study characterizes the transcriptional regulatory mechanisms that drive responses of two patient-derived glioblastoma multiforme (GBM) stem-like cells (PD-GSCs) that have distinct phenotypes - one sensitive and another resistant to  the drug pitavastatin. This study investigates the differing mechanisms driving drug response in the two PD-GSCs at the single-cell level, and",phs003501.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003501,James H. Park,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2024-05-14,GRU-PUB,RNA-Seq,Case Set;Single Cell Analysis;Stem Cell Lines;Transcriptome Analysis,Glioma,2.0,29.0,,IDH1;MGMT,"Glioblastoma;Cells, Cancer Stem","Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme"
Luminal Androgen Receptor-Enriched Triple Negative Breast Cancer,This is a study to determine the efficacy of androgen receptor (AR) inhibitors in LAR (luminal androgen receptor)-enriched triple-negative breast cancer (TNBC) in the neoadjuvant setting. Twenty-four patients were treated  with neoadjuvant AR inhibitor enzalutamide and paclitaxel for 12 weeks. Whole exome sequencing and RNA-sequencing was performed prior to treatment.,phs003586.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003586,Bora Lim;Naoto T. Ueno,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2024-05-13,GRU,RNA-Seq;WXS,Case Set,Breast Neoplasms,2.0,4.0,,AR,"Triple Negative Breast Neoplasms;Neoadjuvant Therapy;Receptors, Androgen;Androgen Receptor Antagonists;Drug Resistance, Neoplasm;High-Throughput Nucleotide Sequencing",Triple Negative Breast Neoplasms; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors
Detecting and Subtyping Lung Cancer Through Analysis of Circulating Tumor    DNA,"Small cell lung cancer (SCLC) is among the most aggressive tumors with poor clinical outcomes. Tumors are rarely resected, which is a major barrier to molecular profiling of tumor tissue;  therefore, non-invasive approaches using circulating tumor DNA (ctDNA) from liquid biopsies are needed to help advance research and clinical care for",phs003570.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003570,David MacPherson;Gavin Ha,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),38598634,,2024-05-10,GRU,Targeted-Capture;WGS,Case-Control;Cohort,Lung Neoplasms,143.0,348.0,,ASCL1;ATOH1;NEUROD1;POU2F3,"Small Cell Lung Carcinoma;Circulating Tumor DNA;Cell-Free Nucleic Acids;Carcinoma, Neuroendocrine","Carcinoma, Neuroendocrine; Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung"
Analysis of Epigenomes and Genome Topology in Colorectal Cancer,"When diagnosing cancer, pathologists use nuclear morphology as a hallmark of tumor cells, but the topological changes linked to alterations in the shape of the nucleus were poorly understood. To  uncover the molecular changes that occur in the 3D structure of cancer genomes, we integrated topological maps for colon tumors and normal colon",phs002288.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002288,"Bradley E. Bernstein, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),32841603,DP1 CA216873;R35 GM133580;R01 GM083084;T32 GM074897;T32 CA009216,2024-05-10,DS-GRR-MDS,Hi-C;Bisulfite-Seq;OTHER;WGS;RNA-Seq;ChIP-Seq,Cohort;Epigenetics;Full Transcriptome Sequencing,Computational Biology,28.0,99.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133928,APC;BRAF;KRAS;MLH1;TP53,Epigenomics;Colorectal Neoplasms;Molecular Conformation,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
The Melbourne Urological Research Alliance (MURAL) Collection of    Patient-Derived Models of Prostate Cancer,1. Low-Dose Carboplatin Modifies the Tumor Microenvironment to Augment CAR T Cell Efficacy in Human Prostate Cancer Models Single-cell RNA sequencing (scRNA-seq) was performed to analyze the transcriptional modifications in  the tumor microenvironment of prostate cancer patient-derived xenografts (PDX). The analyzed PDX tumor was PDX-287R from the MURAL collection of PDXs,phs003369.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003369,"Renea A. Taylor, PhD;Mitchell G. Lawrence, PhD;Nicholas Choo;Gail P. Risbridger;Shivakumar Keerthikumar;Laura H. Porter;David L. Goode;Rosalia Quezada Urban",,,37660083;34413304;38578195,Idea Grants;Mid-career Research Fellowships;W81XWH1810349;Science and Medicine Grants;EJ Whitten Foundation;Rotary Club of Manningham;Global Action Plan1;Grants-in-Aid;Priority-Driven Collaborative Cancer Research Scheme;Peter and Lyndy White Foundation;International Research Scholarship;National Council of Science and Technology,2024-05-09,GRU,RNA-Seq,RNA Sequencing;Single Cell Analysis;Transcriptome Sequencing;Xenograft,Prostatic Neoplasms,10.0,89.0,,BBC3;CCL20;CXCL10;CXCL11;FAS;IFI6;JUN;RACK1;STAT1;STAT2;STING1;AR;ASCL1;BRD4;CREBBP;EP300;CHGA;SYP;NCAM1;NKX3-1;KLK3,"Receptors, Chimeric Antigen;Drug Therapy;Heterografts;Adenocarcinoma;Neuroendocrine Tumor;RNA-Seq, Single-Cell;Transcriptome Analysis","Adenocarcinoma; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant; Malignant Adenoma"
"Combined PDCD1, BRAF and MAP2K7 Inhibition in BRAFV600E Colorectal    Cancer: A Phase 2 Trial","In this study, we evaluated the clinical efficacy of combined PDCD1, BRAF, and MAP2K7 inhibition in metastatic BRAFV600E Colorectal Cancer (CRC) patients (NCT03668431). We performed bulk whole exome sequencing (WXS)  and bulk RNA sequencing (RNA-Seq) in 35 pre-treatment tumor biopsies and matching germline for tumor mutational burden (TMB), BM1/BM2 transcriptional",phs003178.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003178,Ryan B. Corcoran;Gad Getz;Nir Hacohen,Freddie Pruitt,Center for Cancer Genomics (CCG),36702949;32047001;27354468;26457756,"P50 CA127003;U54CA224068;R01 CA208756;SU2C-AACR-DT22-17;Arthur, Sandra, and Sarah Irving Fund for Gastrointestinal Immuno-Oncology",2024-05-09,DS-CA-MDS,RNA-Seq;WXS,Case Set;Cohort;Tumor vs. Matched-Normal,Colorectal Neoplasms,34.0,159.0,,BRAF;MAP2K7;PDCD1;KRAS;NRAS,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Genomic Profiling of Melanoma,"This study reports on genomic profiling [whole-exome sequencing (WXS), bulk RNA sequencing (RNA-seq), and/or single-cell RNA sequencing (scRNA-seq)] of patient-derived melanoma samples and matched normal samples. The goal is to  elucidate the genetic and cellular basis of sun-exposed and sun-shielded melanomas and to relate these findings to survival and regional metastasis.",phs000933.v4.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000933,"Ruth Halaban, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),35197475;28186096;28018970;26214590;22842228,1 P50 CA121974;Melanoma Research Alliance;Gilead Sciences;Howard Hughes Medical Institute;Yale Department of Dermatology;Yale Comprehensive Cancer Center;The Roslyn and Jerome Meyer Award;The Stinehart-Reed foundation (AMN);The Stanford Bio-X Interdisciplinary Initiatives Seed Grants Program (IIP) (AMN);Grant 81620108024 (XC),2024-05-06,DS-M-MDS-GSO,RNA-Seq;Seq_DNA_SNP_MAF_Ind;WXS;Seq_DNA_SNP_MAF_Sum,Case Set,Melanoma,403.0,999.0,,BRAF;NF1;NRAS,High-Throughput Nucleotide Sequencing,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Functional Genomic Landscape of Acute Myeloid Leukemia,The implementation of targeted therapies for acute myeloid leukemia has been challenged by complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most  mutational events. The initial findings from the Beat AML program were from a cohort of 672 tumor specimens collected from 562 patients. Additional,phs001657.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001657,"Jeffrey W. Tyner, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,;1U54CA224019;1U01CA217862;3P30CA069533-18S5,2024-05-02,DS-LEU,RNA-Seq,Longitudinal,"Leukemia, Myeloid, Acute",829.0,2161.0,http://www.vizome.org,,,AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL
"Childhood Cancer Data Initiative (CCDI): Enhancement of Data Sharing in    Pediatric, Adolescent and Young Adult Cancers","NCI's Childhood Cancer Data Initiative (CCDI) is building a community centered around childhood cancer care and research data. Through enhanced data sharing, we can improve our understanding of cancer biology  to improve preventive measures, treatment, quality of life, and survivorship, as well as ensure that researchers learn from every child with cancer.",phs002431.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002431,"Rajen Mody, MD, MS",Joseph Flores-Toro,Office of Data Sharing (ODS),,,2024-04-23,HMB,,Cohort;Copy Number Variation (CNV);Exome Sequencing;Individual-Level Genomic Data;Metastasis;Sequencing;Transcriptome Analysis;Transcriptome Sequencing;Tumor;Tumor vs. Matched-Normal,Neoplasms,611.0,1448.0,https://www.pathology.med.umich.edu/mctp/mi-oncoseq-study;https://www.cancer.gov/research/areas/childhood/childhood-cancer-data-initiative;https://www.pathology.med.umich.edu/static/apps/cms/ckfinder/userfiles/388/files/OncoSeq-Test-Definition-V6a.pdf,,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Prediction of Resistance and Sensitivity to HER2 Targeted Therapy in the    Neoadjuvant Setting,"Women with breast cancers that overexpress HER2 are at greater risk for disease progression and death than women whose tumors do not overexpress HER2. Trastuzumab, a recombinant humanized monoclonal antibody  against the extracellular domain of the HER2 protein blocks downstream signaling of HER2 and substantially improves the efficacy of chemotherapy in",phs003275.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003275,"Lisa Carey, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),24095300;38546612,R01CA229409,2024-04-17,HMB-NPU,RNA-Seq,Case Set;Clinical Trial,Breast Neoplasms,245.0,245.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE234519,ERBB2,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
"Childhood Cancer Data Initiative (CCDI): Integrating Longitudinal    Clinical, Sociodemographic and Genomic Data into the NCCR","The goal of this study is to contribute clinical and genomic data from a large institutional cohort of pediatric cancer patients who had tumor genomic profiling between 2013 and 2019  at Dana-Farber/Boston Children's Hospital Cancer and Blood Disorders Center. Clinical data include demographics, diagnosis (classified according to",phs002677.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002677,"Katherine A. Janeway, MD",Joseph Flores-Toro,Office of Data Sharing (ODS),38992034,,2024-04-16,HMB,,Longitudinal Cohort,Pediatrics,835.0,835.0,https://www.dana-farber.org/research/integrative-research/cancer-genomics/profile,ALK;ARID1B;ARIDA1A;ATM;ATRX;BCOR;BRAF;BRCA1;BRCA2;CCND1;CCND2;CCND3;CDK4;CDK6;CDKN2A;CDKN2B;CRNNB1;CTNNB1;DICER1;EGFR;ERBB2;ETV6;EWSR1;FANCG;FGFR1;FGFR2;FGFR3;FGFR4;FLT3;H3F3A;HRAS;IDH1;KIT;KRAS;MAP2K1;MAPK1;MET;MTOR;MYC;MYCN;NF1;NF2;NRAS;NTRK1;NTRK3;PDGFRA;PI3KCA;PIK3CA;PIK3R1;POLE;PTCH1;PTEN;RAF1;RB1;RET;SMARCB1;SMO;TET2;TP53;TSC1;TSC2;VHL,"Neoplasms;Brain Neoplasms;Rare Diseases;Sequence Analysis, DNA;Osteosarcoma;Sarcoma, Ewing;Neuroblastoma;Rhabdomyosarcoma;Wilms Tumor;Glioma","Rare Diseases; Sarcoma, Ewing; Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm"
Epigenetic Damage in Women Living in LA Food-Desert Zip Codes,"This study investigated the impact of insulin resistance on chromatin acetylation and inflammation. Blood samples were obtained from women consented to City of Hope Institutional Review Board (IRB)-approved COH Protocol#/Ref#:18306/158149.  Women provided demographic information and completed a survey assessing diet, housing and medical history. BMI was obtained from medical records.",phs003522.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003522,Victoria L. Seewaldt;Dustin E Schones,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2024-04-15,GRU,ChIP-Seq,Case Set,Insulin Resistance,30.0,30.0,,,,
Characterization of Prostate Cancer Organoids,"Using models from the LuCaP series as well as those generated at the National Cancer Institute, we have established organoids for in vitro mechanistic testing, including drug screening and genetic  manipulation. The major findings from these continuing studies is the durability of organoids for maintaining complex subpopulation and intratumoral",phs001587.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001587,Kathleeen Kelly,Kathleen Calzone,Center for Cancer Research (CCR),37183816;29748182;37725435,,2024-04-09,GRU,ATAC-seq;WGS;RNA-Seq;ChIP-Seq;WXS;Array_SNP,Case Set,Prostatic Neoplasms,34.0,165.0,,AR;CD276,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Multivalent State Transitions Shape the Intratumoral Composition of Small    Cell Lung Carcinoma,"Small cell lung carcinoma (SCLC) is an aggressive, tobacco-associated tumor characterized by rapid growth, early metastases, and initial response followed by almost invariable resistance to chemotherapy. Studies to date have  not resolved the extent that diverse transcriptional programs drive SCLC and contribute to its lethality. We combined patient-derived xenograft (PDX)",phs003102.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003102,Mohamed E. Abazeed,Ian Fingerman,Division of Cancer Biology (DCB),,,2024-04-03,GRU-IRB,RNA-Seq,RNA Sequencing;Single Cell Analysis;Tumor;Xenograft,Small Cell Lung Carcinoma,64.0,70.0,,ASCL1;NEUROD1;POU2F3;YAP1,xenograft,"Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL"
Spatial Transcriptomics Reveals Discrete Tumor Microenvironments and    Autocrine Loops Within Ovarian Cancer Subclones,Ovarian masses from patients with high grade serous ovarian carcinoma undergoing debulking surgery were subjected to spatial transcriptomics profiling using the 10x Genomics Visium (fresh frozen) platform. Copy number inference  using inferCNV predicted the presence of subclones with mutually exclusive copy number alterations (CNAs) in 5 of the 8 patient samples studied. In,phs003561.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003561,Alistair Forrest,Freddie Pruitt,Center for Cancer Genomics (CCG),38570491,,2024-03-25,DS-CA,WGS,Tumor,"Carcinoma, Ovarian Epithelial",2.0,13.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE211956,,,"Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian; Epithelial Cancer, Ovarian"
Integrating Genomic and Transcriptomic Data to Identify Breast Cancer    Susceptibility Genes,"Genetic factors play an important role in the etiology of both sporadic and familial breast cancer. Since 2007, common genetic variants in 200 loci have been identified in genome-wide association  studies (GWAS) in relation to breast cancer risk. However, it is often difficult to translate GWAS findings to disease prevention and treatment since",phs003535.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003535,Wei Zheng;Jirong Long,,,,,2024-03-22,DS-BRCA-PUB-NPU-MDS,RNA-Seq;Array_SNP,Genotype;RNA Sequencing;Tissue Expression;Transcriptome Analysis,Breast Neoplasms,150.0,150.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
MSK SPECTRUM - SPatiotemporal Evolution of Cancer Traced Using    Multimodalities,"MSK SPECTRUM is a multi-modal, interdisciplinary prospective study of spatiotemporal determinants of high-grade serous ovarian cancer (HGSOC) evolution, treatment and response. Accounting for 80% of ovarian cancers, HGSOC is the  most lethal gynecological malignancy and is a cancer of major unmet clinical need. Challenges in disease management relate to several unresolved",phs002857.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002857,Sohrab Shah;Dmitriy Zamarin,Joseph Flores-Toro,Office of Data Sharing (ODS),36517593,Cycle for Survival;Collaborative Research Development Grant (648007);Liz Tilberis Award (657721);Ann Schreiber Mentored Investigator Award (650687);W81XWH-20-1-0565;W81XWH-21-1-0561;;C42358/A27460;P30-CA008748,2024-03-22,GRU,WGS,Case Set;Clinical Cohort;Collection;Longitudinal Cohort;Prospective;Repository;Single Cell Analysis;Transcriptome Sequencing;Tumor vs. Matched-Normal;Whole Genome Sequencing,Ovarian Neoplasms,51.0,167.0,https://componcmsk.org/msk-spectrum/;https://www.synapse.org/msk_spectrum;https://cellxgene.cziscience.com/collections/4796c91c-9d8f-4692-be43-347b1727f9d8;https://www.cbioportal.org/study/summary?id=msk_spectrum_tme_2022;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE180661,CDK12;CCNE1;BRCA2;BRCA1;TP53,Genomic Instability;Tumor Microenvironment,"Genomic Instability; Genome Instabilities; Genome Instability; Genomic Instabilities; Instabilities, Genome; Instabilities, Genomic"
Serrated Colorectal Cancer: An Emerging Disease Subtype,"This dataset represents two combined study populations. Serrated Colorectal Cancer: An Emerging Disease Subtype (called the Advanced Colorectal Cancer of Serrated Subtype Study or ACCESS Study) was a grant awarded  to investigate a newly-recognized, biologically-distinct subtype of colorectal cancer (CRC) called &#x0201c;serrated CRC.&#x0201d; The objective of",phs002171.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002171,Polly Newcomb,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2024-03-22,DS-CC-MDS;GRU,Imputation_SNP;PCR_DNA_STR,Case Set;GWAS;Observational;Population;Prospective,Colorectal Neoplasms,1364.0,1466.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Integration of Clinical and Molecular Biomarkers for Melanoma Survival    (Berwick),The long-term goal of the InterMEL Program Project: Integration of Clinical and Molecular Biomarkers for Melanoma Survival is to identify molecular and clinical factors that predict survival of melanoma patients.  Our overarching hypothesis is that we can identify factors in the primary melanoma tumor that will lead to more aggressive disease. Melanoma patients,phs003099.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003099,Marianne Berwick,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2024-03-21,GRU,Array_DNA_Methylation;Targeted-Capture;Array_miRNA_Expression,Case-Control;Copy Number Variation (CNV);Epigenetics;Individual-Level Genomic Data;Marker Discovery;Multicenter;Sequencing;Tumor;Tumor vs. Matched-Normal,"Biomarkers, Tumor",697.0,697.0,,,,Not Provided
Whole Genome Scan for Pancreatic Cancer Risk in the Pancreatic Cancer    Cohort Consortium and Pancreatic Cancer Case-Control Consortium    (PanScan),"Within the framework of the NCI-sponsored Cohort Consortium, investigators from 12 prospective epidemiologic cohorts formed the Pancreatic Cancer Cohort Consortium in 2006. This study, also known as ""PanScan"", is funded  by the National Cancer Institute (NCI) and involves conducting a genome-wide association study (GWAS) of common genetic variants to identify markers",phs000206.v6.p3,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000206,Laufey Amundadottir;Brian Wolpin;Rachael Stolzenberg-Solomon,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),20101243;25086665;19648918,HHSN261200800001E;the Lustgarten Foundation for Pancreatic Cancer Research;NIH/NCI K07 CA140790,2024-03-18,HMB-PUB-NPU-MDS-GSO;DS-PACA-IRB-COL-GSO;GRU;DS-PACA-GSO;CADM,Array_SNP,Case-Control;Longitudinal Cohort,Pancreatic Neoplasms,9437.0,9702.0,http://epi.grants.cancer.gov/PanScan/,,,"Cancer of the pancreas; Neoplasia of the pancreas; Neoplasm of Pancreas; Neoplasm of the Pancreas; Neoplasm, Pancreas; Neoplasm, Pancreatic"
Pediatric Preclinical Testing Consortium (PPTC),"The Pediatric Preclinical Testing Consortium (PPTC) is addressing the unmet need of streamlining the development of new therapies for childhood cancers. The PPTC seeks to develop robust biomarkers of anticancer  drug activity, and the majority of these are predicted to be genetic mutations that can be detected in tumor DNA and/or RNA. In order to design the",phs001437.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001437,John M. Maris,,,31693904,,2024-03-14,GRU,RNA-Seq;WXS,Cohort;Xenograft,"Leukemia, Lymphoid",267.0,301.0,,,"Osteosarcoma;Neuroblastoma;Brain Neoplasms;Sarcoma, Ewing;Wilms Tumor;Medulloblastoma;Neoplasms, Germ Cell and Embryonal;Astrocytoma;Rhabdomyosarcoma","Neoplasms, Germ Cell and Embryonal; Sarcoma, Ewing; ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm"
Clinical and Molecular Features of Acquired Resistance to Immunotherapy    in Non-Small Cell Lung Cancer,"PD-(L)1 blockade has been shown to promote durable responses in non-small cell lung cancer (NSCLC) patients and has been rapidly incorporated into the treatment regimens for many with advanced disease.  Despite this, mechanisms of acquired resistance (AR) to PD-(L)1 have not been well understood. To address the clinical and molecular landscape of AR",phs002834.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002834,Matthew Hellmann,Freddie Pruitt,Center for Cancer Genomics (CCG),"29658856;27718847;34487855;30498383;28031159;28789707;28228279;29025772;31201935;26883990;28596308;29070816;27433843;27912061;31398344;32916126;29578107;23323831;32483290;33558725;27667683;26952546;29107330;29625050;29934517;25754329;30388456;25765070;32271377;33199494;27158780;29773717;23945592;29695832;29056346;31898484;26645196;14525967;29296022;37001526;27350335;32917656;33979178;34385708;29370992;30936194;23079694;23104886;25822800;32289269;33055240;25605792;21546393;31340985;19451168;21478889;32461654;25703262;30778252;24633410;27270079;30371878;16199517;22455463;25786235;22728672;18463140;30357391;2231712;29132144;24695404;31408414;30783653;27855702;33137190;22388286;33590861;18798982;33270111;20679213;31810882;No PMID: 458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC). | Schoenfeld A, Lee S, Paz-Ares L, Doger B, Gettinger S, Haefliger S, et al.;37079675",Grant CI-98-18;Support grant/core grant P30 CA008748;Lung Cancer Dream Team Translational research grant SU2C-AACR-DT17-15;Grant # 19-029 MIA,2024-03-13,HMB,WXS,Case Set,Immune Checkpoint Inhibitors,29.0,57.0,,,"Immunotherapy;Carcinoma, Non-Small-Cell Lung","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell"
Genome-Wide Association Study of Genetic Susceptibility for Graft-vs-Host    Disease Cohort 1,"Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is the only curative therapy for many advanced hematologic malignancies. Allo-HSCT is associated with significant morbidities and mortality, mainly because of the graft-versus-host disease  (GVHD) caused by donor T cells recognizing antigens present in recipient tissues, and initiating an alloimmune response resulting in damage to many",phs002185.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002185,"Vahid Afshar-Khargan, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,"R01CA231141;X01HG007923;HHSN268201700006I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2024-03-13,NRUP;DS-HCTCT-GSO,Array_SNP_CNV;Imputation_SNP_CNV,Cohort,Graft vs Host Disease,9408.0,9518.0,,,"Leukemia, Myeloid, Acute;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Myelodysplastic-Myeloproliferative Diseases","Myelodysplastic-Myeloproliferative Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Disease, Graft-Versus-Host; Disease, Graft-vs-Host; Disease, Homologous Wasting; Disease, Runt"
Genomic Analysis of Prostate Tumor Heterogeneity in Metastasis,"To investigate the molecular changes, mutations, and signaling pathways that characterize the initial steps of prostate cancer metastasis to the lymph nodes, we analyzed 19 discrete lymph node (LN) metastases,  97 primary tumor foci, 39 benign lymph nodes, and 10 normal adjacent prostate tissue samples from 43 patients enrolled in a clinical trial",phs003404.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003404,"Carlos S. Moreno, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),38067373,R21-CA256375,2024-03-12,GRU,RNA-Seq;Seq_DNA_SNP_MAF_Ind;WXS;Seq_DNA_SNP_CNV,Tumor vs. Matched-Normal,Prostatic Neoplasms,43.0,302.0,https://doi.org/10.3390/cancers15235671,SPOP;TP53;EYA1;CSMD3;FLT4;NCOR2;PCDH15,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor    Musculoskeletal Symptoms (AIMSS),Aromatase Inhibitor-Associated Musculoskeletal Symptoms (AIMSS) are common and frequently lead to Aromatase Inhibitor (AI) discontinuation. Single nucleotide polymorphisms (SNPs) in candidate genes have been associated with AIMSS and AI discontinuation.  E1Z11 is a prospective cohort study designed to validate associations between 10 SNPs and AI discontinuation due to AIMSS. We enrolled postmenopausal,phs003517.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003517,Vered Stearns,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2024-03-07,GRU,Array_SNP,Case-Control;Clinical Cohort;Genotype;Multicenter,Musculoskeletal System,970.0,970.0,https://clinicaltrials.gov/study/NCT01824836,CYP19A1;ESR1;HTR2A;TCL1A,,Not Provided
A Missense SNP in the Tumor Suppressor SETD2 Reduces H3K36me3 and Mitotic    Spindle Integrity in Drosophila,"While examining DNA from renal cell carcinoma (RCC) patients we observed a single nucleotide polymorphism (SNP; rs58906143,chr3:47163422 C&#x02192;G (hg19); E902Q ) within SETD2 that was overrepresented in kidney cancer patients  compared to control patients. This original study utilized directed sequencing of 14 genes. In an expanded study using a Taqman assay to study the",phs003474.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003474,"Rebecca S. Arnold, PhD;Dorothy A. Lerit,  PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,W81XW1910859;BX003367-01;5K12GM000680;5K99GM143517;R01GM138544;RSG-22-874157-01-CCB;UL1TR002378,2024-03-05,GRU,PCR_DNA_SNP;Targeted-Capture,Case-Control,Kidney Neoplasms,758.0,758.0,,SETD2,,Kidney Tumor; Kidney cancer; Kidney neoplasm; Neoplasia of the kidneys; Neoplasm of Kidney; Neoplasm of the Kidney
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small    Cell Lung Cancer,"We performed a trial of adoptive cell therapy using tumor infiltrating lymphocytes (TIL) in metastatic non-small cell lung cancer (NSCLC). We conducted a single-arm open- label phase 1 trial (NCT03215810)  of TIL administered with nivolumab in 20 patients with advanced NSCLC. Patients had tumor metastases resected for TIL, and the sequencing data from",phs002486.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002486,"Ben Creelan, MD",Joseph Flores-Toro,Office of Data Sharing (ODS),34385708,SU2C-AACR-CT04-17,2024-03-01,HMB-PUB-NPU,RNA-Seq;WXS,Clinical Trial;Interventional;Sequencing;Transcriptome Sequencing;Tumor vs. Matched-Normal,"Carcinoma, Non-Small-Cell Lung",20.0,103.0,https://progress.standuptocancer.org/trials/lung-immunotherapy,ALKAL1;CCDC6;CD74;CREM;EGFR;EML4;EWSR1;KRAS;PIK3CA;RET;ROS1;TRB,"Adenocarcinoma of Lung;Carcinoma, Squamous Cell;Immunotherapy, Adoptive;Lymphocytes, Tumor-Infiltrating;organ-specific neoantigen","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma"
A Human Lymphoma Organoid Model for Evaluating and Targeting the    Follicular Lymphoma Tumor Immune Microenvironment,"Heterogeneity in the tumor microenvironment (TME) of follicular lymphoma (FL) can affect clinical outcomes. We developed a new organoid culture method for cultivating patient-derived lymphoma organoids (PDLOs), which include cells  from the native FL TME. We generated organoids from 12 FL patients at diagnosis, clinical progression, or relapse. These organoids were profiled with",phs003410.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003410,Ash A. Alizadeh;Lisa E. Wagar,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,U54CA217378;P30AR075047,2024-02-29,DS-HLCA-IRB-PUB-COL,RNA-Seq;Seq_Read_Counts;Targeted-Capture,Case Set,"Lymphoma, Follicular",12.0,127.0,,,Organoids,"Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers; FOLLICULAR LYMPHOMA, SOMATIC; Follicle Center Lymphoma"
Acquired Cross-Resistance in Small Cell Lung Cancer Patient-Derived    Xenografts,"Here we present whole genome sequencing and RNA sequencing of patient-derived xenograft (PDX) models of small cell lung cancer (SCLC). These models were derived at a variety of clinical time  points from either biopsy/resection samples, malignant effusions, or circulating tumor cells (CTCs), and grown in the subcutaneous flank of NSG",phs003486.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003486,"Benjamin J. Drapkin, MD, PhD;Sihan Wu, PhD;Michael S. Lawrence, PhD;Nicholas J. Dyson, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),37425738,U01CA220323;RR20007,2024-02-12,GRU,Seq_DNA_SNP_CNV;WGS;RNA-Seq;WXS;Seq_RNA_Expression,Xenograft,Small Cell Lung Carcinoma,42.0,133.0,,MYC;MYCL;MYCN,Chemoradiotherapy;DNA Damage,DNA Damage; DNA Injuries; DNA Injury; DNA Lesion; DNA Lesions; Deoxyribonucleic acid damage
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma,"In this study, we show that the plasma representation of mutations exceeds the bulk tumor representation in most cases, making classic Hodgkin Lymphoma (cHL) particularly amenable to noninvasive profiling. Leveraging  single-cell transcriptional profiles of cHL tumors, we demonstrate hazard ratios (HRs) circulating tumor DNA (ctDNA) shedding to be shaped by",phs003435.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003435,"Ash A. Alizadeh, MD. PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),38081297,,2024-02-12,DS-LYM-IRB-PUB-COL,RNA-Seq;Seq_RNA_Expression;WXS;Targeted-Capture,Case-Control;Sequencing,Hodgkin Disease,445.0,1281.0,,DNASE1L3;IL4R;IL13,Cell-Free Nucleic Acids;Circulating Tumor DNA,"CHL; Classic Hodgkin disease; Disease, Hodgkin; Disease, Hodgkin's; Disease, Hodgkins; Familial Hodgkin Disease"
University of Michigan Clinical Sequencing Exploratory Research (CSER),"Overview. The personalization of therapy for cancer will require molecular characterization of unique and shared genetic aberrations. In particular, patients who have a sarcoma or other rare cancers and are  candidates for clinical trials could potentially benefit by identifying eligibility for ""targeted"" drugs based on the ""actionable"" genes in their",phs000673.v5.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000673,"Arul Chinnaiyan, MD PhD",,,24185510;26325560;28783718,1UM1HG006508,2024-02-12,GRU,RNA-Seq;WXS;Targeted-Capture,Case Set,Neoplasms,1427.0,4403.0,,,Breast Neoplasms;Sarcoma;Prostatic Neoplasms;Aromatase Inhibitors;Hematologic Neoplasms,Sarcoma; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors
The Multiethnic Cohort (MEC) Study,"The Multiethnic Cohort (MEC) study of over 215,000 men and women in Hawaii and California is unique in that it is population-based and includes large representations of older adults (45-75  years at baseline) for five US racial/ethnic groups (Japanese Americans, African Americans, European Americans, Latinos and Native Hawaiians) at",phs002183.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002183,"Lo&#239;c Le Marchand, PhD;Lynne Wilkens, DrPH;Christopher Haiman, PhD",,,10695593;10695594,"R01CA63464, X01HG010416 (R37CA54281,
  P01CA33619, U01CA136792, U01CA98758, U01CA164973);HHSN268201700006I, NIH contract ""High throughput genotyping
  and DNA sequencing for studying the genetic contributions to human health and
  disease""",2024-02-09,HMB-PUB;NRUP;DS-CA-PUB,Array_SNP_CNV,,Neoplasms,204248.0,34213.0,https://www.uhcancercenter.org/mec;https://www.uhcancercenter.org/mec-publications,,Dietary;Risk factors;Ethnic groups,Risk Factors; Blastoma; CA; CA - Cancer; Cancer; MT
MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment    Sequencing for Minimal Residual Disease Detection in Cohort Studies,"MAESTRO-Pool builds upon the technology MAESTRO (Minor Allele Enriched Sequencing Through Recognition Oligonucleotides) by pooling tumor-specific MAESTRO probes from multiple patients and applying these to all samples from all patients.  In this study, MAESTRO-Pool was applied to a cohort of 9 melanoma patients where 98 plasma samples were screened for 22,333 mutations. Additionally,",phs003447.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003447,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),38069911,,2024-02-08,DS-MSC-MDS,Seq_DNA_SNP_MAF_Sum;Targeted-Capture;WGS,Case Set;Individual-Level Genomic Data;Longitudinal;Methods Development;Sequencing;Tumor;Tumor vs. Matched-Normal;Whole Genome Sequencing,Melanoma,9.0,234.0,,,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
A Phase I Study with a Personalized Neoantigen Cancer Vaccine in Melanoma,Effective anti-tumor immunity in humans has been associated with presence of T cells targeting neoantigens that arise from non-silent tumor-specific mutations. Here we conducted whole-exome sequencing of tumor and normal  cells from individual patients to identify mutations. We assessed the expression of mutated alleles by RNA-sequencing of tumor. We demonstrated the,phs001451.v5.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001451,Patrick Ott;Catherine J. Wu,Ian Fingerman,Division of Cancer Biology (DCB),28678778;34290406;35508657;34663921,5R01CA155010-02;5R01HL103532-03;2P50CA101942-11A1;R50-RCA211482A;Blavatnik Family Foundation;Francis and Adele Kittredge Family Immuno-Oncology and Melanoma Research Fund;Faircloth Family Research Fund;DFCI Center for Cancer Immunotherapy Research Fellowship;Leukemia and Lymphoma Society,2024-01-26,GRU,RNA-Seq;WXS;OTHER;WGS,Clinical Trial,Melanoma,12.0,132.0,,,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Gabriella Miller Kids First (GMKF) Pediatric Research Program in    Susceptibility to Ewing Sarcoma Based on Germline Risk and Familial    History of Cancer,"Ewing sarcoma (EWS) is a deadly bone cancer that occurs in children and adolescents. Mounting evidence suggests that a genetic predisposition exists for this pediatric cancer, although the specific genetic  contribution has yet to be identified. EWS has never been linked to a specific cancer predisposition syndrome, although several case reports have",phs001228.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001228,"Joshua D. Schiffman, MD",,,,,2024-01-26,GRU,,Parent-Offspring Trios,"Sarcoma, Ewing",1332.0,1505.0,https://commonfund.nih.gov/kidsfirst/X01Projects#Schiffman,,Neoplasms,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Genomic Analysis of Follicular Lymphoma,We included tumors from newly diagnosed or untreated follicular lymphoma in this study. Samples consented to the University of Iowa and Mayo Clinic Lymphoma Specialized Program of Research Excellence (SPORE)  were included for data sharing. RNA was extracted from 1) CD19 sorted B cells from tumor cell suspension frozen in dimethyl sulfoxide (DMSO; RNA,phs002989.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002989,Anne Novak,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),38428430,P50CA097274,2024-01-24,GRU,RNA-Seq;WXS,Case Set;Exome Sequencing;RNA Sequencing;Tumor vs. Matched-Normal,"Lymphoma, Follicular",117.0,430.0,,,,"Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers; FOLLICULAR LYMPHOMA, SOMATIC; Follicle Center Lymphoma"
Evolutionary Analysis of Chronic Lymphocytic Leukemia Cells During    Relapse After Allogeneic Hematopoietic Stem Cell Transplant,"We investigated the molecular dynamics driving relapse of chronic lymphocytic leukemia (CLL) following allogeneic hematopoietic stem cell transplant (allo-HSCT) through an integrated analysis of whole exome, bulk transcriptome, bulk methylome  and single cell transcriptional data from paired leukemic samples representing 19 patients. We found that their clinical kinetics corresponded to",phs001998.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001998,"Catherine Wu, MD",Ian Fingerman,Division of Cancer Biology (DCB),34663921,1R01CA155010;P01CA206978;U10CA180861,2024-01-24,DS-HM-MDS;GRU,RNA-Seq;WXS;Bisulfite-Seq;OTHER,Case Set;Longitudinal,"Leukemia, Lymphocytic, Chronic, B-Cell",19.0,40.0,,,"Transplantation, Homologous","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic"
Profiling RNA Translation in Pediatric Medulloblastoma,This study provides RNA-sequencing and ribosome profiling data for patient-derived cell lines and patient tissue samples for children with medulloblastoma. Ribosome profiling is a variant protocol of RNA-sequencing that directly  sequences ribosome-bound RNA fragments only. Associated RNA-seq and Ribo-seq data obtained separately for some cancer cell lines can be found on the,phs003446.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003446,John Prensner,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),37205492;28579404;32601440,,2024-01-18,HMB,RNA-Seq;OTHER,RNA Sequencing,Medulloblastoma,21.0,57.0,,,Ribosome Profiling;Open Reading Frames,"Arachnoidal Cerebellar Sarcoma, Circumscribed; Circumscribed arachnoidal cerebellar sarcoma; Desmoplastic Medulloblastomas; Desmoplastic Nodular Medulloblastoma; Desmoplastic medulloblastoma; Medulloblastoma, Desmoplastic"
The Institute for Genomic Medicine at Nationwide Children's Hospital    Pediatric Cancer and Blood Disorder Project,"The aim of this study is to enable the unification of the clinical and research arms of comprehensive genomic profiling in the setting of cancer and hematologic disease. Increasingly, studies  of the genomic etiology of cancer and hematologic diseases are being utilized for patient management, including prognostication, informing diagnosis,",phs001820.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001820,Catherine Cottrell,,,31949013;31271967;31626289;29434027,Nationwide Foundation Pediatric Innovation Fund,2024-01-18,GRU-NPU;NRUP,WGA;WGS;RNA-Seq;Seq_DNA_SNP;Seq_RNA_Expression;WXS;FL-cDNA,Cohort,Neoplasms,261.0,1088.0,https://www.nationwidechildrens.org/specialties/institute-for-genomic-medicine,,Brain Neoplasms;Carcinoma;Hematologic Diseases;Hematologic Neoplasms,Hematologic Diseases; Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour
GATA2 Deficiency and the MonoMAC Syndrome,"The aim of this study was to identify the germline mutation(s) in an extended family with individuals having MonoMAC Syndrome/GATA2 deficiency but lacking a canonical GATA2 mutation. GATA2 deficiency patients  develop bone marrow failure, severe immunodeficiency and may progress to myeloid malignancies, including myelodysplastic syndrome (MDS), acute",phs003269.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003269,"Dennis Hickstein, MD;Steven Holland, MD",Kathleen Calzone,Center for Cancer Research (CCR),34529785;36455197;24077845;29412158,,2024-01-17,GRU,WGA;Seq_DNA_SNP_CNV,Case-Cohort;Family;Pedigree Whole Genome Sequencing;Whole Genome Sequencing,Bone Marrow Failure Disorders,6.0,6.0,https://clinicaltrials.gov/ct2/show/NCT01861106;https://clinicaltrials.gov/ct2/show/NCT01905826,GATA2,Congenital Bone Marrow Failure Syndromes;Bone Marrow Transplantation,"Bone Marrow Transplantation; Congenital Bone Marrow Failure Syndromes; Bone Marrow Failure; Bone marrow hypoplasia; Failure, Bone Marrow; Hypoplastic bone marrow"
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational    Epigenetic Combination Therapy,"Essential epigenetic dependencies have become evident in many cancers. Based on functional antagonism between BAF/SWI/SNF and PRC2 in SMARCB1-deficient sarcomas, we and colleagues recently completed the clinical trial of the  EZH2 inhibitor tazemetostat, leading to its FDA approval. However, the principles of tumor response to epigenetic therapy in general and tazemetostat",phs003188.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003188,Alex Kentsis,Ian Fingerman,Division of Cancer Biology (DCB),,,2024-01-17,HMB,RNA-Seq,Clinical Cohort;Clinical Trial;Epigenetics;Marker Discovery;RNA Sequencing;Transcriptome Analysis,"Drug Resistance, Neoplasm",11.0,17.0,,EZH2;SMARCB1,"Epigenomics;EZH2 protein, human;Tazemetostat",Not Provided
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus    Nivolumab in Stage IV Squamous Cell Lung Cancer,"Lung-MAP (S1400, NCT02785952) was a multicenter, open-label, phase III randomized clinical trial. The Lung-MAP-I substudy (S1400I) was conducted from December 2015 to April 2018, through the National Clinical Trials Network  and led by the SWOG Cancer Research Network. The trial compared nivolumab plus ipilimumab (nivo+ipi) with nivolumab monotherapy (nivo) in patients",phs003412.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003412,Scott Gettinger;Roy Herbst;Lyudmila Bazhenova,Freddie Pruitt,Center for Cancer Genomics (CCG),38277235,U24CA224285;U24CA224319;U24CA224316;U10CA180888;U10CA180819,2024-01-11,GRU,,Controlled Trial,"Carcinoma, Non-Small-Cell Lung",160.0,731.0,,CSF-1;CXCL13;IL-6;IL-8;LAMP3;LRP1B;MMP12,Immune Checkpoint Inhibitors,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER"
"HTAN Pilot Project: Single-Cell Transcriptomics Toolbox for Fresh and    Frozen Human Tumors (Lung, Breast, Ovarian, Melanoma, Neuroblastoma,    Sarcoma, Glioblastoma, Glioma, and Leukemia)","Single cell transcriptomics is a powerful tool to map the complex tumor microenvironment, providing unprecedented resolution into cell types, cell states, cell interactions, and tumor heterogeneity. Depending on their tissue  site and whether processing begins from a fresh or frozen sample, different tumors require different optimizations in order to obtain high quality",phs001983.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001983,"Aviv Regev, PhD;Orit Rozenblatt-Rosen, PhD;Asaf Rotem, PhD;Bruce E. Johnson, MD;Nikhil Wagle, MD;Ursula A. Matulonis, MD;Natalie B. Collins, MD, PhD;Michael A. Dyer, PhD;Michael R. Clay, MD;Elizabeth H. Stover, MD, PhD;Raphael Bueno, MD;Mario L. Suva, MD, PhD;Suzanne J. Baker, PhD;Aaron N. Hata, MD, PhD;Charles H. Yoon, MD, PhD, FACS;F. Stephen Hodi, MD;Rizwan Haq, MD, PhD;Benjamin Izar, MD, PhD;Catherine J. Wu, MD;Peter J. Tramontozzi, BS;Lan Nguyen, BS;Satyen H. Gohil, PhD, MB;Avinash Waghray, PhD;Masashi Nomura, MD, PhD;Simon Gritsch, MD, PhD;Asa Karlstrom, PhD;Anand G. Patel, MD, PhD;Mei-Ju Su, MS;Sara Napolitano, BS;Judit Jane-Valbuena, PhD;Sebastien Vigneau, PhD;Danielle Dionne, BS;Jingyi Wu, BS;Isaac Wakiro, BS;Eugene Drokhlyansky, PhD;Julia Waldman, BS;Michal Slyper, PhD;Bo Li, PhD;Matan Hofree, PhD;Joshua Gould, MS;Yanay Rosen, BS;Johanna Klughammer, PhD;Ofir Cohen, PhD;Livnat Jerby-Arnon, PhD;Alexander M. Tsankov, PhD;Timothy L. Tickle, PhD;Gabriela Smith-Rosario, BS;Christopher Smillie, PhD;Orr Ashenberg, PhD;Caroline B. M. Porter, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),32405060,Task Order No. HHSN261100039 under Contract No. HHSN261201500003I,2024-01-10,DS-CA-MDS;HMB;GRU,RNA-Seq,Case Set,"Carcinoma, Non-Small-Cell Lung",23.0,40.0,https://humantumoratlas.org/hta1/;https://tumor-toolbox.broadinstitute.org;https://github.com/klarman-cell-observatory/HTAPP-Pipelines;https://github.com/klarman-cell-observatory/Cumulus,,"Neuroblastoma;Breast Neoplasm;Glioblastoma;Glioma;Leukemia, Lymphoid;Ovarian Neoplasms;Melanoma;Sarcoma","Leukemia, Lymphoid; Sarcoma; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor"
Genomic Characterization CS-MATCH-0007 Arm S2,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs002178.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002178,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;37053535;37322121,Division of Cancer Treatment and Diagnosis,2024-01-08,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,3.0,3.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,GNA11;GNAQ,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Genomic Characterization CS-MATCH-0007 Arm S1,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs002153.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002153,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;37053535;37322121,Division of Cancer Treatment and Diagnosis,2024-01-08,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,41.0,41.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,NF1,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Genomic Characterization CS-MATCH-0007 Arm Z1I,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs002058.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002058,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;37322121,Division of Cancer Treatment and Diagnosis,2024-01-08,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,26.0,26.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,BRCA1;BRCA2,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Genomic Characterization CS-MATCH-0007 Arm R,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs002029.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002029,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;31924734;37322121,Division of Cancer Treatment and Diagnosis,2024-01-08,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,28.0,28.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,BRAF,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Transcriptomic and Epigenetic Profiling of SCLC Patient Samples,Small cell lung cancer (SCLC) is an aggressive disease with poor outcomes and limited treatment options. Recent studies have identified transcriptionally defined subsets of SCLC that may allow for the  personalization of treatment. Here we use transcriptomic sequencing and methylation profiling (RRBS) of biopsy and cfDNA to develop a highly accurate,phs003416.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003416,"Lauren A. Byers, MD;John V. Heymach, MD PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,U01-CA256780;P50-CA070907;U01-CA213273;P30-CA016672;R50-CA243698;R01-CA207295;R50-CA265307;CA217450;CA224276;CA233259,2023-12-28,GRU,RNA-Seq;Bisulfite-Seq,Epigenetics;Transcriptome Sequencing,Small Cell Lung Carcinoma,181.0,344.0,,,,"Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL"
Childhood Cancer Data Initiative (CCDI): Genomic Analysis in Pediatric    Malignancies,"Pediatric solid tumors are highly heterogeneous, encompassing a large number of histotypes. The genomic landscape of these diseases is characterized by few single-nucleotide variants (SNVs) compared to adult cancers. In  contrast, many exhibit a high prevalence of structural or epigenetic changes that alter gene expression, underlining the need for comprehensive",phs002430.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002430,"Alejandro Sweet-Cordero, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),30266815;37703185,,2023-12-27,GRU,,Clinical Genetic Testing;Full Transcriptome Sequencing;Individual-Level Genomic Data;Longitudinal;RNA Sequencing;Tumor vs. Matched-Normal;Whole Genome Sequencing,Pediatrics,239.0,500.0,,BRAF;MYC;RB1;TP53,Whole Transcriptome Sequencing;Whole Genome Sequencing;Neoplasms/Genetics;Genetic Testing;Tumor Xenograft Assay;Neuroblastoma;Rare Disease;Neoplasms;Osteosarcoma,Rare Disease; Blastoma; CA; CA - Cancer; Cancer; MT
Integrative Somatic and Germline Computational Biology to Redefine    Clinical Actionability in Solid Tumors,"Neuroendocrine tumors (NETs) are rare cancers that arise in the gastrointestinal tract and pancreas. The fundamental mechanisms driving gastroenteropancreatic NETs (GEP-NETs) growth remain incompletely elucidated; however, the heterogeneous clinical behavior  of GEP-NETs suggests that both cellular lineage dynamics and tumor microenvironment influence tumor pathophysiology. Here, we performed single-cell",phs003141.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003141,"Eliezer Van Allen, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,R01CA227388;U01CA233100,2023-12-21,HMB,RNA-Seq,Case Set;Single Cell Analysis,Gastro-enteropancreatic neuroendocrine tumor,8.0,8.0,,,Pancreatic Neoplasms;Carcinoid Tumor;Neuroendocrine Tumors;Stomach Neoplasms;Intestinal Neoplasms,Carcinoid Tumor; Intestinal Neoplasms; Neuroendocrine Tumors; Carcinoid; Carcinoid tumor (disease); Carcinoid tumors
A Phase I Study With a Personalized Neoantigen Cancer Vaccine in    Glioblastoma Multiforme,"Neoantigens, which are derived from tumor-specific protein-coding gene mutations, are exempt from central tolerance, can generate robust immune responses and function as bona fide antigens that facilitate tumor rejection. A  strategy of using multi-epitope and personalized neoantigen vaccination has previously been tested in patients with high-risk melanoma. We",phs001519.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001519,David Reardon,Ian Fingerman,Division of Cancer Biology (DCB),30568305;34663921,,2023-12-20,HMB;GRU,RNA-Seq;WXS;OTHER,Case Set;Clinical Trial,Glioblastoma,11.0,33.0,,,,"Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme"
Translating Gene-Calcium Interactions to Precision Medicine for    Colorectal Cancer,"Identify functional and rare SNPs and their interactions with Ca intake levels in relation to risk of incident adenoma using whole-exome resequencing of 2468 colorectal adenoma cases and controls from  PLCO. We will genotype promising rare and functional SNPs associated with incident adenoma in 570 incident cancer cases, 1,710 healthy controls, 710",phs002164.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002164,"Qi Dai, PhD;Todd Edwards, PhD",Claire Zhu,Division of Cancer Prevention (DCP),,,2023-12-19,GRU,Seq_DNA_SNP_CNV,Case-Control;Exome Sequencing;Individual-Level Genomic Data,Colorectal Adenoma,2269.0,2269.0,,,,Not Provided
Genomics and Methylation of Neuroendocrine Prostate Cancer from cfDNA    (Cornell/Trento 2019),A subset of castration resistant prostate cancers develop small cell neuroendocrine prostate cancer (NEPC) as a mechanism of treatment resistance. Metastatic tissue biopsies to evaluate for NEPC transformation are invasive  and challenging to perform serially. We performed whole exome and whole genome bisulfite sequencing of plasma cfDNA and matched tumor biopsy samples,phs001752.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001752,Himisha Beltran;Francesca Demichelis,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),26855148;22389870;26537258,National Cancer Institute SPORE P50-CA211024;ERC Consolidator Grant 648670;Department of Defense PCRP W81XWH-13-1,2023-12-18,HMB-IRB,WXS;Bisulfite-Seq,Cohort,Adenocarcinoma,65.0,185.0,,,Prostatic Neoplasms;Neuroendocrine tumors,"Neuroendocrine Tumors; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant; Malignant Adenoma"
"Breast Cancer in Blacks: Impact of Genomics, Healthcare Use and Lifestyle    on Outcomes (BRIGHT)",Young Black females bear a disproportionate burden of breast cancer (BC) mortality compared to White females and are underrepresented in clinical studies. It remains critical to understand factors that contribute  to the high mortality from BC among young Black females in order to improve outcomes. The higher BC mortality rate among young Black females with,phs003466.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003466,"Tuya Pal, MD, FACMG",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2023-12-15,DS-BRCA-GSO,Array_mRNA_Expression;Array_SNP,Individual-Level Genomic Data;Longitudinal Cohort,Breast Neoplasms,378.0,481.0,,,Genetics,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Single-Cell Genomic Analysis of Gastrointestinal Cancer,"Our study aimed to define the heterogeneity of gastrointestinal cancers at a single-cell resolution. We subjected single-cell suspensions derived from surgical resections of gastrointestinal cancer tissue, paired normal tissue, peripheral  blood mononuclear cells (PBMCs) or their ex vivo cultures to high-throughput microfluidics based single-cell RNA and DNA sequencing. We analyzed the",phs001818.v4.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001818,Hanlee Ji,,,32060101;31829268;36239989,NCI U01CA217875,2023-12-11,HMB,OTHER;WGS,Case Set,Stomach Neoplasms,40.0,136.0,,,Metaplasia;Colorectal Neoplasms;Appendiceal cancer,Appendiceal Cancer; Metaplasia; Appendiceal Neoplasm; Appendiceal Neoplasms; Appendiceal tumor; Appendix Tumor
Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome (RS),"Richter's syndrome arising from chronic lymphocytic leukemia is a striking example of an aggressive malignant histology that emerges from indolent cancer. To understand this process, we reconstructed phylogenies based on  whole exome sequencing of matched normal, CLL and RS samples. We computationally deconvoluted CLL and RS clones and identified drivers of",phs002458.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002458,Catherine Wu,Ian Fingerman,Division of Cancer Biology (DCB),,;P01- NCI,2023-12-05,DS-HM-MDS;HMB;GRU,RNA-Seq;WXS;WGS,Longitudinal,"Leukemia, Lymphocytic, Chronic, B-Cell",133.0,384.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE163579,,"Cell Transformation, Neoplastic","Cell Transformation, Neoplastic; Cell Neoplastic Transformation; Cell Neoplastic Transformations; Cell Transformations, Neoplastic; Neoplastic Cell Transformations; Neoplastic Transformation, Cell"
CALGB/SWOG 80405: Genome-Wide Association Study of Patients with Advanced    or Metastatic Colorectal Cancer Treated with First-Line Chemotherapy    Combined with Cetuximab and/or Bevacizumab,"CALGB/SWOG 80405 (NCT00265850) was a randomized phase III study of bevacizumab, cetuximab, or the combination of these two monoclonal antibodies, in addition to systemic chemotherapy for patients with untreated metastatic  adenocarcinoma of the colon or rectum. We prospectively collected germline DNA and conducted genome-wide association studies using clinical outcomes",phs003428.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003428,Kouros Owzar,Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),28632865;29871907;32958699;34965954;34528705,,2023-12-04,DS-CA-COL,Seq_DNA_SNP,eQTL;GWAS;Multicenter;Phase III;Randomized Controlled Clinical Trial,Colorectal Neoplasms,1464.0,1464.0,,,Adenocarcinoma;Neoplasm Metastasis;Survival Analysis,"Adenocarcinoma; Neoplasm Metastasis; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant"
Cryptic Splice Mutation in the Fumarate Hydratase Gene in Patients With    Clinical Manifestations of Hereditary Leiomyomatosis and Renal Cell    Cancer (HLRCC),"Four patients with hysterectomy were evaluated for biochemical and molecular evidence of autosomal dominant Fumarate Hydratase (FH) alterations causing Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). HLRCC is an autosomal  dominant condition characterized by the development of cutaneous and uterine leiomyomas, and risk for development of an aggressive form of papillary",phs003381.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003381,"W. Marston Linehan, MD",Abid Al Reza,Center for Cancer Research (CCR),,,2023-12-04,GRU,Seq_DNA_SNP_CNV;WGS,Case Set,Hereditary leiomyomatosis and renal cell cancer,4.0,4.0,https://www.ncbi.nlm.nih.gov/clinvar/RCV001553262/,FH,Fumarate Hydratase,Cutaneous leiomyomata with uterine leiomyomata; FH Deficiency; Familial leiomyomatosis; Familial leiomyomatosis and renal cell cancer; Familial leiomyomatosis cutis et uteri; Familial leiomyomatosis with renal carcinoma
Single Duplex DNA Sequencing with CODEC Detects Mutations with High    Sensitivity,"Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (single duplexes) to  discern the true mutations on both strands. Here, we present Concatenating Original Duplex for Error Correction (CODEC) which confers single duplex",phs003255.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003255,Viktor Adalsteinsson,Nathaniel Boyd,Office of Data Sharing (ODS),37106072,,2023-12-04,HMB-IRB;NRUP;HMB;GRU,Targeted-Capture;WGS,Case-Control;Clinical Cohort;Sequencing,Neoplasms,8.0,30.0,,,Breast Neoplasms;Colonic Neoplasms,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
KRT17High/CXCL8+ Tumor Cells Display Both Classical and Basal Features    and Regulate Myeloid Infiltration in the Pancreatic Cancer    Microenvironment,Recent studies have uncovered the co-existence of basal and classical subtypes within pancreatic ductal adenocarcinoma (PDAC). We sought to characterize these intermediary cells using single-cell RNA sequencing of PDAC. We  performed subtyping on 18 single-cell RNA sequencing human PDAC samples to identify multiple intermediary subtypes. We compared single-cell profiling,phs003436.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003436,"Marina Pasca di Magliano, PhD",Justin Benavidez,Division of Cancer Biology (DCB),37851080,R01-CA268426;R01-CA260752;R01-CA271510;U01- CA264843;U01-CA274154;U54CA274371,2023-11-30,DS-PACA,RNA-Seq,Observational,"Carcinoma, Pancreatic Ductal",6.0,6.0,,KRT17;CXCL8;CLDN18,Single-Cell Analysis;Myeloid Cells,"Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas; Duct Cell Carcinoma, Pancreas"
Temporal Evolution Reveals Bifurcated Lineages in Aggressive    Neuroendocrine Small Cell Prostate Cancer Trans-Differentiation,"Trans-differentiation from adenocarcinoma to small cell neuroendocrine (SCN) cancer is an adverse consequence of treatment escape in various cancers, including prostate, lung, and bladder cancers (Balanis and Sheu et al.,  2019 Cancer Cell). Expression of dominant negative p53 (TP53DN), myrAkt1, RB1-shRNA, c-Myc, and Bcl2(PARCB forward transformation) using human",phs003230.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003230,Thomas Graeber;Owen Witte,Ian Fingerman,Division of Cancer Biology (DCB),30287662;31287989;31871155,,2023-11-27,GRU,ATAC-seq;Seq_RNA_Expression_SC;OTHER;RNA-Seq;ChIP-Seq;Seq_RNA_Expression,Longitudinal;RNA Sequencing;Sequencing;Single Cell Analysis;Transcriptome Analysis;Transcriptome Sequencing;Xenograft,"Carcinoma, Neuroendocrine",11.0,66.0,,,"Carcinoma, Small Cell;Prostatic Neoplasms;ASCL1 protein, human;ASCL2 protein, human;TFAP4 protein, human;POU2F3 protein, human","Carcinoma, Small Cell; Carcinoma, Oat Cell; Carcinomas, Oat Cell; Carcinomas, Small Cell; Oat Cell Carcinoma; Oat Cell Carcinomas"
Altered Interactions between Circulating and Tissue-Resident CD8 T Cells    with the Colonic Mucosa Define Checkpoint Inhibitor Colitis,"Therapeutic immune checkpoint blockade has revolutionized oncology, but treatments are limited by immune-related adverse events, including checkpoint inhibitor colitis (irColitis). To define molecular drivers of irColitis, we profiled 300,000 cells  from the colonic mucosa and blood of 29 patients and controls. Patients with irColitis showed expanded mucosal Tregs (regulatory T cells), CD8",phs003418.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003418,Alexandra-Chloe Villani,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2023-11-21,GRU,RNA-Seq,Case-Control;RNA Sequencing;Single Cell Analysis;Transcriptome Analysis,Colitis,33.0,171.0,,,,
Genomic Characterization of Duke Melanoma Brain Metastases,"Previous work has shown that melanoma brain metastases (MBM) have a unique molecular profile compared to extracranial metastases (ECM). Description of the biology of MBM and associations between biological features  and clinical outcomes will facilitate the design of rational therapies for patients with MBM. To better characterize the molecular profile of MBM, we",phs003009.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003009,,Freddie Pruitt,Center for Cancer Genomics (CCG),30787016,"Duke Cancer Institute Cancer Center Support Grant (P30-CA014236-47);Translating Duke Health Initiative, Duke University School of Medicine",2023-11-21,GRU-NPU,RNA-Seq;WXS,Case Set;Exome Sequencing;Metastasis;RNA Sequencing;Tumor;Tumor vs. Matched-Normal,Brain Neoplasms,14.0,43.0,,,"Melanoma;Exome Sequencing;Sequencing Analysis, RNA;Tumor Microenvironment",Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour; Neoplasm of Brain; Neoplasm of the Brain
Genetic Analysis of Latin American Cervical Cancer,HPV16 is the most oncogenic type of human papillomaviruses (HPV). Integration of HPV into the human genome is an important mechanism of carcinogenesis but is absent in at least 30%  of HPV16+ tumors. We applied long-read whole-genome sequencing (WGS) to cervical cancer cell lines and tumors to characterize HPV16 carcinogenesis in,phs002810.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002810,Michael Dean,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),36971511,,2023-11-21,HMB-NPU,WGS,Case Set,Uterine Cervical Neoplasms,58.0,58.0,,,,"Cervical Neoplasm, Uterine; Cervical Neoplasms; Cervical Tumor; Cervical neoplasm; Cervix Neoplasm; Cervix Neoplasms"
Retinoblastoma Aqueous Humor Liquid Biopsy Repository,"This study involves the use of the aqueous humor (AH, the clear fluid in the front of the eye) as an organ specific liquid biopsy for retinoblastoma. This relatively new  liquid biopsy platform was started at CHLA/USC and was developed to overcome the lack of tumor tissue -- due to contraindication to biopsy -- for",phs003077.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003077,"Jesse L. Berry, MD",Mariam Eljanne,Center for Cancer Training (CCT),29049475;30061186;31019846;31767439;32434859;32799607;33062393;33805776;34283049;34316014;34570090;36130950,,2023-11-20,DS-RET-DIS-IRB-PUB-COL-NPU,WGS,Clinical Cohort,Retinoblastoma,81.0,264.0,https://clinicaltrials.gov/ct2/show/NCT04959097?term=aqueous&cond=Retinoblastoma&draw=2&rank=1,RB1,Aqueous Humor;Retinal Neoplasms,"Retinal Neoplasms; Cancer of the Retina; Cancer, Retinal; Cancers, Retinal; Malignant Neoplasm of Retina; Malignant Neoplasm of the Retina"
The Genomic Landscape of Interval Colorectal Cancers,"Interval colorectal cancers (CRC), cancers diagnosed after a screening/surveillance exam in which no cancer is detected, and before the date of the next recommended exam, reflect an unprecedented challenge in  CRC detection and prevention. To better understand this poorly characterized CRC variant, we examined the clinical and mutational characteristics of",phs003093.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003093,Andrew Chan,Claire Zhu,Division of Cancer Prevention (DCP),35970241;22612596,,2023-11-17,HMB,WXS,Exome Sequencing,Colorectal Neoplasms,168.0,323.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Molecular Determinants of Esophageal Cancer in Tanzania,"We describe the genomic profiles of 61 esophageal squamous cell carcinoma (ESCC) cases from Tanzania and compare them to profiles from an existing cohort of ESCC cases from Malawi. We  also provide a comparison to ESCC tumors in The Cancer Genome Atlas Program (TCGA). Despite a high burden of ESCC in Eastern Africa, investigations",phs003217.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003217,Katherine Van Loon;Elia J. Mmbaga,Freddie Pruitt,Center for Cancer Genomics (CCG),37505926;35837755,A119617,2023-11-16,DS-E-C-NPU,RNA-Seq;WGS,Cohort,Esophageal Neoplasms,61.0,178.0,,TP53,Esophageal Squamous Cell Carcinoma,"Esophageal Neoplasms, Benign and Malignant; Esophageal Tumor; Esophageal Tumors; Esophageal neoplasm; Esophageal tumour; Esophagus Neoplasm"
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and    Clinicopathologic Study of the Predisposition to Gastric Cancer,Gastric cancers are cancers of the stomach. Hereditary cancers are passed from parent to child. Researchers want to gather data about hereditary gastric cancers. Bulk RNA sequencing (RNA-seq) of signet  ring cells (SRCs) and adjacent non-SRC epithelium (NEP) was performed on laser-capture microdissected (LCM) regions of interest found in,phs003422.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003422,"Jeremy Davis, MD",Abid Al Reza,Center for Cancer Research (CCR),37707375,,2023-11-13,GRU,RNA-Seq;Seq_RNA_Expression,Case Set;Tumor vs. Matched-Normal,Stomach Neoplasms,20.0,42.0,,CDH1;CTNNA1;SDHA;SDHB;SDHC;SDHD,,"CA - Cancer of stomach; Ca lesser curvature - stomach; Cancer of Stomach; Cancer of the Stomach; Cancer, Gastric; Cancer, Stomach"
Pathogenesis and Immunity in Endemic Burkitt Lymphoma,"This genomic landscape of Burkitt lymphoma represents a multimodal sequencing of tumors and control tissues and individuals to better understand the etiology, and molecular pathogenesis of Burkitt lymphoma including the  roles of the associated Plasmodium falciparum malaria and EBV infections. Comprehensive sequencing set includes genomic, transcriptomic, and",phs001282.v4.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001282,Ann M. Moormann;Jeffrey A. Bailey;Micah A. Luftig,Ian Fingerman,Division of Cancer Biology (DCB),28465297;27136063;29132323;28400759;31889055;32373555;36878637,NCI R01 CA134051;NCI R01 CA189806;The Thrasher Research Fund 02833-7;UMCCTS Pilot Project Program U1 LTR000161-04;R01 CA234348,2023-11-13,DS-BL-PUB-NPU,RNA-Seq;ssRNA-seq;miRNA-Seq,Case Set,Burkitt Lymphoma,44.0,44.0,http://www.umassmed.edu/;http://www.kemri.org/;http://www.jaramogireferral.go.ke/;https://www.brown.edu/;https://www.duke.edu/,,"Lymphoma, Non-Hodgkin","Lymphoma, Non-Hodgkin; BL; BL - Burkitt's lymphoma; Burkitt Tumor; Burkitt lymphoma/leukemia; Burkitt's Lymphoma"
My Pediatric and Adult Rare Tumor (MyPART) Natural History Study of Rare    Solid Tumors,"The goal of this study is to comprehensively and longitudinally evaluate the natural history of patients with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum  (e.g. disease course and survival). Clinical data, patient reported outcomes (PROs), and biospecimen associated data are collected. Clinical data",phs003143.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003143,"Mary Frances Wedekind, DO;Brigitte C. Widemann, MD;Karlyne M. Reilly, PhD",Kathleen Calzone,Center for Cancer Research (CCR),37345354,"Cancer Moonshot, ZIA BC 0118542",2023-11-03,NRUP;GRU,Seq_DNA_SNP_CNV,Clinical Cohort;Clinical Diagnostic Testing;Clinical Genetic Testing;Copy Number Variation (CNV);Epigenetics;Exome Sequencing;Extended Pedigrees;Full Transcriptome Sequencing;Genotype;Genotype/Expression;Individual-Level Genomic Data;Longitudinal;Longitudinal Cohort;Marker Discovery;Methods Development;Observational;Prospective;Repository;RNA Sequencing;Sequencing;Tissue Expression;Transcriptome Analysis;Transcriptome Sequencing;Tumor;Tumor vs. Matched-Normal;Whole Genome Sequencing;Xenograft,Rare Diseases,522.0,192.0,https://www.cancer.gov/pediatric-adult-rare-tumor/participate/natural-history,APC;ATM;ATRX;CDKN2B;CDKN2A;CFTR;CTNNB1;HRAS;MEN1;MHL1;MSH2;MSH6;MUTYH;NF1;RET;SDHA;SDHB;SDHC;SMARCB1;TP53,"Adrenocortical Carcinoma;Carcinoma, Neuroendocrine;Chordoma;Gastrointestinal Stromal Tumors;Natural History;Neoplasms;Pediatrics","Carcinoma, Neuroendocrine; Chordoma; ACC; Adenoid Cystic Carcinoma; Adrenal Cortex Adenocarcinoma; Adrenal Cortex Cancer"
Phenotypic Signatures of Circulating Neoantigen-Reactive CD8+ T Cells in    Patients with Metastatic Cancers,"Following enrichment of neoantigen-reactive T cells using pHLA tetramers or cell-surface markers, we performed single-cell sequencing (RNA-seq and TCR-seq) of circulating CD8+ T cells from metastatic cancer patient samples (Melanoma,  Colorectal, and Breast cancer). In samples from previously studied patients, we identified cells bearing neoantigen-reactive T cell receptors and",phs003064.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003064,Steven A Rosenberg,Kathleen Calzone,Center for Cancer Research (CCR),,,2023-11-01,GRU,RNA-Seq,Case Set,Breast Neoplasms,9.0,29.0,,,Colorectal Neoplasms;Melanoma,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing    Chemoradiation Therapy for Bladder Cancer,"Bladder preservation with trimodality therapy (TMT), consisting of transurethral tumor resection followed by chemoradiation, is an alternative to radical cystectomy for muscle-invasive bladder cancer (MIBC), but molecular determinants of response  are poorly understood. Patients with cT2-T4aN0M0 MIBC treated with definitive-intent chemoradiation as part of TMT were retrospectively identified",phs003402.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003402,"David Miyamoto, MD, PhD;Jason Efstathiou, MD, DPhil;Kent Mouw, MD, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,C06CA059267;U01CA220714;R0125737;R01CA259007,2023-10-24,DS-BLADDERCA,WXS,Case Set;Sequencing;Tumor,Urinary Bladder Neoplasms,76.0,76.0,,ERCC2,,"Urinary Bladder Neoplasm; Bladder Cancer; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder"
Deterministic Evolution and Stringent Selection During Pre-Neoplasia,"The earliest events during human tumor initiation are poorly characterized but may hold clues as to how to detect and prevent malignancy. Here we model this occult process by engineering  TP53 deficiency in primary human gastric organoids and performing experimental evolution in multiple clonally derived cultures over two years,",phs003249.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003249,Christina Curtis,Ian Fingerman,Division of Cancer Biology (DCB),37258665,,2023-10-24,HMB,RNA-Seq;Seq_DNA_CNV;WGS;AMPLICON,Copy Number Variation (CNV);Longitudinal;RNA Sequencing;Whole Genome Sequencing,Stomach Neoplasms,3.0,193.0,,,Genomics;Gene Expression Profiling;DNA Barcoding;Organoids,"CA - Cancer of stomach; Ca lesser curvature - stomach; Cancer of Stomach; Cancer of the Stomach; Cancer, Gastric; Cancer, Stomach"
Esophageal Squamous Cell Carcinoma Precursor Study,"Esophageal cancer is the sixth most common cause of cancer death in the world. High-risk areas occur across central Asia and from eastern to southern Africa, and in these populations,  nearly all of the cases are esophageal squamous cell carcinoma (ESCC). ESCC has a dismal prognosis, largely because symptoms usually appear late in",phs002814.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002814,Philip R. Taylor,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,ZIA CP000185,2023-10-19,HMB,WGS,Case Set,Esophageal Squamous Cell Carcinoma,33.0,66.0,,,Neoplasms,"ESCC; Esophageal Epidermoid Carcinoma; Esophageal SCC; Esophageal Squamous Cell Carcinoma, NOS; Esophageal Squamous Cell Carcinoma, Not Otherwise Specified; Esophagus SCC"
"A Phase I Study of the Treatment of Recurrent Malignant Glioma with    CAN-3110 (AKA rQNestin34.5v.2), a Genetically Engineered HSV-1 Virus","This study is a ""first-in-human"" phase 1 trial of recurrent, IDH wild-type glioblastoma (rGBM) patients treated with CAN-3110 (aka rQNestin34.5v.2), a genetically modified oncolytic herpes simplex virus 1 (HSV-1). The  study was a 3+3 dose-escalation study starting at a single intra-tumoral injection of 106 PFU CAN-3110 going up to 1010 PFU in half-log increments",phs003378.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003378,E. Antonio Chiocca,Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),37853118,,2023-10-17,HMB,RNA-Seq;Seq_ImmunoTarget_SC;Seq_RNA_Expression,Clinical Cohort;Clinical Trial;Longitudinal;Longitudinal Cohort;RNA Sequencing;Transcriptome Sequencing;Tumor,Glioblastoma,20.0,112.0,,,"Astrocytoma, Grade IV;Grade IV Astrocytoma;Glioblastoma Multiforme","Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme"
Meta-Analysis of Genome-Wide Association Studies of Bladder Cancer Risk,"This meta-analysis consists of genome-wide genotype for 13,447 cases and 342,580 controls of European ancestry to identify novel susceptibility loci for bladder cancer. Cases were defined as histologically confirmed primary  carcinoma of the urinary bladder of all stages, including carcinoma in situ (International Classification of Diseases for Oncology, C670-C679, 188).",phs003342.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003342,"Nathaniel Rothman, MD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),37210288,,2023-10-16,,,Case-Control;GWAS;Meta-Analysis,Urinary Bladder Neoplasms,,,,,,"Bladder Cancer; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder; Cancer, Urinary Bladder"
Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer    Heterogeneity and is Associated with Worse Outcomes,"Small-cell lung cancer (SCLC) is a very aggressive neuroendocrine lung cancer often associated with oncogenic MYC amplifications, which are known to drive SCLC heterogeneity marked by neuroendocrine (NE) and non-neuroendocrine  (non-NE) cell states. The genetic mechanisms of MYC amplification and phenotypic plasticity between cell states is not known. Using data from",phs003190.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003190,Anish Thomas,Kathleen Calzone,Center for Cancer Research (CCR),,,2023-10-16,GRU,RNA-Seq;SRA_supplement;OTHER;WGS,Observational,Small Cell Lung Carcinoma,5.0,23.0,,MYC;MYCL;MYCN,,"Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL"
Melbourne Collaborative Cohort Study DNA Methylation Studies,"This dataset contains raw Illumina 450K blood DNA methylation data from a subset of participants in the Melbourne Cohort Study (MCCS), a prospective study of 41,513 healthy adult volunteers (24,469  women) aged between 27 and 76 years when recruited between 1990 and 1994. Nested case-control studies: DNA methylation data were generated as part of",phs003213.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003213,"Roger L. Milne, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),28641380;36919377;33169152;27457678;31789449,,2023-10-04,HMB,Array_SNP_CNV,Longitudinal;Nested Case-Control,Neoplasms,5951.0,7898.0,https://www.cancervic.org.au/research/epidemiology/health_2020;https://academic.oup.com/ije/article/46/6/1757/3882696,,DNA Methylation;Life Style,DNA Methylation; Life Style; Life Styles; Life pattern; Lifestyle; Blastoma
PEDS-PLAN - Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,"A multi-center clinical trial for newly diagnosed high-risk neuroblastoma patients. Molecular tumor boards selected one of six targeted agents based on tumor-normal whole exome sequencing and tumor RNA sequencing data.  Related Clinical Trails: NCT02559778 Principal Investigator: Giselle Saulnier Sholler, MD, MSc, Pediatric Oncology, Levine Children's Hospital,",phs002303.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002303,"Giselle Saulnier Sholler, MD, MSc",Ian Fingerman,Division of Cancer Biology (DCB),35355452,,2023-10-04,HMB,RNA-Seq;WXS,Case Set,Neuroblastoma,45.0,147.0,,,,Not Provided
BarcUVa-Seq (Biology of Colorectal Cancer Risk Enhancers),"This study was designed to generate a cohort of normal colon mucosal biopsies from the ""average risk"" population. Its primary aims included the development of an RNA-seq dataset of normal  colon mucosal biopsies across three colon regions (ascending, transverse and descending). Further, we aimed to provide plausible prioritization to",phs003338.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003338,Graham Casey;Victor Moreno,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),33601062;37365285;34548904;34389629;36576985;34286847;32764205,,2023-10-03,DS-GID-IRB,RNA-Seq;Imputation_SNP_CNV,Cohort;Genotype/Expression;RNA Sequencing,Colonic Neoplasms,463.0,463.0,https://barcuvaseq.org/,,,"CA - Cancer of colon; COLON CANCER; Cancer of Colon; Cancer of the Colon; Cancer, Colon; Cancer, Colonic"
Targeted Linked-Read DNA-seq Analysis of Castration-Resistant Prostate    Cancers,"Androgen receptor (AR) inhibition is standard of care for advanced prostate cancer (PC). However, its efficacy is limited by progression to castration-resistant PC (CRPC), usually due to AR re-activation via  mechanisms that include AR amplification and structural rearrangement. These two classes of AR alterations often co-occur in CRPC tumors, but it is",phs003343.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003343,"Scott M. Dehm, PhD",Ian Fingerman,Division of Cancer Biology (DCB),37636316,R01CA174777,2023-09-27,DS-PC,OTHER,Case Set,Prostatic Neoplasms,35.0,35.0,,AR,"Receptors, Androgen","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
A Microwell Platform for High-Throughput Longitudinal Phenotyping and    Selective Retrieval of Organoids,"In traditional bulk culture, organoids tend to overlap, hindering the analysis of individual organoid characteristics in a high-throughput manner. Additionally, variations in the local spatial properties of the bulk matrix  make it challenging to distinguish whether phenotypic differences between organoids stem from inherent cellular disparities or disparities in the",phs003315.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003315,Christina Curtis;Polly M. Fordyce,Ian Fingerman,Division of Cancer Biology (DCB),,,2023-09-26,HMB,Seq_DNA_SNP_CNV;ATAC-seq;WGS;RNA-Seq;Seq_DNA_CNV_Segments,Copy Number Variation (CNV);RNA Sequencing;Whole Genome Sequencing,Organoids,1.0,45.0,,,Stomach Neoplasms;Genomics;Gene Expression Profiling,"CA - Cancer of stomach; Ca lesser curvature - stomach; Cancer of Stomach; Cancer of the Stomach; Cancer, Gastric; Cancer, Stomach"
Refractory Cancer (RC) Program,The Refractory Cancer (RC) Program will investigate the underlying genomic hallmarks involved in the observed inferior response to treatment of certain tumor types. Comprehensive genomic characterization will be performed utilizing  the NCI CCG Genome Characterization Pipeline. Subsequent genomic data will be hosted at the NCI Genomic Data Commons (GDC),phs002097.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002097,"Jean Claude Zenklusen, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-09-26,GRU,,Case Set,Neoplasms,278.0,278.0,,,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Refractory Cancer (RC) Burkitt's Lymphoma (BL),The Refractory Cancer (RC) Burkitt's Lymphoma (BL) study will investigate the underlying genomic hallmarks involved in the observed inferior response to treatment of certain Burkitt Lymphoma patients. The study will  utilize a network of sites in the US to obtain the samples and clinical data. Comprehensive genomic characterization will be performed utilizing the,phs002851.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002851,"Jean Claude Zenklusen, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-09-26,GRU-IRB;GRU,,Case Set,Burkitt Lymphoma,20.0,20.0,,,,BL; BL - Burkitt's lymphoma; Burkitt Tumor; Burkitt lymphoma/leukemia; Burkitt's Lymphoma; Burkitt's Tumor
Refractory Cancer - Peripheral T-Cell Lymphoma (RC-PTCL),The Peripheral T-Cell Lymphoma (PTCL) study will investigate the underlying genomic hallmarks involved in the observed inferior response to treatment of certain PTCL patients. The study will utilize a network  of sites in the US and Asia to accrue up to 500 cases per tumor type. Comprehensive genomic characterization will be performed utilizing the NCI CCG,phs002247.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002247,"Jean Claude Zenklusen, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-09-26,GRU,,Case Set,"Lymphoma, T-Cell, Peripheral",174.0,168.0,,,,
Refractory Cancers (RC) HOPE-CARE,"For the HOPE-CARE project, NCI will utilize whole genome sequencing and/or whole exome sequencing in conjunction with transcriptome sequencing to try to identify recurrent genetic alterations (mutations, deletions, amplifications, rearrangements)  and/or gene expression signatures that would be important to the hypothesis(es) submitted by the investigators. The samples will be processed and",phs002098.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002098,"Jean Claude Zenklusen, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-09-26,GRU,,Case Set,Glioma,116.0,90.0,,,,Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia
Genomic Characterization CS-MATCH-0007 Arm I,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs002181.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002181,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;35138919;37322121,Division of Cancer Treatment and Diagnosis,2023-09-25,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,60.0,60.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,PIK3CA,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Genomic Characterization CS-MATCH-0007 Arm U,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs002179.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002179,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;37322121,Division of Cancer Treatment and Diagnosis,2023-09-25,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,23.0,23.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,NF2,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Genomic Characterization CS-MATCH-0007 Arm Z1A,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs001973.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001973,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;33637626;37322121,Division of Cancer Treatment and Diagnosis,2023-09-25,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,45.0,45.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,NRAS,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Genomic Characterization CS-MATCH-0007 Arm W,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs001948.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001948,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;32463741;37322121,Division of Cancer Treatment and Diagnosis,2023-09-25,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,45.0,45.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,FGFR1;FGFR3;FGFR2,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Genomic Characterization CS-MATCH-0007 Arm H,The CS-MATCH-0007 protocol is a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using  pre-and post-treatment tumor biopsy specimens from all patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131). The goal of,phs001888.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001888,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;32758030;37322121,Division of Cancer Treatment and Diagnosis,2023-09-25,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,21.0,21.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,BRAF,Melanoma,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma; Melanoma, Malignant"
Novel Approach to High-Throughput Identification and Characterization of    Neoantigens,"This study focuses on the development of novel approach for the screening, identification and characterization of neoantigen-specific T-cell receptors (TCRs). The developed method consists of collecting targeted RNA-Seq from a  T-cell specific gene panel via 3' end Illumina sequencing combined to Oxford Nanopore based full-length TCR sequencing post T-cell activation. The",phs002372.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002372,Magali Soumillon,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-09-21,NRUP;GRU,AMPLICON,Methods Development,"Receptors, Antigen, T-Cell, alpha-beta",4.0,4.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE214174,TRA;TRB;IL2;IFNG;TNF;TGFB1;PRF1;GZMB;GATA3;TBX21;FOXP3;RORC;RUNX1;RUNX3;BCL6;IL10;IL12A;IL13;IL17A,"Genes, T Cell Receptor;RNA-Seq",Not Provided
Uveal Melanoma Immunogenomics Predict Immunotherapy Resistance and    Susceptibility,"Immunotherapy using immune checkpoint inhibition (ICI) has shown success in treating metastatic cutaneous melanoma but has limited efficacy against metastatic uveal melanoma (UM), a rare variant arising from the immune  privileged eye. To better understand this immune resistance, we performed comprehensive immunogenomic profiling of 100 human UM metastases using",phs003330.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003330,Udai S. Kammula,Nathaniel Boyd,Office of Data Sharing (ODS),,,2023-09-20,GRU,RNA-Seq,RNA Sequencing,Uveal melanoma,84.0,100.0,,,"Immunotherapy, Adoptive;Lymphocytes, Tumor-Infiltrating;Immunotherapy;Biomarkers;Sequence Analysis, RNA;Receptor-CD3 Complex, Antigen, T-Cell",Not Provided
National Cancer Institute (NCI) TARGET: Therapeutically Applicable    Research to Generate Effective Treatments,"The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative seeks to accelerate research in novel marker and drug development, along with understanding the molecular basis of pediatric malignancy, through  identification of genomic changes associated with the following childhood cancers: Acute Lymphoblastic Leukemia (ALL) - A fast-growing type of blood",phs000218.v26.p8,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000218,"Stephen P. Hunger, MD;Soheil Meshinchi, MD, PhD;Robert Arceci, MD, PhD;John M. Maris, MD;Robert Seeger, MD;Javed Khan, MD;Ching Lau, MD, PhD;Paul Meltzer, MD, PhD;Elizabeth J. Perlman, MD;Peter Houghton, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),19129520;19470474;20139093;19880498;20699438;21680795;22897847;23212523;23334666,,2023-09-20,DS-PEDCR,Bisulfite-Seq;WGS;RNA-Seq;ChIP-Seq;miRNA-Seq;WXS;Targeted-Capture,Cohort,Neoplasms,6363.0,13179.0,https://www.cancer.gov/ccg/research/genome-sequencing/target,,"Acute Lymphoblastic Leukemia;Leukemia, Myeloid, Acute;Neuroblastoma;Osteosarcoma;Wilms Tumor;Clear Cell Sarcomas;Rhabdoid Tumor;Xenografts","Acute Lymphoblastic Leukemia; Clear Cell Sarcomas; Rhabdoid Tumor; ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia"
"TARGET: Kidney, Wilms Tumor (WT)","There are 130 fully characterized patient cases with high risk Wilms tumor (all tumor/normal pairs; 8 with additional samples for analysis 3 with tumor adjacent normal, 5 with relapse sample)  that will make up the TARGET WT dataset. Each case will have gene expression, tumor and paired normal copy number analyses, methylation and whole",phs000471.v23.p8,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000471,"Elizabeth J. Perlman, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-09-20,DS-PEDCR,WGS;RNA-Seq;miRNA-Seq;WXS;Targeted-Capture,Cohort,Wilms Tumor,653.0,1018.0,https://www.cancer.gov/ccg/research/genome-sequencing/target/studied-cancers/kidney-tumors,,,Embryonal adenosarcoma; Embryonal nephroma; Kidney Nephroblastoma; NEPHROBLASTOMA; Nephroblastoma (Wilms tumor); Nephroblastomas
"TARGET: Kidney, Rhabdoid Tumor (RT)","To further explore some more aggressive subtypes in pediatric cancer already under study in OCG, CGCI is partnering with TARGET initiative to support extensive sequencing analysis of three hard to  treat childhood cancers: refractory to treatment cases of acute myeloid leukemia and two rare kidney tumors; clear cell sarcoma of the kidney and",phs000470.v23.p8,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000470,"Elizabeth J. Perlman, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-09-20,DS-PEDCR,Bisulfite-Seq;WGS;RNA-Seq;ChIP-Seq;miRNA-Seq,Cohort,Rhabdoid Tumor,70.0,236.0,https://www.cancer.gov/ccg/research/genome-sequencing/target/studied-cancers/kidney-tumors,,,
TARGET: Cancer Model Systems (MDLS): Cell Lines and Xenografts (including    PPTP),"As part of the TARGET initiative, some disease projects characterized tumor cell lines or xenografts, with or without matched normal comparators, as well as some normal non-involved tissues. MDLS includes  acute leukemia cell lines and xenografts with matched primary and/or relapsed tumor information, neuroblastoma cell line and xenografts with matched",phs000469.v23.p8,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000469,"Peter Houghton, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-09-20,DS-PEDCR,Bisulfite-Seq;WGS;RNA-Seq;ChIP-Seq;miRNA-Seq;WXS;Targeted-Capture,Cohort,Xenograft Model Antitumor Assays,132.0,183.0,https://www.cancer.gov/ccg/research/genome-sequencing/target/studied-cancers/model-systems,,,Not Provided
TARGET: Osteosarcoma (OS),"There are 93 fully characterized patient cases that make up the TARGET OS dataset, each with gene expression, tumor and paired normal copy number analyses, methylation, miRNA profiles, along with  comprehensive next-generation sequencing to include mRNA-seq and exome sequencing (whole genome sequencing where available). There are additional",phs000468.v23.p8,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000468,"Ching Lau, MD, PhD;Paul Meltzer, MD, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-09-20,DS-PEDCR,RNA-Seq;WXS;WGS,Cohort,Osteosarcoma,310.0,744.0,https://www.cancer.gov/ccg/research/genome-sequencing/target/studied-cancers/osteosarcoma,,,Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma
TARGET: Neuroblastoma (NBL),"There are 214 fully characterized patient cases with neuroblastoma (all tumor/normal pairs, 10 with relapse sample as well) that will make up the TARGET NBL dataset, along with some cell  lines and xenografts. The dataset includes 24 4S cases as well. Each fully characterized case has gene expression, tumor and paired normal copy",phs000467.v23.p8,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000467,"John M. Maris, MD;Robert Seeger, MD;Javed Khan, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),23334666,,2023-09-20,DS-PEDCR,WGS;RNA-Seq;miRNA-Seq;WXS;Targeted-Capture,Cohort,Neuroblastoma,1204.0,1977.0,https://www.cancer.gov/ccg/research/genome-sequencing/target/studied-cancers/neuroblastoma,,,Not Provided
"TARGET: Kidney, Clear Cell Sarcoma of the Kidney (CCSK)","To further explore some more aggressive subtypes in pediatric cancer already under study in OCG, CGCI is partnering with TARGET initiative to support extensive sequencing analysis of three hard to  treat childhood cancers: refractory to treatment cases of acute myeloid leukemia and two rare kidney tumors; clear cell sarcoma of the kidney (CCSK)",phs000466.v23.p8,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000466,"Elizabeth J. Perlman, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-09-20,DS-PEDCR,RNA-Seq;WGS,Cohort,"Sarcoma, Clear Cell",14.0,45.0,https://www.cancer.gov/ccg/research/genome-sequencing/target/studied-cancers/kidney-tumors,,,Clear Cell Sarcomas; Clear Cell Sarcoma; Clear Cell Sarcoma of Soft Parts; Clear Cell Sarcoma of Tendons and Aponeuroses; Malignant Melanoma of Soft Parts; Malignant melanoma of soft tissue
TARGET: Acute Myeloid Leukemia (AML),"There are 200+ fully characterized patient cases with AML (all tumor/normal pairs, 100 with relapse sample as well) that make up the TARGET AML dataset, each with gene expression, tumor  and paired normal copy number analyses, methylation and comprehensive next-generation sequencing to include whole genome sequencing, mRNA-seq and",phs000465.v23.p8,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000465,"Soheil Meshinchi, MD, PhD;Robert Arceci, MD, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-09-20,DS-PEDCR,WGS;RNA-Seq;miRNA-Seq;WXS;Targeted-Capture,Cohort,"Leukemia, Myeloid, Acute",2505.0,5460.0,https://www.cancer.gov/ccg/research/genome-sequencing/target/studied-cancers/acute-myeloid-leukemia,,,AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL
TARGET: Acute Lymphoblastic Leukemia (ALL) Expansion Phase 2,"There are 175 fully characterized patient cases with relapsed precursor B-cell ALL (all tumor/normal pairs, 85 with relapse sample as well) that will make up Phase II of the TARGET  ALL dataset, each with gene expression, tumor and paired normal copy number analyses, and comprehensive next-generation sequencing to include whole",phs000464.v23.p8,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000464,"Stephen P. Hunger, MD;Mignon Loh, MD;Charles G. Mullighan, MD, MSc;Cheryl Willman, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),25207766,,2023-09-20,DS-PEDCR,RNA-Seq;WXS;miRNA-Seq;WGS,Cohort,Precursor Cell Lymphoblastic Leukemia-Lymphoma,1199.0,3461.0,https://www.cancer.gov/ccg/research/genome-sequencing/target/studied-cancers/acute-lymphoblasic-leukimia,,,"Acute Lymphoblastic Leukemia; ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic"
TARGET: Acute Lymphoblastic Leukemia (ALL) Pilot Phase 1,"There are 189 fully characterized patient cases that make up the pilot phase (Phase I) of the TARGET ALL dataset, each with gene expression, tumor and paired normal copy number  analyses, and at least one type of sequencing (Sanger and/or next-generation) data available. There are 230 cases with partial molecular",phs000463.v23.p8,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000463,"Stephen P. Hunger, MD;Cheryl Willman, MD;Charles G. Mullighan, MD, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),19129520;19470474;20139093;19880498;20699438;21680795;22897847;232125233,,2023-09-20,DS-PEDCR,RNA-Seq;WGS,Cohort,Precursor Cell Lymphoblastic Leukemia-Lymphoma,289.0,65.0,https://www.cancer.gov/ccg/research/genome-sequencing/target/studied-cancers/acute-lymphoblasic-leukimia,,,"Acute Lymphoblastic Leukemia; ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic"
Single Cell Genotypic and Phenotypic Analysis of Measurable Residual    Disease in Acute Myeloid Leukemia,"Acute myeloid leukemia (AML) is a group of blood cancers with high mortality. Even though complete remission is often achieved, majority of the AML patients still relapse. Measurable residual disease  (MRD), defined as the population of cancer cells which persists following chemotherapy, is responsible for AML relapse. Understanding the biology",phs003233.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003233,Wenbin Xiao;Ross Levine,Freddie Pruitt,Center for Cancer Genomics (CCG),35797463;34724563;34258102;33116311;32150611;37729414,,2023-09-19,HMB,AMPLICON,Clinical Genetic Testing;Cohort;Single Cell Analysis,"Leukemia, Myeloid, Acute",91.0,25.0,,ASXL1;ATM;BRAF;CALR;CBL;CHEK2;DNMT3A;EZH2;FLT3;GATA2;IDH1;IDH2;JAK2;KIT;KRAS;MPL;NPM1;NRAS;PHF6;PPM1D;PTPN11;RAD21;RUNX1;SETBP1;SF3B1;SRSF2;STAG2;TET2;TP53;U2AF1;WT1,"Neoplasm, Residual","Neoplasm, Residual; AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult"
Single-Cell Multi-Omic Analysis of the Vestibular Schwannoma Ecosystem    Uncovers a Nerve Injury-Like State,"Vestibular schwannomas are benign tumors that can lead to significant morbidity, including hearing loss, facial nerve paralysis and obstructive hydrocephalus. The genomic landscape of vestibular schwannomas is relatively bland and  the molecular pathophysiology of vestibular schwannomas is poorly understood. Therefore, we performed single cell RNA sequencing on 15 sporadic",phs003318.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003318,"Albert H. Kim, MD, PhD;Sidharth V. Puram, MD, PhD;Allegra A. Petti, PhD;Thomas F. Barrett, MD;Bhuvic Patel, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-09-15,GRU,WXS;Seq_DNA_SNP_CNV,Case Set,"Neuroma, Acoustic",12.0,24.0,,,"Schwannoma, Vestibular","Schwannoma, Vestibular; AN - Acoustic neuroma; Acoustic Neurilemmoma; Acoustic Neurilemmomas; Acoustic Neurilemoma; Acoustic Neurilemomas"
Immune-Related Adverse Events after Immune Checkpoint Blockade-Based    Therapy are Associated with Improved Survival in Advanced Sarcoma,"Immune activation after immune checkpoint blockade (ICB) can lead to a unique group of adverse events (AEs), which have been associated with improved outcome in many carcinomas. The association between  immune-related AEs (irAEs) and outcome in patients with sarcoma is not well studied. This study has two components: (1) a retrospective clinical",phs003284.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003284,"Evan Rosenbaum, MD;Sandra D'Angelo, MD",,,37787759,,2023-09-15,DS-SARC,RNA-Seq,Clinical Trial;RNA Sequencing,Sarcoma,64.0,64.0,,,Immune Checkpoint Inhibitors;Drug-Related Side Effects and Adverse Reactions,Drug-Related Side Effects and Adverse Reactions; ADR; ADR - Adverse drug reaction; Adverse Drug Event; Adverse Drug Events; Adverse Drug Experience
TCGA WGS Variants Across 18 Cancer Types,"Even though whole genome sequence (WGS) data has been generated and published in many studies, much of this information is not yet processed for use in down-stream analysis. This study's  aim is to provide 1342 WGS normal-tumor paired single nucleotide variations (SNP) over 18 different cancer types provided by The Cancer Genome Atlas",phs003155.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003155,John Torcivia,,,,,2023-09-15,GRU,,GWAS;Individual-Level Genomic Data;Tumor vs. Matched-Normal;Whole Genome Sequencing,"Polymorphism, Genetic",1342.0,2684.0,,,"Genetic Variation;Sequence Analysis, DNA",Not Provided
ALLELE Consortium Glioblastoma Project,"Glioblastoma patient samples were sequenced for this project. The purposes of this project are: (1) to establish an umbrella protocol as a mechanism for identifying patients (in the USA and  international sites) who agree to the collection, storage, and broad usage of their specimens and ongoing collection, and review of their medical",phs003000.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003000,"Keith L. Ligon, MD, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,Accelerate Brain Cancer Cure;National Brain Tumor Society;R01CA188228;3000 Miles to the Cure,2023-09-06,HMB,WXS,Case-Control;Clinical Trial;Exome Sequencing;Individual-Level Genomic Data;Multicenter;Sequencing;Tumor vs. Matched-Normal,Glioblastoma,110.0,220.0,,,,"Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme"
University of Pennsylvania CAR T Cell Responding and Non-responding    Patients,"The adoptive transfer of autologous T cells genetically modified to express a CD19-specific, 4-1BB/CD3zeta-signaling chimeric antigen receptor (CAR; CTL019) has shown remarkable activity in patients with B acute lymphoblastic leukemia.  Similar therapy can induce long-term remissions for relapsed/refractory chronic lymphocytic leukemia (CLL) patients, but in only a small subset of",phs001707.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001707,"Carl H. June, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),29713085,P01CA214278;University of Pennsylvania/Novartis Alliance,2023-09-06,GRU-IRB-NPU,RNA-Seq;AMPLICON,Cohort,"Leukemia, Lymphocytic, Chronic, B-Cell",37.0,109.0,,,Sarcoma,"Sarcoma; B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade"
HTAN MCL Pre-Cancer Atlas Pilot Project - Targeted Sequencing Development    Study,"The HTAN-MCL Pre-Cancer Atlas Pilot Project (PCAPP) is the result of a collaboration between the seven members of the MCL consortium. Across four organ types, PCAPP's goal is to collect  and profile pre-malignant lesions for gene expression, DNA mutations, single-cell gene expression and immune-environment. Most PML are small in size",phs002225.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002225,"Christopher Amos, PhD;Olivier Harismendy, PhD",Natalie Abrams,Division of Cancer Prevention (DCP),33208147,U01CA196383;U01CA196386;U01CA196387;U01CA196390;U01CA196403;U01CA196406;U01CA196408,2023-09-01,GRU,RNA-Seq;WXS,Case Set,"Carcinoma, Intraductal, Noninfiltrating",63.0,430.0,https://mcl.nci.nih.gov/,,,"Breast Ductal Carcinoma In Situ, NOS; Carcinoma, Intraductal; Carcinoma, Noninfiltrating Intraductal; Carcinomas, Intraductal; Carcinomas, Noninfiltrating Intraductal; DCIS"
Development and Validation of Organoids from Fibrolamellar Carcinoma    Human Cells,Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare liver tumor affecting adolescents and young adults with no history of primary liver disease or cirrhosis. We collected fibrolamellar tumor tissue and the  adjacent non-tumor liver from patients at the time of surgery. We only used tumor tissue that was validated as fibrolamellar by the presence of the,phs002439.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002439,Sanford M. Simon,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,P50CA210964;U54CA243126,2023-08-31,DS-HCC-IRB-COL,RNA-Seq,Case Set;Full Transcriptome Sequencing;Metastasis;RNA Sequencing;Sequencing;Transcriptome Analysis;Transcriptome Sequencing;Tumor;Tumor vs. Matched-Normal;Xenograft,Fibrolamellar hepatocellular carcinoma,5.0,25.0,https://fibrolamellar.rockefeller.edu/repository;https://fibroregistry.org;https://fibrolamellar.rockefeller.edu,,Organoids;Xenograft Model Antitumor Assays,Hepatocellular carcinoma (fibrolamellar variant); FHCC; FL-HCC; FLC; Fibrolamellar Carcinoma of Liver Cells; Fibrolamellar Carcinoma of the Liver Cells
Molecular Subtyping Reveals Immune Alterations Associated with    Progression of Bronchial Premalignant Lesions,"Exposure to cigarette smoke creates a field of injury throughout the entire respiratory tract inducing genomic alterations that lead to an ""at-risk"" airway where lung cancers develop. Lung squamous cell  carcinoma (SCC) arises in the epithelial layer of the bronchial airways and is often preceded by the development of premalignant lesions (PMLs).",phs003185.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003185,Avrum E. Spira,Nathaniel Boyd,Office of Data Sharing (ODS),31015447;34580161,,2023-08-23,GRU,RNA-Seq,Clinical Cohort;Cohort;Individual-Level Genomic Data;Longitudinal;Longitudinal Cohort;Prospective;RNA Sequencing;Sequencing;Transcriptome Analysis;Transcriptome Sequencing,Lung Neoplasms,50.0,448.0,https://github.com/jbeane0428/Computer-code-for-PML-Molecular-Subtypes,,Disease Progression;Bronchial Neoplasms;Bronchopulmonary Dysplasia,"Bronchial Neoplasms; Bronchopulmonary Dysplasia; Disease Progression; Bronchial Neoplasm; Bronchial tumor; Neoplasm, Bronchial"
Exome Recapture and Sequencing of Prospectively Characterized Clinical    Specimens From Cancer Patients,The study cohort comprises samples from patients whose tumors have been prospectively characterized as part of their care at Memorial Sloan Kettering Cancer Center. This includes a variety of distinct  tumor type and molecular subtypes. DNA samples from tumor tissue were from patients at Memorial Sloan Kettering Cancer Center. Tumor and normal,phs001783.v6.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001783,David B. Solit,,,31292550,U54 OD020355;P01 CA221757;R01 CA207244;P50 CA092629;R01 CA251591-01A1;2T32 CA009512-29A1;I10-0084;1P50CA217694-01A1;R01 CA233899;P50 CA221745;UL1-TR002384;P30-CA008748;R01 CA245069;R01 CA204749;R01 CA227534,2023-08-18,DS-CA-PUB-MDS,WXS,Case Set,Neoplasms,1660.0,3598.0,http://oncotree.mskcc.org,,Genomics,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Merkel Cell Carcinoma Tissue and Data Repository,"Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer with increasing incidence in the United States. In this study we performed the first whole genome sequencing of three  Merkel cell carcinomas with their matched normal tissues for somatic variant calling. From these data we describe the likely mechanism of Merkel cell",phs002189.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002189,James A. DeCaprio,Ian Fingerman,Division of Cancer Biology (DCB),28049147,,2023-08-17,HMB-IRB,RNA-Seq;Seq_DNA_SNP_CNV;WGS,Full Transcriptome Sequencing;Whole Genome Sequencing,"Carcinoma, Merkel Cell",6.0,12.0,,,,"Anaplastic carcinoma of the skin; Cancer, Merkel Cell; Cell Cancer, Merkel; Cutaneous APUDoma; Cutaneous Neuroendocrine Carcinoma; MCC"
AC-ICAM: An Atlas and Compass of Immune-CAncer-Microbiome Interactions in    Colon Cancer,"Fresh frozen tumor samples and matched normal colon specimens from chemotherapy na&#x000ef;ve, consecutive patients with a histological diagnosis of colon adenocarcinoma at Leiden University Medical Center (LUMC) were subjected to  multi-omics profiling at Sidra Integrated Genomics Services, part of Sidra Medicine, Doha, Qatar. This resulted in a high-quality dataset of samples",phs002978.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002978,Wouter Hendrickx;Davide Bedognetti,Brandon Wright,Office of Data Sharing (ODS),37202560,,2023-08-16,DS-CA-PUB-MDS,RNA-Seq;WXS,Case-Cohort;Clinical Cohort;Cohort;Exome Sequencing;RNA Sequencing;Transcriptome Analysis;Tumor;Tumor vs. Matched-Normal,Colonic Neoplasms,348.0,1258.0,https://www.ncbi.nlm.nih.gov/bioproject/941834/,IFNG;IRF1;STAT1;IL12B;TBX21;CD8A;CD8B;CXCL10;CCL5;GZMB;GNLY;PRF1;GZMH;GZMA;CD274;PDCD1;CTLA4;FOXP3;IDO1;CXCL9,Colon Cancer;Colon Adenocarcinomas,"CA - Cancer of colon; COLON CANCER; Cancer of Colon; Cancer of the Colon; Cancer, Colon; Cancer, Colonic"
MP2PRT: Comprehensive Genomic Profiling to Identify Alterations    Associated with Relapse for NCI Standard Risk (SR) B-Lineage ALL and    NCI High Risk (HR) B-Lineage ALL with Favorable Genetic Features,The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI's Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of  biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program.,phs002005.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002005,"Mignon Lee-Cheun Loh, MD;Charles G. Mullighan, MD;Gang Wu, PhD;Ti-Cheng Chang, PhD;Wenan Chen, PhD;Meenakshi Devidas, PhD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),,Contract HHSN261201500003I;Task Order HHSN26100039,2023-08-16,GRU,,Case-Control,Precursor Cell Lymphoblastic Leukemia-Lymphoma,1510.0,1510.0,,,,"Acute Lymphoblastic Leukemia; ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic"
Analysis of Donor Pancreata Defines the Transcriptomic Signature and    Microenvironment of Early Neoplastic Pancreatic Lesions,"The adult healthy human pancreas has been poorly studied given lack of indication to obtain tissue from the pancreas in the absence of disease and rapid postmortem degradation. We obtained  pancreata from brain dead donors thus avoiding any warm ischemia time. We found that neoplastic lesions occur frequently in healthy organs, in donors",phs003229.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003229,"Timothy L. Frankel, MD;Marina Pasca di Magliano, PhD",Ian Fingerman,Division of Cancer Biology (DCB),37021392,R01-CA268426;R01-CA260752;R01-CA271510;U01-CA224145;U01-CA274154;U54CA274371,2023-08-15,GRU,RNA-Seq,Observational,Pancreas,7.0,13.0,,,Pancreatic Neoplasms,"Cancer of the pancreas; Neoplasia of the pancreas; Neoplasm of Pancreas; Neoplasm of the Pancreas; Neoplasm, Pancreas; Neoplasm, Pancreatic"
"Extracellular RNA Profiling of Serum, Plasma, and Urine of Healthy    Subjects","This study was conducted to generate a reference dataset of extracellular RNA (exRNA) from standard human biofluids. Small RNA-seq data was obtained from plasma, serum, and urine of healthy subjects.  Inclusion Criteria: Healthy volunteer subjects Principal Investigator: Jennifer C. Jones, MD, PhD, National Institutes of Health, Bethesda, MD, USA",phs003054.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003054,"Jennifer C. Jones, MD, PhD",Kathleen Calzone,Center for Cancer Research (CCR),,1U01HL126493-01,2023-08-09,GRU-IRB-PUB-COL,RNA-Seq,Longitudinal,Healthy Volunteers,53.0,53.0,,,Sex,Not Provided
Genome-Wide Analysis of Aberrant Position and Sequence of Plasma DNA    Fragment Ends in Patients With Cancer,"This study investigated fragmentation characteristics in plasma cell-free DNA and evaluated the relevance of such analysis for cancer diagnostics. Specifically, we performed whole genome sequencing (WGS) of healthy individuals and  cancer patients, and evaluated genome-wide coverage and sequences surrounding fragment ends. This was a retrospective study of archived plasma",phs003170.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003170,Muhammed Murtaza,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),36630480,,2023-08-03,HMB-PUB-MDS,WGS,Case-Control;Whole Genome Sequencing,Liquid Biopsy,213.0,548.0,,,"Neoplasms;Biomarkers, Tumor",Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
CPTAC: Proteogenomic Studies of Ovarian Tumor Responses to Agents    Targeting the DNA Damage Response,"There is a critical unmet need for predictors of chemo-refractory High-grade serous ovarian cancer (HGSOC). Despite over 3 decades of research on platinum responses in cancer, no predictive biomarker has  been translated into clinical use. Predictors of refractory disease could spare these patients the unnecessary toxicity of a platinum-based regimen",phs003152.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003152,"Amanda G. Paulovich, MD, PhD;Michael J. Birrer, MD, PhD",Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),,U01CA214114,2023-08-03,GRU,RNA-Seq;WGS,Case Set;RNA Sequencing;Whole Genome Sequencing,"Carcinoma, Ovarian Epithelial",148.0,156.0,http://ptrc.cptac-data-view.org/,,"Platinum Compounds;Drug Resistance, Neoplasm","Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian; Epithelial Cancer, Ovarian"
Genomic Characterization CS-MATCH-0007 Arm N,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs002151.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002151,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;37322121,Division of Cancer Treatment and Diagnosis,2023-07-25,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,21.0,21.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,PTEN,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Genomic Characterization CS-MATCH-0007 Arm B,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs002028.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002028,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;37322121,Division of Cancer Treatment and Diagnosis,2023-07-25,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,33.0,33.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,ERBB2,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
A National Translational Science Network of Precision-Based Immunotherapy    for Primary Liver Cancer (PLC),"The primary objective of the NCI-CLARITY study is to establish a biospecimen repository for genomic, genetic and epigenetic analysis to study the biology of primary liver cancer (PLC) development and  progression. Secondary objectives include predicting overall and progression-free survival following immunotherapy. In the retrospective phase,",phs003074.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003074,"Tim Greten, MD;Xin Wei Wang, PhD",Kathleen Calzone,Center for Cancer Research (CCR),37224815,,2023-07-21,HMB,RNA-Seq;WXS,Longitudinal,Liver Neoplasms,93.0,482.0,https://ccr.cancer.gov/liver-cancer-program/nci-clarity-study,,"Carcinoma, Hepatocellular;Cholangiocarcinoma;Immunotherapy","Carcinoma, Hepatocellular; Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells"
Cancer Risk Estimates Related to Susceptibility Genes (CARRIERS),The CARRIERS study utilized custom amplicon-based variant screening of known cancer predisposition genes in germline DNA from breast cancer cases and age matched unaffected controls taken from predominantly cohort-based breast  cancer case-control studies to establish the risks of breast cancer associated with pathogenic variants in these genes. Inclusion Cases - affected,phs002820.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002820,"Fergus Couch, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),34042955;35175286;34125377;34101481,R01CA192393,2023-07-20,DS-CA;DS-CA-IRB-MDS;HMB-IRB;GRU-NPU;HMB-PUB;DS-BROC;HMB-COL-NPU-GSO;HMB-IRB-NPU;GRU;DS-CA-PUB;HMB,Seq_DNA_SNP_CNV,Case-Control,Genetic Predisposition to Disease,75492.0,75490.0,,BRIP1;ATM;BARD1;BRCA1;BRCA2;CDH1;MRE11A;NBN;PTEN;RAD51C;RAD51D;STK11;TP53;XRCC2;CHEK2;PALB2,Genotype;Mutations;Risk Assessment;Breast Cancer,Genetic Predispositions; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors
"A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab and Intralesional    Oncolytic Virotherapy for HER2-Negative Breast Cancer",This study was a single arm phase 1 trial that assessed the regimen safety and feasibility as well as tumor response in patients with localized HER2-negative breast cancer treated with  talimogene laherparepvec (T-VEC) in combination with nivolumab and ipilimumab. The primary objective was to evaluate the safety and adverse event,phs003316.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003316,Vina P. Nguyen;John A. Glaspy;Antoni Ribas,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),37621406,R35 CA197633,2023-07-18,HMB-PUB,RNA-Seq;WXS,Cohort,Breast Neoplasms,6.0,27.0,,,Neoadjuvant Therapy;Immunotherapy,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
"Cell-Free, Methylated DNA in Blood Samples Reveals Tissue-Specific,    Cellular Damage from Radiation Treatment","Radiation therapy is an effective cancer treatment, although damage to surrounding healthy tissues can also occur. Cell-type specific DNA methylation patterns can be used to decode the cellular origins of  cell-free DNA fragments, allowing for minimally-invasive monitoring of tissue damage. To evaluate whether changes in cell-free DNA methylation can",phs003290.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003290,Anton Wellstein,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),37318863,RO1CA231291;P30CA51008;T32CA009686;F30CA250307,2023-07-18,GRU-IRB-COL,Bisulfite-Seq,Epigenetics;Longitudinal,DNA Methylation,29.0,59.0,,,Radiotherapy,
RNA Sequencing of ECOG-E1308,"This study reports the RNA sequencing of HPV positive oropharyngeal squamous cell carcinoma samples from patients with HPV-associated stage III or stage IV cancer of the oropharynx that was surgically  resectible. These patients participated in the ECOG-E1308 trial, a phase II trial that studied paclitaxel, cisplatin, and cetuximab followed by",phs003320.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003320,"Travis Schrank, MD, PhD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),,UG1CA233333,2023-07-13,GRU,RNA-Seq;Seq_RNA_Expression,Case Set,Squamous Cell Carcinoma of Head and Neck,71.0,71.0,,,,Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx
A Phase II Neoadjuvant Study of Palbociclib in Combination with Letrozole    and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+    Breast Cancer (PALTAN),"Women with early stage ER+/HER2+ breast cancer (BC) are less likely to achieve pathological complete response (pCR) after chemotherapy with standard of care dual HER2 blockade than patients with ER-/HER2+  BC. Additionally, the toxicity burden of standard systemic therapy is high. Thus, this single arm phase 2 clinical trial investigated a novel",phs003147.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003147,Foluso Ademuyiwa,Nathaniel Boyd,Office of Data Sharing (ODS),,,2023-07-13,GRU-PUB,RNA-Seq;WXS,Clinical Trial,Breast Neoplasms,17.0,55.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Mutational Landscape of MCPyV-Positive and MCPyV-Negative Merkel Cell    Carcinomas,"Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin most commonly found on the sun-exposed skin of older Caucasian adults. Roughly one-third of patients with MCCs die  of the disease; therefore, MCC is the most lethal skin cancer on a case-by-case basis. 49 cases were studied, and putative cancer driver gene",phs002515.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002515,Jaehyuk Choi,Ian Fingerman,Division of Cancer Biology (DCB),,,2023-07-13,GRU,WXS,Case Set,"Carcinoma, Merkel Cell",49.0,98.0,,,Merkel cell polyomavirus,"Anaplastic carcinoma of the skin; Cancer, Merkel Cell; Cell Cancer, Merkel; Cutaneous APUDoma; Cutaneous Neuroendocrine Carcinoma; MCC"
Whole Genome Sequencing for Metastatic Mutational Burden in Extraskeletal    Myxoid Chondrosarcoma,"Extraskeletal myxoid chondrosarcoma (EMC) is an ultra-rare cancer. Though it has a favorable prognosis and an indolent course, it has high rates of local recurrence and metastasis to the lungs.  EMC is most often characterized by a translocation involving the NR4A3 gene most often fusing with EWSR1, leading to constitutive expression of",phs003305.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003305,Kurt Weiss,Freddie Pruitt,Center for Cancer Genomics (CCG),39086683,,2023-07-12,GRU,WGS,Case Set;Genotype;Individual-Level Genomic Data;Single Patient;Tumor;Tumor vs. Matched-Normal;Whole Genome Sequencing,Sarcoma,1.0,4.0,https://www.frontiersin.org/articles/10.3389/fmmed.2023.1152550/abstract,MYO18B;VPS13A;UBD;TRIM37;OR5F1;IL7R;KCNJ5;ARHGEF12;UROC1,"Neoplasms, Connective and Soft Tissue;Chondrosarcoma","Chondrosarcoma; Neoplasms, Connective and Soft Tissue; Sarcoma, Spindle Cell; Sarcomas, Spindle Cell; Spindle Cell Sarcomas; spindle cell sarcoma"
Hi-C Profiling of Solid Tumor Samples,"Structural variants, such as translocations, inversions, duplications, and deletions, have long been recognized as mutations that can contribute to the initiation and progression of cancer. This can occur through a  variety of mechanisms, including changes in gene dosage and the generation of fusion genes. In recent years, it is becoming increasingly clear that",phs003227.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003227,Jesse R. Dixon,Ian Fingerman,Division of Cancer Biology (DCB),,,2023-07-12,HMB-MDS,Hi-C;chromatin_conformation,Case Set;Epigenetics;Tumor,Neoplasms,10.0,10.0,,,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Supraphysiologic MDM2 Expression Impacts P53-Independent Chromatin    Networks and Therapeutic Responses in Sarcoma,"We collected multiple liposarcoma samples from different patients, including different subtypes (DD, WD) and normal adipose tissue as control. This study provides the biggest liposarcoma cohort to date, and examined  the molecular regulatory circuits associated with MDM2 overexpression. To this end, we obtained not only RNA-seq data, but also ChIP-seq from Jun,",phs003272.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003272,Bradley E. Bernstein;Sarah E. Johnstone,Ian Fingerman,Division of Cancer Biology (DCB),,David Liposarcoma Research Initiative;DP1CA216873;K08CA259623,2023-07-11,HMB-MDS,RNA-Seq;Hi-C;ChIP-Seq,Cohort,Liposarcoma,26.0,40.0,,MDM2,,"DDLPS; DDLS; Dedifferentiated Liposarcomas; Liposarcoma, Dedifferentiated; dedifferentiated liposarcoma"
Mapping the Evolution of T Cell States During Response and Resistance to    Adoptive Cellular Therapy,We investigated single T cell transcriptional states that define donor lymphocyte infusion (DLI) response and resistance from cryopreserved bone marrow mononuclear cells from 15 patients with relapsed chronic myeloid leukemia  (CML) after allogeneic hematopoietic stem cell transplant. By integrating bulk ATAC-seq data from sorted T cell populations from these bone marrow,phs002877.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002877,"Catherine Wu, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,1R01CA155010;P01CA206978;U10CA180861;K99CA230195;K08CA248458;U54CA209975,2023-07-11,HMB,OTHER,Longitudinal,"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",17.0,106.0,,,"Transplantation, Homologous;High-Throughput Nucleotide Sequencing",BCR-ABL Positive chronic myelogenous leukaemia; BCR-ABL Positive chronic myelogenous leukemia; CGL - Chronic granulocytic leukemia; CML; CML - Chronic myeloid leukemia; CML - chronic myelogenous leukaemia
National Cancer Institute Cancer Genome Characterization Initiative    (CGCI),The Office of Cancer Genomics at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing technologies  in cancer. The CGCI program included comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. CGCI,phs000235.v21.p6,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000235,"Marco A. Marra, PhD;Victor Velculescu, MD, PhD;Daniela S. Gerhard, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),20081860;21190999;21796119;21163964,,2023-07-11,GRU-IRB;DS-CA-MDS;GRU,RNA-Seq;WXS;miRNA-Seq;WGS,Cohort;Tumor vs. Matched-Normal,Neoplasms,762.0,884.0,https://www.cancer.gov/ccg/research/genome-sequencing/cgci,,"Lymphoma, Large B-Cell, Diffuse;Lymphoma, Follicular;Lymphoma, Non-Hodgkin;Lymphomas, Histiocytic;Lymphoma, AIDS-Related;Lung Neoplasms;Uterine Cervical Neoplasms","Lung Neoplasms; Lymphoma, AIDS-Related; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lung Tumor; Lung cancer"
National Cancer Institute (NCI) Cancer Genome Characterization Initiative    (CGCI): Non-Hodgkin Lymphoma,The Office of Cancer Genomics (OCG) at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing  technologies in cancer. The CGCI program included comprehensive characterization of the genetic aberrations found in different pediatric and/or adult,phs000532.v18.p6,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000532,"Marco A. Marra, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),20081860;21190999;21796119,"N01-C0-12400;NIH 1U01CA114778 ""Molecular Signatures to Improve Diagnosis and Outcome in Lymphoma"";Grant #019001, Biology of Cancer: Insights from Genomic Analyses of Lymphoid Neoplasms;Genome Canada/Genome BC Grant Competition III: High Resolution Analysis of Follicular Lymphoma Genomes",2023-07-11,GRU-IRB;DS-CA-MDS;GRU,RNA-Seq;WXS;WGS,Cohort,"Lymphoma, Non-Hodgkin",118.0,207.0,https://www.cancer.gov/ccg/research/genome-sequencing/cgci,,"Lymphoma, Large B-Cell, Diffuse;Lymphoma, Follicular","Lymphoma, Follicular; Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers; FOLLICULAR LYMPHOMA, SOMATIC"
National Cancer Institute (NCI) Cancer Genome Characterization Initiative    (CGCI): Medulloblastoma,The Office of Cancer Genomics (OCG) at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing  technologies in cancer. The CGCI program includes comprehensive characterization of the genetic aberrations found in different pediatric and/or adult,phs000531.v18.p6,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000531,"Victor Velculescu, MD, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,N01-C0-12400,2023-07-11,,,Cohort,Medulloblastoma,,,https://www.cancer.gov/ccg/research/genome-sequencing/cgci,,,"Arachnoidal Cerebellar Sarcoma, Circumscribed; Circumscribed arachnoidal cerebellar sarcoma; Desmoplastic Medulloblastomas; Desmoplastic Nodular Medulloblastoma; Desmoplastic medulloblastoma; Medulloblastoma, Desmoplastic"
National Cancer Institute (NCI) Cancer Genome Characterization Initiative    (CGCI): HIV+ Tumor Molecular Characterization Project - Lung Cancer    (HTMCP - LC),The Office of Cancer Genomics at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing technologies  in cancer. The CGCI program included comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. All,phs000530.v18.p6,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000530,,Freddie Pruitt,Center for Cancer Genomics (CCG),,N01-C0-12400,2023-07-11,GRU-IRB;DS-CA-MDS;GRU,RNA-Seq;miRNA-Seq;WGS,Cohort,"Lymphoma, AIDS-Related",39.0,65.0,https://www.cancer.gov/ccg/research/genome-sequencing/cgci;https://www.cancer.gov/ccg/research/genome-sequencing/cgci/about/projects#hiv-tumor-molecular-characterization-project-htmcp,,Lung Neoplasms,Lung Neoplasms; Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung
National Cancer Institute (NCI) Cancer Genome Characterization Initiative    (CGCI): HIV+ Tumor Molecular Characterization Project - Diffuse Large    B-Cell Lymphoma (HTMCP - DLBCL),The Office of Cancer Genomics at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing technologies  in cancer. The CGCI program includes comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. All,phs000529.v18.p6,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000529,,Freddie Pruitt,Center for Cancer Genomics (CCG),,N01-C0-12400,2023-07-11,GRU-IRB;DS-CA-MDS;GRU,RNA-Seq;miRNA-Seq;WGS,Cohort,"Lymphoma, AIDS-Related",70.0,77.0,https://www.cancer.gov/ccg/research/genome-sequencing/cgci;https://www.cancer.gov/ccg/research/genome-sequencing/cgci/about/projects#hiv-tumor-molecular-characterization-project-htmcp,,"Lymphoma, Large B-Cell, Diffuse;Lymphoma, Non-Hodgkin","Lymphoma, Non-Hodgkin; AIDS Associated Lymphoma; AIDS Lymphoma; AIDS Related Lymphoma; AIDS-Associated Lymphoma; AIDS-Associated Lymphomas"
National Cancer Institute (NCI) Cancer Genome Characterization Initiative    (CGCI): HIV+ Tumor Molecular Characterization Project - Cervical    Cancer (HTMCP - CC),The Office of Cancer Genomics at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing technologies  in cancer. The CGCI program includes comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. All,phs000528.v18.p6,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000528,,Freddie Pruitt,Center for Cancer Genomics (CCG),,N01-C0-12400,2023-07-11,GRU-IRB;DS-CA-MDS;GRU,,Cohort,"Lymphoma, AIDS-Related",212.0,212.0,https://www.cancer.gov/ccg/research/genome-sequencing/cgci;https://www.cancer.gov/ccg/research/genome-sequencing/cgci/about/projects#hiv-tumor-molecular-characterization-project-htmcp,,Uterine Cervical Neoplasms,AIDS Associated Lymphoma; AIDS Lymphoma; AIDS Related Lymphoma; AIDS-Associated Lymphoma; AIDS-Associated Lymphomas; AIDS-Related Lymphoma
National Cancer Institute (NCI) Cancer Genome Characterization Initiative    (CGCI): Burkitt Lymphoma Genome Sequencing Project (BLGSP),The Office of Cancer Genomics at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing technologies  in cancer. The CGCI program included comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. All,phs000527.v18.p6,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000527,,Freddie Pruitt,Center for Cancer Genomics (CCG),,N01-C0-12400,2023-07-11,GRU-IRB;DS-CA-MDS;GRU,,Cohort,"Lymphoma, Non-Hodgkin",323.0,323.0,https://www.cancer.gov/ccg/research/genome-sequencing/cgci,,"Lymphomas, Histiocytic",Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology; Reticulum-Cell Sarcoma
ARST17B2-Q Germline and Somatic Genetic Landscape of Pediatric    Rhabdomyosarcoma,"Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. While these malignancies display aberrant myogenic differentiation, relatively little is known about genetic susceptibility to RMS, or how genetic  variants influence subsequent somatic events and may be used in risk stratification strategies. A small percentage of cases are associated with",phs003192.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003192,Philip Lupo;Lisa Mirabello,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,,2023-06-29,GRU,Array_SNP,Case Set,Rhabdomyosarcoma,920.0,920.0,,,,Not Provided
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment    of a Repository for Related Biologic Studies (10C0086),"This study (10-C-0086) collected and analyzed tumor and circulating tumor omics of pediatric and young adult patients with relapsed rhabdomyosarcoma who were co-enrolled in and receiving treatment on the interventional  study 17-C-0049. We sought to describe the summary genomic findings of tumors, and report on the detection of circulating tumor DNA (ctDNA) in serial",phs003243.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003243,"Rosandra N. Kaplan, MD",Kathleen Calzone,Center for Cancer Research (CCR),,,2023-06-27,GRU,RNA-Seq;WGS,Observational,Rhabdomyosarcoma,12.0,66.0,https://clinicaltrials.gov/ct2/show/NCT01109394?term=rosandra+kaplan&draw=2&rank=2;https://clinicaltrials.gov/ct2/show/NCT03041701?term=heske&draw=2&rank=1,,"Rhabdomyosarcoma, Alveolar;Rhabdomyosarcoma, Embryonal","Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Alveolar Rhabdomyosarcomas; Alveolar rhabdomyosarcoma (disease); Monomorphous Round Cell Rhabdomyosarcoma; RHABDOMYOSARCOMA 2"
Characterization of High-Grade Serous Ovarian Cancer Subtypes via    Single-Cell Profiling,"We measured gene expression in single-cell RNA sequencing samples from patients with high-grade serous ovarian cancer (HGSOC), for a study on improving HGSOC subtype definition by taking into account varying  cell type proportions within tumors. The initial dataset (added October, 2020) contains 3 samples (3 individuals). The next dataset (added November,",phs002262.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002262,Jason Gertz;Jennifer Anne Doherty;Casey S. Greene;Stephanie C. Hicks,,,,,2023-06-27,GRU,RNA-Seq,Case Set;RNA Sequencing;Single Cell Analysis;Tissue Expression;Tumor,"Carcinoma, Ovarian Epithelial",13.0,37.0,,,Ovarian Cancer,"Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian; Epithelial Cancer, Ovarian"
International Cancer Proteogenomics Consortium (ICPC): Proteogenomics of    East-Asian Breast Cancer,"The incidence of invasive breast cancer is rapidly increasing in East Asia, enriching in younger patients and luminal disease. We presented a deep proteogenomic landscape of a prospectively enrolled early-stage  cohort in Taiwan to uncover the etiology, age-related subtype and oncogenic vulnerabilities underlying the heterogeneous disease. Multilayer",phs003150.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003150,"Ya-Hsuan Chang, PhD;Yi-Ju Chen;Zhi-Jie Hong;Yi-Jing Hsiao;Hsuan-Yu Chen, PhD;Sung-Liang Yu;Jyh-Cherng Yu;Yu-Ju Chen",Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),,,2023-06-26,GRU-NPU,RNA-Seq;WXS;Seq_DNA_SNP_CNV,Exome Sequencing;Full Transcriptome Sequencing;RNA Sequencing;Transcriptome Sequencing;Tumor vs. Matched-Normal,Breast Neoplasms,138.0,690.0,,,RNA-Seq;Exome Sequencing,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Characterization of Immune Evasion in Merkel Cell Carcinoma,"Merkel cell carcinoma (MCC) is a rare, neuroendocrine skin carcinoma that is caused by the Merkel cell polyomavirus (MCPyV) in 80% of cases and by ultraviolet (UV) damage in 20%  of cases. MCC should theoretically elicit a strong cytotoxic T cell response due to the high neoantigen and viral antigen burden in MCPyV- and MCPyV+",phs002260.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002260,Derin B. Keskin;Catherine J. Wu;James A. DeCaprio,Ian Fingerman,Division of Cancer Biology (DCB),36719743;35775490;32188490,1R01CA155010;U24 CA224331;R35CA232128,2023-06-22,DS-MCC-IRB-MDS,ATAC-seq;Bisulfite-Seq;WGS;RNA-Seq;WXS,Case Set;Cohort,"Carcinoma, Merkel Cell",49.0,132.0,https://www.brighamandwomens.org/surgery/surgical-oncology/merkel-cell-carcinoma;https://www.dana-farber.org/merkel-cell-carcinoma/our-team/,ATOH1;B2M;CCER2;HES6;HLA-A;HLA-B;HLA-C;ISL1;KRT8;NLRC5;PSMB8;PSMB9;SOX2;TAP1;TAP2;TAPBP;WWTR1;YAP1,,"Anaplastic carcinoma of the skin; Cancer, Merkel Cell; Cell Cancer, Merkel; Cutaneous APUDoma; Cutaneous Neuroendocrine Carcinoma; MCC"
CIDR: The Role of Rare Coding Variation in Prostate Cancer in Men of    African Ancestry - RESPOND Project 2,"In RESPOND Project 2, we seek to identify rare genetic factors that are associated with prostate cancer (PCa) risk and aggressiveness in men of African ancestry (AA). We will conduct  exome sequencing of 15,000 prostate cancer cases and 5,000 controls from the RESPOND cohort and the African Ancestry Prostate Cancer Consortium",phs002637.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002637,Christopher Haiman,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,"1U19CA214253;HHSN268201700006I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2023-06-14,DS-PC;DS-CA-IRB;HMB-PUB;GRU;DS-CA-PUB;DS-UC-MDS;NRUP;DS-CHDSAD-MDS;HMB;DS-PC-PUB-MDS;DS-PC-MDS,WXS;Seq_DNA_SNP_CNV,Case-Control;Cohort;Exome Sequencing,Prostatic Neoplasms,12093.0,12171.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Whole Exome Sequencing of Primary Mediastinal B-cell Lymphoma,"Primary mediastinal large B-cell lymphomas (PMBLs) are aggressive tumors that typically present as large mediastinal masses in young women. PMBLs share clinical, transcriptional, and molecular features with classical Hodgkin lymphoma  (cHL), including constitutive activation of nuclear factor kappaB (NF-kappaB), JAK/STAT signaling, and programmed cell death protein 1",phs000450.v5.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000450,Margaret A Shipp;Gad Getz,Ian Fingerman,Division of Cancer Biology (DCB),31697821,,2023-06-08,DS-CA-MDS;DS-BLD-MDS;GRU-NPU-MDS;HMB,WXS;Seq_DNA_SNP,Case Set;Tumor,Primary Mediastinal B-cell Lymphoma,361.0,517.0,,,,Not Provided
Molecular Biomarkers of Obesity and Metformin Response in Endometrial    Cancer: Analysis of GOG-0286B,"The primary endpoint for the phase 2 study was progression free survival (PFS), and the primary endpoint for the phase 3 study was overall survival (OS). Data from phase 2  were included in the phase 3 analysis. Tissue was collected from patients with endometrial cancer who participated in the study (NCT02065687). The",phs002934.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002934,"Victoria Bae-Jump, MD, PhD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),,,2023-06-07,DS-ECA,RNA-Seq;Targeted-Capture,Case Set;Clinical Trial,Endometrial Neoplasms,375.0,738.0,,PIK3CA;PTEN;PIK3R1;TP53,Obesity,Endometrial Tumor; Endometrial neoplasm; Endometrium Neoplasm; Endometrium Tumor; Neoplasm of Endometrium; Neoplasm of the Endometrium
Tamoxifen Response at Single Cell Resolution in Estrogen Receptor    Positive Primary Human Breast Tumors,"Primary breast tissue, normal and cancerous, was collected immediately after resection. The tissue was dissociated and treated with 10uM tamoxifen or control media for 12 hours in suspension. Single cell  libraries were then created using a 10x Genomics gel bead droplet-based kit and sequenced via Illumina sequencing platforms. Differences in cell",phs003186.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003186,"Philip M. Spanheimer, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,"UNC Lineberger Comprehensive Cancer Center Core Support Grant P30CA016086;NIH/National Cancer Institute P50CA058223;Junior Faculty Award, Society of University Surgeons Foundation",2023-05-30,DS-BRCA,RNA-Seq;Seq_RNA_Expression_SC,Case Set,Breast Neoplasms,13.0,26.0,,,"Carcinoma, Ductal, Breast;Breast Carcinoma In Situ","Breast Carcinoma In Situ; Carcinoma, Ductal, Breast; LCIS - lobular carcinoma in situ; LCIS, Lobular Carcinoma In Situ; Lobular Carcinoma In Situ; Lobular carcinoma, noninfiltrating"
Therapy-Induced APOBEC3A Drives Evolution of Resistance to Targeted    Therapies in Non-Small Cell Lung Cancer,The purpose of this study was to identify mechanisms of resistance and associated mutational signatures in non-small cell lung cancers (NSCLCs) treated with targeted therapies. Whole genome sequencing (WGS) and  whole exome sequencing (WES) were performed on tumor tissue or cell lines derived from oncogene-driven NSCLCs before and after treatments with,phs003256.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003256,Aaron Hata,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2023-05-25,GRU,WXS;Seq_DNA_SNP;WGS,Individual-Level Genomic Data,"Carcinoma, Non-Small-Cell Lung",24.0,98.0,,ALK;EGFR;NTRK1;APOBEC3A,Molecular Targeted Therapy,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER"
Genomic Analysis of Low Grade B-Cell Lymphoma,"We included tumors from 64 newly diagnosed or untreated Low Grade B-Cell Lymphoma (LGBCL) patients, consisting of SMZL (n 48), NMZL (n 6), EMZL (n 2), LPL (n 5), and  B-NOS (n 3) in this study. Samples were selected from cases consented to the Molecular Epidemiology Resource (MER) of the University of Iowa and Mayo",phs002552.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002552,Anne Novak,,,37254453,,2023-05-25,GRU,RNA-Seq;WXS,Case Set;Exome Sequencing;RNA Sequencing;Tumor vs. Matched-Normal,"Lymphoma, Non-Hodgkin",64.0,183.0,,,,Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology; Reticulum-Cell Sarcoma
Genomic Analyses of Germline and Somatic Variation in High-Grade Serous    Ovarian Cancer,The goal of this study was to identify and characterize germline and somatic genetic variation in women with high grade serous ovarian cancers treated at a single cancer center and  their associations with relapse-free and overall survival. We conducted paired tumor/normal targeted next-generation sequencing of 577 genes in,phs003198.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003198,Susan L. Neuhausen,Nathaniel Boyd,Office of Data Sharing (ODS),,,2023-05-22,GRU-NPU,Targeted-Capture;Array_CNV,Case Set;Longitudinal,"Carcinoma, Ovarian Epithelial",71.0,185.0,,BRCA1;BRCA2;CHEK2;MRE11A;BLM;PALB2;MAP2K4;PTEN;RB1;SLX4;STK11;CREBBP;NF1;NOTCH3;ZNF536;PIK3R2,Recombinational DNA Repair;High-Throughput Nucleotide Sequencing,"Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian; Epithelial Cancer, Ovarian"
MAITS in HCC,"Hepatocellular Carcinoma (HCC) is a leading cause of cancer-related death and can be considered a prototype of inflammation-derived cancer arising from chronic liver injury. The cell composition of the HCC  tumor immune microenvironment (TiME) has a major impact on cancer biology as the TiME can have divergent capacities on tumor initiation, progress,",phs003279.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003279,Tim F. Greten,Kathleen Calzone,Center for Cancer Research (CCR),,,2023-05-18,GRU,Seq_RNA_Expression_SC,Single Cell Analysis,Hepatocellular carcinoma; Mucosal-Associated Invariant T Cells;    tumor-associated macrophages; single-cell sequencing,8.0,36.0,,,,Not Provided
Investigating the Role of Neddylation in the Repair of Topoisomerase    I-Mediated DNA Damage in Colorectal Cancer,"Colorectal cancer is one of the most lethal cancers worldwide. First-line chemotherapy for metastatic CRC (mCRC) entails a combination of irinotecan with 5-fluorouracil and leucovorin (FOLFIRI). Irinotecan is a prodrug  that is converted within the cell to its active metabolite SN38, a potent TOP1 inhibitor. TOP1 relieves DNA torsional strain arising from DNA",phs003257.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003257,"Yves
  Pommier, MD, PhD",Kathleen Calzone,Center for Cancer Research (CCR),,Z01 BC 006150,2023-05-16,GRU,RNA-Seq,Cohort,Colorectal Neoplasms,3.0,3.0,,ANXA1;FABP6;ACE2;FXYD5;LY6E;SERPINE2;SCD;BMP4;CEACAM6;TESC;TGFBI,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
S&#x000e9;zary Syndrome Originates from Heavily Mutated Hematopoietic Progenitors,"The pathogenesis of cutaneous T cell lymphoma (CTCL) remains unclear. To study the malignant transformation of CTCL, we collected matched hematopoietic stem cell (HSC) extracts from bone marrow, CD4+CD26- malignant  T cells, CD4+CD26+ normal T cells, and CD34+ HSCs from apheresis performed on 4 patients. To establish the baseline for calling true mutations",phs003158.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003158,Jose R. Conejo-Garcia,Ian Fingerman,Division of Cancer Biology (DCB),,R01CA240434,2023-05-16,GRU,WXS,Case Set,Sezary Syndrome,4.0,23.0,,,"Lymphoma, T-Cell, Cutaneous;Hematopoietic Stem Cells;Fibroblasts;CD24 Antigen;CD26 Antigen;CD34 Antigen","Lymphoma, T-Cell, Cutaneous; Granulomatous Slack Skin; Slack Skin, Granulomatous; CTCL / Sezary syndrome; Erythroderma, Sezary; Lymphoma, Sezary's"
Expression of Activation Induced Cytidine Deaminase and Risk of    Transformation in Follicular Lymphoma,"It is currently unclear how to identify follicular lymphoma (FL) patients with low disease burden but high risk for early progression. Building on a prior study demonstrating early transformation in  FLs with high variant allele frequency (VAF) BCL2 mutations at activation-induced cytidine deaminase (AICDA) sites, we examined 11 AICDA mutational",phs002845.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002845,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2023-05-11,GRU,AMPLICON,Clinical Cohort;Sequencing;Tumor,"Lymphoma, Follicular",199.0,199.0,,FAS;RHOH;BCL2;BCL6;MYC;PAX5;PIM1;SOCS1;BCL2L11,"Adult;Cell Transformation, Neoplastic;Chromosomes, Human, Pair 14;Chromosomes, Human, Pair 18;Cohort Studies;Disease-Free Survival;Female;Humans;Lymphoma, Follicular / mortality*;Male;Mutation;Prevalence;Proto-Oncogene Proteins c-bcl-2;Risk Factors;Survival Rate","Cell Transformation, Neoplastic; Risk Factors; Cell Neoplastic Transformation; Cell Neoplastic Transformations; Cell Transformations, Neoplastic; Neoplastic Cell Transformations"
Methylation Profiles of Cell-Free DNA Using Nanopore Sequencing,"Epigenetic characterization of cell-free DNA (cfDNA) is an emerging approach for detecting and characterizing diseases such as cancer. We developed a strategy using nanopore-based single-molecule sequencing to measure cfDNA methylomes.  This approach generated up to hundreds of millions of reads for a single cfDNA sample from cancer patients, an order of magnitude improvement over",phs002950.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002950,Hanlee Ji,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,1R33CA247700-01A1,2023-05-10,GRU,WGS,Case-Control;Methods Development,Neoplasms,27.0,65.0,,,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Transcriptomic Profiling of Oropharyngeal Squamous Cell Carcinoma,The study is a retrospective transcriptomic profiling of oropharyngeal squamous cell carcinoma. The pathologic database was queried for squamous cell carcinoma tumors originating from the anatomic oropharynx (tonsil or tongue  base) with available samples from surgical archives. This retrospective RNA sequencing cohort included cases dating prior to the routine,phs002935.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002935,"Travis P. Schrank, MD PhD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),,,2023-05-10,GRU,RNA-Seq;Seq_RNA_Expression,Case Set,Squamous Cell Carcinoma of Head and Neck,133.0,133.0,,,,Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx
Tissue Sampling and Biorepository to improve Cancer Cell Therapy,This study focuses on the elucidation of determinants of response and resistance to anti-CD19 CAR T-cells in large B-cell lymphoma. Plasma samples were collected prior to treatment and serially post  CAR T-cell infusion. Pre-treatment and relapse tumor samples were also obtained as available. Germ-line DNA isolated from Peripheral Blood,phs003145.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003145,"Ash Alizadeh, MD, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2023-05-09,DS-LYD-IRB-PUB-COL,Seq_RNA_Expression;Targeted-Capture,Case Set;RNA Sequencing;Tumor;Tumor vs. Matched-Normal,"Lymphoma, Non-Hodgkin",139.0,795.0,,PAX5;IRF8;CD274;TMEM30A;TP53,"Receptors, Chimeric Antigen;Immunotherapy, Adoptive",Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology; Reticulum-Cell Sarcoma
Single Cell Colony Whole Genome Sequencing Data From Individuals With    Telomere Syndromes,This is an observational study which examined the phylogenetic evolution of somatic clonal mutations in POT1 mutation carriers. Two individuals with telomere syndromes who carry a heterozygous germline POT1 p.R273Q  variant and one related control who did not carry this variant were studied. Single cell hematopoietic colonies were derived from peripheral blood,phs003207.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003207,"Mary Armanios, MD",Ian Fingerman,Division of Cancer Biology (DCB),37140166,R01CA160433,2023-05-08,NRUP;HMB-IRB-PUB-NPU,WGS,Case-Control;Observational,Clonal Hematopoiesis,7.0,152.0,,DNMT3A;JAK2;POT1,,"ARCH; ARCH Age related Clonal Hematopoiesis; ARCH Age-related Clonal Hematopoiesis; Age related Clonal Hematopoiesis; Age-related Clonal Hematopoiesis; Clonal Hematopoiesis, Age-related"
Immune Profiling in Patients with High-Risk Smoldering Myeloma,"Single-cell RNA-sequencing identifies immune biomarkers of response to immunotherapy in patients with high-risk Smoldering Multiple Myeloma (SMM). We conducted a Phase II trial of the immunotherapeutic anti-SLAMF7 antibody, Elotuzumab, in  combination with Lenalidomide and Dexamethasone (E-PRISM study), to determine the utility and safety of early immunotherapy in patients with",phs002476.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002476,"Irene M. Ghobrial, MD",Ian Fingerman,Division of Cancer Biology (DCB),36379208,R01 CA205954;SU2C-AACR-CT05-17;Leukemia and Lymphoma Society;Multiple Myeloma Research Foundation;Dr. Miriam and Sheldon G. Adelson Medical Research Foundation,2023-05-03,HMB,RNA-Seq;Seq_RNA_Expression_SC;Seq_Immuno_Target;OTHER,Case-Control;Clinical Trial,Smoldering Multiple Myeloma,55.0,240.0,,,Multiple Myeloma,"Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma; Kahler Disease"
Genomic and Transcriptomic Profiling of Patients with Malignant Pleural    and Peritoneal Mesothelioma: The NCI Cohort,"Malignant mesothelioma is an aggressive cancer with limited treatment options and poor prognosis. Better understanding of mesothelioma genomics and transcriptomics could advance novel therapies. We performed whole-exome sequencing (WXS) of  germline and tumors of 122 patients, and RNA-sequencing (RNA-Seq) of tumor samples of 100 patients with pleural, peritoneal, and tunica-vaginalis",phs002207.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002207,Raffit Hassan,Kathleen Calzone,Center for Cancer Research (CCR),36773602,ZIA BC010816,2023-05-03,GRU,RNA-Seq;WXS,Case Set;Longitudinal Cohort;Prospective,Mesothelioma,122.0,347.0,https://clinicalstudies.info.nih.gov/ProtocolDetails.aspx?id=2013-C-0202;https://clinomics.ccr.cancer.gov/clinomics/public/,BAP1,"Mesothelioma, Malignant",
Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity    within Individual Tumors and across Evolutionary Time,"A key characteristic of osteosarcoma is extensive and complex genomic rearrangements. However, published models explaining how these genomic rearrangements occur disagree about if these rearrangements occur early in tumor progression  and then are stable afterwards, or if there is ongoing genomic instability. Previous studies have employed bulk sequencing technologies to",phs003209.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003209,"Ryan D. Roberts, MD, PhD;Ben Raphael, PhD;Simone Zaccaria",Ian Fingerman,Division of Cancer Biology (DCB),37066022,K08CA201638;;;;;;;;UL1TR002733,2023-04-28,GRU-PUB-NPU,Seq_DNA_SNP_CNV;WGS;OTHER;Seq_DNA_SNP_CNV_SC,Copy Number Variation (CNV);Sequencing;Single Cell Analysis;Tumor;Tumor vs. Matched-Normal;Whole Genome Sequencing;Xenograft,Osteosarcoma,8.0,19.0,,,Sarcoma;Pediatrics;Chromosomal Instability,"Chromosomal Instability; Sarcoma; Chromosomal Instabilities; Chromosome Instabilities; Chromosome Instability; Instabilities, Chromosomal"
Genomics of Blastic Plasmacytoid Dendritic Cell Neoplasm,"The goal of this study was to understand the genetic evolution and tumor phylogeny of blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN can present in patients with skin tumors of  leukemia cells and no bone marrow or blood involvement, or alternatively, with both skin tumors and blood/bone marrow leukemia cells at the time of",phs003228.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003228,Andrew A. Lane,Ian Fingerman,Division of Cancer Biology (DCB),,,2023-04-24,HMB,WXS;WGS,Longitudinal;Tumor vs. Matched-Normal;Whole Genome Sequencing,High-Throughput Nucleotide Sequencing,6.0,25.0,,,,Not Provided
Molecular Biomarkers in Glioma (Mechanisms and Therapeutic Implications    of Hypermutation in Gliomas),"This study seeks to genomically and mechanistically examine the basis for resistance of glioblastoma to chemotherapy, radiation therapy, and targeted therapy including immunotherapies. The study design addresses two Aims. In  Aim 1, we will test the hypothesis that treatment with radiation and temozolomide or other therapies leads to consistent genetic changes in human",phs001967.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001967,Keith L. Ligon;Franck Bielle;Pratiti Bandopadhayay;Rameen Beroukhim,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),28557599,R01 CA188228,2023-04-21,GRU-IRB,WXS;Targeted-Capture;WGS,Case Set,Glioma,3.0,90.0,,MSH6;MLH1;MSH2;PMS2,Diffuse Intrinsic Pontine Glioma;Astrocytoma;DNA Mismatch Repair;Programmed Cell Death 1 Receptor;Immunotherapy,Diffuse Intrinsic Pontine Glioma; ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm; Astrocytoma (excluding glioblastoma)
Single Cell RNA-Sequencing in Adenoid Cystic Carcinoma,"This study of salivary adenoid cystic carcinoma aimed to profile individual malignant and stromal cells in treatment-naive head and neck adenoid cystic carcinoma, with or without metastatic cervical lymph nodes.  Clinical and pathologic information was collected on all patients, in addition to a fresh biopsy sample from the primary tumor and/or metastatic",phs003070.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003070,"Sidharth V. Puram, MD, PhD;Yotam Drier, PhD",Mariam Eljanne,Center for Cancer Training (CCT),,V Foundation for Cancer Research;Cancer Research Foundation;Barnes Jewish Hospital Foundation;1K08CA237732;2020 Grant 949029;Adenoid Cystic Carcinoma Research Foundation,2023-04-14,DS-ACC-IRB-MDS,RNA-Seq,Case Set;Epigenetics;Full Transcriptome Sequencing;Metastasis;RNA Sequencing;Sequencing;Single Cell Analysis;Transcriptome Sequencing;Tumor,"Carcinoma, Adenoid Cystic",7.0,10.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE210171,NOTCH1;MYB;DLL1;JAG1;JAG2,"Single-Cell Analysis;Paracrine Communication;NOTCH1 protein, human","Adenocarcinoma, cylindroid; Adenocystic Carcinoma; Adenocystic Carcinomas; Adenoid Cystic Carcinomas; Carcinoma, Adenocystic; Carcinomas, Adenocystic"
Genetic Epidemiology of Ovarian Cancer Histotypes,"Epithelial ovarian cancer is a highly fatal malignancy with known genetic etiology; however, it is estimated that a substantial portion of narrow sense heritability remains to be discovered. The goal  of this research was to use genetic information from distantly related ovarian cancer cases to identify regions of the genome that may harbor rare",phs003140.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003140,"Mollie E. Barnard, ScD",Mariam Eljanne,Center for Cancer Training (CCT),"No PMID: A Pedigree-Based Approach to Ovarian Cancer Risk Variant Discovery in the Utah Population Database | Barnard ME, Sargent R, Christensen GB, Mahaffey BA, Albro J, Jarboe EA, Rhodes T, Camp NJ, Doherty JA",K00CA212222;Huntsman Cancer Foundation;P30CA2014,2023-04-13,DS-CA-GSO,Array_SNP,Case Set,Ovarian Neoplasms,15.0,15.0,,,"Carcinoma, Ovarian Epithelial","Carcinoma, Ovarian Epithelial; Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian"
E5103 Correlative Studies,"ECOG-ACRIN E5103 (E5103) was a phase III adjuvant breast cancer trial that randomized 4994 patients with node-positive or high-risk node-negative breast cancer to intravenous doxorubicin and cyclophosphamide every 2 or  3 weeks (at the discretion of treating physician), for four cycles of adriamycin and cyclophosphamide (AC) followed by 12 weeks of weekly paclitaxel",phs003201.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003201,Bryan Paul Schneider,Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),26138065,U10R180280 for E5103 parent trial;Komen Promise and Leadership grant;Vera Bradley Monogram Medicine for E5103 correlative studies,2023-04-12,GRU-COL,WXS;Array_SNP,Case-Control,Breast Neoplasms,3215.0,3215.0,,POR,Paclitaxel;Peripheral Neuropathy;Anthracycline;Bevacizumab,Peripheral Neuropathy; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors
RNA-Seq Data From Early Stage Triple Negative Breast Cancer Tumors    Treated With TVEC and Chemotherapy (MCC18621),"This study is a phase 1/phase 2 trial testing the combination of talimogene laherparepvec (TVEC) and neoadjuvant chemotherapy for the treatment of stage II-III triple negative breast cancer. The trial  demonstrated that the addition of TVEC to neoadjuvant chemotherapy was feasible, and resulted in a pathological complete response (pCR) rate of",phs003199.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003199,"Hatem Soliman, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),36759673;33219014,Amgen Inc.,2023-04-07,GRU,RNA-Seq,Case Set;Interventional,Triple Negative Breast Neoplasms,45.0,75.0,,AQP3;CNTN6;FLG;GJBB6;KRT6A;KRTDAP;MUC19;RFX4;SBSN;ST18,ER-Negative PR-Negative HER2-Negative Breast Cancer,"ER-Negative PR-Negative HER2-Negative Breast Cancer; Breast Cancer, Triple-Negative; Breast Cancers, Triple-Negative; Breast Neoplasm, Triple-Negative; Breast Neoplasms, Triple-Negative; ER Negative PR Negative HER2 Negative Breast Cancer"
Neoantigen-Targeted CD8+ T-Cell Responses 1 With PD-1 Blockade Therapy,"Background: The primary target of T-cell responses induced against cancer cells are peptides derived from non-synonymous mutations presented by HLA (neoantigens). However, the large diversity of HLA alleles and restricted  availability of clinical samples have limited the study of the specificity and the evolution over time of the neoantigen-specific T cell responses",phs003153.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003153,"Antoni Ribas, MD, PhD;Cristina Puig-Saus, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),36890230,R35 CA197633;P01 CA244118,2023-03-30,HMB-PUB,RNA-Seq;WXS,Case Set,Melanoma,11.0,33.0,,,Immune Checkpoint Inhibitors,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Genomics from LCCC1525: A Priming Dose of Cyclophosphamide Prior to    Pembrolizumab to Treat mTNBC,"This phase II, single-arm, multicenter study will evaluate pembrolizumab therapy, 200 mg IV, given every 3 weeks (Q3W), following a single priming dose of cyclophosphamide, 300 mg/m2 IV, in patients  with advanced triple-negative breast cancer (TNBC) who have received at least one prior line of therapy. Data uploaded consists of FASTQ sequencing",phs002659.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002659,"E. Claire Dees, MD, MSc, ScM",Freddie Pruitt,Center for Cancer Genomics (CCG),35121644,P30 CA016086;Merck Sharp & Dohme Corp,2023-03-30,DS-BRCA-IRB,RNA-Seq;Seq_RNA_Expression;WXS;AMPLICON,Case Set,Triple Negative Breast Neoplasms,33.0,279.0,,,Breast Neoplasms,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
The Ultrasound Study of Tamoxifen,"The Ultrasound Study of Tamoxifen is a 12-month longitudinal study to describe volumetric breast density change over time among women with and without tamoxifen exposure. Women were enrolled at the  Karmanos Cancer Institute and Henry Ford Health Systems in Detroit, Michigan between 2011-2014. Enrollment included women prescribed tamoxifen for",phs003183.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003183,Gretchen Gierach,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,,2023-03-29,DS-BRCA,Seq_DNA_SNP_CNV;AMPLICON,Cohort;Longitudinal;Prospective,Tamoxifen,60.0,60.0,https://dceg.cancer.gov/research/cancer-types/breast-cancer/ultrasound-study-tamoxifen,,Breast Cancer;Breast Neoplasms,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Functional Multiomics of Cellular Therapy and Immune Checkpoint Blockade    Therapy for Solid Tumors,"Tumor samples were collected from a patient with synovial sarcoma, which acquired resistance to ACT targeting NY-ESO-1. Biopsies (n 3; primary, metastasis, and recurrence) were subjected to bulk tumor DNA  and RNA sequencing, as well as high-dimensional spatial profiling of RNA and protein targets. Bulk tumor whole exome and RNA sequencing corresponding",phs002762.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002762,Theodore S. Nowicki,,,30573690,,2023-03-29,DS-SARC-PUB,RNA-Seq;Seq_RNA_Expression;WXS;Seq_DNA_SNP_CNV,Longitudinal;Transcriptome Sequencing;Tumor vs. Matched-Normal,Adoptive Transfer,1.0,7.0,,CTAG1B;CTNNB1,Synovial Sarcoma,"Synovial Sarcoma; Malignant synovioma; Sarcoma, Synovial; Sarcomas, Synovial; Synovial Sarcomas; Synovialosarcoma"
Kids First: Pediatric Research Project on Adolescent Idiopathic Scoliosis,"Both childhood cancers and structural birth defects are critical and costly conditions associated with substantial morbidity and mortality. Elucidating the underlying genetic etiology of these diseases has the potential to  profoundly improve preventative measures, diagnostics, and therapeutic interventions. For the current study, families with inherited adolescent",phs001410.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001410,"Jonathan Rios, PhD",,,,"R01HD052973;Project 867;Scoliosis Research Society, Milwaukee, WI, USA;Crystal Charity Ball, Dallas, TX, USA;P01 HD084387",2023-03-29,DS-MUS-SKEL-IRB;NRUP;HMB,,Cohort,Scoliosis,650.0,598.0,https://commonfund.nih.gov/kidsfirst/overview,,,"Cobb angle greater than ten degrees; Scolioses; Scoliosis,"
A Platform Study of Combination Immunotherapy for the Neoadjuvant and    Adjuvant Treatment of Patients with Surgically Resectable    Adenocarcinoma of the Pancreas,"This is a single-institutional, randomized, open label platform clinical trial testing various immunotherapy combinations. Patients with newly diagnosed and surgically resectable pancreatic ductal adenocarcinoma (PDA) and scheduled to undergo the  Whipple procedure at Johns Hopkins Hospital were eligible to participate in this study. Criteria for determining resectability strictly followed",phs003002.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003002,Lei Zheng;Elizabeth M. Jaffee,,,36306792;35404390,R01 CA169702;R01 CA197296;P30 CA006973;Viragh Foundation,2023-03-28,HMB-IRB-NPU,RNA-Seq;Seq_DNA_SNP,Clinical Trial;Exome Sequencing;RNA Sequencing;Tumor,Pancreatic Neoplasms,25.0,98.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE197613,CD4;CD8A;CD19;ITGAM;KRAS;TP53,"Carcinoma, Pancreatic Ductal","Carcinoma, Pancreatic Ductal; Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas"
Lineage Plasticity and Immune Cell Heterogeneity Are Coordinately    Dysregulated Through Changes in FOXA1 Expression in Bladder Cancers    with Squamous Differentiation,"We performed whole exome sequencing (WES) of paired, macrodissected regions of urothelial carcinoma (UC), not otherwise specified (NOS-UC) and squamous differentiation (SqD) from 21 bladder tumors in which distinct and  separable NOS-UC and SqD regions were present (total 42 exomes, in addition to matched normal exomes). Mean tumor mutational burden (TMB) was higher",phs002357.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002357,"Hikmat Al-Ahmadie, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,R01CA233899,2023-03-28,DS-BLADDERCA-PUB-MDS,RNA-Seq;Seq_RNA_Expression;WXS,Exome Sequencing;RNA Sequencing;Single Cell Analysis;Transcriptome Sequencing;Tumor vs. Matched-Normal,"Carcinoma, Transitional Cell",13.0,36.0,,ADIRF;AHNAK2;ALOX5AP;BASE47;BHMT;CAPN5;CDK6;CHST15;CYP2J2;CYP4B1;EMP3;FAM174B;FBP1;FOXA1;GAREM;GATA3;GDPD3;GLIPR1;GPD1L;HMGCS2;MSN;MT1X;MT2A;PALLD;PDGFC;PLEKHG6;PPARG;PPFIBP2;PRKCDBP;PRRX1;RAB15;RNF128;SCNN1B;SCNN1G;SEMA5A;SLC27A2;SLC9A2;SPINK1;TBX2;TMEM97;TMPRSS2;TOX3;TRAK1;TUBB6;UPK1A;UPK2;VGLL1,Pathology;Genetics,
Single Cell Analysis Reveals Immune Dysfunction from the Earliest Stages    of CLL that can be Reversed by Ibrutinib,"We applied single cell RNA sequencing to broadly characterize circulating immune cells co-existing with leukemic cells during natural chronic lymphocytic leukemia (CLL) progression. We used peripheral blood mononuclear cells from  patients diagnosed from monoclonal B-lymphocytosis (MBL) and CLL at different time-points, and age-matched healthy donors (HDs). We analyzed the",phs002705.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002705,Catherine J. Wu,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-03-23,HMB,RNA-Seq,Observational,Lymphocytosis,16.0,30.0,,BST2;CD86;CTLA4;LGALS9;TNFRSF14;LILRA4;HAVCR2;BTLA,Chronic Lymphocytic Leukemias,"B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic"
Bladder Cancer Organoids as a Functional System to Model Different    Disease Stages and Therapy Response,"The study 'Bladder Cancer Organoids as a Functional System to Model Different Disease Stages and Therapy Response' reports the genomic characterization at the single allele level upon Whole Exome Sequencing  of Bladder Cancer (BLCa) Patient Tumor (PT) samples obtained from 18 patients and corresponding Patient Derived Organoids (PDOs), implementing the",phs003149.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003149,Marianna Kruithof De-Julio;Francesca Demichelis,Nathaniel Boyd,Office of Data Sharing (ODS),34731645,189149 and 184933;OC-2019-003;648670,2023-03-22,HMB,WXS,Case Set;Case-Cohort;Exome Sequencing;Genotype;Sequencing;Tumor;Tumor vs. Matched-Normal,Urinary Bladder Neoplasms,18.0,61.0,,,"Organoids;Sequencing, Exome","Bladder Cancer; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder; Cancer, Urinary Bladder"
NCT03343197: Clinical Biomarker Data,"Patients with IDH1-mutated low-grade glioma were treated with AG-120 (ivosidenib), AG-881 (vorasidenib), or Placebo for 28 days before surgical resection. A portion of the surgical sample was submitted for exome  capture-based transcriptome sequencing (Personalis ACE Whole Transcriptome). Following surgery, subjects had the option to continue (or initiate)",phs003148.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003148,Sung Choe,Nathaniel Boyd,Office of Data Sharing (ODS),,,2023-03-22,DS-GL,RNA-Seq,Clinical Trial,Glioma,41.0,41.0,https://clinicaltrials.gov/ct2/show/NCT03343197,IDH1,IDH1;AG-120;ivosidenib;vorasidenib,Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia
RNA Splicing Dysregulation in the Pathogenesis of Chronic Lymphocytic    Leukemia,"RNA splicing dysregulation is a hallmark of cancers, promoting the onset and progression of disease. In chronic lymphocytic leukemia (CLL), spliceosome mutations leading to aberrant splicing occurs in approximately 20%  of patients. However, the underlying mechanism for splicing defects in spliceosome unmutated CLL cases remains elusive. To discover",phs003191.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003191,Lili Wang,Ian Fingerman,Division of Cancer Biology (DCB),,,2023-03-21,DS-CLL-PUB-NPU,RNA-Seq;OTHER,Cohort;RNA Sequencing,"Leukemia, Lymphocytic, Chronic, B-Cell",48.0,56.0,,METTL3;METTL16;SF3B1,,"B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic"
Development and Validation of Patient-Derived Xenografts from    Fibrolamellar Carcinoma Human Tissue,"We developed and validated Patient-Derived Xenografts (PDX) of Fibrolamellar Carcinoma human tissue from surgical resections. Human tissues from primary liver tumor, recurrent liver, and liver metastases were implanted into NOD-SCID-Gamma  (NSG) mice (Jackson laboratories) and monitored for tumor growth. Some of the original tissues were frozen for further analysis including RNA",phs002435.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002435,Sanford M. Simon,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),34127480,P50CA210964;U54CA243126,2023-03-17,DS-HCC-IRB-COL,RNA-Seq,Case Set;Full Transcriptome Sequencing;Metastasis;RNA Sequencing;Transcriptome Sequencing;Tumor;Tumor vs. Matched-Normal;Xenograft,"Carcinoma, Hepatocellular",5.0,19.0,https://fibrolamellar.rockefeller.edu/repository;https://fibroregistry.org/;https://fibrolamellar.rockefeller.edu/,,Xenograft Model Antitumor Assays;Drug Repositioning,"Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells"
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic    Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer    Brain Metastases,This study is a phase I trial combining ado-trastuzumab emtansine (T-DM1) with Temozolomide (TMZ) for the prevention of additional brain metastases after previous occurrence and local treatment in HER2+ breast  cancer patients. Twelve patients were enrolled in this study. Data includes whole exome sequencing (WES) from patients' cerebrospinal fluid (CSF) and,phs003165.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003165,Stan Lipkowitz,Kathleen Calzone,Center for Cancer Research (CCR),,,2023-03-16,GRU,Seq_DNA_SNP_Target;WXS,Case Set;Clinical Trial;Exome Sequencing,Breast Neoplasms,12.0,69.0,,DNMT3A;ELP1;NOTCH4;KMT2B;CRLF2;KCNJ18,Brain Neoplasms;Blood;Cerebrospinal Fluid;Exome Sequencing;Cell-Free Nucleic Acids,Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour; Neoplasm of Brain
Germline Genetics of Myelodysplastic Syndromes (MDS) and Acute Myeloid    Leukemia (AML),"Myelodysplastic syndromes (MDS) are part of a heterogeneous and overlapping group of clonal diseases including acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), and the hybrid MDS/MPN entities that arise in  hematopoietic stem or progenitor cells. Individuals with MDS have a high risk of progressing to leukemia, with approximately 30% expected to develop",phs002962.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002962,"Jenny N. Poynter, PhD",,,33416407;33392905;32285234;31058390;27603749;27121678;26720913;26063191;25701277,R01CA142714,2023-03-16,GRU-PUB;NRUP,Array_SNP,Case-Control,Myelodysplastic Syndromes,1715.0,1711.0,,,Acute Myeloid Leukemia,AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL
PDAC Prognosis Biomarkers in Genomic and Transcriptomic Molecular Data,"Our study was designed to identify biomarkers related to the prognosis of Pancreatic Ductal AdenoCarcinoma (PDAC) patients using genomic variants and gene expression in coding regions of the human genome  (exome). PDAC is the 7th cause of cancer deaths and is among types of cancer having the poorest prognosis. To improve treatment outcomes of PDAC,",phs002347.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002347,"Taesung Park, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,,2023-03-15,GRU,RNA-Seq;Seq_DNA_SNP;WXS;Seq_DNA_SNP_MAF_Sum,Copy Number Variation (CNV);Exome Sequencing;Full Transcriptome Sequencing;Individual-Level Genomic Data;RNA Sequencing;Tumor vs. Matched-Normal,"Carcinoma, Pancreatic Ductal",150.0,450.0,,,Adenocarcinoma,"Adenocarcinoma; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant; Malignant Adenoma"
Single Cell Analysis of Sporadic Human Basal Cell Carcinomas,"To explore tumor heterogeneity in sporadic human basal cell carcinoma tumors, we profiled three individual patient tumors by scRNA-Seq and scATAC-Seq. Basal cell carcinomas (BCCs) are driven by hedgehog signaling  with GLI1 representing the key downstream transcription factor that drives tumor growth. GLI1 as such is a readout of active hedgehog signaling. We",phs003103.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003103,"Anthony Oro, MD, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),36473848,R01AR04786;R37ARO54780,2023-03-09,GRU,Seq_RNA_Expression_SC;OTHER,Case Set,"Carcinoma, Basal Cell",3.0,6.0,,LY6D;GLI1,"Carcinoma, Squamous Cell;Basal Cell Nevus Syndrome",Basal Cell Nevus Syndrome; BCNS; BCNS - Basal cell nevus syndrome; BCNS1; Basal cell carcinoma syndrome; Fifth Phacomatoses
NSD2 E1099K Drives Relapse in Pediatric Acute Lymphoblastic Leukemia by    Disrupting 3D Chromatin Organization,"NSD2 p.E1099K (EK) is a mutation shown to be enriched in patients that relapse with pediatric Acute Lymphoblastic Leukemia (ALL). This work aims to uncover 3D chromatin architecture-related mechanisms responsible  for drug resistance or therapy failure in these patients. We investigated this by performing Hi-C, ATAC-Seq, and RNA-Seq on three B-ALL cell lines",phs003195.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003195,Sonali Narang;Nikki A. Evensen,,,37016431;32332049,,2023-03-08,GRU,RNA-Seq,Phase III,Precursor Cell Lymphoblastic Leukemia-Lymphoma,3.0,6.0,https://childrensoncologygroup.org/aall1331;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE149159;https://www.stjude.org/research/departments/computational-biology.html,NSD2,"ALL, Childhood;Childhood ALL;Neoplasm;Pediatrics","ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic; Leukemia, Lymphoblastic, Acute, L1"
Single Cell Genomic Analysis of Lymphoma,"Our study aimed to define the extent of heterogeneity between anatomically separated tumor manifestations in follicular lymphoma at single-cell resolution. We subjected single-cell suspensions derived from nodal, synchronously-acquired fine needle  aspirations from two distinct tumor sites to high-throughput microfluidics-based single-cell RNA sequencing. By comparing the relative composition of",phs002188.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002188,"Ronald Levy, MD",,,33728464,R35 CA197353;TRP 6539-18;Hoogland&#160;Lymphoma Research Fund,2023-03-03,GRU,OTHER,Single Cell Analysis,Lymphoma,10.0,22.0,,,Follicular lymphoma,"Follicular Lymphoma; Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers; FOLLICULAR LYMPHOMA, SOMATIC"
Improved T Cell Immunity Following Neoadjuvant Chemotherapy in Ovarian    Cancer,This study characterized the evolution of the peripheral immune cell function and composition across the course of standard of care platinum and taxane chemotherapy in ovarian cancer using bulk and  single cell transcriptomic approaches. Serial blood samples were collected from ten patients with advanced high-grade serous ovarian cancer treated,phs002862.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002862,"Catherine Wu, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),30568305;33479501;31178118;27707838;32209603;24462293;32572264;36130281,"Specialized Program of Research
  Excellence (SPORE) in Ovarian Cancer (PAK, UAM, CJW)",2023-03-02,GRU,OTHER,Longitudinal,"Carcinoma, Ovarian Epithelial",10.0,10.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE206339,HLA-DPA1;HLA-DPB1;HLA-DQA1;HLA-DQB1;HLA-DRA;HLA-DRB1;HLA-DRB5,Immunity;Antigen Presentation,"Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian; Epithelial Cancer, Ovarian"
NCI-Maryland Prostate Cancer Case-Control Study,"The study seeks to examine the genetic and ancestral basis of prostate cancer-associated inflammation using a genome-wide association approach. The study population are the participants of the NCI Maryland Prostate  Cancer Case-Control study. This study recruited both African American and European American men, and investigated the causes for the excessive burden",phs002939.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002939,"Stefan Ambs, PhD",Kathleen Calzone,Center for Cancer Research (CCR),28292923,ZIA BC 010499,2023-03-01,HMB-IRB-PUB-NPU-MDS,Array_SNP,Case-Control,Prostatic Neoplasms,1450.0,1450.0,,,Genetics;Disease-Free Survival,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Childhood Cancer Data Initiative (CCDI): Clonal Evolution During    Metastatic Spread in High-Risk Neuroblastoma,"The goal of this study is to deliver a detailed characterization of the patterns of disease dissemination at diagnosis, during progression and in response to therapy in high-risk neuroblastoma. Longitudinal  and spatially distinct tumors were collected from patients. Clinical data includes diagnosis and treatment information. Biospecimen data includes",phs003111.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003111,"Elli Papaemmanuil, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),37169874,,2023-02-28,HMB,RNA-Seq;WGS,Longitudinal Cohort;Transcriptome Sequencing;Whole Genome Sequencing,Rare Diseases,129.0,487.0,,MYCN;ATRX;TERT,Neoplasms;Pediatrics;Neuroblastoma,Rare Disease; Blastoma; CA; CA - Cancer; Cancer; MT
Childhood Cancer Data Initiative (CCDI): Comprehensive Genomic Sequencing    of Pediatric Cancer Cases (CMRI/KUCC),"This study provides paired tumor normal genomic sequencing data from 200 children with cancer, including both solid tumors and leukemias, done by the Children's Mercy Research Institute (CMRI) and University  of Kansas Cancer Center (KUCC). These data include whole genome sequencing (generally, 20x), whole exome sequencing (generally, 300x), bulk RNA",phs002529.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002529,"Roy Jensen, MD;Midhat Farooqi, MD, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,"National Cancer Institute, Center for Biomedical
  Informatics and Information Technology 3P30CA168524-09S3;Big Slick;Children's Mercy Research Institute;Black & Veatch;Braden's HOPE For Childhood Cancer;Curing Kid's Cancer;Alex&#8217;s Lemonade Stand;Noah's Bandage Project;Children's Mercy Cancer Center Auxiliary Research Fund;Department of Defense, U.S. Army Medical Research and
  Development Command W81XWH-20-1-0358;Masonic Cancer Alliance, Partner's Advisory Board",2023-02-28,DS-CA,RNA-Seq;WXS;WGS;ATAC-seq,Case Set;Clinical Cohort;Clinical Genetic Testing;Exome Sequencing;Full Transcriptome Sequencing;Individual-Level Genomic Data;Mixed;Probands;Repository;RNA Sequencing;Sequencing;Single Cell Analysis;Transcriptome Sequencing;Tumor;Tumor vs. Matched-Normal;Whole Genome Sequencing,Whole Genome Sequencing,193.0,372.0,,ALK;BRAF;CRLF2;CTNNB1;ETV6;EWSR1;FLT3;FOXO1;IKZF1;KMT2A;KRAS;MYCN;NOTCH1;NPM1;NRAS;NUP98;P2RY8;RUNX1;SMARCB1;TP53,Leukemia;Neoplasms;Pediatrics;Exome Sequencing;RNA-Seq,Leukemia; Blood (Leukemia); Blood cancer; Leucocythaemia; Leucocythaemias; Leucocythemia
Comparison Between qPCR and RNA-Seq Reveals Challenges of Quantifying HLA    Expression,Human leukocyte antigen (HLA) class I and HLA class II loci are essential elements of innate and acquired immunity. Their exceptional influence on disease outcome is well documented by GWAS  and candidate gene studies. The impact of HLA allelic variation on human disease through allele-specific presentation of antigenic peptides to T,phs003177.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003177,Mary Carrington,Kathleen Calzone,Center for Cancer Research (CCR),36707444,,2023-02-24,GRU,RNA-Seq,Genotype/Expression,HLA Antigens,96.0,125.0,,HLA-A;HLA-B;HLA-C,RNA-Seq;Real-Time Polymerase Chain Reaction,Not Provided
Whole Exome Sequencing of Calcitonin Producing Pancreatic Neuroendocrine    Neoplasms (CT-pNENs) Indicates a Unique Molecular Signature,"Calcitonin-producing pancreatic neuroendocrine neoplasms (CT-pNENs), which can mimic clinical and laboratory features of medullary thyroid carcinoma, are an extremely rare clinical entity with approximately 60 cases reported worldwide. The molecular  profile of CT-pNENs is not yet known. Whole-exome sequencing (WES) was performed on tumor and corresponding serum samples of five patients with",phs003060.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003060,Detlef Klaus Bartsch,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-02-24,GRU,WGS,Clinical Cohort;Cohort;Copy Number Variation (CNV);Exome Sequencing;GWAS;Prospective;Sequencing;Tumor;Tumor vs. Matched-Normal,Insulinoma,5.0,10.0,,,,"Adenoma, beta Cell; Adenoma, beta-Cell; Adenomas, beta-Cell; Beta cell adenoma; Insulinomas; Insuloma"
Gene Expression of Small Cell Carcinoma of the Ovary-Hypercalcemic Type    (SCCOHT),"Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare and aggressive form of ovarian cancer afflicting young women at a median age of 24 years. SCCOHTs are characterized  by loss of protein expression of SWI/SNF chromatin remodeling ATPases SMARCA4 and SMARCA2 through mutation and epigenetic silencing, respectively.",phs001528.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001528,Jeffrey Trent,Ian Fingerman,Division of Cancer Biology (DCB),29440177,"Anonymous philanthropic donation;R01 CA195670 to Jeffrey Trent, Bernard Weissman, and David Huntsman;Terry Fox Research Institute PPG #1082 to David Huntsman",2023-02-24,HMB,RNA-Seq,Case Set,Ovarian Neoplasms,9.0,9.0,,SMARCA2;SMARCA4,,"Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian"
Oncoarray Consortium - Lung Cancer Studies,"The study was conducted under the auspices of the Transdisciplinary Research In Cancer of the Lung (TRICL) Research Team, which is a part of the Genetic Associations and MEchanisms in  ONcology (GAME-ON) consortium, and associated with the International Lung Cancer Consortium (ILCCO). Ethics: All participants provided written",phs001273.v4.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001273,"Christopher Amos, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),35915169;28604730;27697780;24880342;24681604;22899653,"U19 CA148127;HHSN268201200008I. NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2023-02-24,DS-CA;CHRONIC;EPIMEDCA;HMB-PUB;DS-CA-MDS;GRU-COL;GRU;LCEDOE;DS-CA-GSO;HMB-MDS-GSO;LDS;DS-CALD-PUB-NPU;DS-CA-PUB-NPU;HMB;DS-CA-COL-NPU-MDS;CADM,Imputation_SNP_CNV;Array_SNP,Case-Control,Lung Neoplasms,38721.0,39518.0,,BRCA2;CHRNA3;CHRNA5;MSH5;RAD52;TERT;BAG6;TP63;CHEK2;CLPTM1L,"Adenocarcinoma;Neoplasms, Squamous Cell","Adenocarcinoma; Neoplasms, Squamous Cell; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant"
"Advancing Precision Oncology in a Humanized, Fully Autologous Mouse Model","Progress in the early detection and treatment of cancer requires accurate model systems to further evaluate new, promising discoveries. Small animal and, in particular, mouse model systems are attractive to  researchers for numerous reasons, including their ease of use and well-described platforms. The ability to grow human tumors in immune-deficient mice",phs003090.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003090,Ryan C. Fields;Richard A. Flavell,Ian Fingerman,Division of Cancer Biology (DCB),,,2023-02-14,GRU,RNA-Seq;WXS,Cohort,Melanoma,4.0,40.0,,VEGFA,Heterografts;Cell Line;Tumor Microenvironment,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Urothelial Cancer - Genomic Analysis to Improve Patient Outcomes and    Research (UC-GENOME): a Bladder Cancer Advocacy Network (BCAN)-Led    Collaborative Research Pilot Study - for Samples Collected at Johns    Hopkins,UC-GENOME is a real-world cohort of patients with metastatic urothelial carcinoma (UC). The study consisted of two co-equal aims: 1) to provide targeted DNA sequencing for clinical decision making at  no cost to patients; and 2) to create a resource for collaborative translational science including a clinically annotated biobank. The submitted data,phs003094.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003094,Matthew Milowsky MD;William Kim MD,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),36333289,"James Family Foundation, The JPB Foundation, and The Gerald C. McNamara and Renee K. Petrofes Charitable Fund;R01-CA241810;P30-CA016086",2023-02-09,DS-TCC-IRB-NPU,RNA-Seq;Targeted-Capture,Prospective,Urinary Bladder Neoplasms,8.0,14.0,https://clinicaltrials.gov/ct2/show/NCT02643043,TP53;APOBEC3A;APOBEC3B;KMT2D;ARID1A;FGFR3;CD8;ERCC2;FANCC;ATM;RB1,Cancer of Urinary Tract;Immunotherapy,"Bladder Cancer; Cancer of Urinary Tract; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder"
Metastatic Colorectal Adenocarcinoma Tumor Purity Assessment from Whole    Exome Sequencing Data,"As molecular medicine wields greater and greater influence on cancer patient care, including therapeutic selection, it becomes increasingly important to understand the power and deficiencies of computational tools used in  decision making processes. Here we use a set of unselected metastatic colorectal tumor samples in a head-to-head comparison between the calculation",phs003059.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003059,Luika Timmerman;Robert S. Warren,Joseph Flores-Toro,Office of Data Sharing (ODS),"22439926;22865778;20407439;25706628;33425983;24562872;33015524;26634437;25544022;25319062;27999612;30343529;19451168;19505943;20601685;29165669;32807924;29692415;22810696;29316426;33495476;24323355;No PMID: Scaling accurate genetic variant discovery to tens of thousands of samples | Poplin R, Ruano-Rubio V, DePristo MA, Fennell TJ, Carneiro MO, Van der Auwera GA, et al.",,2023-02-08,GRU,WXS,Case Set;Exome Sequencing;Metastasis;Sequencing;Tumor;Tumor vs. Matched-Normal;Xenograft,Colorectal Neoplasms,18.0,30.0,,KRAS;TP53,Neoplasm Metastases,Neoplasm Metastases; CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine
Genomic Characterization CS-MATCH-0007 Arm Y,The CS-MATCH-0007 protocol is a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using  pre-and post-treatment tumor biopsy specimens from all patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131). The goal of,phs001904.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001904,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;33377972;37322121,Division of Cancer Treatment and Diagnosis,2023-02-07,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,31.0,31.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,AKT1,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
"An Advanced Molecular Medicine Case Report of a Rare Human Tumor Using    Genomics, Pathomics, and Radiomics","The associated data of this study is derived from a single female patient with pulmonary sclerosing pneumocytoma (PSP). The aim of this study is to provide the most comprehensive, multi-modality  sequencing study of a single case of PSP to-date. To this end, the following sequencing experiments were performed: i) RNA-Seq of the primary tumor",phs003154.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003154,"Donald J. Johann, Jr.",Nathaniel Boyd,Office of Data Sharing (ODS),,,2023-02-06,GRU-PUB,RNA-Seq;Targeted-Capture;WGS,Case-Control;Copy Number Variation (CNV);Full Transcriptome Sequencing;RNA Sequencing;Single Patient;Tumor vs. Matched-Normal,Pulmonary Sclerosing Hemangioma,1.0,16.0,,AKT1;MDM2,,"Hemangioma, Sclerosing, Pulmonary; Lung Sclerosing Angioma; Lung Sclerosing Hemangioma; Lung Sclerosing Hemangiomas; Pneumocytoma; Pulmonary Sclerosing Hemangiomas"
Novel Strategies to Eliminate Resistance to B-cell Receptor Inhibitor    Therapy in Lymphoid Malignancies,"Ibrutinib and acalabrutinib are BTK inhibitors (BTKi) used as frontline therapies for chronic lymphocytic leukemia (CLL). Clonal evolution during ibrutinib treatment has previously been studied, but limited study of clonal  evolution in patients receiving acalabrutinib has been done. Our group analyzed 216 blood samples from 38 CLL patients at multiple time points during",phs003042.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003042,"Deborah M. Stephens, DO",Mariam Eljanne,Center for Cancer Training (CCT),35476648,K23 CA212271,2023-02-06,GRU,WXS,Case Set;Longitudinal,Clonal Evolution,38.0,216.0,,BTK;TP53,"Leukemia, Lymphocytic, Chronic, B-Cell;acalabrutinib;ibrutinib","Evolution, Clonal; B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade"
SU2C-MARK Lung Cancer Consortium - Checkpoint Blockade Response Project,"Immune checkpoint inhibitors have become a critical part of the armamentarium against advanced Non-Small Cell Lung Cancer (NSCLC). While early studies have identified Tumor Mutation Burden (TMB) and PD-L1 staining  as important biomarkers of response, they remain imperfect predictors. Here we describe a multi-institutional effort as part of the SU2C-MARK Lung",phs002822.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002822,Justin Gainor,Freddie Pruitt,Center for Cancer Genomics (CCG),,Stand Up To Cancer (SU2C) - American Cancer Society Lung Cancer Dream Team Translational Research Grant;Mark Foundation for Cancer Research - Expanding Therapeutic Options for Lung Cancer (EXTOL),2023-02-02,DS-CATHLU-MDS;HMB-MDS;GRU,Seq_RNA_SNP_MAF_Ind;Targeted-Capture,Clinical Cohort,"Carcinoma, Non-Small-Cell Lung",230.0,463.0,,,Squamous Cell Carcinoma;Adenocarcinoma;Large Cell Carcinoma,"Adenocarcinoma; Large Cell Carcinoma; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant"
Whole-Genome Sequencing Analysis of Extrachromosomal DNA with Amplicon    Architect,"The study is related to our manuscript entitled ""Single-cell genetic heterogeneity linked to immune infiltration in glioblastoma"". Using multiplexed FISH analysis of 3-4 tumor cores from 17 glioblastoma formalin-fixed paraffin-embedded  (FFPE) tumors, we identified two classes of tumors based on single cell co-occurrence of EGFR and CDK4 amplification. Tumors with a low odds ratio",phs003100.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003100,Michalina Janiszewska,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2023-01-31,GRU,WGS,Tumor;Whole Genome Sequencing,Glioblastoma,6.0,6.0,https://www.biorxiv.org/content/10.1101/2021.09.20.461080v1,EGFR;CDK4,DNA Copy Number Variations;Genomic Structural Variation,"Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme"
RNA-Sequencing of B-Lymphoblastic Leukemia with Glucocorticoids and PI3K    Delta Inhibition,"Mononuclear cells were isolated from bone marrow or peripheral blood of 7 pediatric subjects with B-lymphoblastic leukemia at the time of diagnosis. To determine the effect of PI3K delta inhibition  on glucocorticoid-induced gene regulation, B-lymphoblastic leukemia cells were treated with glucocorticoids +/- the PI3K delta inhibitor, idelalisib,",phs003085.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003085,"Miles A. Pufall, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,P30CA086862;K12HD027748;Aiming for a Cure Foundation Grant,2023-01-31,GRU,RNA-Seq;Seq_RNA_Expression,Case Set;RNA Sequencing;Tumor,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma,7.0,65.0,,,,"Leukemia, Pre B Cell; Leukemia, Pre-B-Cell; Leukemias, Pre-B-Cell; Pre B ALL; Pre B Cell Leukemia; Pre B-ALL"
Targeted Long-Read Sequencing of the Ewing Sarcoma 6p25.1 Susceptibility    Locus,"Ewing Sarcoma (EwS) is rare but the second most common cancer in children, adolescents and young adults. Recent studies suggest germline variation in or around GGAA microsatellites may interact with  fusion oncoprotein binding causing changes in binding affinity and potentially impacting enhancer activity on nearby target genes. This study aims to",phs003159.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003159,Mitchell Machiela,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),30093639,,2023-01-27,DS-ES,AMPLICON,Case-Control,"Sarcoma, Ewing",231.0,462.0,,RREB1,,ES; Ewing Sarcoma; Ewing Tumor; Ewing tumour; Ewing's Sarcoma; Ewing's Tumor
Radiation-Related Genomic Profile of Papillary Thyroid Cancer after the    Chernobyl Accident,"The April 26, 1986 accident at the Chernobyl nuclear power plant in northern Ukraine resulted in the release of radioactive contaminants, which were deposited in the surrounding areas in Ukraine,  Belarus, and Russia. The main radiation-related health effect resulting from these exposures is the increased occurrence of thyroid cancer among",phs001134.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001134,"Stephen J. Chanock, MD",,,22394998,"Intramural funds, ZIA CP010132-19",2023-01-24,NRUP;GRU,Array_SNP,Case Set,"Thyroid Cancer, Papillary",442.0,4615.0,https://www.chernobyltissuebank.com/,,"Chernobyl Nuclear Accident;Neoplasms, Radiation-Induced;Iodine Radioisotopes","Neoplasms, Radiation-Induced; Neoplasm, Radiation-Induced; Neoplasms, Radiation Induced; Radiation Induced Neoplasm; Radiation Induced Neoplasms; Radiation-Induced Neoplasm"
"Multi-Modal Single-Cell and Whole-Genome Sequencing of Small, Frozen    Clinical Specimens","Clinical application of single-cell sequencing technologies has been hampered by their need for quick processing of relatively large, fresh specimens. Here, we benchmarked the performance of a new technique for  single-cell sequencing from snap-frozen clinical samples, vs. sequencing from fresh samples, on 5 samples from cutaneous melanoma brain metastasis, 6",phs003097.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003097,"Benjamin Izar, MD, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),36624340,,2023-01-18,GRU,WXS;OTHER;WGS,Cohort;Collection;Epigenetics;Metastasis;RNA Sequencing;Sequencing;Single Cell Analysis;Tumor,Neoplasm Metastasis,41.0,94.0,,,"Melanoma;Uveal melanoma;Carcinoma, Non-Small-Cell Lung","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell"
Urothelial Cancer - Genomic Analysis to Improve Patient Outcomes and    Research (UC-GENOME): A Bladder Cancer Advocacy Network (BCAN)-Led    Collaborative Research Pilot Study,UC-GENOME is a real-world cohort of patients with metastatic urothelial carcinoma (UC). The study consisted of two co-equal aims: 1) to provide targeted DNA sequencing for clinical decision making at  no cost to patients; and 2) to create a resource for collaborative translational science including a clinically annotated biobank. The submitted data,phs003066.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003066,Matthew Milowsky MD;William Kim MD,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),"No PMID: Urothelial Cancer - Genomic Analysis to Improve Patient Outcomes and Research (UC-GENOME): a Bladder Cancer Advocacy Network (BCAN)-led Collaborative Research Pilot Study | Damrauer JS, Beck W, Klomp G, Zhou M, Plimack ER, Galsky MD, Grivas P, Hahn NM, O&#8217;Donnell PH, Iyer G, Quinn DI, Vincent BG, Quale, DZ, Wobker SE, Hoadley KA, Kim WY, Milowsky MI","James Family Foundation, The JPB Foundation, and The Gerald C. McNamara and Renee K. Petrofes Charitable Fund;R01-CA241810;P30-CA016086",2023-01-12,DS-UC,RNA-Seq;Targeted-Capture,Prospective,Urinary Bladder Neoplasms,194.0,353.0,https://clinicaltrials.gov/ct2/show/NCT02643043,TP53;APOBEC3A;APOBEC3B;KMT2D;ARID1A;FGFR3;CD8;ERCC2;FANCC;ATM;RB1,Cancer of the Urinary Tract;Immunotherapy,"Bladder Cancer; Cancer of the Urinary Tract; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder"
Genomic Characterization CS-MATCH-0007 Arm Q,The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).,phs001926.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001926,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),33048619;31922567;31504139;37322121,Division of Cancer Treatment and Diagnosis,2023-01-10,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,35.0,35.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,HER2,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Aurora US Metastatic Breast Cancer Retrospective Project,The AURORA US Metastatic Breast Cancer project is funded by the Breast Cancer Research Foundation (BCRF) Evelyn H. Lauder Founder's Fund for Metastatic Breast Cancer Research. This multi-center effort conducted  within the Translational Breast Cancer Research Consortium (TBCRC) and cancer researchers to better understand the metastatic process through the,phs002622.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002622,Charles M. Perou;Tari King,Freddie Pruitt,Center for Cancer Genomics (CCG),36585450,,2023-01-06,DS-BRCA;NRUP;HMB;GRU,Array_DNA_Methylation;WXS;RNA-Seq;WGS,Case Set,Breast Neoplasms,58.0,477.0,https://auroraus.org/;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE212375,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Genome Sequencing of Circulating Tumor Cells for Minimally Invasive    Molecular Characterization of Multiple Myeloma Pathology,"&#x0200b;&#x0200b;Multiple Myeloma (MM) develops from well-defined precursor stages known as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering MM (SMM); however, invasive bone marrow (BM) biopsy limits screening and monitoring  strategies for patients. In this study, we enumerated circulating tumor cells (CTCs) from patients with precursor and overt diseases, and developed a",phs003084.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003084,Irene Ghobrial;Gad Getz,Ian Fingerman,Division of Cancer Biology (DCB),,,2023-01-05,HMB,WGS,Tumor vs. Matched-Normal;Whole Genome Sequencing,Multiple Myeloma,51.0,135.0,,,Monoclonal Gammopathy of Undetermined Significance;Smoldering Multiple Myeloma,Monoclonal Gammopathy of Undetermined Significance; Smoldering Multiple Myeloma; Asymptomatic monoclonal gammopathy; Benign Monoclonal Gammapathies; Benign Monoclonal Gammapathy; Benign Monoclonal Gammopathies
Multiregional Single-Cell Transcriptomic Analysis of Liver Cancer,"In this study, we performed single-cell transcriptomic profiling of human liver tissues collected from hepatocellular carcinoma and intrahepatic cholangiocarcinoma patients. A total of seven primary liver cancer patients enrolled in  this study. Samples were collected from multiple regions, including tumor core, tumor border and adjacent non-tumor tissue. The 10x Genomics platform",phs003117.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003117,"Xin Wei Wang, PhD",Kathleen Calzone,Center for Cancer Research (CCR),,,2023-01-04,HMB-IRB-NPU;DS-LCCLD-IRB-NPU;GRU-COL,RNA-Seq,Case Set;Single Cell Analysis,"Carcinoma, Hepatocellular",7.0,34.0,,,Cholangiocarcinoma;Liver Neoplasms,"Liver Neoplasms; Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells"
The Genomics of Pilocytic Astrocytoma Formation in Neurofibromatosis Type    1,Neurofibromatosis type 1 (NF1) inherited cancer predisposition syndrome is one of the most common autosomal dominant tumor predisposition syndromes in which affected individuals develop brain tumors. These low-grade glial neoplasms  (pilocytic astrocytomas) typically arise in children younger than 7 years of age and are hypothesized to result from a combination of germline and,phs000563.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000563,"David Gutmann, MD, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),23222849,Doris Duke Fellowship;UL1-RR024992,2022-12-23,DS-BST-GSO,Array_DNA_Methylation;WGS,Case Set,Astrocytoma,4.0,10.0,,,Glioma;Neurofibromatosis Type 1,Neurofibromatosis Type 1; Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Glioma
The MD Anderson Colorectal Cancer Case Control Study,"Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the US. Driven by common disease common variants hypothesis, genome-wide association studies only identified a number of common  susceptibility loci that explained a small portion of CRC heritability. We conducted a case-control study using whole exome sequencing to identify",phs002691.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002691,"Yuanqing Ye, PhD;Chad D. Huff, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,R01-CA177935,2022-12-22,HMB-PUB,WXS;Seq_DNA_SNP_CNV,Case-Control,Colorectal Neoplasms,5384.0,5384.0,,,Family Medical History,Family Medical History; CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine
Circulating Tumor DNA in Intermediate Risk Rhabdomyosarcoma,"In this study, we evaluated circulating tumor DNA (ctDNA) as a biomarker in the serum of 124 patients with newly diagnosed intermediate risk rhabdomyosarcoma (IR RMS) from the&#x000a0;Children's Oncology Group&#x000a0;(COG)  biorepository. In addition to pre-treatment serum, we also analyzed matched tumor tissue and germline in a subset of patients. We profiled samples",phs002866.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002866,Brian D. Crompton,Joseph Flores-Toro,Office of Data Sharing (ODS),31174239;19770373,,2022-12-21,HMB,Targeted-Capture;WGS,Case Set;Cohort,Rhabdomyosarcoma,124.0,295.0,https://childrensoncologygroup.org/,CTNNB1;FGFR4;FOXO1;MYOD1;NRAS;PAX3;PAX7;ARID1A;BCOR,,Not Provided
Wistar PDX Development and Trial Center,"Overall the outcomes of patients with metastatic melanoma have improved dramatically over the last decade due to an improved understanding of the molecular drivers of this disease. In particular, multiple  targeted therapy regimens have been approved for patients with a BRAFV600E/K mutation, which are present in 50% of cutaneous melanomas. These",phs002432.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002432,Meenhard Herlyn,Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),,,2022-12-21,GRU-COL,,Case Set;Exome Sequencing;RNA Sequencing,Melanoma,46.0,185.0,,,Skin Neoplasms,"Skin Neoplasms; Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant"
Phase IB/II Study of Bazedoxifene in Combination with Palbociclib in    Patients with Endocrine Resistant Hormone Receptor-Positive Breast    Cancer,"In this phase Ib/II clinical trial, the investigators evaluated the efficacy and safety of the combination of palbociclib with bazedoxifene in patients with a metastatic endocrine-resistant hormone receptor-positive, HER2-negative breast  cancer. Furthermore, whole exome sequencing of cell-free tumor DNA was done on serial samples from these patients, revealing potential molecular",phs002802.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002802,"Rinath Jeselsohn, MD;Gad Getz, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),36215125,,2022-12-15,HMB,WXS;WGS,Prospective,Breast Neoplasms,32.0,98.0,,ESR1;PIK3CA,Cyclin-Dependent Kinase 4;Cyclin-Dependent Kinase 6;Circulating Tumor DNA;bazedoxifene [Supplementary Concept];palbociclib [Supplementary Concept],Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
HCI-PDX Trial Center for Breast Cancer Therapy,"The HCI-PDX Trial Center for Breast Cancer Therapy study is a collection of patient-tumor samples that are serially established as patient-derived tumor xenografts (human tumor in mouse) and matching organoids.  For this study, we describe valuable methods and resources to generate organoids and use them as cost-effective models for precision drug screens.",phs002479.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002479,"Alana Welm, PhD;Bryan Welm, PhD;K-T Varley, PhD;Gabor Marth, DSc",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),35221336,U54CA224076;U01CA217617,2022-12-15,GRU,Seq_DNA_SNP_MAF_Ind;RNA-Seq;WXS;Seq_RNA_Expression;Array_CNV,Case Set;Exome Sequencing;Genotype;RNA Sequencing,Breast Neoplasms,37.0,227.0,,,Xenograft Model Antitumor Assays;Organoids,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
"The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)","The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large population-based randomized trial designed and sponsored by the National Cancer Institute (NCI) to determine the effects of  screening on cancer-related mortality and secondary endpoints in over 150,000 men and women aged 55 to 74. The screening component of the trial was",phs001286.v3.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001286,"Neal Freedman, PhD, MPH",,,26435289;24115361,NCI Division of Cancer Prevention contract mechanisms and NCI Division of Cancer 			Epidemiology and Genetics intramural funds,2022-12-12,CADM,Array_SNP_CNV;Imputation_SNP_CNV,Cohort,Neoplasms,110559.0,112062.0,http://prevention.cancer.gov/major-programs/prostate-lung-colorectal,,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Childhood Cancer Data Initiative (CCDI): OncoKids - NGS Panel for    Pediatric Malignancies,"This study aimed to systematically collect clinical, registry and genomic data on pediatric cancer patients, and to contribute to the CCDI Pediatric Data Ecosystem. Clinical, treatment and outcome data on  1,039 pediatric cancer patients whose molecular profile was characterized on OncoKids gene panel at Children's Hospital Los Angeles was abstracted",phs002518.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002518,"Amie E. Hwang, PhD, MPH",Joseph Flores-Toro,Office of Data Sharing (ODS),,,2022-12-07,GRU,AMPLICON,Case Set;Clinical Genetic Testing,Neoplasms,1039.0,2246.0,,,Childhood;Pediatric,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Spatiotemporal Evolution of the ccRCC Microenvironment Links    Intra-Tumoral Heterogeneity to Immune Escape CINOMA,"We utilize temporal multi-regional multi-omics profiling to uncover the mechanisms of immune escape in clear cell renal cell carcinoma (ccRCC) in 29 patients including 17 patients from a neoadjuvant nivolumab  clinical trial. We observe that tumors can be broadly categorized into intra-tumoral heterogeneity (ITH) high and low, which correlates across",phs003079.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003079,"A. Ari Hakimi, MD",Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),,,2022-11-21,GRU,RNA-Seq;WXS;AMPLICON,Clinical Trial,"Carcinoma, Renal Cell",29.0,449.0,,CDKN2A;CDKN2B;HLA-A;HLA-B;HLA-C;PBRM1;SETD2;VHL,,"ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell"
Genomic Landscape of Pediatric Germ Cell Tumors,"Germ cell tumors (GCTs) are cancers of the testis, ovary and extragonadal sites that occur in infants, children, adolescents, and adults. Post-pubertal (type II) malignant GCTs may present as a  seminoma, non-seminoma or with mixed histologies. In contrast, pre-pubertal (type I) GCTs are limited to (benign) teratomas and (malignant) yolk sac",phs002009.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002009,"James Amatruda, PhD",Ian Fingerman,Division of Cancer Biology (DCB),31839537;31087453,"CA135731 to JFA;CA151284 to JNP;T32 CA099936 to JB;U10180886 supports the Children's Oncology Group;U24CA114766 supports the Children's Oncology Group;U10CA180899 supports the Children's Oncology Group;St. Baldrick's Foundation Consortium award (to ALF, MDK, and JFA);RP110394 to JFA",2022-11-21,DS-PEDCR,RNA-Seq,Case Set,"Neoplasms, Germ Cell and Embryonal",32.0,32.0,,APC;CTNNB1;FAT1,Seminoma,"Seminoma; Germ Cell and Embryonal Neoplasms; Germ Cell and Embryonic Neoplasms; Neoplasms, Germ Cell and Embryonic"
Genomic Analysis of Nucleic Acid Sequences from Pancreatic Cancer,"Our study aims to perform multi-omics analysis of pancreatic ductal adenocarcinoma. We performed dual single-cell RNA sequencing and whole genome sequencing on fresh tumor specimens and dual bulk RNA-sequencing and  16S amplicon sequencing on frozen tumor specimens to identify human and non-human nucleic acid sequences. Additionally, we identified microbial",phs003035.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003035,Subhajyoti De,Ian Fingerman,Division of Cancer Biology (DCB),,,2022-11-16,GRU,RNA-Seq;WGS;AMPLICON,Sequencing,"Carcinoma, Pancreatic Ductal",12.0,36.0,,,,"Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas; Duct Cell Carcinoma, Pancreas"
The Transcriptomic Landscape of Oncogenic PI3K Reveals Key Functions in    Splicing and Gene Expression Regulation,"This study includes RNA-seq of paired tumor biopsies from PIK3CA-mutated breast cancer patients that underwent treatment with PI3K&#x003b1; inhibitors. Patients with known PIK3CA mutations were enrolled in an open-label, phase  I dose-escalation study of oral daily GDC-0077 alone (Arm A), in combination with endocrine therapy with or without palbociclib (Arm C: GDC-0077 +",phs002840.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002840,"Eneda Toska, PhD, MS",Mariam Eljanne,Center for Cancer Training (CCT),35442400,,2022-11-14,DS-BRCA,RNA-Seq,Clinical Trial;RNA Sequencing;Transcriptome Sequencing,Breast Neoplasms,18.0,36.0,,PIK3CA,ER-Positive Breast Cancer,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Identification of Somatic Changes in Tumors from Fanconi Anemia Patients,This study focused on the identification of genomic signatures present in tumors from Fanconi anemia patients. Fanconi anemia is a rare hereditary disease caused by defects in DNA interstrand crosslink  repair. The primary patient phenotypes are bone marrow failure and cancer predisposition. We concentrated on squamous cell carcinomas and used whole,phs002652.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002652,"Agata Smogorzewska, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,"Pershing Square Sohn Prize for Young Investigators in Cancer Research;Fanconi Anemia Research Fund award;R01 HL120922;R01 CA204127;National Center for Advancing Translational Sciences (UL1 TR001866);Rubicon fellowship  (019.153LW.038);KWF Kankerbestrijding Young Investigator Grant (12797/2019-2, Bas Mulder Award);Howard Hughes Faculty Scholar Award",2022-11-14,NRUP;GRU,WXS;Synthetic-Long-Read;OTHER;WGS;RNA-Seq;Array_DNA_Methylation,Copy Number Variation (CNV);Exome Sequencing;Single Cell Analysis;Transcriptome Sequencing;Tumor vs. Matched-Normal;Whole Genome Sequencing,Fanconi Anemia,50.0,137.0,,FANCA;FANCC;FANCG;FANCD2;FANCM;FANCJ;FANCP;PIK3CA;MYC;EGFR;BRCA1;BRCA2;p53,Squamous Cell Carcinoma of Head and Neck;Genomic Instability;DNA Damage;DNA Copy Number Variations,DNA Damage; Genomic Instability; DNA Injuries; DNA Injury; DNA Lesion; DNA Lesions
Genetics of Prostate Cancer in Africa,"African Americans (AA) suffer from the highest rates of Prostate Cancer (CaP) in the world, but while men of African descent around the world suffer disproportionately from CaP compared to  men of other races or ethnicities, our understanding of the reasons for these disparities remains incomplete. To date, few exposure, lifestyle, or",phs002718.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002718,Timothy R Rebbeck;Ben Adusei;Ilir Agalliu;Judith Jacobson;Joseph Lachance;Serigne Magueye Gueye;Mohamed Jalloh;James E Mensah;Andrew Adjei;Ann Hsing;Pedro Fernandez;Akindele Olupelumi Adebiyi;Oseremen Inokhoife Aisuodionoe-Shadrach;Maureen Joffe;Elvira Singh,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),32393663;30260756;29953920;27986209,,2022-11-04,DS-PC;DS-CA-IRB;GRU,Imputation_SNP_CNV;Array_SNP,Case-Control;Genotype;GWAS;Meta-Analysis;Multicenter;Population Genomics,Prostatic Neoplasms,4728.0,4728.0,https://www.madcapnetwork.org,,African;Genetics;Risk,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Prospective Procurement of Solid Tumor Tissue to Identify Novel    Therapeutic Targets,Recent advances and insights into the molecular pathogenesis of cancer have led to the development of novel molecular and biologic targeted therapies for the treatment of advanced cancer patients. A  critical challenge in extending these studies involves the identification and validation of new therapeutic targets for future cancer therapies. In,phs001003.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001003,Steven A. Rosenberg,,,31164343,Intramural Research Program,2022-11-04,GRU,RNA-Seq;WXS;WGS,Cohort,Melanoma,210.0,970.0,https://clinicaltrials.gov/ct2/show/NCT01658917,,"Colonic Neoplasms;Ovarian Neoplasms;Stomach Neoplasms;Cholangiocarcinoma;Pancreatic Neoplasms;Rectal Neoplasms;Esophageal Neoplasms;Colorectal Neoplasms;Endometrial Neoplasms;Paraneoplastic Syndromes, Ocular","Esophageal Neoplasms; Paraneoplastic Syndromes, Ocular; Rectal Neoplasms; Bile duct cancer; CC; CCA"
A Pilot Study to Evaluate Tissue- and Plasma-based DNA Driver Mutations    in a Cohort of Patients with Pancreatic Intraductal Papillary Mucinous    Neoplasms,This is a retrospective study aimed at evaluating concordance between intraductal papillary mucinous neoplasm (IPMN) tissue and patient-matched plasma circulating tumor DNA (ctDNA) using a targeted sequencing approach. Archival solid  tissue genomic DNA was available for 46 patient FFPE blocks patient-matched plasma ctDNA was available from 15 of those patients. All tissues were,phs003043.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003043,"Jennifer B. Permuth, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),36454217,,2022-11-03,HMB-NPU,Targeted-Capture,Sequencing;Tumor,Pancreatic Intraductal Neoplasms,46.0,61.0,,RNF43;KRAS,"Cyst, Pancreatic;Sequencing, Next Generation","Cyst, Pancreatic; Intraductal Neoplasm, Pancreatic; Cyst of Pancreas; Cyst of the Pancreas; Cysts, Pancreatic; Multiple pancreatic cysts"
Kidney Two-Hit Mapping,Germ-line genetic variants identified thus far generally account for only part of the genetic risk predicted for most cancers. A component of the remaining risk may be explained by functionally  consequent genetic variants that are individually very rare (or private to that individual's family). While their identification may be highly,phs001971.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001971,"James McKay, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,R21 CA175979,2022-11-03,DS-KD,WXS,Case Set,Kidney Neoplasms,57.0,108.0,,,Blood,Kidney Tumor; Kidney cancer; Kidney neoplasm; Neoplasia of the kidneys; Neoplasm of Kidney; Neoplasm of the Kidney
Molecular Analysis of Short- Versus Long-Term Survivors of High-Grade    Serous Ovarian Carcinoma,"The underlying determinants for long-term survival (LTS, &#x02265;10 years) versus short-term survival (STS, 3 years) of patients diagnosed with high-grade serous ovarian carcinoma (HGSC) are largely unknown. The present study  sought to identify molecular predictors of LTS for women with HGSC. A cohort of 24 frozen HGSC samples (12 LTS and 12 STS) were collected and",phs003020.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003020,Anil K. Sood,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),36077735,,2022-11-02,HMB-IRB-PUB-COL,RNA-Seq;WGS,Copy Number Variation (CNV);Genotype/Expression;RNA Sequencing,Survival Analysis,24.0,69.0,,TMEM62,Ovarian Neoplasms,"Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian"
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the    Oral PARP Inhibitor Olaparib in Patients with Recurrent Triple    Negative Breast Cancer or High Grade Serous Ovarian Cancer,We analyzed massive parallel sequence data from patients with breast and ovarian cancer and identified single base substitution mutational signature 3 (Sig3) - extracted using SigMA - as a biomarker  of homologous recombination deficiency (HRD) and predictive for response to PARP inhibitors. Participants were patients enrolled in clinical trials,phs003019.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003019,Gerburg M. Wulf,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2022-10-27,HMB,WXS,Clinical Trial;Exome Sequencing;Prospective;Tumor,Neoplasms by Site,37.0,38.0,,,,"Neoplasm Site; Neoplasm Sites; Neoplasms by Sites; Site, Neoplasm; Sites, Neoplasm"
Kids First: Genetics of Kidney and Urinary Tract Malformations,"Congenital defects of the kidney and urinary tract are a common cause of kidney failure in children and adults and elucidation of the genetics of these disorders will provide new  opportunities for diagnosis, risk stratification and prevention of complications. Around 550 trios were selected for whole genome sequencing as part",phs002162.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002162,"Ali Gharavi, MD",,,,X01 HL145698-01,2022-10-21,GRU,,Cohort;Parent-Offspring Trios,Renal Adysplasia,1667.0,1673.0,https://commonfund.nih.gov/kidsfirst/X01Projects,,Hydronephrosis;Vesicoureteral Reflux,Hydronephrosis; Vesicoureteral Reflux; Hydronephroses; HEREDITARY RENAL APLASIA; HRA; RENAL AGENESIS
Single Cell Genome Variation Induced by Mutational Processes in Cancer -    HGSOC Trios Study,Mutational signatures derived from whole genome sequencing have potential prognostic significance. Identification of high grade serous ovarian cancer patients with deficiency in homologous recombination repair pathways could identify a subset  of patients that would benefit from homologous recombination deficiency-specific treatments independent of identification of a pathological BRCA1/2,phs003036.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003036,Sohrab P. Shah,Heather Basehore,Office of Data Sharing (ODS),,,2022-10-19,GRU,WGS,Tumor vs. Matched-Normal;Whole Genome Sequencing,Ovarian Neoplasms,8.0,26.0,,,,"Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian"
Circulating Tumor DNA Sequencing Provides Comprehensive Mutation    Profiling for Pediatric Central Nervous System Tumors,"Tumor molecular profiling is increasingly important for the diagnosis and clinical management of childhood brain tumors, including diffuse midline glioma (DMG). We established a targeted deep sequencing approach using the  TruSight Oncology 500 ctDNA exome panel to detect tumor genomic mutations and copy number variations in circulating tumor DNA from children diagnosed",phs003022.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003022,Javad Nazarian;Mickey Williams,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),36068285,,2022-10-19,GRU-IRB,WXS;Targeted-Capture,Cohort;Collection;Exome Sequencing;Tumor,Brain Neoplasms,10.0,29.0,,H3-3A;H3C2,Liquid Biopsy,Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour; Neoplasm of Brain; Neoplasm of the Brain
Characterizing Advanced Breast Cancer Heterogeneity and Treatment    Resistance through Serial Biopsies and Comprehensive Analytics,"This dataset accompanies the manuscript ""Characterizing Advanced Breast Cancer Heterogeneity and Treatment Resistance Through Serial Biopsies and Comprehensive Analytics"". In this study we discuss the clinical implications and consequences of  molecular heterogeneity in a metastatic breast cancer patient identified through serial biopsies, multi-omic analysis, and longitudinal patient",phs002321.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002321,"Zahi I. Mitri, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),33772089,Precision Oncology;The Prospect Creek Foundation;OHSU Knight Cancer Institute NCI Cancer Center Support Grant P30CA069533,2022-10-19,HMB,RNA-Seq;Seq_RNA_Expression;Array_Protein,RNA Sequencing;Single Patient;Tumor,Breast Neoplasms,1.0,2.0,https://www.synapse.org/#!Synapse:syn22975916/wiki/606342,CCND1;ERBB2;PIK3CA;TP53,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Integrative Analysis of Lung Adenocarcinoma in EAGLE (Phase 2),We performed whole genome sequencing and whole exome sequencing of 31 lung adenocarcinoma (LUAD) samples from the Environment And Genetics in Lung cancer Etiology (EAGLE) study. Lung adenocarcinoma cases only  Note for data in GDC: Molecular profiling data from CDDP EAGLE-1 study can be found at The NCI's Genomic Data Commons (GDC),phs001239.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001239,"Maria Teresa Landi, MD, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,"Intramural program, NCI, DCEG",2022-10-18,DS-LDS-MDS,,Case Set,Adenocarcinoma of Lung,50.0,150.0,https://dceg.cancer.gov/research/cancer-types/lung/environment-genetics-lung-cancer-etiology-eagle,,Adenocarcinoma of Lung,"ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma"
Genomic Characterization CS-MATCH-0007 Arm Z1D,The CS-MATCH-0007 protocol is a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using  pre-and posttreatment tumor biopsy specimens from all patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131). The goal of this,phs001859.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001859,"Lyndsay Harris, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),31922567;33048619;31765263;37322121,Division of Cancer Treatment and Diagnosis,2022-10-17,GRU-COL,,Cohort;Exome Sequencing;RNA Sequencing,Neoplasms,36.0,36.0,https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match,MLH1;MSH2,Turcot syndrome,Turcot syndrome; Blastoma; CA; CA - Cancer; Cancer; MT
Genomic Landscape of High-Grade Neuroendocrine Neoplasms,"This project is a multi-omics study of high grade (grade 3) neuroendocrine neoplasms across diverse organs. Genomic analysis using low-pass whole genome sequencing for copy number analysis, whole exome sequencing  and whole transcriptomic sequencing using RNAseq were performed. As high grade neuroendocrine neoplasms are highly lethal with a median survival of",phs002070.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002070,"Pamela Kunz, MD",Ian Fingerman,Division of Cancer Biology (DCB),,The Helen B. Rodde Fund,2022-10-13,GRU,RNA-Seq;Seq_RNA_Expression;WXS,Cohort,"Carcinoma, Neuroendocrine",36.0,69.0,,,Neuroendocrine tumors,Neuroendocrine Tumors
RB1 Loss Triggers Dependence on ESRRG in Retinoblastoma,"Retinoblastoma (Rb) is a deadly childhood eye cancer that is classically initiated by inactivation of the RB1 tumor suppressor. Clinical management continues to rely on nonspecific chemotherapeutic agents that are  associated with treatment resistance and toxicity. Here, we analyzed whole exomes from primary Rb tumors to identify novel Rb dependencies. Several",phs002859.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002859,J. William Harbour,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2022-10-11,GRU-PUB,WXS,Exome Sequencing;Tumor vs. Matched-Normal,Retinoblastoma,31.0,51.0,,ESRRG;RB1;BCOR,,"Cancer, Retinoblastoma Eye; Cancers, Retinoblastoma Eye; Eye Cancer, Retinoblastoma; Eye Cancers, Retinoblastoma; RB; RB - retinoblastoma"
Mayo Clinic Adult Diffuse Glioma Illumina OncoArray SNP data,These data are from adult diffuse glioma subjects genotyped on the Illumina OncoArray. Data from this study were used for case control association studies and developing polygenic risk scores. Inclusion  Criteria All subjects were pathologically confirmed to have glioma. Subjects had to be consented at 18 years of age or older. All subjects provided a,phs003041.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003041,"Robert Jenkins, MD, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),32386320;30624711,,2022-10-07,HMB,Array_SNP,Case Set,Glioma,794.0,794.0,,IDH1;IDH2;TERT;D2HGDH;FAM20C,"Genome-Wide Association Study;Polymorphism, Single Nucleotide",Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia
Transcriptional and Epigenetic Profiles of Male Breast Cancer at    Single-Cell Resolution Nominate Salient Cancer Specific Enhancers,We performed matched single-cell RNA sequencing (scRNA-seq) and single-cell chromatin accessibility sequencing (scATAC-seq) for two fresh human tumors collected from male breast cancer patients. The integration of these datasets revealed  the intratumoral heterogeneity in both transcription and chromatin accessibility for each male breast cancer patient and allowed for comparisons to,phs003006.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003006,"Hector. L. Franco, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,NIH/National Cancer Institute P50CA058223;NIH/National Cancer Institute 5UG1CA233333,2022-10-07,HMB,RNA-Seq;Seq_RNA_Expression_SC;ATAC-seq,Case Set,"Carcinoma, Ductal, Breast",2.0,4.0,,,,"BREAST CANCER, INVASIVE DUCTAL; Carcinoma, Infiltrating Duct; Carcinoma, Invasive Ductal, Breast; Carcinomas, Infiltrating Duct; Infiltrating Ductal Adenocarcinoma; Infiltrating Ductal Breast Carcinoma"
Adoptive Cell Therapy of Autologous T cell Receptor-Engineered T Cells    Targeting the p53 Neoantigens in Human Solid Tumors,"Adoptive T cell therapy (ACT) using T cell receptor (TCR)-engineered T cells can mediate regression of advanced human cancers. How TCR-transduced T cells change post-ACT in vivo is currently not  well understood. We screened 78 patients for TP53 mutations by whole exome sequencing and whole transcriptome sequencing. Of the 78 patient samples,",phs002928.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002928,Steven A. Rosenberg,Kathleen Calzone,Center for Cancer Research (CCR),35749374,,2022-10-06,GRU,RNA-Seq;WXS,Clinical Trial,"Immunotherapy, Adoptive",23.0,194.0,,TP53,"Neoplasms;Tumor Suppressor Protein p53;Genes, T-Cell Receptor",Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
BRCA Mutation Status Shapes the Microenvironment of Pancreatic    Adenocarcinoma,"This study was established in order to address how the stromal landscape is influenced by BRCA-mutated and BRCA Wild-type (WT) pancreatic ductal adenocarcinoma (PDAC). A primary cohort of 12 PDAC  patients (7 BRCA-WT and 5 germline BRCA-mut) was analyzed by laser-capture microdissection, RNA-sequencing and multiplexed immunofluorescence. Only",phs002994.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002994,"Scherz-Shouval, Ruth;Kelsen, David",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2022-10-05,HMB,RNA-Seq;Seq_RNA_Expression,Cohort;RNA Sequencing;Tumor,"Genes, BRCA2",12.0,12.0,https://www.biorxiv.org/content/10.1101/2021.08.18.456576v1.full,BRCA2;BRCA1;CLU;HSF1;GREM1,"Genes, BRCA1;Carcinoma, Pancreatic Ductal","Carcinoma, Pancreatic Ductal; Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas"
Exome Sequencing of Chordoma Cases,"Chordoma is a rare tumor that is believed to develop from notochord remnants. We previously identified germline duplication of the TBXT gene as a major susceptibility mechanism in several chordoma  families. Currently, we are using whole exome sequencing to identify additional susceptibility genes in chordoma families without TBXT duplication as",phs001280.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001280,"Rose Yang, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),35762214;34070849;32559743;24990759,Intramural Research,2022-10-05,DS-CHR-MDS,WXS;Seq_RNA_Expression;AMPLICON,Case Set;Family,Chordoma,132.0,374.0,,TBXT,,"CHDM; Chordomas; Notochordal sarcoma; chordoma (disease); chordoma, malignant; chordoma, susceptibility to"
"CIDR Estrogen Receptor Negative Breast Cancer in African American Women:    DNA Methylation, Reproductive Events, and Mammary Epithelial Cell    Populations","We conducted methylation profiling of breast tumor DNA from Formalin-Fixed Paraffin-Embedded (FFPE) samples for 1,550 cases from a cohort of Black women from the Black Women's Health Study (BWHS), the  Women's Circle of Health Study (WCHS), and from the Pathways Study using the Illumina MethylationEPIC array. We will examine differentially",phs002688.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002688,"Christine B. Ambrosone, PhD;Julie R. Palmer, ScD;Lawrence H. Kushi, ScD;Michael J. Higgins, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,"HHSN268201700006I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2022-10-04,HMB-IRB-PUB-NPU-MDS-GSO;HMB-IRB-PUB-NPU-GSO;HMB-COL-NPU-GSO,Array_DNA_Methylation,Case Set,Breast Neoplasms,1550.0,1550.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
APOLLO1: Proteogenomic Analysis of Lung Adenocarcinoma,"APOLLO is a proteogenomic study seeking to describe the major genome, transcriptome, proteome and phosphoproteome alterations, subtypes, and molecular predictors of patient outcomes. This study includes 87 lung adenocarcinomas and  matched normal tissues from the Lung Cancer Biospecimen Resource Network (https://lungbio.sites.virginia.edu/). Tumor tissues were profiled by whole",phs003011.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003011,"Christopher A. Moskaluk, MD, PhD",Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),36384096,,2022-10-03,GRU,,Tumor,Adenocarcinoma of Lung,87.0,261.0,https://proteomics.cancer.gov/programs/apollo-network;https://gdc.cancer.gov/about-data/publications/APOLLO-LUAD-2022,,,"ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma"
Genome-Wide Pleiotropy Scan Across Multiple Cancers,"A whole-exome sequencing (WES) study was conducted in 3,233 cases diagnosed with multiple primary cancers and 3,229 matched cancer-free controls (90% non-Hispanic white, 3% African-American, 3% East Asian, and 4%  Latino) selected from individuals in the Kaiser Permanente Research Bank (KPRB) who were members of the Kaiser Permanente Northern California (KPNC)",phs002809.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002809,"John S. Witte, PhD;Lori C. Sakoda, PhD;Rebecca E. Graff, ScD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),33087929;36199081,CA201358 (R01);AG036607 (RC2),2022-10-03,HMB-IRB-NPU,WXS;Seq_DNA_SNP,Case-Control;Exome Sequencing;Individual-Level Genomic Data;Prospective,"Neoplasms, Multiple Primary",5432.0,5432.0,,,,"Multiple Primary Neoplasm; Multiple Primary Neoplasms; Multiple Primary Neoplasms, Synchronous; Neoplasm, Multiple Primary; Neoplasm, Synchronous; Neoplasms, Synchronous"
A Genomic Approach to Improved Diagnosis and Treatment of Neuroendocrine    Tumors,"These are RNA-Seq samples from patients undergoing surgery for small bowel and pancreatic neuroendocrine tumors. Normal tissue, primary tumors, lymph nodes, and liver metastases were collected at surgery and stored  in RNAlater until RNA extraction was carried out for RNA-Seq. Patients having surgery for small bowel and pancreatic neuroendocrine tumors.",phs001772.v3.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001772,M. Sue O'Dorisio,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),29154080;30721156,1 P50 CA174521-01,2022-10-03,HMB-PUB-COL,RNA-Seq,Case Set,Intestinal Neoplasms,62.0,210.0,,,Pancreatic Neoplasms;Neoplasm Metastasis,Neoplasm Metastasis; Intestinal Tumor; Intestinal Tumors; Intestines Neoplasm; Intestines Neoplasms; Neoplasm of Intestines
Exploiting New Patterns of Genome Damage in Triple Negative Breast Cancer,"Genomic instability, a feature of triple negative breast cancers (TNBC), represents an opportunity for discovery of biologic and clinically relevant subgroups of patients. Owing to TP53 mutation in the majority  of cases, DNA repair deficiency through loss of BRCA1 and BRCA2, and by expression features patterning a basal cell of origin, TNBC represents a",phs003038.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003038,Sohrab P. Shah,Ying Huang,Office of Data Sharing (ODS),,,2022-09-30,GRU,Seq_DNA_SNP_MAF_Ind,Tumor vs. Matched-Normal;Whole Genome Sequencing,Triple Negative Breast Neoplasms,16.0,32.0,,,,"Breast Cancer, Triple-Negative; Breast Cancers, Triple-Negative; Breast Neoplasm, Triple-Negative; Breast Neoplasms, Triple-Negative; ER Negative PR Negative HER2 Negative Breast Cancer; ER Negative PR Negative HER2 Negative Breast Neoplasms"
The Genetic and Transcriptomic Evolution of Melanoma,"The overarching goal of the study was to better understand the evolution of melanoma. To do this, we collected archival tissue of melanomas adjacent to their intact, remnant precursor lesions.  We also collected archival tissue of primary melanomas and their matching metastases. From the formalin-fixed paraffin-embedded (FFPE) blocks, we",phs001550.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001550,"Boris C. Bastian, MD, PhD;A. Hunter Shain, PhD;Robert L. Judson, PhD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),26559571,R35 CA220481;DP5 OD019787,2022-09-30,DS-M-NPU,Hi-C;RNA-Seq;miRNA-Seq;WXS;Targeted-Capture,Tumor;Tumor vs. Matched-Normal,Melanoma,85.0,361.0,,BRAF;CDKN2A;TERT,Nevus;Clonal Evolution,"Clonal Evolution; Nevus; Evolution, Clonal; Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma"
Immune Profiles Study,"This study assesses glioma patient blood methylation longitudinally beginning pre-surgery through other clinically important timepoints. Progression and survival are studied in relation to methylation derived immunologic profiles and other characteristics.  For this study, patients scheduled for surgery at University of California San Francisco (UCSF) for a possible newly diagnosed glioma (grades 2-4) or",phs002998.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002998,"John Wiencke, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),35716311,,2022-09-29,GRU,Array_DNA_Methylation,Case Set,Glioma,135.0,135.0,,,,Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia
Functional Analysis of Genetic Variants in African Americans with Breast    Cancer,The goal of this study is to identify and characterize novel genetic variants associated with a predisposition to breast cancer (BCa) in African Americans (AAs) using a family case-family control  study design. Variants of unknown clinical significance (VUS) were characterized using bioinformatics tools. Future studies will further characterize,phs002977.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002977,"Luisel Ricks-Santi, PhD;J. Tyson McDonald, PhD",Ian Fingerman,Division of Cancer Biology (DCB),10480351;12942367;12491487;10417303,R15CA239100,2022-09-28,DS-BRCA,WXS,Affected Sib Pairs;Case-Control;Exome Sequencing;Extended Pedigrees;Family;Family Linkage;Genotype;Marker Discovery;Parent-Offspring;Probands,Breast Neoplasms,88.0,88.0,,,"Breast Cancer, Familial [Supplementary Concept];Hereditary Breast and Ovarian Cancer Syndrome",Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Whole-Genome Sequencing Reveals Complex Genomic Features Underlying    Anti-CD19 CAR T-Cell Treatment Failure in Lymphoma,"We performed Whole-Genome Sequencing (WGS) on 100 tumor and matched germline samples from 49 CD19-directed chimeric antigen receptor (CAR-19)-treated diffuse large B cell lymphoma (DLBCL) patients. We found that the  presence of complex structural variants, APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide) mutational signatures, and genomic",phs003023.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003023,Michael Jain,Freddie Pruitt,Center for Cancer Genomics (CCG),35476848,,2022-09-22,GRU-NPU,WGS,Whole Genome Sequencing,Lymphoma,49.0,100.0,,,"Lymphoma, Large B-Cell, Diffuse;Immunotherapy",Cancer of lymphatic system; Germinoblastic Sarcoma; Germinoblastic Sarcomas; Germinoblastoma; Germinoblastomas; Lymphoma (Hodgkin and Non-Hodgkin)
A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant    Therapy in Patients with Locally Advanced Squamous Cell Cancer of the    Head and Neck,"This genomic study was an analysis of DNA samples from subjects enrolled in a randomized, interventional, parallel assignment trial of everolimus versus placebo in advanced Head and Neck Cancer. Next  Generation Sequencing was performed on samples obtained from primary tumors before treatment. The purpose was to evaluate potential associations",phs002986.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002986,"Siddharth Sheth, DO, MPH",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),36194164,UG1CA233333,2022-09-21,GRU,Targeted-Capture,Case Set,Squamous Cell Carcinoma of Head and Neck,42.0,42.0,,TP53,,Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx
CCG Multicentric Italian Lung Detection (MILD),"For the CCG-MILD project, NCI will utilize whole genome sequencing and/or whole exome sequencing in conjunction with transcriptome sequencing to try to identify recurrent genetic alterations (mutations, deletions, amplifications, rearrangements)  and/or gene expression signatures that would be important to the hypothesis(es) submitted by the investigators. The samples will be processed and",phs002253.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002253,"Jean Claude Zenklusen, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2022-09-21,GRU,,Case Set,Lung Neoplasms,160.0,160.0,,,,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
Detection of Colorectal Cancer Susceptibility Loci Using Genome-Wide    Sequencing,The Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) is a collaborative effort comprised of a coordinating center and scientific researchers from well-characterized cohort and case-control studies. This international consortium  aims to accelerate the discovery of common and rare genetic risk variants for colorectal cancer by conducting large-scale meta-analyses of existing,phs001554.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001554,"Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),30510241,U01 CA164930,2022-09-19,HMB-IRB;HMB-IRB-NPU;GRU;DS-CC-NPU-GSO;CADM,Seq_DNA_SNP_CNV;WGS,Case-Control;Cohort;Nested Case-Control,Colorectal Neoplasms,2892.0,2892.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of    Castration Resistant Prostate Cancer (CRPC) Patients Treated with    Abiraterone Acetate,"The Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study uses genetic clues in castration-resistant prostate cancer that may identify an individualized treatment approach for men with the disease. Understanding the  molecular biology behind castration-resistant prostate cancer has led to more treatment options, but there are still no definite conclusions about",phs001141.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001141,"Manish Kohli, MD;Leiwei Wang, MD, PhD;Winston Tan, MD;Alan H. Bryce",Joseph Flores-Toro,Office of Data Sharing (ODS),26695660;27084275;29069303;30899904;39175441,"FP00069182;A.T. Suharya and Ghan D.H.;Joseph and Gail Gassner;Mayo Clinic Schulze Cancer for Novel Therapeutics in Cancer Research;U19GM61388;P30 CA015083;Research study drug supply was provided in part by Janssen Research & Development, LLC",2022-09-16,GRU,RNA-Seq;Seq_DNA_SNP;WXS,Case Set,"Prostatic Neoplasms, Castration-Resistant",88.0,398.0,http://mayoresearch.mayo.edu/center-for-individualized-medicine/prostate-cancer-study.asp,AR;FOXA1;PTEN;TP53;WNT5A;SPOP;WIF1;DKK1;SOST,Prostatic Neoplasms,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
UNC Tumor Donation Program Set 2021,"The goal of this study is to study gene expression patterns in primary, metastatic tumors, and normal tissues. The samples were obtained through the UNC tumor donation program. Inclusion criteria  were UNC patients with metastatic breast cancer with and without treatment options.&#x000a0; Principal Investigator: Charles M. Perou, PhD,",phs002429.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002429,"Charles M. Perou, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),23000897;29480819;32573490,P50 CA058223,2022-09-02,DS-CA;HMB,RNA-Seq,Case Set,Breast Neoplasms,30.0,125.0,,,Metastasis;RNA Sequence Analysis,Metastasis; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors
Myelofibrosis Etiology and Transplant Outcomes,"The Myelofibrosis Etiology and Transplant Outcomes study is a collaboration between the National Cancer Institute and the Center for International Blood and Marrow Transplant Research (CIBMTR). The study aims to  identify genomic factors affecting myelofibrosis pathogenesis and prognosis. Principal Investigator: Shahinaz Gadalla, PhD, MD, National Institutes",phs002635.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002635,"Shahinaz Gadalla, PhD, MD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,Intramural Research Program,2022-08-30,DS-HCTCT-IRB,Imputation_SNP_CNV;Array_SNP;AMPLICON,Case Set,Primary Myelofibrosis,548.0,1096.0,,,Neoplasms,AMM; Agnogenic Myeloid Metaplasia; Agnogenic Myeloid Metaplasias; Bone Marrow Fibroses; Bone Marrow Fibrosis; CIMF
Accurate Genome-Wide Germline DNA Profiling from Decade-Old Archival    Tissue Specimens,"We evaluate the validity of repurposing archival tissue specimens for germline genetic studies. We performed lc-WGS and imputed genotypes on 10 pairs of matching blood and tumor tissue and benchmarked  the accuracy of genome-wide genotypes, HLA haplotypes, and several polygenic risk scores (PRSs). The reported results indicate the high accuracy of",phs002865.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002865,Olivier Harismendy,Joseph Flores-Toro,Office of Data Sharing (ODS),,,2022-08-25,GRU,WGS,Sequencing,Neoplasms,50.0,50.0,,,"Multifactorial Inheritance;Carcinoma, Ductal, Breast;Breast Neoplasms;Breast Carcinoma In Situ;Sequence Analysis;High-Throughput Nucleotide Sequencing;Genotyping Techniques;Prognosis","Breast Carcinoma In Situ; Carcinoma, Ductal, Breast; Multifactorial Inheritance; LCIS - lobular carcinoma in situ; LCIS, Lobular Carcinoma In Situ; Lobular Carcinoma In Situ"
Scalable Whole-Exome Sequencing of Cell-Free DNA Reveals High Concordance    with Metastatic Tumors,"We performed whole genome sequencing and whole-exome sequencing of cell-free DNA (cfDNA) and whole-exome sequencing of matched tumor biopsies and germline DNA from patients with metastatic cancer. Using ichorCNA, a  software tool that quantifies tumor content in ultra-low pass whole genome sequencing ( 0.1x) of cfDNA without prior genomic characterization of the",phs001417.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001417,Viktor A. Adalsteinsson,Ian Fingerman,Division of Cancer Biology (DCB),29109393,P30-CA14051;Gerstner Family Foundation,2022-08-18,DS-CA-MDS;DS-PC-MDS;DS-BRCA-MDS,WXS;WGS,Case Set;Longitudinal Cohort,Neoplasms,545.0,1722.0,,,Neoplasm Metastasis,"Neoplasm Metastasis; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize"
Colon Cancer Family Registry (Colon CFR),"The Colon Cancer Family Registry Cohort (CCFRC www.coloncfr.org) is a cohort of families recruited through six study sites located in the USA, Canada, Australia, and New Zealand. The CCFRC was  formed as a resource to support studies on the etiology, prevention, and clinical management of colorectal cancer. Recruitment protocols fall broadly",phs002733.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002733,Jane A. Figueiredo;Steven Gallinger;Robert W. Haile;John L. Hopper;Jeremy R. Jass;Mark A. Jenkins;Loic Le Marchand;Noralane M. Lindor;Polly A. Newcomb;Rish K. Pai;Amanda I. Phipps;John D. Potter;Steven N. Thibodeau,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),17982118;29490034,U01 CA167551;UM1 CA167551;U01 CA044778;U01 CA074783;U24 CA074783;U01 CA074799;U24 CA074799;U01 CA097735;U24 CA097735;U01 CA074806;U24 CA074806;U01 CA074800;U24 CA074800;U01 CA074794;U24 CA074794;R01 CA104132;R01 CA118699;R01 CA076366,2022-08-15,DS-COC-IRB-COL;DS-CC-MDS;DS-CA-MDS;DS-CA-IRB-PUB-NPU-MDS;HMB;DS-CA-PUB-MDS;HMB-IRB-COL,,Case-Control;Cohort;Collection;Epigenetics;Extended Pedigrees;Family;Genotype;Genotype/Expression;GWAS;Individual-Level Genomic Data;Multicenter;Multiplex Families;Observational;Probands;Prospective;Tissue Expression;Tumor;Tumor vs. Matched-Normal,Colorectal Neoplasms,38362.0,0.0,https://www.coloncfr.org/,BRAF;MSH6;KRAS;EPCAM;MLH1;MSH2;MYH;PMS2,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
"UCSF Database for the Advancement of JMML - Integration of Metadata with    ""Omic"" Data",Juvenile myelomonocytic leukemia (JMML) is a rare and frequently fatal myeloproliferative/myelodysplastic disorder of early childhood with an estimated incidence of 1.2 cases per million. It is associated with a spectrum  of diverse outcomes ranging from spontaneous resolution in rare patients to transformation to acute myeloid leukemia in others. The overwhelming,phs002504.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002504,"Elliot Stieglitz, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),25704135;26457647;29259179;29528181;31347788;31511612;32815876;33139265;33375775,,2022-08-05,GRU,AMPLICON;WGA;Bisulfite-Seq;RNA-Seq;WXS,Clinical Cohort;Epigenetics;Exome Sequencing;Individual-Level Genomic Data;Longitudinal;Transcriptome Sequencing;Tumor vs. Matched-Normal,"Leukemia, Myelomonocytic, Juvenile",188.0,328.0,,RUNX1;CBL;DNMT3A;EZH2;FLT3;GATA2;JAK3;KRAS;NF1;NRAS;PTPN11;RRAS;ZRSR2;SH2B3;RRAS2;SETBP1;ASXL1,Neurofibromatosis 1,Neurofibromatosis 1; JCML; JCML - Juvenile chronic myeloid leukemia; JMML; Juvenile Chronic Myelogenous Leukemia; Juvenile Myelomonocytic Leukemias
Defining and Overcoming Intrinsic T Cell Dysfunction to Enable Pediatric    Immunotherapy,"T-cells from 71 children and young adults with B-cell malignancies on trial to receive anti-CD19 CAR T-cell therapy were analyzed. These T-cells represent the pre-manufacture T-cells that were subsequently used  for CAR T manufacture. Bulk RNA-Seq was performed on sorted T-cell subsets for all patients, in addition to CITE-Seq and single-cell ATAC-Seq on a",phs002323.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002323,Kai Tan;David Barrett,Ian Fingerman,Division of Cancer Biology (DCB),,,2022-08-03,DS-CTOGVHD-IRB-NPU,Seq_DNA_SNP_CNV;ATAC-seq;Seq_RNA_Protein_SC;Seq_RNA_Expression_SC;RNA-Seq;WXS;Seq_RNA_Expression,Case Set,Immunotherapy,84.0,393.0,,,,Not Provided
Germline Whole-Exome Sequencing of Lung Cancer in EAGLE,"EAGLE is a large population-based case-control study designed and conducted to investigate the genetic and environmental determinants of lung cancer and smoking persistence using an integrative approach that allows combined  analysis of genetic, environmental, clinical, and behavioral data. Here, we applied whole exome sequencing (WES) to EAGLE study, in a group of 2,777",phs002496.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002496,"Maria Teresa Landi, MD, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),18538025;35717579,Intramural Research Program,2022-08-02,DS-LDS-MDS,WXS,Case-Control,Lung Neoplasms,4036.0,4036.0,https://eagle.cancer.gov,,,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
NCI Expanded Genome-Wide Association Study of Renal Cell Carcinoma,"The National Cancer Institute (NCI) expanded genome-wide association study (GWAS) of renal cell carcinoma (RCC) was a 2nd GWAS of this cancer performed by NCI to further investigate common genetic  variants associated with RCC risk. The GWAS includes 2,781 cases and 2,940 controls of European background from 13 studies conducted in the US and",phs001736.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001736,"Mark Purdue, PhD",,,28598434,National Cancer Institute Intramural Research Program,2022-08-02,DS-RCC;GRU-IRB-NPU;GRU;CADM,Imputation_SNP_CNV;Seq_DNA_SNP_CNV,Case Set;Cohort,"Carcinoma, Renal Cell",2385.0,2385.0,,,,"ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell"
CPTAC: Molecular Dissection of Chemotherapy Response in Triple Negative    Breast Cancer,"Sporadic Triple Negative Breast Cancer (TNBC) represents 10-15% of breast cancers (BC) worldwide. Non-specific chemotherapy remains the standard of care as there are no targeted agents. In 50% of cases,  pathological complete response (pCR) is not achieved, and these individuals experience poor survival. Predictive markers for chemotherapy have proved",phs002505.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002505,Matthew J. Ellis,Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),31988290,U01 CA214125,2022-08-01,HMB;GRU,RNA-Seq;WXS,Case Set;Case-Cohort,Triple Negative Breast Neoplasms,48.0,135.0,,,,"Breast Cancer, Triple-Negative; Breast Cancers, Triple-Negative; Breast Neoplasm, Triple-Negative; Breast Neoplasms, Triple-Negative; ER Negative PR Negative HER2 Negative Breast Cancer; ER Negative PR Negative HER2 Negative Breast Neoplasms"
"CALGB 40601: Randomized Phase III Trial of Paclitaxel Combined With    Trastuzumab, Lapatinib, or Both As Neoadjuvant Treatment of    HER2-Positive Primary Breast Cancer","This randomized phase III trial studies paclitaxel and trastuzumab with or without lapatinib to see how well they work in treating patients with stage II or stage III breast cancer  that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by",phs001570.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001570,"Lisa A. Carey, MD",,,26527775;27704226;28089784;27449492;33095682,U10CA180821;U10CA180882;1U10CA180838;1U10CA180867;1U10CA180801;1U10CA180791;P50-CA58223;Breast Cancer Research Foundation;CA31946;CA33601,2022-08-01,HMB-COL,RNA-Seq;WXS,Case Set,Neoplasms,277.0,682.0,,,"Breast Neoplasms;Breast Neoplasms, Male;Neoplasms by Site;Breast Diseases;Skin Diseases;Paclitaxel;Lapatinib;Albumin-Bound Paclitaxel;Trastuzumab;Antineoplastic Agents, Phytogenic;Antineoplastic Agents;Tubulin Modulators;Antimitotic Agents;Mitosis Modulators;Molecular Mechanisms of Pharmacological Action;Protein Kinase Inhibitors;Enzyme Inhibitors","Breast Diseases; Breast Neoplasms, Male; Molecular Mechanisms of Pharmacological Action; Neoplasms by Site; Skin Diseases; Breast Disease, Endocrine"
CALGB/SWOG 80405 ct DNA Biomarker Evaluation,"To investigate treatment-specific mutations that underlie resistance to treatment with chemotherapy +/- bevacizumab or cetuximab in first line metastatic Colorectal Cancer (mCRC) patients, we performed targeted sequencing of circulating free  DNA (cfDNA) from longitudinal plasma samples. These samples were collected at baseline (PRE, n 354), during treatment (OTH, n 259), and/or at",phs002941.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002941,Xueping Qu,Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),28632865,,2022-07-29,DS-CA-COL;GRU-COL,WXS,Longitudinal,Colorectal Neoplasms,367.0,968.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Breast Cancer Family Registry,"The Breast Cancer Family Registry (BCFR) is a multi-center prospective cohort, comprised of over 30,000 women and men from nearly 12,000 families from the United States, Canada, and Australia. Our  BCFR resource has been used, and continues to be used, by breast cancer researchers around the world in order to find new ways to prevent, diagnose,",phs002835.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002835,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),29446198;29330856;29422015;28448241;28377418;28632866;29059683;27711073;27796716;28263368;28649645;28399571;28145423;28062399;28338721;28196846;28430825;28503721;28840378;28350789;29075496;29058716;28376175;28346442;29262523;29232439;29116004;28436984;29553968;28283652;28670784;29158497;28690137;28302160;29244822;28179314;26174520;26621531;26677205;26909793;26921362;26928228;26857456;26787654;26884359;26969729;27117709;27052111;27087578;27197191;26829160;27171545;27149063;27053251;27270457;27269948;27305206;26245632;27459855;27463617;27402876;27432226;27551723;27556229;27587788;27640304;27595995;27601076;27708667;27604360;27380242;27792995;27829436;27836010;27902704;27630279;27466510;25568166;25604794;25529635;25168388;25575445;25336561;25487306;25586992;25581431;25849327;25447460;25378557;25830658;25925750;25823661;25890600;25855707;25897948;25849179;26029704;25956172;25940428;25652398;25939597;25975955;25862352;26012643;26586665;26606455;26125186;26538066;26464424;26414677;26296642;26354892;26275715;26317411;26138067;25751625;26073781;25503493;25398451;26124344;26482668;25227710;25900795;26014596;24548884;24493630;24172832;24398512;24618999;24548865;24097051;24821458;24248812;24743323;24927736;24816206;25050558;24357391;24698998;24943594;24937182;24887515;24845866;24753038;24852375;24894818;24493794;24523857;24484606;24636975;25857409;25231870;25342443;25919761;25390939;25088804;25248036;25327703;25242497;23065704;23535731;22923054;23544013;23599027;23540573;23535733;23544012;23705888;23535729;23456555;23583978;23213058;23544014;23430226;23354978;23468962;23448497;23233716;23225141;23475944;23853209;23942072;23918944;23984098;24242184;24237098;24206657;24169466;23787919;23774992;24177181;24062231;24130221;24290378;22348646;23316232;22274685;22753153;22729891;22351618;22832964;22705975;22729394;22929433;21874311;22532573;22228098;22267197;22147742;22879957;22198256;22237986;22357627;22561519;22669161;22037784;22768030;22461340;23300655;22731764;22144499;22990654;22464251;22253144;22788119;22970196;22976474;22331459;22532574;23011509;22454379;22266113;22859399;23109706;22850554;22527103;22678115;22665578;22792104;22134622;21593217;21157446;21327470;21039431;21596841;21852243;21890493;21772329;21852249;21723415;21787400;22188651;22037553;21850394;21775986;21597964;21896163;21424757;22042950;21244692;21258862;21632523;21278746;21466675;22110403;21795498;21771852;21931171;22053997;21425134;21998595;21858661;20512660;21541012;21385923;21169536;21799032;20921021;21281505;21343941;22033276;21636973;21733824;21835029;20978112;20930546;21191117;21467941;21118973;20852631;20824062;20877337;20332279;21060860;19415783;19876733;20140702;19685187;20829330;21194473;23331366;21182766;19330027;19190154;19656774;19209174;18563556;19034644;19461885;18688698;19141360;19229608;18785005;19843668;19188678;18481171;18463975;19336551;19263198;21119756;19567422;19843326;18704680;19347964;19920816;19505912;18523885;19584272;18543099;19781682;19330030;19667198;19296215;19755643;19339271;17902052;18349832;18355772;18406867;17972172;18204050;18058226;18812548;18451181;19047150;18437204;18210156;18577746;18951437;17549625;17909964;19064567;18329258;17592773;18268356;18566018;18194538;18824713;19020755;18262047;18375895;18951461;18285836;17922223;17999359;17661812;17197928;17683639;17466083;17627006;17293864;17529967;17115108;17567920;17673440;17478602;17889706;18159056;17372900;17545637;17317153;17416769;17268812;17255289;17511879;17971899;16736286;16958054;16492927;17018785;16489001;16783605;17021353;17264405;16032703;16492929;16341153;16896052;16672066;17102813;17393978;16595073;16595072;16575876;16434590;16474849;16409581;15642171;15994883;16154023;15987458;16049810;16226618;16121340;15657342;16030124;16030102;15851767;15734957;15987430;15851764;16023682;16061562;16111488;15743497;16211554;15880680;15734952;15593089;15941936;15111770;15051280;15122511;15478194;15066923;15604633;15132217;15217505;15598789;14744747;14664778;15058800;14966094;15203725;14994235;14871810;15545966;15598764;14973065;15389930;12819189;12606894;12677558;14580256;12471628;14648661;12941822;12719539;12652520;12644538;14636569;12939459;12652521;12566312;12837841;12690007;14583766;14578152;12708474;12651200;12920083;12509407;12920094;14669280;12601471;12707957;12704633;12509408;12813729;14557986;12055172;12112659;11940085;11830610;12133652;12208195;12353265;12439712;11994239;12019772;11750237;12406802;11980831;12203401;12412159;11788959;12142725;11927503;12010857;12354477;12473176;11792833;11352867;11705483;11133358;12036267;11314429;11305950;11562179;11954590;11306339;11597326;14965632;11329690;11751447;11165472;11535547;11170893;10716962;10871720;11076055;10989983;27899185;10852372;10986947;11036113;10739759;10739758;10213514;10889865;10430798;10577933;10889864;10854492;10577931;10206074;10616939;10571952;10550164;9887168;10070948;10359549;10413426;11281885;10889863;9840533;9485035;9598274;9667259;9683359;9805131;9650154;9781655;9639385;9731522;9665464;9154367;9054927;9140390;8707299;29804257;30794303;30683880;30554720;29795440;3038320;30759253;31138522;30787463;30988301;31107507;30831215;30771221;30999962;31414075;31421228;31213659;30312457;30824819;30563985;31324826;31162093;30873510;30799262;31429809;31300563;31402456;30822522;30725480,,2022-07-29,DS-CA;DS-CA-IRB-MDS;DS-CA-IRB;DS-CA-PUB-NPU-MDS;DS-BOCC-IRB,,Cohort,Breast Neoplasms,32726.0,0.0,http://www.bcfamilyregistry.org/,BRCA1;BRCA2,Ovarian Neoplasms;Hereditary Breast and Ovarian Cancer Syndrome,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Single-Cell RNA-Sequencing Analysis of Responses to Pembrolizumab in    Sezary Syndrome,"This phase 2 single arm clinical trial assessed the efficacy of pembrolizumab in patients with previously treated mycosis fungoides or Sezary syndrome. Pembrolizumab was found to have a 38% overall  response rate, and a 27% overall response rate in subjects with Sezary syndrome. We performed single-cell RNA-sequencing on samples collected before",phs002933.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002933,"Michael Khodadoust, MD, PhD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),31532724,K08 CA207882;5UM1CA154967;Haas Family Foundation,2022-07-28,GRU-COL,RNA-Seq,Single Cell Analysis,Sezary Syndrome,6.0,15.0,,,pembrolizumab;cutaneous t cell lymphoma;immune checkpoint inhibitors,"Cutaneous T Cell Lymphoma; CTCL / Sezary syndrome; Erythroderma, Sezary; Lymphoma, Sezary's; SC)zary syndrome; SEZARY SYNDROME, SOMATIC"
Multi-Omic Investigation of Beckwith-Wiedemann Syndrome Wilms Tumor,"Wilms' Tumor (WT), also known as nephroblastoma, is one of the most common malignant kidney tumors diagnosed in children. One of the most common WT predisposition syndromes is Beckwith-Wiedemann Syndrome  (BWS, OMIM: 130650), which affects approximately 1/10,000 live births. In this study, we perform Whole Exome Sequencing (WES), DNA methylation array,",phs002769.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002769,"Jennifer Kalish, MD, PhD",Mariam Eljanne,Center for Cancer Training (CCT),,,2022-07-27,GRU-PUB-COL-NPU,Array_DNA_Methylation;Seq_RNA_Expression;WXS,Cohort,Wilms Tumor,14.0,27.0,,,Beckwith-Wiedemann Syndrome,Beckwith-Wiedemann Syndrome; BWS; Beckwith Wiedemann Syndrome; Beckwith's syndrome; Beckwith-Wiedemann syndrome chromosome region; EMG SYNDROME
The Role of CDX2 in Controlling ABCB1 Expression and Chemosensitivity in    Human Colon Cancer,"This study reports the results of RNA sequencing (RNA-seq) experiments performed on two human colon cancer cell lines (HT-29, DLD-1) that were genetically engineered to achieve either the constitutive expression  (in HT-29 cells) or the selective inactivation (in DLD-1 cells) of the transcription factor CDX2, a master regulator of embryonic gut development and",phs002903.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002903,"Piero Dalerba, MD",Joseph Flores-Toro,Office of Data Sharing (ODS),26789870,DRR-44-16;Schaefer Scholar Research Program;TL1 TR001875;T32 DK007328;P30 CA013696;UL1 TR001873,2022-07-26,GRU,RNA-Seq,Marker Discovery;RNA Sequencing;Tumor,Colonic Neoplasms,2.0,12.0,,CDX2;ABCB1,Antineoplastic Agents;Paclitaxel,"CA - Cancer of colon; COLON CANCER; Cancer of Colon; Cancer of the Colon; Cancer, Colon; Cancer, Colonic"
Single-Cell Analysis of CD19-Specific CAR T Cell Treatment of    Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia,"By leveraging single-cell transcriptome and T cell receptor (TCR) sequencing, we aimed to track the transcriptional signatures of chimeric antigen receptor (CAR) T cell clonotypes throughout the course of treatment  and furthermore identify molecular patterns leading to potent CAR T cell cytotoxicity. The data presented in this study encompass blood and bone",phs002966.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002966,,Joseph Flores-Toro,Office of Data Sharing (ODS),35792801,,2022-07-25,GRU-PUB-NPU,RNA-Seq;OTHER,Clinical Cohort;Longitudinal Cohort,Allergy and Immunology,16.0,200.0,,,"Immunotherapy, Adoptive;Leukemia, B-Cell;Single-Cell Analysis;Receptors, Antigen, T-Cell, alpha-beta","Leukemia, B-Cell; B Cell Leukemia; B Lymphocytic Leukemia; B-Cell Leukemia; B-Cell Leukemias; B-Cell Lymphocytic Leukemia"
Decade-Long Leukemia Remissions with Persistence of CD4+ CAR T-Cells,"Two patients with chronic lymphocytic leukemia (CLL) were treated with CD19 targeted CAR T therapy and followed over several years. Peripheral blood from both patients at multiple time points was  collected, and 5' CITE-Seq with TCR profiling was performed on sorted CD3+CAR+ T cells at multiple time points. Here, we deposit the raw sequencing",phs002931.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002931,J. Joseph Melenhorst;Kai Tan;Carl H. June,Freddie Pruitt,Center for Cancer Genomics (CCG),35110735,,2022-07-22,HMB,RNA-Seq,Case Set,"Leukemia, Lymphocytic, Chronic, B-Cell",2.0,6.0,,,,"B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic"
"CIDR: Discovery, Biology, and Risk of Inherited Variants in Glioma","This is a gliogene brain tumor family study. This study includes glioma cases with a family history of glioma in a first, second, or third degree relative.&#x000a0; Inclusion criteria: Glioma  cases with a reported family history of glioma Note for data in CDS: The raw sequencing files for this study are available via the NCI Cancer Data",phs002250.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002250,Melissa Bondy,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),28346443;25482530,"R01CA217105, X01HG009883, R01CA139020;HHSN268201700006I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2022-07-22,NRUP;GRU,Seq_DNA_SNP_CNV;WGS,Family;Whole Genome Sequencing,Glioma,171.0,146.0,http://www.gliogene.org,,,Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia
Melanoma Brain Metastasis Single-Cell RNA Sequencing Atlas,"Melanoma brain metastasis (MBM) frequently occurs in patients with advanced melanoma, yet our understanding of the underlying salient biology is rudimentary. Here, we performed single-cell/nucleus RNA-seq in 22 treatment-naive MBM  (scRNA-seq n 5; snRNA-seq n 17) and 10 extracranial melanoma metastases (ECM; all snRNA-seq), and matched spatial single-cell transcriptomics (n 16)",phs002944.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002944,"Benjamin Izar, MD, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),35803246,,2022-07-13,DS-M,RNA-Seq;OTHER;ATAC-seq,Cohort;Collection;Epigenetics;Metastasis;RNA Sequencing;Sequencing;Single Cell Analysis;Tumor,Melanoma,35.0,105.0,,,Neoplasm Metastasis,"Neoplasm Metastasis; Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant"
Genomic Analysis of Extra-Nodal Natural Killer/T-Cell Lymphoma (ENKTCL),"In this study, we performed extensive genetic profiling on 209 extra-nodal natural killer/T-cell lymphoma (ENKTCL) nasal-type cases, including 174 Chinese from four hospitals in China, and 31 Hispanic and 4  Caucasian patients from City of Hope and Eberhard Karls University of T&#x000fc;bingen. All of the cases were reviewed by experienced",phs002925.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002925,"John Chan, MD;Gehong Dong, MD",Brandon Wright,Office of Data Sharing (ODS),35697790,Grant P30CA033572;Grant No. 7132062;Grant No. 2014-37;Start-up funds;Dr. Norman and Melinda Payson Professorship in Hematologic Cancers,2022-06-29,GRU-NPU,Targeted-Capture,Exome Sequencing;Sequencing;Tumor,"Lymphoma, Extranodal NK-T-Cell",209.0,209.0,,,"Sequence Analysis, DNA;High-Throughput Nucleotide Sequencing;mutation;DNA Copy Number Variations","Angiocentric T-Cell Lymphoma; Extranodal NK T Cell Lymphoma, Nasal; Extranodal NK T Cell Lymphoma, Nasal Type; Extranodal NK T Cell Lymphoma, Nasal and Nasal Type; Extranodal NK-T-Cell Lymphoma, Nasal; Extranodal NK-T-Cell Lymphoma, Nasal Type"
NCI CCSG CCDI Supplement Additional Genomic Submission,The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic  agents for most mutational events. This supplement data from the Beat AML program provides Adolescent and Young Adult (AYA) and pediatric tumor,phs002599.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002599,"Jeffrey Tyner, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,Leukemia and Lymphoma Society;5P30CA069533,2022-06-09,GRU,RNA-Seq;WXS;Targeted-Capture,Case Set;Exome Sequencing;RNA Sequencing,"Leukemia, Myeloid, Acute",104.0,203.0,,,Neoplasms,AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL
A Phase 2 Study of Lamivudine in Patients with p53 Mutant Metastatic    Colorectal Cancer,"This was an open-label, single-arm Phase II study of lamivudine in patients who had progressed on systemic therapy for advanced colorectal cancer with TP53 mutations. The phase II study had  a two-stage design, with a target accrual of 20 evaluable patients for the first stage and a total of 32 patients for the whole study. The first 9",phs002833.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002833,David T. Ting;Aparna Parikh,Ian Fingerman,Division of Cancer Biology (DCB),,R01CA240924;U01CA228963;R01GM130680;R01CA240816;T32GM007753;1F30CA232407-01,2022-06-07,HMB,RNA-Seq;WGS,Clinical Trial;Interventional,Colorectal Neoplasms,31.0,67.0,,TP53,Tumor Suppressor Protein p53;Lamivudine,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Integrative Tissue Analysis of Men with Prostate Cancer,"Prostate cancer is readily curable if detected early. The goal of this research is to assess the molecular alterations that contribute to prostate cancer development, and how the interaction of  tumor-cell autonomous alterations and immune cell proportions contribute to the predictability of recurrence. Inclusion: Men diagnosed with localized",phs001813.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001813,"Adam Sowalsky, PhD",Kathleen Calzone,Center for Cancer Research (CCR),31528835;32681068,ZIA BC011680;ZIA BC011679;W81XWH-15-1-0136;W81XWH-15-1-0710,2022-06-07,GRU,RNA-Seq;WXS;WGS;AMPLICON,Case Set,Prostatic Neoplasms,255.0,1624.0,,,Watchful Waiting;Prostatectomy;Circulating Tumor DNA;Liquid Biopsy,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Intercepting Progression from Pre-Invasive to Invasive Lung    Adenocarcinoma,An improved understanding of the biology of lung cancer is needed to intercept the disease at an early point in its progression. In this project we have used multidimensional methods  to profile the tumor microenvironment (TME) and to determine the crosstalk between cancer cells and the TME in pre-invasive to invasive human lung,phs002818.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002818,"Nasser Altorki, MD",Natalie Abrams,Division of Cancer Prevention (DCP),,UH3CA244697,2022-06-06,GRU,WXS,Exome Sequencing,Lung Neoplasms,42.0,84.0,,,"Adenocarcinoma of Lung;Carcinoma, Non-Small-Cell Lung","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma"
Large Cancer Fingerprint Screening for Detection of Minimal Residual    Disease.,"We describe an approach for large cancer fingerprint screening and its application to cell-free DNA from patients with cancer. Our approach involves tracking somatic mutations identified from patients' tumor biopsies,  in the cell-free DNA from a blood draw. All patients provided written informed consent to allow the collection of blood and/or tumor tissue and",phs001977.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001977,Viktor A. Adalsteinsson,Ian Fingerman,Division of Cancer Biology (DCB),,,2022-06-06,HMB-MDS;HMB,WXS;Targeted-Capture;WGS,Case-Control;Cohort;Longitudinal,Neoplasms,158.0,788.0,,,Neoplasm Metastasis,"Neoplasm Metastasis; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize"
Characterizing TP53 and PPM1D Mutations as Resistance Drivers to    Radiation Therapy in Diffuse Intrinsic Pontine Gliomas,"Pediatric high-grade gliomas (pHGGs), encompassing diffuse midline gliomas (DMGs) and hemispheric tumors, represent the most common cause of cancer-related deaths in children age 0-14 years. Over the last decade, several  landmark papers have revealed recurrent single nucleotide variants (SNVs) in the core histones H3.3 and H3.1, co-occurring with alterations in the",phs002380.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002380,"Rameen Beroukhim, MD, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),"No PMID: Structural Variants shape driver combination and outcomes in pediatric High-Grade Glioma | Dubois F, Shapira O, Greenwald N, Zack T, Wala J, Tsai JW, Hadjad D, Crane A, Harutyunyan AS, Kumar K, Blattner-Johnson M, Vogelzang JR, Kang KS, Sinai C, Wang D, Khadka P, Malkin H, Ho P, O&#8217;Rourke R, Gold R, Deng D, Serrano J, Snuderl M, Wright KD, Chi SN, Grill J, Kleinman C, Goumnerova LC, Jabado N, Jones D, Kieran MW, Ligon K, Beroukhim R, Bandopadhayay P",R01 5R01CA219943-03,2022-05-26,HMB,RNA-Seq;Seq_DNA_SNP_CNV;WGS,Case Set;Clinical Cohort;Cohort;Exome Sequencing;Genotype;Sequencing;Tumor;Whole Genome Sequencing,Brain Neoplasms,61.0,122.0,,MET;MYC;MYCN;PDGFRA,glioma;pediatrics;molecular sequencing data;genome structural variants,Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Glioma; Neoplasm of Neuroglia
Washington University PDX Development and Trial Center,"This data set is a collection of patient specimens from common and rare cancers that have been developed into patient-derived xenograft (PDX) models at the Washington University PDX Development and  Trial Center (WU-PDTC). The goal of the PDTC is to develop and characterize PDX models, gaining insight into tumor biology, and validating biomarkers",phs002305.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002305,Govindan Ramaswamy;Li Ding;Shunqiang Li,Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),34429404,,2022-05-26,DS-SARC;GRU,,Tumor;Tumor vs. Matched-Normal,Neoplasms,127.0,495.0,,,"Gastrointestinal Neoplasms;Pancreatic Neoplasms;Colonic Neoplasms;Rectal Neoplasms;Melanoma;Urinary Bladder Neoplasms;Head and Neck Neoplasms;Carcinoma, Squamous Cell;Lung Neoplasms;Breast Neoplasms;Kidney Neoplasms;Soft Tissue Neoplasms;Bone Neoplasms",Bone Neoplasms; Gastrointestinal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Rectal Neoplasms; Soft Tissue Neoplasms
Clonal Evolution and Transcriptomic Analysis of Chronic Lymphocytic    Leukemia Treated with Ibrutinib,Disease progression has been increasingly appreciated with the use of ibrutinib to treat chronic lymphocytic leukemia (CLL). Understanding the pattern of clonal evolution and transcriptomic changes during the early treatment  period with ibrutinib may provide insight into the mechanisms of resistance. We performed whole exome sequencing on sequential samples with matched,phs001473.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001473,Adrian Wiestner;Catherine Wu,Ian Fingerman,Division of Cancer Biology (DCB),29259203,,2022-05-25,GRU,RNA-Seq;WXS;Bisulfite-Seq,Longitudinal,"Leukemia, Lymphoid",77.0,317.0,,MUM1;ANK1;BIRC3;ATM;ATRX;BAI2;BAX;BRAF;BTK;CCND2;CDC25B;CDKN1B;CENPB;CHD2;CHKB;CREB1;CREBBP;DDX3X;DYRK1A;EEF1A1;EGR2;ELF4;EWSR1;GNB1;GPS2;GSR;HIST1H1E;IKBKB;IRF4;ITIH2;ITPKB;KRAS;MBD1;MYD88;NFKB1;NFKBIB;NFKBIE;CNOT3;NOTCH1;NRAS;PLCG2;MED1;MAPK4;MAP2K1;PTPN1;PTPN11;RELA;RPS15;RPS16;RSC1A1;SCN8A;TFCP2;TP53;TRAF2;TRAF3;XPO1;KMT2D;ARID1A;FUBP1;USP8;FAM50A;ZMYM3;ADAMTS4;MED12;ARPC4;NXF1;MSL3;BAZ2A;MAP4K5;CHEK2;SP140;IKZF3;DIS3;ZNF292;CUL9;MGA;SF3B1;POT1;SAMHD1;SETD2;INO80;BCOR;ANKHD1;FBXW7;TRMT1;POLR3B;KLHL6;SENP7;NSD1;SPEN;RFX7;BRCC3;NKAP;RUFY1;CDCA7;ARID5B;CARD11;ZC3H18;FAM65C;ASXL1;NEK8;IGLL5,,"Leukemia, Lymphocytic; Leukemias, Lymphocytic; Leukemias, Lymphoid; Lymphatic leukemia; Lymphocytic Leukemia; Lymphocytic Leukemias"
DNA Double Strand Breaks in KMT2A-Rearranged AML patients,"DNA breakage at specific rearrangement-participating genes, which are more sensitive to a range of environmental and chemotherapeutic agents than other regions of the human genome, contributes to the generation of  leukemia-causing rearrangements, and can be used as a predictor of susceptibility to cancer caused by gene rearrangements. As a direct",phs002804.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002804,Yuh-Hwa Wang,Freddie Pruitt,Center for Cancer Genomics (CCG),34405474,Chair Recruitment Funds,2022-05-19,GRU,OTHER,Case-Control,"DNA Breaks, Double-Stranded",6.0,6.0,,,Acute Myeloid Leukemia,AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL
"Whole Exome and Whole Genome Profiling as well Genome-Wide Methylation    Profiling from Early to Advanced Chronic Lymphocytic leukemia (CLL),    Genome-Wide Methylation Profiling in Monoclonal B Cell Lymphocytosis    (MBL)",Serial whole exome sequencing of samples collected from 21 patients at multiple time points during progression from early to late chronic lymphocytic leukemia (CLL) and one matching non-tumor tissue sample  from each patient. Additional whole genome sequencing of samples from 3 selected patients. Genome-wide B cell methylation compared between 5 healthy,phs001431.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001431,Alexander Meissner;Catherine Wu,Ian Fingerman,Division of Cancer Biology (DCB),,,2022-05-19,GRU,RNA-Seq;WXS;Bisulfite-Seq;WGS,Case Set,"Leukemia, Lymphocytic, Chronic, B-Cell",35.0,227.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125499,,,"B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic"
A Pilot Study of NKTR-214 and Nivolumab in Selected Patients with Locally    Advanced/Metastatic Sarcoma,"Study cohort comprises samples derived from patients that received treatment on an open-label, non-randomized, non-comparative pilot study of bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist, with nivolumab in refractory sarcoma at  Memorial Sloan Kettering/MD Anderson Cancer Centers (NCT03282344). Patient tumors include a variety of sarcoma subtypes. Samples include whole exome",phs002852.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002852,"Sandra D'Angelo, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,SPORE in Soft Tissue Sarcoma NIH/NCI P50 CA217694,2022-05-18,DS-SARC-PUB,RNA-Seq;WXS;AMPLICON,Clinical Trial;Exome Sequencing;Multicenter;RNA Sequencing;Tumor vs. Matched-Normal,Sarcoma,54.0,195.0,,,,"Sarcoma, Spindle Cell; Sarcomas, Spindle Cell; Spindle Cell Sarcomas; spindle cell sarcoma"
Rapid Idiosyncratic Mechanisms of Clinical Resistance to KRAS G12C    Inhibition,"Using deep RNA and whole exome sequencing of pre- and post-treatment autopsy samples, we reveal diverse clonal populations that occurred through altered cell intrinsic, tumor microenvironment and immunologic remodeling mechanisms  of resistance. Deceased lung cancer patient treated at UNC hospitals Related Genes: KRAS, MAPK1, YAP1 Principal Investigator: Chad Pecot, MD,",phs002734.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002734,"Chad Pecot, MD",Ian Fingerman,Division of Cancer Biology (DCB),,R01CA258451,2022-05-18,GRU,RNA-Seq;Seq_RNA_Expression;WXS,Case Set;Tumor vs. Matched-Normal,Adenocarcinoma of Lung,1.0,42.0,,KRAS;MAPK1;YAP1,,"ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma"
Personalized Breast Cancer Vaccines Based on Genome Sequencing,"This study is from a phase I clinical trial of neoantigen DNA vaccines in triple negative breast cancer patients with persistent disease following neoadjuvant chemotherapy. The exome and RNA sequences  used to identify somatic mutations, predict neoantigens, and design vaccines is within. Principal Investigator: William Gillanders, MD, Washington",phs002787.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002787,"William Gillanders, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2022-05-13,GRU,RNA-Seq;WXS,Exome Sequencing;RNA Sequencing;Tumor vs. Matched-Normal,Triple Negative Breast Neoplasms,18.0,54.0,,,,"Breast Cancer, Triple-Negative; Breast Cancers, Triple-Negative; Breast Neoplasm, Triple-Negative; Breast Neoplasms, Triple-Negative; ER Negative PR Negative HER2 Negative Breast Cancer; ER Negative PR Negative HER2 Negative Breast Neoplasms"
Pan Cancer Investigation of Human Leukocyte Antigen Loss of    Heterozygosity,"Cancer cells can escape immune recognition through human leukocyte antigen (HLA) loss of heterozygosity (LOH) which results in deletion of HLA alleles, causing a reduction in presentation of tumor neoantigens.  Despite its influence on immunotherapy response, few methods exist to detect HLA LOH, and accuracy of the approaches is poorly defined. Here, we",phs002783.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002783,Sean M. Boyle,Freddie Pruitt,Center for Cancer Genomics (CCG),,"Personalis, Inc",2022-05-13,GRU-NPU,WXS,Case Set;Collection;Exome Sequencing,HLA Antigens,559.0,1118.0,,,Neoplasms;Loss of Heterozygosity,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and    BRCA2 Wild-Type Patients,"The Talazoparib Beyond BRCA (TBB), a phase II proof-of-concept clinical trial, was designed to test the efficacy of talazoparib, a potent, orally bioavailable PARP inhibitor, with an established Phase II  recommended dose, in the treatment of advanced BRCA wildtype (WT), HER2-negative breast cancer and other solid tumors with homologous recombination",phs002803.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002803,Melinda Telli;Joshua Gruber,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2022-05-12,GRU,WXS;OTHER,Clinical Trial,Breast Neoplasms,20.0,89.0,,BRIP1;ATM;ATR;BRCA1;BRCA2;FANCA;PTEN;RAD51C;CHEK2;PALB2,"PALB2 protein, human;talazoparib;Poly(ADP-ribose) Polymerase Inhibitors;Homologous Recombination",Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
"Circulating Tumor DNA as a Biomarker in Patients with Stage III and IV    Wilms Tumor: Analysis from a Children's Oncology Group Trial, AREN0533",We evaluated the utility of circulating tumor DNA (ctDNA) as a biomarker in the serum and urine of 50 patients with Stage III or Stage IV Wilms tumor (WT) that  were enrolled on Children's Oncology Group&#x000a0;(COG) trial AREN0533. 49 out of 50 patients had matched tumor samples available for comparison. We,phs002847.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002847,Brian D. Crompton,Joseph Flores-Toro,Office of Data Sharing (ODS),29659330,,2022-05-11,HMB,Targeted-Capture;WGS,Case Set;Cohort,Wilms Tumor,50.0,149.0,https://childrensoncologygroup.org/,CTNNB1;MYCN;WT1;ARID1A;DICER1;BCOR;BCORL1,,Embryonal adenosarcoma; Embryonal nephroma; Kidney Nephroblastoma; NEPHROBLASTOMA; Nephroblastoma (Wilms tumor); Nephroblastomas
Characterization of CNS Metastases,"Metastatic disease to the central nervous system (CNS) is devastating, with a poor prognosis. There are limited treatment options for patients with CNS metastases, and in particular with leptomeningeal carcinomatosis  (LMD). In this study, we evaluated the molecular and cellular features of parenchymal brain metastases and LMD. We used single-cell RNA and cell-free",phs002416.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002416,Priscilla K. Brastianos,,,,,2022-05-06,GRU,RNA-Seq,Case Set,Meningeal Carcinomatosis,46.0,71.0,,,,"Leptomeningeal Carcinomatosis; Carcinomatoses, Leptomeningeal; Carcinomatoses, Meningeal; Carcinomatosis of the Meninges; Carcinomatosis, Leptomeningeal; Carcinomatosis, Meningeal"
Blood Somatic Mutations in TCGA Donors Suffering from Solid Tumors,"Blood somatic mutations identified across 8,530 solid tumor patients in TCGA cohort. We reasoned that low-coverage whole-genome sequencing of blood samples routinely carried out in cancer genomics projects may be  repurposed to detect clonal hematopoiesis (CH). Thus, inspired by a previous approach to identify early mutations in the development of the",phs002867.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002867,Nuria Lopez-Bigas,Brandon Wright,Office of Data Sharing (ODS),,,2022-05-04,GRU,Seq_DNA_SNP_MAF_Ind,Case Set,Clonal Hematopoiesis,8315.0,8315.0,https://www.biorxiv.org/content/10.1101/2020.10.22.350140v1,DNMT3A;PPM1D;TET2,,"ARCH; ARCH Age related Clonal Hematopoiesis; ARCH Age-related Clonal Hematopoiesis; Age related Clonal Hematopoiesis; Age-related Clonal Hematopoiesis; Clonal Hematopoiesis, Age-related"
Molecular Signatures of DCIS to Invasive Progression for Basal-Like    Breast Cancers: An Integrated Mouse Model and Human Tumor Study,We studied the genomic signatures of progression in breast ductal carcinoma in situ (DCIS) as it progresses towards triple negative invasive breast cancer (TNBC). Single cell RNA sequencing (scRNAseq) was  performed on the C3Tag genetically engineered mouse model that forms human breast-like DCIS and TNBC. Bulk RNA sequencing was performed on RNA,phs002443.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002443,"Charles M. Perou, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,P50 CA058223,2022-05-04,GRU,RNA-Seq,Cohort,"Carcinoma, Intraductal, Noninfiltrating",11.0,18.0,,,Triple Negative Breast Neoplasms,"Triple Negative Breast Neoplasms; Breast Ductal Carcinoma In Situ, NOS; Carcinoma, Intraductal; Carcinoma, Noninfiltrating Intraductal; Carcinomas, Intraductal; Carcinomas, Noninfiltrating Intraductal"
Feasibility and Clinical Utility of Whole Genome Profiling in Pediatric    and Young Adult Cancers,"Comprehensive Whole Genome Sequencing and Whole Transcriptome (RNASeq) analyses from 114 pediatric patients at Memorial Sloan Kettering. This dataset was used as a prospective clinical utility and feasibility study. By  using our Isabl infrastructure for precision medicine, we developed a 2-week end-to-end pipeline to analyze cfDNA, WGS and WTS, which we refer to as",phs002620.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002620,Elli Papaemmanuil;Andrew Kung,Joseph Flores-Toro,Office of Data Sharing (ODS),,"The Scarlett Fund. Olayan Fund for
 Precision Pediatric Cancer Medicine.",2022-05-02,GRU,RNA-Seq;WGS,Case Set;Clinical Cohort;Prospective,Neoplasms,114.0,326.0,,,Pediatrics;Whole Genome Sequencing;RNA-Seq,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Genome-Wide Analysis of Diffuse Large B-Cell Lymphoma (De Novo and    Derived from the High Grade Transformation of Follicular Lymphoma),"Version 1. Diffuse Large B-cell Lymphoma (DLBCL) represents the most common form of B-cell non-Hodgkin Lymphoma (B-NHL), accounting for 30% of the de novo diagnoses and also arising as a  frequent clinical evolution of Follicular Lymphoma (FL). The molecular pathogenesis of DLBCL is associated with multiple genetic lesions that in part",phs000328.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000328,Riccardo Dalla-Favera;Laura Pasqualucci,Freddie Pruitt,Center for Cancer Genomics (CCG),21390126;21804550;21156281;19412164;24388756;35794478,PO1-CA-092625;RO1 CA-37295,2022-04-29,DS-CA-PUB-MDS,WXS;WGS;Targeted-Capture;Array_SNP,Case-Control;Tumor vs. Matched-Normal,"Lymphoma, Large B-Cell, Diffuse",194.0,333.0,,,"Lymphoma, Follicular;Lymphoma, Non-Hodgkin","Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers"
Transcriptomic Profiles of Neoantigen-Reactive T Cells in Human    Gastrointestinal Cancers,"This study explores the transcriptomic profiles of neoantigen-reactive tumor-infiltrating lymphocytes (TILs) from human bile duct and pancreatic cancer. The submitted data are bulk tumor RNA-Seq, tumor and germline whole-exome sequencing  from 10 patients, and single cell RNA-Seq data from TIL of 5 of these patients. Inclusion: patients with gastrointestinal cancer Related Genes: GZMA,",phs002765.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002765,Eric Tran,Freddie Pruitt,Center for Cancer Genomics (CCG),35413272,Providence Portland Medical Foundation;Cholangiocarcinoma Foundation,2022-04-28,GRU,RNA-Seq;Seq_RNA_Expression;WXS;AMPLICON,Case Set,Gastrointestinal Neoplasms,10.0,3134.0,,GZMA;KRAS;ADGRG1;CXCL13;HOPX,"Cholangiocarcinoma;Carcinoma, Pancreatic Ductal","Carcinoma, Pancreatic Ductal; Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas"
MP2PRT: Identification of Genetic Changes Associated with Relapse and/or    Adaptive Resistance in Patients Registered as Favorable Histology    Wilms Tumor on AREN03B2,The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI's Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of  biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program.,phs001965.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001965,"Elizabeth Jones Perlman, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),,Contract HHSN261201500003I,2022-04-22,GRU,,Case Set,Wilms Tumor,84.0,84.0,,,,Embryonal adenosarcoma; Embryonal nephroma; Kidney Nephroblastoma; NEPHROBLASTOMA; Nephroblastoma (Wilms tumor); Nephroblastomas
Combined Targeting of CDK4/6 and HER2 Signaling in Orthotopic    Patient-Derived Xenografts of HER2-Positive Breast Cancer Brain    Metastases,"Patients with metastatic HER2-positive (HER2+) breast cancer will frequently develop brain metastases (BCBMs). Here, we report that p16INK4A, a tumor suppressor, is deficient in the majority of HER2+ BCBMs. Furthermore,  p16INK4A deficiency, as measured by protein immunohistochemistry, can be a predictive marker associated with response to combined treatment with",phs002482.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002482,"Jean J. Zhao, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),35304445,,2022-04-15,HMB,RNA-Seq;WXS,Exome Sequencing;Metastasis;RNA Sequencing;Tumor vs. Matched-Normal;Xenograft,Breast Neoplasms,39.0,96.0,,RB1;ERBB2;CDKN2B;CDKN2A,Neoplasm Metastasis;Brain Neoplasms;Neoplasm Transplantation;Molecular Targeted Therapy,Neoplasm Metastasis; Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour
CIDR: Molecular Pathological Epidemiology of Colorectal Cancer,"Colorectal cancer, the second most commonly diagnosed cancer is a biologically heterogeneous disease. To characterize the molecular attributes of colorectal tumors, we conducted targeted sequencing at the Center for Inherited  Disease Research (CIDR) on 4,518 tumor and matched normal DNA samples from the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) and",phs001905.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001905,"Ulrike Peters, PhD, MPH",,,,"U01CA137088;HHSN268201700006I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2022-04-14,HMB-PUB;DS-COC-MDS;DS-CA-MDS;GRU;HMB;HMB-IRB-NPU-GSO;CADM,Seq_DNA_SNP_CNV,Case Set,Colorectal Neoplasms,3824.0,7825.0,https://www.fredhutch.org/en/research/divisions/public-health-sciences-division/research/cancer-prevention/genetics-epidemiology-colorectal-cancer-consortium-gecco.html,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Transcriptional Profiling of Macrophages In Situ in Metastatic Melanoma    Reveals Localization-Dependent Phenotypes and Function,"Therapeutic interventions modulating immune function at the tumor site could improve outcomes in cancer. Here we analyzed metastatic melanoma, a tumor type highly responsive to T-cell based therapies, and found  that the tumor-infiltrating T cells are localized closely to CD14+ monocytes/macrophages rather than to melanoma cells. Using novel",phs002564.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002564,"Karolina Palucka, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,R01CA195712,2022-04-11,GRU,RNA-Seq,Metastasis;RNA Sequencing;Tissue Expression,Melanoma,8.0,64.0,,CD2;CD14;LY75,Myeloid infiltrate,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Count Me In (CMI): The Metastatic Prostate Cancer (MPC) Project    (CMI-MPCproject),Count Me In - The Metastatic Prostate Cancer Project: A Patient-Driven Research Initiative to Accelerate Metastatic Prostate Cancer Research The Metastatic Prostate Cancer Project (MPCproject; http://mpcproject.org/) is a research study  that empowers men with metastatic and advanced prostate cancer to partner directly with researchers by sharing their samples and clinical,phs001939.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001939,"Nikhil Wagle, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),"No PMID: A patient-driven clinicogenomic partnership through the Metastatic Prostate Cancer Project | Crowdis J, Balch S, et al",Institutional Funding,2022-04-07,GRU,,Cohort,Prostatic Neoplasms,63.0,126.0,https://www.mpcproject.org/data-release,,Neoplasm Metastasis;Carcinoma,"Neoplasm Metastasis; Epithelial Carcinoma; Epithelial Neoplasm, Malignant; Epithelial Neoplasms, Malignant; Epithelial Tumor, Malignant; Epithelial Tumors, Malignant"
Combined Tumor and Immune Signals From Genomes or Transcriptomes Predict    Outcomes of Checkpoint Inhibition in Melanoma,"Cancer immunotherapy with checkpoint blockade (CPB) leads to improved outcomes in melanoma and other tumor types, but a majority of patients do not respond. High tumor mutation burden (TMB) and  high levels of tumor-infiltrating T cells have been associated with response to immunotherapy, and integrative models using DNA and RNA have improved",phs002683.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002683,"Nir Hacohen, PhD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),30643254;31792460;30388456;29132144;28251903;30851984;30309915;29657129;30388455,U54CA224068;5U54HG003067;R01CA208756,2022-04-06,DS-MSC-MDS,RNA-Seq;WXS,Case Set;Exome Sequencing;Full Transcriptome Sequencing,Melanoma,61.0,169.0,,TBX3;MAP4K1,Immunotherapy,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
University of Texas PDX Development and Trial Center Grant,"The goal for the University Texas PDX Development and Trial Center (UTPDTC) is to optimize personalized biomarker-based cancer therapy and identify effective targeted drugs based on the molecular characteristics of  each tumor. Our short-term goals are to establish a biobank of clinically, and molecularly-annotated Patient-Derived Xenografts (PDXs) and to use",phs001980.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001980,"Jack A Roth, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),,U54CA224065,2022-04-01,DS-LC-COL,RNA-Seq;WXS,Cohort,Lung Neoplasms,36.0,77.0,,EGFR;KRAS;STK11;TP53,"Carcinoma, Non-Small-Cell Lung;Small Cell Lung Carcinoma","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell"
Relapsed Acute Lymphoblastic Leukemia (ALL): Mutational Landscape,"Multi-agent combination chemotherapy can be curative in acute lymphoblastic leukemia (ALL). Still, patients with primary refractory disease or those with relapsed leukemia have a very poor prognosis. Here we report  the mutational landscape of matched diagnostic and relapsed pediatric and adult ALL samples. Our data provides comprehensive annotation of genetic",phs001951.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001951,"Adolfo Ferrando, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,R35CA210065,2022-04-01,GRU,WXS;WGS,Longitudinal,Precursor Cell Lymphoblastic Leukemia-Lymphoma,56.0,159.0,,,,"ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic; Leukemia, Lymphoblastic, Acute, L1"
Functional Significance of Prostate Cancer Risk-SNPs,"Prostate Cancer (PrCa), the most frequently diagnosed solid tumor in men in the U.S., results in 192,000 new cases and 27,000 deaths per year. Although the variation of PrCa incidence  is likely to be the result of several factors, there is a large body of literature that strongly implicates a genetic etiology. Genome-wide",phs000985.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000985,Stephen N. Thibodeau,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25983244;26611117;30958860;35432445,R01CA151254-05,2022-03-30,DS-PC-PUB-MDS,Seq_miRNA_Expression;Seq_RNA_Expression;Array_SNP,Cohort;Control Set,Prostatic Neoplasms,471.0,1383.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Characterization of Neoantigen-reactive T cells by Single-Cell Analysis,"Through CITE-seq and TCR-seq analysis of non-small cell lung cancer (NSCLC) tumor-infiltrating lymphocytes (TIL), we developed a neoantigen-reactive T-cell signature based on clonotype frequency and CD39 protein and CXCL13 mRNA  expression. There are four datasets from four NSCLC cases. Each dataset includes (1) Transcriptome of tumor infiltrating lymphocytes (TIL), (2) Cell",phs002792.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002792,James C. Yang,,,,,2022-03-25,GRU,RNA-Seq,Case Set,"Lymphocytes, Tumor-Infiltrating",4.0,48.0,,ENTPD1;ITGAE;PDCD1;CXCL13,Single Cell Analysis;Non Small Cell Lung Carcinoma,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell"
Genomic Characterization of Brain Metastases from Lung Cancer,Metastatic disease to the brain is associated with a poor prognosis. Our understanding of the genetic drivers of metastasis remain limited. Whole-exome sequencing was performed from brain metastases from lung  adenocarcinoma to identify putative drivers of metastatic progression. We identified patients with brain metastases from lung adenocarcinoma from our,phs001920.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001920,Priscilla Brastianos;Scott Carter,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),32203465,"Damon Runyon Cancer Research Foundation, New York, NY, USA;National Institutes of Health, Bethesda, MD, USA",2022-03-25,DS-LCTC-MDS;DS-BT;GRU,WXS,Cohort,Neoplasm Metastasis,40.0,120.0,,,,"Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize; Neoplasm Metastases"
Selenium Chemoprevention: Benefits and Harms,"Selenium is a trace element that may have anti-carcinogenetic effect, but heterogenous treatment effects have been observed. This genome-wide association study investigates if genetic variation modifies the effect of selenium  chemoprevention in the Selenium and Celecoxib Trial, a randomized, double-blind, placebo-controlled trial conducted at the University of Arizona",phs002283.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002283,"Elizabeth T. Jacobs, PhD",Claire Zhu,Division of Cancer Prevention (DCP),23060037;27530657;33382417,Selenium Chemoprevention: Benefits and Harms,2022-03-14,GRU-IRB-COL-NPU,Array_SNP,Clinical Trial;Double-Blind;GWAS;Randomized,"Neoplasms, Second Primary",1323.0,1323.0,,,Selenium,"Malignancies, Second; Malignancy, Second; Metachronous Neoplasm; Metachronous Neoplasms; Metachronous Second Primary Neoplasms; Neoplasm, Metachronous"
Exceptional Responders Initiative,The Exceptional Responders Initiative is a pilot study to investigate the underlying molecular factors driving exceptional treatment responses of cancer patients to drug therapies. Study researchers will examine molecular profiles  of tumors from patients either enrolled in a clinical trial for an investigational drug(s) and who achieved an exceptional response relative to other,phs001145.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001145,"Barbara Conley, MD",,,,,2022-03-11,GRU,,Case-Control,Neoplasms,170.0,170.0,,,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
"Tumor Mutation Burden, Expressed Neoantigen and Immune Microenvironment    in Diffuse Gliomas","A consistent correlation between tumor mutation burden (TMB) and tumor immune microenvironment has not been observed in gliomas as in other cancers. Driver germline and somatic mutations, TMB, neoantigen, and  immune cell signatures were analyzed using whole exome sequencing (WES) and transcriptome sequencing of tumor and WES of matched germline DNA in a",phs002653.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002653,"Jing Wu, MD, PhD;Javed Khan, MD",Kathleen Calzone,Center for Cancer Research (CCR),,NIH Intramural Research Program,2022-03-09,GRU,RNA-Seq;WXS,Aggregate Genomic Data;Case Set;Exome Sequencing;RNA Sequencing;Sequencing;Transcriptome Sequencing;Tumor,Glioma,48.0,66.0,https://clinomics.ccr.cancer.gov/clinomics/public/viewProjectDetails/26281,IDH1;IDH2,,Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia
"Foregut Microbiome and Risk of Gastric Intestinal Metaplasia, and Gastric    Cancer Risk","The study is composed of two sub-studies. The first study, conducted by NYU Grossman School of Medicine, is a case-control study of 89 cases with gastric intestinal metaplasia (IM) and  89 matched controls who underwent upper gastrointestinal endoscopy at three sites affiliated with NYU Langone Health. Shotgun metagenomic sequencing",phs002566.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002566,"Yu
  Chen, PhD;Xiao-ou
  Shu, PhD;Zhiheng
  Pei, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),34664721;34664266,,2022-03-09,HMB-PUB-NPU;DS-GICA;DS-GICA-NPU,WGS,Case-Control;Cohort;Multicenter;Observational;Population;Prospective;Whole Genome Sequencing,Metaplasia,679.0,776.0,,,Stomach Neoplasms,"CA - Cancer of stomach; Ca lesser curvature - stomach; Cancer of Stomach; Cancer of the Stomach; Cancer, Gastric; Cancer, Stomach"
Genomic Features of Lung Adenocarcinoma from Individuals with    10    Pack-Year Smoking History,Actionable oncogenic alterations are identified in a subset of lung adenocarcinomas. Many of these driver alterations are enriched in lung adenocarcinomas from individuals with minimal smoking history and are generally  mutually exclusive of one another. We generated whole-exome and RNA-seq data from lung adenocarcinomas obtained from individuals with &#x02264;10,phs002556.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002556,"Frederick Wilson, MD, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,P50CA196530;K08CA204732;2019080,2022-03-08,DS-LC,RNA-Seq;WXS;Seq_DNA_SNP_CNV,Case Set,Adenocarcinoma of Lung,25.0,75.0,,RASGRF1,,"ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma"
Integrative Genomic and Transcriptomic Analyses of Refractory Multiple    Myeloma,"This study reports results from integrative sequencing analyses that combine capture transcriptome sequencing with a comparative analysis of exome capture between the malignant plasma cells and normal cells of patients  with relapsed and refractory multiple myeloma (RRMM). This approach has enabled the detection of point mutations, insertions/deletions, gene fusions",phs002498.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002498,"Arul M. Chinnaiyan, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,ORSP 19-PAF05802;R35-CA231996;U01-CA214170;Prostate Cancer Foundation;U24-CA210967,2022-03-07,DS-MM,RNA-Seq;Targeted-Capture,Case Set;Exome Sequencing;Full Transcriptome Sequencing;Tumor vs. Matched-Normal,Neoplasms,511.0,1530.0,https://www.pathology.med.umich.edu/mctp/mi-oncoseq-study;https://trials.themmrf.org/trials/NCT02884102,ATM;PRDM1;BRAF;CDKN1B;CDKN2C;CREBBP;CYLD;DDX3X;DDX5;EP300;FGFR3;NR3C1;IDH1;IL6ST;IRAK1;IRF4;KRAS;MAX;MBD1;MYC;NF1;NFKBIA;NRAS;PTPN11;RB1;SP3;TP53;TRAF2;TRAF3;ARID1A;CUL4B;SP140;DIS3;LATS2;SETD2;CRBN;UBR5;KDM3B;ATAD2B;FAM46C;BCORL1;ARID2,Multiple Myeloma;Smoldering Multiple Myeloma;Monoclonal Gammopathy of Undetermined Significance;primary plasma cell leukemia;Plasmacytoma;Immunoglobulin Light-chain Amyloidosis,Immunoglobulin Light-chain Amyloidosis; Monoclonal Gammopathy of Undetermined Significance; Plasmacytoma; Smoldering Multiple Myeloma; AL; AL AMYLOIDOSIS
Germ Cell and Associated Heme Malignancies Evolve from a Common Shared    Precursor,"Germ cell tumors (GCTs) are the most common cancer in men between the ages of 15-40. While most patients are cured, those with disease arising in the mediastinum have distinctly  poor outcomes. One in every 17 patients with primary mediastinal non-seminomatous GCTs develop an incurable hematologic malignancy and prior data",phs002231.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002231,"Omar Abdel-Wahab, MD;Darren Feldman, MD",Anil Wali,Center to Reduce Cancer Health Disparities (CRCHD) ,32897884,1K08CA230319-01;The Marie-Josee and Henry R. Kravis Center for Molecular Oncology;Cycle for Survival;P30 CA008748,2022-03-07,HMB,WXS,Individual-Level Genomic Data;Tumor vs. Matched-Normal,"Neoplasms, Germ Cell and Embryonal",5.0,19.0,https://www.jci.org/articles/view/139682,KRAS;NRAS;TP53,Hematologic Neoplasms;Mediastinal Neoplasms,"Mediastinal Neoplasms; HEMOLYMPHORETICULAR tumor, malignant; Hematopoietic Cancer; Hematopoietic Malignancies; Hematopoietic Malignancy; Hematopoietic Neoplasm"
Multiple Myeloma Genomic Study (MMGS),"Multiple Myeloma (MM) is a plasma cell dyscrasia characterized by bone marrow (BM) infiltration and lytic bone lesions. Recent studies of massive parallel sequencing of tumor cells obtained from the  BM of patients with MM have demonstrated significant clonal heterogeneity in MM. Despite this remarkable clonal heterogeneity, it could be envisioned",phs001323.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001323,Irene M. Ghobrial,Ian Fingerman,Division of Cancer Biology (DCB),24072855;24429703;24434212;26282654;27531699,,2022-03-07,DS-PCD,RNA-Seq;WXS;Targeted-Capture,Cohort,Multiple Myeloma,883.0,1078.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE193531,,Monoclonal Gammopathy of Undetermined Significance,Monoclonal Gammopathy of Undetermined Significance; Asymptomatic monoclonal gammopathy; Benign Monoclonal Gammapathies; Benign Monoclonal Gammapathy; Benign Monoclonal Gammopathies; MGUS
Transcriptome and TCR Sequencing of T Cells from Metastectomies,"T cells were sorted from metastatic tumors (colon, rectal, breast, anal, melanoma primary histologies) following tumor dissociation and single-cell sequencing was performed (RNAseq and TCRseq). For samples from tumors that  had been previously studied, cells were analyzed comparing known neoantigen-reactive TCR-expressing cells to other T cells. For samples without",phs002748.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002748,"Steven A. Rosenberg, MD, PhD",Kathleen Calzone,Center for Cancer Research (CCR),35113651,,2022-03-02,GRU,RNA-Seq;WXS,Case Set;RNA Sequencing;Single Cell Analysis,Colonic Neoplasms,15.0,123.0,,CXCL13,Rectal Neoplasms;Breast Neoplasms;Anus Neoplasms;Melanoma,"Anus Neoplasms; Rectal Neoplasms; Anal Neoplasms; Anal Neoplasms, Benign and Malignant; Anal Tumor; Anal Tumors"
Tumor Infiltrating Lymphocytes (TIL) Recognize Unique Somatic Mutations    and Mediate Objective Clinical Responses in Metastatic Breast Cancer,The purpose of this study is to investigate the immunogenicity of tumor mutations in patients with metastatic cancer. Harvest and analysis of progressing metastatic lesions are used for generation of  tumor infiltrating lymphocyte (TIL) cultures and the detections of somatic mutations. In vitro T cell activation assays are used to examine the,phs002735.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002735,Steven A. Rosenberg,Kathleen Calzone,Center for Cancer Research (CCR),,Center for Cancer Research Intramural Research Program,2022-02-02,GRU,RNA-Seq;WXS,Cohort;Tumor vs. Matched-Normal,Breast Neoplasms,42.0,358.0,,,"Lymphocytes, Tumor-Infiltrating",Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin    +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by    Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast    Cancer,"This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be  removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop",phs001863.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001863,"William M. Sikov, MD",,,25092775;27449492;26222764;28089784,U10CA180821;U10CA031946;CA33601;CA076001;CA025224;CA32102;CA46368;Genentech/ F. Hoffman-La Roche;Breast Cancer Research Foundation;Coalition for Cancer Cooperative Groups,2022-02-01,DS-CA-COL,RNA-Seq,Clinical Trial;Interventional;Randomized,Breast Neoplasms,389.0,389.0,,,"Triple Negative Breast Neoplasms;Neoplasms by Site;Breast Diseases;Carcinoma;Skin Diseases;Paclitaxel;Liposomal doxorubicin;Albumin-Bound Paclitaxel;Bevacizumab;Cyclophosphamide;Carboplatin;Doxorubicin;Endothelial Growth Factors;Antibodies;Immunoglobulins;Antibodies, Monoclonal;Immunoglobulin G;Antineoplastic Agents, Phytogenic;Tubulin Modulators;Antimitotic Agents;Mitosis Modulators;Angiogenesis Inhibitors [Pharmacological Action];Angiogenesis Modulating Agents","Breast Diseases; Neoplasms by Site; Skin Diseases; Triple Negative Breast Neoplasms; Breast Disease, Endocrine; Breast Diseases, Endocrine"
Genomic and Transcriptomic Markers Associated with Response to Immune    Checkpoint Blockade,"The neoantigen presentation score (NEOPS) study was designed to better understand molecular determinants of response to immunotherapies, including pembrolizumab and nivolumab in stage III or IV melanoma patients. From this  work, we developed a composite approach to predicting neoantigens (NEOPS), which takes into account additional escape mechanisms, including HLA LOH",phs002388.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002388,"Richard Chen, MD",Ian Fingerman,Division of Cancer Biology (DCB),,,2022-01-25,GRU,RNA-Seq;Seq_RNA_Expression;WXS,Clinical Cohort;Exome Sequencing;RNA Sequencing,Melanoma,52.0,199.0,,,Immunotherapy,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Health Professionals Follow-Up Study,"Health Professionals Follow-up Study (HPFS) is a prospective cohort study of men designed to evaluate hypotheses about men's health related to diet and lifestyle to the incidence of serious illnesses,  such as cancer, heart disease, and other vascular diseases. It consisted of 51,529 U.S. male health professionals who were 40-75 years old at",phs002460.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002460,Walter C. Willett;Lorelei Mucci,,,32079915;33022699;32164144;31026211;33627383;30867564;32530938;33231639;33692100;30602500,U01CA167552,2022-01-20,HMB,,Longitudinal;Longitudinal Cohort;Observational;Population;Prospective,Diet,20064.0,0.0,https://sites.sph.harvard.edu/hpfs/;https://sites.sph.harvard.edu/hpfs/publications-using-health-professionals-follow-up-study-data/,,,Not Provided
Integrated Metabolic Profiling and Gene Expression Analysis Reveals    Therapeutic Modalities in Breast Cancer,"In this study, we performed metabolite profiling and RNA-sequencing on human breast cancer tumors and normal breast tissue samples, including triple negative breast cancer (TNBC), estrogen receptor positive breast cancer  (ER+) and paired normal samples, and patient-derived xenografts (PDX) samples. Here, we report two distinctive groups defined by metabolites; a",phs002396.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002396,"Qing Zhang, PhD;Charles M. Perou, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,P50 CA058223,2022-01-13,GRU,RNA-Seq,Tumor vs. Matched-Normal;Xenograft,Triple Negative Breast Neoplasms,26.0,40.0,,,"Receptors, Estrogen","Breast Cancer, Triple-Negative; Breast Cancers, Triple-Negative; Breast Neoplasm, Triple-Negative; Breast Neoplasms, Triple-Negative; ER Negative PR Negative HER2 Negative Breast Cancer; ER Negative PR Negative HER2 Negative Breast Neoplasms"
OICR: Molecular Pathological Epidemiology of Colorectal Cancer,"Colorectal cancer, the second most commonly diagnosed cancer, is a biologically heterogeneous disease. To characterize the molecular attributes of colorectal tumors, we conducted targeted sequencing at the Ontario Cancer Research  Institution (OICR) of tumor and matched normal DNA samples from 2,542 colorectal cancer cases in the Genetics and Epidemiology of Colorectal Cancer",phs002050.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002050,"Ulrike Peters, PhD, MPH",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),32686686,U01CA137088,2022-01-12,HMB-IRB;HMB-IRB-NPU;DS-CC-MDS;GRU;DS-CC-NPU-GSO;HMB-IRB-COL,WXS;Seq_DNA_SNP,Case Set,Colorectal Neoplasms,2528.0,5056.0,"https://www.fredhutch.org/en/research/divisions/public-health-sciences-division/research/cancer-prevention/genetics-epidemiology-colorectal-cancer-consortium-gecco.html""",,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Identification and Characterization of Skin-Resident Memory T cells in    Patients with Melanoma-Associated Vitiligo,"Metastatic melanoma patients who develop melanoma-associated vitiligo, an autoimmune cutaneous side effect after receiving immunotherapy, have better overall survival than those who do not develop vitiligo. The objective of this  study is to determine the tumor-specific memory T cell responses in the skin, tumor and blood of melanoma patients with vitiligo. Matched melanoma",phs002309.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002309,"Mary Jo Turk, PhD;Christina V. Angeles, MD",Ian Fingerman,Division of Cancer Biology (DCB),,R01 #CA225028;National Institute of General Medical Sciences #P20GM130454;5P30 #CA023108-40 (Immune Monitoring and Genomics and Molecular Biology Shared Resources),2021-12-27,GRU,RNA-Seq;Seq_RNA_Expression_SC;Targeted-Capture,Cohort;Single Cell Analysis;Tumor vs. Matched-Normal,Melanoma,5.0,32.0,,,Vitiligo,"Vitiligo; Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant"
Advanced Genetic and Molecular Analysis of Solid Tumors,This study is designed to understand the role of immunosuppressive regulatory B cells (Breg) in pancreatic cancer. Breg and conventional B cells (Bcon) from patients are compared by RNA sequencing  analysis. Bregs and Bcon were isolated from freshly isolated PBMCs in peripheral blood. These data represent the examination of differentially,phs001999.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001999,Yuliya Pylayeva-Gupta,Ian Fingerman,Division of Cancer Biology (DCB),32024640;29980536,R37 CA230786;13-70-25-PYLA;V2016-016,2021-12-23,DS-CA,RNA-Seq,Case-Control,"Carcinoma, Pancreatic Ductal",1.0,2.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144504,IL12A;EBI3,"B-Lymphocytes, Regulatory","Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas; Duct Cell Carcinoma, Pancreas"
Integrated Genomic and Transcriptomic Analysis of Small Cell Lung Cancer    Reveals Inter- and Intratumoral Heterogeneity and a Novel    Chemotherapy-Refractory Subtype,"We integrated histology, transcriptome, exome, and treatment outcomes of small cell neuroendocrine cancer (SCNC) from a range of metastatic sites, revealing complex intra- and intertumoral heterogeneity of neuroendocrine (NE) differentiation  and transcriptomic subtypes (ASCL1, NEUROD1, POU2F3, YAP1 and ATOH1). High NE SCNCs were more likely to benefit from replication stress-targeted",phs002541.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002541,Anish Thomas,Kathleen Calzone,Center for Cancer Research (CCR),31063862;33848478,,2021-12-08,GRU,RNA-Seq;WXS,Cross-Sectional,Small Cell Lung Carcinoma,72.0,168.0,,ASCL1;INSM1;MYC;MYCL;MYCN;NEUROD1;YAP1;POU2F3,,"Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL"
Immunogenomics of Malignant Brain Tumors,"We performed systematic and comprehensive multi-sector immunogenomic analyses on 93 samples from a cohort of 30 patients with primary or recurrent gliomas or metastatic brain tumors, representing the largest cohort  of these brain cancers studied spatially to date. For each patient, we characterized multiple spatially distinct regions using whole-exome (WES),",phs002612.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002612,Gavin Dunn;Malachi Griffith,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),34610950,,2021-12-07,GRU,RNA-Seq;Seq_RNA_Expression;Seq_DNA_CNV;WXS,Exome Sequencing;Metastasis;RNA Sequencing;Transcriptome Analysis;Tumor vs. Matched-Normal,Genetic Heterogeneity,30.0,203.0,,,Glioblastoma Multiforme;Brain Neoplasms,Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour; Neoplasm of Brain
Genomic Analysis of Metastatic Brain Cancer,"This study contains targeted exome and transcriptome sequencing of metastatic brain tumors from 68 patients. Sequencing data includes i) targeted Tempus xT exome sequencing from matched tumor/normal from 68 patients,  and ii) whole-transcriptome RNA sequencing from a subset of 65 patients. Related Genes: BRAF, CDKN2A, KRAS, SMAD4, MCL1, NFE2L2, NRAS, PIK3CA, PTEN,",phs002639.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002639,"Analiz Rodriguez, MD, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2021-12-02,GRU,RNA-Seq;Targeted-Capture,RNA Sequencing;Tumor vs. Matched-Normal,Neoplasm Metastasis,68.0,201.0,,BRAF;CDKN2A;KRAS;SMAD4;MCL1;NFE2L2;NRAS;PIK3CA;PTEN;RB1;STK11;TP53;VHL;ARID1A;KEAP1;PBRM1;C8orf34;ARID2,Brain Neoplasms,Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour; Neoplasm of Brain
Mechanisms of Extreme Genomic Instability at Large Transcribed Genes,"Inhibiting DNA replication leads to copy number variant (CNV) formation throughout the genome, especially at chromosome fragile sites (CFSs). We previously showed that these hotspots for genome instability reside in  late-replicating domains associated with large transcribed genes. In this study, we compared aphidicolin (APH)-induced CNV and CFS frequency between",phs002066.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002066,"Thomas E. Wilson, MD, PhD;Thomas W. Glover, PhD",Ian Fingerman,Division of Cancer Biology (DCB),25373142,R01 CA200731,2021-11-22,GRU,OTHER;WGS;RNA-Seq;Seq_RNA_Expression;Array_CNV,Case-Control,Chromosome Fragile Sites,2.0,182.0,,FHIT,DNA Copy Number Variations;Genomic Instability,"Genomic Instability; Genome Instabilities; Genome Instability; Genomic Instabilities; Instabilities, Genome; Instabilities, Genomic"
Multiethnic Cohort Adiposity Phenotype Study (MEC-APS),"A total of 1,861 healthy men and postmenopausal women aged 60-77 years with body mass indexes (BMIs) of 17.1-46.2 kg/m2 were enrolled into the study. Stratified sampling was conducted based  on sex, race/ethnicity, and six BMI categories (18.5-21.9, 22-24.9, 25-26.9, 27-29.9, 30-34.9, and 35-40 kg/m2) to balance the sample size across the",phs001689.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001689,Loic Le Marchand,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,P01 CA168530,2021-11-22,HMB-PUB,Array_SNP,Cross-Sectional,Intra-Abdominal Fat,1849.0,1849.0,,,Obesity,Not Provided
Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to    Transcriptional CDK Inhibitors through Antagonism of E2F-Driven    Oncogenic Gene Expression,"Leiomyosarcoma (LMS) is a smooth muscle-derived mesenchymal cancer commonly found to have recurrent loss of tumor suppressor genes and a poorly defined oncogenic program. Empiric cytotoxic chemotherapy is the standard  systemic treatment for LMS, and while more targeted and effective therapies are urgently needed, insights into therapeutic vulnerabilities in LMS",phs002587.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002587,,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2021-11-18,HMB,RNA-Seq;WGS,RNA Sequencing,Leiomyosarcoma,11.0,67.0,,,,"Epithelioid Leiomyosarcomas; Leiomyosarcoma, Epithelioid; Leiomyosarcomas, Epithelioid; epithelioid leiomyosarcoma"
High-Throughput and High-Dimensional Single Cell Analysis of    Antigen-Specific CD8+ T Cells,"We developed a high-dimensional, tetramer associated T cell receptor sequencing (TetTCR-SeqHD) method to simultaneously profile cognate antigen specificities, TCR sequences, targeted gene-expression, and surface protein expression. Cultured antigen-specific CD8+ T  cell clones were studied as a proof-of-concept experiment. In addition, both the antigen specific CD8+ T cells from healthy subjects and Type I",phs002441.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002441,"Ning Jiang, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,"S10OD020072;R33CA225539;R56AG064801;1653866;F1785;Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation;191856",2021-11-18,GRU-NPU,AMPLICON,Cohort,"Diabetes Mellitus, Type 1",22.0,16.0,,PTPRC;GNLY;B3GAT1,,"DIABETES MELLITUS, INSULIN-DEPENDENT; DIABETES MELLITUS, INSULIN-DEPENDENT, 1; Diabetes Mellitus, Insulin Dependent; Diabetes Mellitus, Juvenile Onset; Diabetes Mellitus, Juvenile-Onset; Diabetes Mellitus, Sudden Onset"
A Comprehensive Genomic Study of Pediatric Malignancy,Malignancy remains the leading cause of disease-related death in children. DNA sequencing studies have shown a paucity of actionable genomic alterations and a low mutation burden across pediatric cancers at  diagnosis. We perform a comprehensive genomic and epigenomic analysis of pediatric tumor and normal tissues using next-generation sequencing to,phs001928.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001928,"Javed Khan, MD",,,,,2021-11-18,GRU,RNA-Seq,Cohort,Neuroblastoma,267.0,401.0,,,"Rhabdomyosarcoma;Sarcoma, Ewing;Wilms Tumor;Hepatoblastoma;Desmoplastic Small Round Cell Tumor;Osteosarcoma;Melanoma;Sarcoma, Alveolar Soft Part;Sarcoma;Sarcoma, Clear Cell;Sarcoma, Synovial;Endodermal Sinus Tumor;Teratoma","Desmoplastic Small Round Cell Tumor; Endodermal Sinus Tumor; Hepatoblastoma; Sarcoma; Sarcoma, Alveolar Soft Part; Sarcoma, Clear Cell"
Metagenomic Analysis to Identify Novel Infectious Agents in Systemic    Anaplastic Large Cell Lymphoma,"Anaplastic large cell lymphoma (ALCL) is a rare T-cell non-Hodgkin lymphoma (NHL). Risk of systemic ALCL is markedly increased among immunosuppressed people, such as those with human immunodeficiency virus (HIV)  infection or solid organ transplant recipients. This increased risk in immunosuppressed populations suggests a viral etiology, given similar",phs002064.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002064,"Eric A. Engels, MD, MPH",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),34775986,Intramural Research Program,2021-11-17,GRU,RNA-Seq,Case-Control,"Lymphoma, Large-Cell, Anaplastic",26.0,26.0,,,,"ALCL; Anaplastic Large-Cell Lymphoma; Anaplastic Large-Cell Lymphomas; Anaplastic large cell lymphoma (ALCL) CD30+; Anaplastic large cell lymphoma CD30 positive; Anaplastic large cell lymphoma, CD30+"
Genomic and Genetic Characterization of Prostate Tumors Treated with    Neoadjuvant Intense Androgen Deprivation Therapy,"The purpose of this study was to develop better ways of detecting prostate cancer before and after pre-operative treatment, and to test the feasibility of multi parametric magnetic resonance imaging  (mpMRI) for the localization and detection of focal prostate cancer both before and after pre-operative treatment with ADT and enzalutamide. In this",phs001938.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001938,"William Dahut, MD",Kathleen Calzone,Center for Cancer Research (CCR),32054861;31000430;33023952;34415294;33785256,,2021-11-15,GRU-IRB-PUB,AMPLICON;WGS;RNA-Seq;WXS;Array_SNP,Case Set,Prostatic Neoplasms,39.0,487.0,,AR;ERG;PTEN;TP53,"Receptors, Androgen;MDV 3100;Magnetic Resonance Imaging","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Comprehensive Analysis of the Immunogenomics of Triple Negative Breast    Cancer Brain Metastases from LCCC1419,"Triple negative breast cancer (TNBC) is an aggressive subset of breast cancer that lacks expression of the estrogen and progesterone receptors (ER and PR) and HER2. Nearly 50% of patients  with advanced TNBC will develop brain metastases (BrM), commonly with progressive extracranial disease. Immunotherapy has shown promise in the",phs002457.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002457,"Carey K. Anders, MD",Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),"14737219;31061481;33177107;19706884;24157944;24888378;31159741;29069305;25516281;16199517;23323831;25822800;25924071;27559159;28263959;24891321;19505943;30357393;24884790;28978689;38340557;17158513;No PMID: forestplot: Advanced Forest Plot Using 'grid' Graphics | Max Gordon M, Lumley T.;37244159",,2021-11-10,HMB,RNA-Seq;WXS,Tumor vs. Matched-Normal,Triple Negative Breast Neoplasms,25.0,95.0,,TP53,Brain Neoplasms;Neoplasm Metastasis,Neoplasm Metastasis; Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour
Genomic Profiling of Relapsed and Refractory Childhood Cancers,"Through clinical trials focused on molecularly guided therapy in pediatric cancers (NCT01355679, NCT01802567, NCT02162732), the Beat Childhood Cancer Consortium performed paired tumor/normal whole exome sequencing and/or tumor mRNA sequencing for  202 pediatric or adolescent young adult patients with rare, relapsed and refractory cancers (including neuroblastoma, Ewing sarcoma, osteosarcoma,",phs002238.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002238,Jeffrey M. Trent;Giselle L. Saulnier Sholler,Ian Fingerman,Division of Cancer Biology (DCB),34610968,,2021-11-09,HMB-MDS,RNA-Seq;WXS,Cohort;Exome Sequencing;Transcriptome Sequencing;Tumor vs. Matched-Normal,Neoplasms,202.0,683.0,,,"Neuroblastoma;Osteosarcoma;Rhabdomyosarcoma;Brain Neoplasms;Sarcoma;Wilms Tumor;Hepatoblastoma;Desmoplastic Small Round Cell Tumor;Ependymoma;Glioblastoma;Sarcoma, Ewing","Desmoplastic Small Round Cell Tumor; Hepatoblastoma; Sarcoma; Sarcoma, Ewing; Brain Neoplasms; Brain Tumor"
Multi-Omic Investigation of Beckwith-Wiedemann Syndrome Hepatoblastoma,"Hepatoblastoma (HB) is the most common malignant liver tumor diagnosed in children under 5 years of age. One of the most common HB predisposition syndromes is Beckwith-Wiedemann Syndrome (BWS, OMIM  130650), which affects approximately 1/10,000 live births. In this study, we perform Whole Exome Sequencing (WES), DNA methylation array, messenger",phs002614.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002614,"Jennifer M. Kalish, MD, PhD",,,,K08CA193915,2021-11-08,GRU-PUB-COL-NPU,Array_DNA_Methylation;Seq_RNA_Expression;WXS,Epigenetics;Exome Sequencing;Transcriptome Sequencing;Tumor vs. Matched-Normal,Beckwith-Wiedemann Syndrome,12.0,17.0,,,hepatoblastoma,Hepatoblastoma; BWS; Beckwith Wiedemann Syndrome; Beckwith's syndrome; Beckwith-Wiedemann syndrome chromosome region; EMG SYNDROME
A Multi-Omic Single-Cell Atlas of Human Gynecological Malignancies,Matched single-cell transcriptomic sequencing (scRNA-seq) and single-cell chromatin accessibility sequencing (scATAC-seq) were performed for 11 fresh human tumors collected from the endometrium or ovary. More detailed information for each patient  tumor will be provided in selected phenotype/attributes data. Both scRNA-seq and scATAC-seq assays revealed the underlying cellular heterogeneity in,phs002340.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002340,Hector L. Franco,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),"No PMID: A multi-omic single-cell atlas of human gynecologic malignancies&#160; | Matthew J. Regner, Kamila Wisniewska, Susana Garcia-Recio, Aatish Thennavan,&#160;Raul Mendez-Giraldez,&#160;Venkat S. Malladi,Gabrielle Hawkins,&#160;Joel Parker,&#160;Charles M. Perou, Victoria L. Bae-Jump,&#160;Hector L. Franco*&#160;",5-P50-CA058223-25;CCR19608601;V2019-015,2021-11-04,GRU,RNA-Seq;ATAC-seq,Case Set,"Carcinoma, Ovarian Epithelial",11.0,22.0,,CLDN4;RHEB;LAPTM4B,"Carcinoma, Endometrioid;Gastrointestinal Stromal Tumors","Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian; Epithelial Cancer, Ovarian"
Characterization of Immune-Related Gene Expression in Lung Cancer,We performed a comprehensive analysis of inter- and intratumor heterogeneity of immune gene expression in 160 lung cancer patients from the Environment And Genetics in Lung cancer Etiology (EAGLE) study.  The transcriptome was profiled with RNA sequencing in 269 tumor samples and 110 normal tissue samples from 160 subjects. Lung cancer cases only,phs002346.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002346,"Maria Teresa Landi, MD, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,"Intramural program, NCI, DCEG",2021-11-03,DS-LDS-MDS,RNA-Seq,Case Set,Lung Neoplasms,160.0,378.0,https://dceg.cancer.gov/research/who-we-study/cancer-cases-controls/eagle-study,,,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
A Single Cell Atlas of MMRd and MMRp Colorectal Cancer,"Immune responses to cancer vary across cancer types and patients. Colorectal cancer tumors with mismatch repair-deficiency (MMRd) show an elevated immune cell activity as compared to mismatch repair proficient (MMRp)  tumors. To understand the immune response patterns in these two types of colorectal cancer, we transcriptionally profiled 371,223 tumor and adjacent",phs002407.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002407,Nir Hacohen;Aviv Regev,Ian Fingerman,Division of Cancer Biology (DCB),34450029,"NIH/NCI R01CA208756;Arthur, Sandra and Sarah Irving Fund for Gastrointestinal Immuno-Oncology;NIH/NCi HTAPP HHSN261201500003;Evergrande Center for Immunologic Diseases;Klarman Cell Observatory",2021-10-27,GRU,RNA-Seq,Case Set;RNA Sequencing;Single Cell Analysis;Tumor vs. Matched-Normal,Colorectal Neoplasms,62.0,181.0,https://singlecell.broadinstitute.org/single_cell/study/SCP1162,CXCR3;CXCL1;IFNG;IL1B;IL17;CXCL10;CXCL9;CXCL11;CXCL14;CXCL13;RSPO3,Microsatellite Instability;DNA Mismatch Repair,Microsatellite Instability; CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine
Mentored Patient Oriented Research in Lymphoma,"Significant racial differences have been observed in the incidence and clinical outcomes of diffuse large B-cell lymphoma (DLBCL) in the United States, but to the authors' knowledge it remains unclear  whether genomic differences contribute to these disparities. To understand the influences of genetic ancestry on tumor genomic alterations, the",phs002434.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002434,"Christopher Flowers, MD",Mariam Eljanne,Center for Cancer Training (CCT),28985567;32469082,K24 CA208132/NIH/NCI,2021-10-18,,,Cohort,"Lymphoma, Large B-Cell, Diffuse",,,,,African Continental Ancestry Group,Centroblastic diffuse large B-cell malignant lymphoma; Centroblastic diffuse malignant lymphoma; Centroblastic malignant lymphoma; DLBCL; DLBCL - diffuse large B cell lymphoma; Diffuse Histiocytic Lymphoma
Study of Tumor Recurrence Related to the Expression of the PAX3-FOXO1    Oncogenic Transcription Factor in Fusion-Positive Rhabdomyosarcoma,"Alveolar rhabdomyosarcoma (ARMS) is a highly aggressive pediatric soft tissue cancer characterized by a recurrent 2;13 chromosome translocation. This translocation generates a PAX3-FOXO1 (P3F) fusion gene, which encodes a chimeric  transcription factor with oncogenic activity. Using a human myoblast system that models targeted therapy directed against P3F, we demonstrated that",phs002344.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002344,"Frederic G. Barr, MD, PhD",Kathleen Calzone,Center for Cancer Research (CCR),,,2021-10-14,GRU,Array_SNP_CNV,Case Set,Rhabdomyosarcoma,17.0,17.0,,FGF8;FOXO1;PAX3,,Not Provided
Transplant Outcomes in Aplastic Anemia (TOAA),"The TOAA study is a research collaboration between the National Cancer Institute and the Center for International Blood and Marrow Transplant Research. The study aims to identify molecular predictors of  outcomes after hematopoietic cell transplant in patients with severe aplastic anemia. Principal Investigator: Shahinaz Gadalla, MD, PhD, National",phs001710.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001710,"Shahinaz Gadalla, MD, PhD",,,,,2021-10-07,DS-HCTCT-IRB,Array_SNP,Cohort,"Anemia, Aplastic",416.0,416.0,,,,
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance    Mechanisms in EGFR Mutant Lung Cancer,Current understanding of acquired resistance to osimertinib in EGFR-mutant lung cancer is largely based on the use of targeted sequencing platforms and cell-free DNA. In this study we examined the  clonal evolution and heterogeneity of acquired resistance mechanisms to osimertinib through whole exome and RNA-sequencing of prospectively collected,phs002001.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002001,"Udayan Guha, MD, PhD",Kathleen Calzone,Center for Cancer Research (CCR),,Intramural Research Program,2021-09-30,GRU,RNA-Seq;WXS;Targeted-Capture,Longitudinal,Lung Neoplasms,15.0,133.0,,BRAF;EGFR;MET,,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
Epigenomics Studies in Acute Myeloid Leukemia (AML),Acute Myeloid Leukemia (AML) remains a clinical challenge since most patients diagnosed with AML will die from the disease. Some patients harbor treatment-refractory disease and many others relapse with disease  that in many cases is resistant to treatments. Our study was designed to understand the molecular basis of disease progression in AML through,phs001027.v4.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001027,"Francine Garrett-Bakelman, MD, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25260792;27322744;33580203;33500244,K08CA169055,2021-09-23,GRU-PUB,Seq_DNA_SNP_CNV;Bisulfite-Seq;WGS;RNA-Seq;WXS;Targeted-Capture,Cohort;Epigenetics;Individual-Level Genomic Data,"Leukemia, Myeloid, Acute",155.0,961.0,,,,AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL
UCSF Adult Glioma Study,"The UCSF Adult Glioma Study is a case-control study conducted at the University of California, San Francisco. The goals of the study were to discover inherited (genetic), developmental, immunologic and  other risk factors for glioma and to determine molecular level tumor markers that would be helpful in classifying glioma into more homogeneous",phs001497.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001497,"Margaret Wrensch, PhD;John Wiencke, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),19578366;26061753;28346443,R01CA52689;P50CA097257;R01CA139020,2021-09-22,GRU;DS-BT-CA-MDS,Array_DNA_Methylation;Array_SNP,Case-Control,Glioma,3173.0,3173.0,,,,Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia
Transcriptomic Profiling of Patient Derived Alternative Lengthening of    Telomeres (ALT) and Non-MYCN-Amplified Neuroblastoma Cell Lines,"Patient derived neuroblastoma cell lines are excellent tools to study biology of the disease. While many previous studies sequenced neuroblastoma cell lines, there are very few ALT and non-MYCN-amplified neuroblastoma  cell lines that were sequenced previously. Here, we present raw RNA sequencing data for 3 ALT (CHLA-90, SK-N-FI, COG-N-515) and 8 non-MYCN-amplified",phs002421.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002421,"C. Patrick Reynolds, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),34408079;34408079,,2021-09-20,GRU,RNA-Seq;Seq_RNA_Expression,Cohort,Neuroblastoma,11.0,11.0,,,,Not Provided
Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable    (MSS) and Microsatellite Instable (MSI) High Colorectal and Pancreatic    Cancer,"This is a single-arm, non-randomized, phase 2 trial (NCT03104439) combining radiation, ipilimumab and nivolumab in patients with metastatic MSS Colorectal Cancer (CRC; n 40) and Pancreatic Ductal Adenocarcinoma Cancer (PDAC;  n 25). Patients were previously treated population, and the primary endpoint was disease control rate. Pre- and post-treatment samples were subjected",phs002545.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002545,Theodore S. Hong;Aparna R. Parikh;David T. Ting,Freddie Pruitt,Center for Cancer Genomics (CCG),,SU2C-AACR-DT22-17;P50CA127003;Career Development Award;SU2C-Lustgarten;Robert L. Fine Cancer Research Foundation (RLFCRF),2021-09-17,HMB,WXS,Case Set;Clinical Trial,Immunotherapy,26.0,72.0,https://www.clinicaltrials.gov/ct2/show/NCT03104439,,Colorectal Neoplasms;Pancreatic Neoplasms,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
OncoArray: Follow-up of Ovarian Cancer Genetic Association and    Interaction Studies (FOCI),The Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI) was one of five projects funded in 2010 as part of the NCI's Genetic Associations and Mechanisms in Oncology  (GAME-ON) initiative (http://epi.grants.cancer.gov/gameon/). FOCI represents a collective effort that builds upon the strengths and history of,phs001882.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001882,"Thomas A. Sellers, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),28346442;30898391;31043753;30054336;31001917;30683880;30559148;30499236,U19-CA148112;R01-CA149429;R01-CA058598;CA1X01HG007491-01;HHSN268201200008I,2021-09-13,DS-OVCA-NPU;GRU-NPU;DS-OVCA-MDS-GSO;DS-BROC;GRU-COL;DS-CA-PUB;DS-OVCA-MDS;GRU-PUB-NPU;DS-BOED-MDS;DS-CA;DS-OVCA;DS-BCEMOPCA-NPU-MDS;HMB-PUB-MDS;HMB;CADM;DS-OVTU;HMB-PUB-NPU;DS-BRCA-MDS;DS-OVCA-NPU-MDS;HMB-PUB;DS-CA-NPU-GSO;DS-CA-MDS;GRU;OVCA,Array_SNP,Case-Control,"Carcinoma, Ovarian Epithelial",50315.0,50671.0,https://epi.grants.cancer.gov/oncoarray/,,"Genital Neoplasms, Female;Genome-Wide Association Study","Genital Neoplasms, Female; Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian"
Circulating Tumor Cell Heterogeneity in Neuroendocrine Prostate Cancer by    Single Cell Copy Number Analysis,"Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. Combined loss  of tumor suppressors RB1, TP53, PTEN are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical",phs002462.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002462,Himisha Beltran,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,P50CA211024,2021-09-09,DS-PC-IRB,WGS;Seq_DNA_SNP_CNV_SC,Case Set,Prostatic Neoplasms,12.0,215.0,,,"Carcinoma, Neuroendocrine","Carcinoma, Neuroendocrine; NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic"
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed    Hematologic Malignancies After Allogeneic Hematopoietic Cell    Transplantation,Relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is characterized by poor outcomes and novel therapeutic options are urgently needed. Immune checkpoint blockade using CTLA-4 and PD-1 blocking antibodies are  a potential concept for reinstating a dormant graft-versus-leukemia (GvL) effect.This study investigated transcriptomic changes in biopsies obtained,phs002377.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002377,Catherine J. Wu,Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),32478814;27410923,P01CA229092;U24CA224331;U24CA224316;U24CA224319;5R01CA183559;5R01CA183560;5UM1CA186709;P01CA190174;U01DK124165,2021-09-03,HMB-COL,RNA-Seq,Clinical Trial,Hematologic Neoplasms,36.0,78.0,,CD80;CD86;CTLA-4;PD-1;PD-L1,"Relapse;Allogeneic Grafting;Stem Cell Transplantation, Hematopoietic;Immune Checkpoint Inhibitor","Relapse; HEMOLYMPHORETICULAR tumor, malignant; Hematopoietic Cancer; Hematopoietic Malignancies; Hematopoietic Malignancy; Hematopoietic Neoplasm"
Germ Cell Tumor Molecular Heterogeneity Revealed through Analysis of    Primary and Metastasis Pairs,"Purpose: While primary germ cell tumors (GCTs) have been extensively characterized, molecular analysis of metastatic sites has been limited. We performed whole-exome sequencing and targeted next-generation sequencing on paired primary  and metastatic GCT samples in a patient cohort enriched for cisplatin-resistant disease. Experimental Design: Tissue sequencing was performed on 100",phs002229.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002229,"Darren Feldman, MD",Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),33163850,P30 CA008748;The Marie-Josee and Henry R. Kravis Center for Molecular Oncology,2021-08-30,GRU,WXS,Case Set,"Neoplasms, Germ Cell and Embryonal",10.0,30.0,,MDM2;PIK3CD;TP53;BCL2L11;SETD2,"Drug Resistance, Neoplasm;Testicular Neoplasms","Testicular Neoplasms; Germ Cell and Embryonal Neoplasms; Germ Cell and Embryonic Neoplasms; Neoplasms, Germ Cell and Embryonic; Neoplasm of Testis; Neoplasm of the Testis"
Genetic Factors associated with Conversion from Active Surveillance to    Treatment for Prostate Cancer,"This is a genome-wide association study (GWAS) of conversion from active surveillance (AS) for prostate cancer (PC) to treatment. AS is the monitoring with screening tests and/or biopsies over time  of men usually with low-risk, early-stage PC to avoid harmful side effects of PC treatment. ""Conversion"" refers to patients who withdraw from AS",phs002056.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002056,"William Catalona, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),26709152;27571263;29892016;34993496,"P50-CA180995;HHSN268201700006I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease"";Research Award",2021-08-25,HMB-IRB-MDS;DS-PC;HMB-MDS;DS-CA-MDS;DS-PC-IRB-MDS;DS-PC-IRB-PUB-MDS;GRU;HMB-PUB-MDS;NRUP;DS-PC-PUB-MDS;DS-PC-IRB-NPU-MDS;DS-PC-MDS;DS-PC-PUB-NPU-MDS,Array_SNP_CNV;Imputation_SNP_CNV,Case Set,Prostatic Neoplasms,6394.0,6577.0,,,"Prostatectomy;Watchful Waiting;Prostate-Specific Antigen;Neoplasm Recurrence, Local;Neoplasm Metastasis;Death","Death; Neoplasm Metastasis; Neoplasm Recurrence, Local; Deceased; End Of Life; End-Of-Life"
Metformin for Oral Cancer Prevention,"The M4OC-PREVENT clinical trial addressed whether metformin has utility in the prevention of oral cancer. It is a phase IIa clinical trial of metformin ER 2,000 mg per day given  for 12-14 weeks to individuals with oral premalignant lesions, either oral leukoplakia or erythroplakia (which are precursors to oral cancer). The",phs002437.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002437,Scott Lippman,Natalie Abrams,Division of Cancer Prevention (DCP),22467081;31292160;25681087;34255745,,2021-08-24,GRU,WXS,Case Set;Clinical Cohort;Clinical Trial;Exome Sequencing;Individual-Level Genomic Data;Interventional;Tumor vs. Matched-Normal,"Leukoplakia, Oral",17.0,34.0,,,Leukoplakia;Erythroplasia,"Erythroplasia; Leukoplakia; Erythroplasias; erythroplakia; Keratotic Plaque; Lesion, Leukoplakic"
Kids First: Whole Genome Sequencing of Nonsyndromic Craniosynostosis,"Nonsyndromic craniosynostosis (NCS) is a common, major structural birth defect - due to the premature fusion of one or more cranial sutures - that requires extensive surgical correction and is  associated with considerable ongoing medical problems and health care costs. Because little is known about the causes of NCS, whole genome sequencing",phs001806.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001806,Simeon Boyd;Paul Romitti,,,23160099;28985029;28160402,X01 HL140535-01,2021-08-19,HMB-GSO;GRU,,Cohort;Multiplex Families;Parent-Offspring Trios,Craniosynostoses,974.0,1036.0,https://commonfund.nih.gov/kidsfirst/X01Projects,FGFR1;FGFR3;FGFR2;TWIST1,Craniofacial Abnormalities,"Craniofacial Abnormalities; Abnormalities, Craniofacial; Abnormality, Craniofacial; Craniofacial Abnormality; CRANIOSTENOSIS; CRS"
Integrative Molecular Characterization of Breast Cancer,"We have performed integrative analyses of breast cancer tumors, including whole exome sequencing of tumor & normal pairs, whole transcriptome sequencing, and single-cell/nucleus RNA sequencing, to determine molecular correlates of  response to novel and immune therapies. We have focused on dissecting the role of anticancer immunity in response to these therapies and",phs002419.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002419,"Eliezer M. Van Allen, MD",,,,R37 CA222574;R01 CA227388,2021-08-18,HMB,RNA-Seq;WXS,Case Set,Breast Neoplasms,58.0,159.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Gabriella Miller Kids First Pediatric Research Program for Infantile    Hemangiomas Associated with Multi-Organ Structural Birth Defects,"Infantile hemangiomas are the most common benign vascular tumor in infants, affecting 4-5% of children. Thirty percent of segmental infantile hemangiomas on the face and scalp are associated with birth  defects of multiple organs. This condition is known as PHACE, an acronym for posterior fossa brain malformations, segmental facial hemangiomas,",phs001785.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001785,"Dawn Siegel, MD",,,19858157;8607636;28686325,X01 HL140519-0,2021-08-17,HMB;DS-PHACE,,Cohort,Hemangioma,274.0,274.0,https://commonfund.nih.gov/kidsfirst/X01Projects,,"Heart Defects, Congenital","Abnormality of cardiac morphology; Abnormality of the heart; Abnormality, Heart; Abnormally shaped heart; Cardiac abnormalities; Cardiac abnormality"
Germline Genetic Variants in Cancer-Susceptibility Genes in Patients with    Osteosarcoma,We conducted whole-exome sequencing of germline DNA from patients with osteosarcoma to estimate the frequency of pathogenic/likely pathogenic germline genetic variants in known cancer-susceptibility genes in a large population of  osteosarcoma patients unselected for family history. Osteosarcoma cases of all ages unselected for family history from 10 international centers or,phs002444.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002444,"Lisa Mirabello, PhD, MS",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),32191290,,2021-08-11,HMB,WXS,Case Set,Osteosarcoma,720.0,720.0,,,,Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma
Transcriptome and Epigenome of TIL Infusion for Cancer Immunotherapy,Adoptive T cell therapy (ACT) using ex vivo&#x02013;expanded autologous tumor-infiltrating lymphocytes (TILs) can mediate complete regression of certain human cancers. The impact of TIL phenotypes on clinical success of TIL-ACT  is currently unclear. Samples were analyzed from TIL infusion products from metastatic melanoma human patients who responded to TIL-ACT (responders),phs002436.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002436,Steven A Rosenberg,Kathleen Calzone,Center for Cancer Research (CCR),33303615,,2021-07-21,GRU,RNA-Seq;ATAC-seq,Case Set;Single Cell Analysis,Melanoma,13.0,36.0,,ENTPD1;CD69,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
GATA2 Deficiency,The aim of this study is to identify somatic mutations that contribute to the progression of GATA2 Deficiency patients from bone marrow failure to myelodysplastic syndrome (MDS) to acute myeloid  leukemia (AML) or chronic myelomonocytic leukemia (CMML). We investigated somatic mutations in 100 patients by whole exome and myeloid malignancy,phs002311.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002311,"Dennis D. Hickstein, MD",Kathleen Calzone,Center for Cancer Research (CCR),,,2021-07-09,NRUP;GRU,WXS;Seq_DNA_SNP_MAF_Ind;Targeted-Capture,Case Set,Neoplasms,108.0,294.0,https://clinicaltrials.gov/ct2/show/NCT02565004?term=Calzone&cond=Familial+analysis&cntry=US&rank=1,DNMT3A;GATA2;STAG2;ASXL1,Immune System Diseases,"Immune System Diseases; Disease, Immune; Disease, Immune System; Disease, Immunologic; Disease, Immunological; Diseases of Immune System"
Chromatin Accessibility Landscape of Human Pancreatic Ductal    Adenocarcinoma (PDAC),"Therapeutic options in pancreatic ductal adenocarcinoma (PDAC) are largely limited to cytotoxic chemotherapy without the benefit of molecular markers predicting response. By ATAC-seq analyses of EpCAM+ PDAC malignant epithelial cells  sorted from 54 freshly resected human tumors, we discovered a signature of 1092 chromatin loci displaying differential accessibility between patients",phs002394.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002394,Steven D. Leach;Christina S Leslie,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2021-07-08,DS-PACA-PUB,OTHER;ATAC-seq,Clinical Cohort,Pancreatic Neoplasms,53.0,174.0,,HNF1B;ZKSCAN1,epigenetics;recurrence,"Recurrence; Cancer of the pancreas; Neoplasia of the pancreas; Neoplasm of Pancreas; Neoplasm of the Pancreas; Neoplasm, Pancreas"
Landscape of Intratumoral NK Cell and ILC in Head and Neck Squamous Cell    Carcinoma,"In this study, total innate lymphoid cells (ILCs), including natural killer (NK) cells, were FACS-sorted from eight dissociated primary head and neck squamous cell carcinoma (HNSCC) tumors. In addition, ILCs  and NK cells were sorted from peripheral blood of tumor patients. The ILCs and NK cells were analyzed by single-cell RNA sequencing (scRNA-seq) using",phs002002.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002002,"John B. Sunwoo, MD",Claire Zhu,Division of Cancer Prevention (DCP),,R01 CA158516;U54 CA209971,2021-07-07,GRU-NPU,RNA-Seq,Case Set,Squamous Cell Carcinoma of Head and Neck,8.0,2747.0,,,Tongue Neoplasms;Pharyngeal Neoplasms,"Pharyngeal Neoplasms; Tongue Neoplasms; Neoplasia of the pharynx; Neoplasm of Pharynx; Neoplasm of the Pharynx; Neoplasm, Pharyngeal"
Genomic sequencing of Pediatric Rhabdomyosarcoma,"Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood accounting for approximately 350 newly diagnosed cases yearly in the United States. With the development of multimodal chemotherapy regimens,  relapse-free survival rates have improved to 70-80% in patients with localized disease albeit with significant toxicity. Unfortunately, despite",phs000720.v4.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000720,"Javed Khan, MD",Kathleen Calzone,Center for Cancer Research (CCR),24436047;34095712,National Cancer Institute,2021-07-02,DS-CA-MDS;GRU-PUB-MDS,WGS;RNA-Seq;WXS;Targeted-Capture;Array_SNP,Case Set,Rhabdomyosarcoma,807.0,953.0,http://home.ccr.cancer.gov/oncology/oncogenomics/,,"Rhabdomyosarcoma, Alveolar;Rhabdomyosarcoma, Embryonal","Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Alveolar Rhabdomyosarcomas; Alveolar rhabdomyosarcoma (disease); Monomorphous Round Cell Rhabdomyosarcoma; RHABDOMYOSARCOMA 2"
Genomic Evolution of Low- and High-Grade Glioma,"Malignant transformation (MT) of IDH-mutant low-grade glioma (LGG) to aggressive high-grade tumors is an event of major clinical significance, eventually leading to death in the majority of LGG patients. While  patients with primary glioblastoma (GBM) have benefited from increased overall survival due to treatment with the alkylating chemotherapy",phs002034.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002034,"Joseph F. Costello, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,P50 CA097257,2021-07-01,HMB-MDS-GSO,RNA-Seq;WXS,Longitudinal,Glioma,42.0,157.0,,IDH1;TERT,Glioblastoma,"Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme"
CRU-Ukrainian National Research Center for Radiation Medicine Trio Study,"Data on transgenerational effects following nuclear accidents are important for understanding fully the consequences of parental exposure to ionizing radiation. Few studies to date have had adequate statistical power to  detect effects of the magnitude expected based on animal data, and most have not been of low-dose, protracted exposures associated with nuclear",phs001163.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001163,Stephen J. Chanock,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,DCEG Intramural,2021-06-17,NRUP;GRU,,Parent-Offspring Trios,Germ-Line Mutation,348.0,340.0,,,,Not Provided
Genomics of Prostate Cancer,"This dataset includes genomic data from patients with prostate cancer. Specimens include archival active surveillance biopsies, radical prostatectomy specimens selected based on evidence of PD-L1 expression and/or T lymphocyte infiltrates,  and rapid autopsy material from patients deceased of prostate cancer. These data include low pass whole genome sequencing and targeted sequencing",phs002398.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002398,Steven Balk;Adam Sowalsky;David Einstein;Joshua Russo,Ian Fingerman,Division of Cancer Biology (DCB),,Challenge Award 18CHAL09;Young Investigator Award 18YOUN24;Developmental Research Project Award P20 CA233255;Research Program Project P01 CA163227;SPORE in Prostate Cancer P50 CA090281;Intramural Research Program;Physician Research Award W81XWH-17-1-0350;Early Investigator Research Award W81XWH-18-1-0531;Idea Development Award W81XWH-18-1-0379;Idea Development Award W81XWH-20-1-0925,2021-06-11,GRU,OTHER;WGS,Case Set;Clinical Cohort;Cross-Sectional,Prostatic Neoplasms,43.0,129.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Childhood Cancer Survivor Study (CCSS),"Background and Rationale for the Childhood Cancer Survivor Study (CCSS) Over the last several decades, advances in treatments for childhood and adolescent cancer have substantially improved survival following diagnosis. These  improvements gave rise to the responsibility for investigating long-term treatment-associated morbidity and mortality. Early efforts to describe late",phs001327.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001327,"Gregory T. Armstrong, MD, MSCE;Lindsay M. Morton, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),11920786;19364957;29059430,U24 CA55727,2021-06-04,HMB-MDS,WXS;Imputation_SNP_CNV,Cohort;Longitudinal,Neoplasms,30716.0,11363.0,https://ccss.stjude.org/,,"Neoplasm;Cardiovascular Diseases;Metabolic Diseases;Infertility;Heart Failure;Stroke;Cognitive Dysfunction;Lung Diseases, Obstructive;Obesity;Renal Insufficiency;Bone Diseases;Dwarfism, Pituitary","Bone Diseases; Cardiovascular Diseases; Cognitive Dysfunction; Dwarfism, Pituitary; Heart Failure; Infertility"
Notch Signaling and Efficacy PD-1/PD-L1 Blockade in Relapsed Small Cell    Lung Cancer,"Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine (NE) cancer that accounts for approximately 15% of all lung cancer, with an annual incidence of more than 34,000 in  the United States alone. SCLC is characterized by loss of function of p53 and RB and high tumor mutational burden, which suggests that these tumors",phs002176.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002176,Anish Thomas,Kathleen Calzone,Center for Cancer Research (CCR),,,2021-06-01,GRU,RNA-Seq;WXS;OTHER,Clinical Trial,Small Cell Lung Carcinoma,38.0,101.0,,NOTCH1,,"Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL"
The Role of CTCF in the Organization of the Centromeric 11p15 Imprinted    Domain Interactome,"Beckwith-Wiedemann Syndrome (BWS) is the most common human imprinting disorder and comprises a spectrum of overgrowth phenotypes. While approximately 35% of BWS cases are caused by isolated loss of methylation  (LOM) at the human imprinting center 2 (IC2) on chromosome 11p15, only around 5% of patients develop BWS due to structural alterations to the IC2",phs002408.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002408,"Jennifer
  M. Kalish, MD PhD;Nora
  Engel, PhD",,,34107024,K08CA193915,2021-05-27,GRU-PUB-COL-NPU,Seq_Interactions;WGS,Case-Control,Beckwith-Wiedemann Syndrome,7.0,9.0,,CDKN1C;KCNQ1;KCNQ1OT1,,BWS; Beckwith Wiedemann Syndrome; Beckwith's syndrome; Beckwith-Wiedemann syndrome chromosome region; EMG SYNDROME; EMG Syndromes
National Cancer Institute (NCI) Primary Human Melanocyte QTL Study,"In order to create a melanocyte-specific QTL resource, we obtained primary human melanocyte cultures isolated from foreskin of 106 healthy newborn males predominantly of European descent. Melanocytes were cultured in  lot-matched culture medium in randomized batches to minimize variability that could be introduced by culturing conditions. RNA sequencing and direct",phs001500.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001500,"Kevin M. Brown, PhD;William J. Pavan, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),30333196,"National Cancer Institute Intramural Research Program;NIH Intramural Sequencing Center (NISC), 			National Human Genome Research Institute, 			National Institutes of Health, Bethesda, MD, USA",2021-05-27,GRU,Array_DNA_Methylation;Seq_RNA_Expression;RNA-Seq;Array_SNP,eQTL,Melanocytes,106.0,106.0,,,,Not Provided
Ghana Breast Health Study,"The Ghana Breast Health Study (GBHS) was a multi-disciplinary, population-based case-control study conducted in Accra and Kumasi, Ghana that was designed to investigate breast cancer etiology in the West Africa  region. The study enrolled 1,126 invasive breast cancer cases and 2,106 frequency matched population-based controls using census-based sampling. GHBS",phs002387.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002387,"Montserrat Garc&#237;a-Closas, MD, DPH",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),28295287;30990841,Intramural funds,2021-05-20,HMB,Array_SNP_CNV,Case-Control;Population;Population Genomics,Breast Neoplasms,2529.0,2529.0,https://dceg.cancer.gov/research/cancer-types/breast-cancer/ghana-breast-study,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Genomics of Pediatric Renal Medullary Carcinomas,"Version 1 We derived faithful cancer cell lines from patients with a diagnosis of renal medullary carcinomas (RMC). These models have been sequenced with whole genome, exome and transcriptome technologies  along with the patient's primary germline and tumor samples. We took these faithful models and performed loss-of-function genetic perturbation",phs001800.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001800,"Matthew Meyerson, MD PhD;Andrew Hong, MD;William C. Hahn, MD PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),30860482,132943-MRSG-18-202-01-TBG;K12 HD052896;P50 CA101942;U01 CA176058,2021-05-20,DS-CA-MDS;HMB;GRU,RNA-Seq;WXS;WGS,Cohort,SMARCB1 Protein,15.0,30.0,,CCNB1;HBB;PSMB5;SMARCB1;UBE2C,Kidney Neoplasms;African Continental Ancestry Group;Proteasome Inhibitors,Kidney Neoplasms; Kidney Tumor; Kidney cancer; Kidney neoplasm; Neoplasia of the kidneys; Neoplasm of Kidney
Study of 5'UTR Mutations in Prostate Cancer,"The 5' untranslated region (5' UTR) of mRNA controls the translation of specific transcripts through encoded cis-regulatory elements. Yet exceedingly little is known about the prevalence and function of 5'  UTR mutations in cancer. We have uncovered many 5' UTR mutations in our analysis of localized and castration resistant prostate cancer patients, and",phs001825.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001825,"Andrew C. Hsieh, MD",Ian Fingerman,Division of Cancer Biology (DCB),,2016 V Scholars Awards;2017 V Scholars Plus Award;2016 Movember Foundation-PCF Challenge Award;2016 AACR-Bayer NextGen Grant for Transformative Cancer Research;R37CA230617;2016 Cancer Center Support Pilot Grant;2016 AACR-Bristol Myers Squibb Oncology Fellowship;Prostate Cancer Postdoctoral Training Award,2021-05-19,HMB-PUB-MDS,WXS,Cohort,Prostatic Neoplasms,82.0,164.0,,,"Prostatic Neoplasms, Castration-Resistant","Prostatic Neoplasms, Castration-Resistant; NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic"
Single Cell RNA-Seq Reveals Malignant and Stromal Programs Associated    with Metastasis in Head and Neck Cancer,"This study of head and neck cancer aimed to profile individual malignant, stromal, and immune cells in treatment-naive oral cavity squamous cell carcinoma, with or without matched metastatic cervical lymph  nodes. Clinical and pathologic information was collected on all patients, in addition to a fresh biopsy sample from the primary tumor and/or",phs001474.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001474,"Bradley Bernstein, MD PhD;Derrick Lin, MD;Aviv Regev, PhD",,,,"National Institutes of Health, Bethesda, MD, USA;Broad Institute and Klarman Cell Observatory, Cambridge, MA, USA;Howard Hughes Medical Institute,	Boston, MA, USA;Koch Institute,	Cambridge, MA, USA;Massachusetts Eye and Ear Infirmary,	Boston, MA, USA;American Academy of Otolaryngology;New England Otolaryngology Society",2021-05-18,GRU,RNA-Seq;Seq_DNA_SNP;WXS,Cohort,"Carcinoma, Squamous Cell",18.0,24.0,,TGFBI,Mouth;Neoplasm Metastasis;Epithelial-Mesenchymal Transition;Head and Neck Neoplasms,"Neoplasm Metastasis; Carcinoma, Epidermoid; Carcinoma, Planocellular; Carcinoma, Squamous; Carcinomas, Epidermoid; Carcinomas, Planocellular"
Germline and Somatic Genetic Landscape of Pediatric Rhabdomyosarcoma,"Dynamic approaches that integrate population-based research and molecular biology are needed to explain the mechanisms underlying pediatric rhabdomyosarcoma (RMS) and to determine novel prevention strategies. RMS, the most common soft-tissue  sarcoma in children and adolescents, has one of the poorest 5-year survival rates among all pediatric cancers (less than 65%). One of the strongest",phs002304.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002304,Philip J. Lupo,Ian Fingerman,Division of Cancer Biology (DCB),33372952,RP170071,2021-05-12,GRU,WXS,Exome Sequencing,Rhabdomyosarcoma,621.0,621.0,,,Sarcoma;Neoplasms,Sarcoma; Blastoma; CA; CA - Cancer; Cancer; MT
Molecular Profiling of Gallbladder Cancer (MPOG),"The purpose of this study is to investigate the underlying genetic factors involved in gallbladder cancer. All cases from the Shanghai Biliary Cancer Study and the Chile Gallbladder Cancer Pilot  Study with fresh frozen tissue that were included in the molecular profiling analysis. Principal Investigator: Jill Koshiol, PhD, National Institutes",phs001404.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001404,"Jill Koshiol, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),33276026,Z01 CP010218,2021-05-10,GRU,WXS;RNA-Seq;Array_DNA_Methylation;Targeted-Capture;Array_CNV,Case Set,Gallbladder Neoplasms,158.0,433.0,,,,"Gallbladder Cancer; Bladder Cancer, Gall; Bladder Cancers, Gall; Cancer of Gallbladder; Cancer of the Gallbladder; Cancer, Gall Bladder"
Molecular Genetics of Secondary Histiocytic/Dendritic Sarcoma,"This is a comprehensive genomic analysis of a rare set of secondary histiocytic/dendritic sarcomas from the consult service of the Hematopathology section of the Laboratory of Pathology, NCI, NIH. All  archived consult cases with a confirmed pathologic diagnosis of secondary histiocytic/dendritic sarcoma were eligible for this study. Principal",phs001942.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001942,"Elaine S. Jaffe, MD",Kathleen Calzone,Center for Cancer Research (CCR),,,2021-05-05,GRU,WXS;Seq_DNA_SNP_MAF_Ind,Case Set,Histiocytic Sarcoma,16.0,19.0,,,Lymphoma,"Histiocytic Lymphoma, True; Histiocytic Lymphomas, True; Histiocytic Sarcomas; Histiocytoses, True Malignant; Histiocytosis, True Malignant; Lymphoma, True Histiocytic"
Rb and p53-Deficient Pleomorphic Myofibroblastic Sarcomas Require Skp2,"Myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) are highly genetically complex soft tissue sarcomas. Up to 50% of patients develop distant metastases, but current systemic therapies have limited efficacy. MFS  and UPS have recently been shown to commonly harbor copy number alterations or mutations in the tumor suppressor genes RB1 and TP53. As these",phs001982.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001982,"Samuel Singer, MD FACS",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,P50 CA140146;P30 CA008748,2021-04-23,GRU,WXS,Case Set,Sarcoma,62.0,62.0,,CDKN1A;PSMD9;RB1;SKP2;TP53,"Histiocytoma, Malignant Fibrous","Histiocytoma, Malignant Fibrous; Sarcoma, Soft Tissue; Fibrohistiocytic Tumor, Malignant; Fibrohistiocytic Tumors, Malignant; Fibrous Histiocytoma, Malignant; Fibrous Histiocytomas, Malignant"
Genomic Damage in HIV-Uninfected Children with In Utero Zidovudine    Exposure,"Zidovudine (ZDV) is a nucleoside reverse transcriptase inhibitor (NRTI) which competitively inhibits HIV reverse transcriptase and is incorporated into the viral DNA, resulting in DNA chain termination. It was the  first approved antiretroviral medication used for preventing HIV transmission from mother to child. However, in vitro and animal studies have",phs002061.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002061,"Eric Engels, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),7935654;10526209;11058153,ZIA CP010115,2021-04-22,DS-HIV-COL,WXS;Seq_DNA_SNP_CNV,Cohort,HIV,186.0,364.0,,,DNA Copy Number Variations;Mutation,Not Provided
Whole Genome Sequencing of Skull-Based Chordoma,"Chordoma is a rare bone tumor, which is believed to originate from notochordal remnants. Based on the United States Surveillance Epidemiology and End Results (SEER) data, the incidence of chordoma  varies by gender and race; however, little is known about the etiologic factors that predispose to it. Genomic profiling studies of chordoma are",phs002301.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002301,Yazhuo Zhang,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,Z171100000117002;201402008,2021-04-14,DS-CHR,RNA-Seq;WGS,Case Set,Chordoma,80.0,198.0,,,,"CHDM; Chordomas; Notochordal sarcoma; chordoma (disease); chordoma, malignant; chordoma, susceptibility to"
Identification of 22 Novel Loci Associated with Susceptibility to    Testicular Germ Cell Tumors,"Testicular germ cell tumors (TGCT) are the most common cancers in young men of European ancestry aged 20 to 39 years. The Testicular Cancer Consortium (TECAC) has brought together the  largest genome-wise association study (GWAS) study of TGCT to date. We conducted a GWAS of 5,602 cases and 5,006 controls aggregated from 12",phs001349.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001349,"Katherine Nathanson, MD;Peter Kanetsky, PhD, MPH;Stephen Schwartz, PhD;D. Timothy Bishop, PhD;Katherine McGlynn, PhD;Mark Greene, MD;Fredrik Wiklund, PhD;Ewa Rajpert-De Meyts, MD, DMSc;Clare Turnbull, MD, PhD, MA, MSc, MRCP",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),28604732;28604728;19483682;21551455;20543847;25609015;26461055,"U01-CA16947;R01-CA114478;Intramural Research program of the National Cancer Institute;Abramson Cancer Center at the University of Pennsylvania;Institute of Cancer Research, Cancer Research UK;Wellcome Trust Case Control Consortium (WTCCC);Movember Foundation;PhD Fellowship, Cancer Research UK;Norwegian Cancer Society Grants 418975 - 71081 - PR-2006-0387 and PK01-2007-0375;Nordic Cancer Union Grant S-12/07;Swedish Cancer Society Grant numbers 2008/708, 2010/808, 2011/484 and CAN2012/823;Villum Kann Rasmussen Foundation;NABIT Grant from the Danish Strategic Research Council;Novo Nordisk Foundation;Danish Cancer Society;Danish Childhood Cancer Foundation;Cancer Research UK Programme Award C588/a19167",2021-04-14,DS-TGCT-MDS;DS-CA-MDS;HMB;DS-TGCT-PUB-MDS,Array_SNP,Case-Control,Testicular Germ Cell Tumor,10608.0,10608.0,,AR;BAK1;DMRT1;CENPI;PPP2R5A;RAD52;SP1;TERT;TNXB;ZNF217;TKTL1;CYTH1;BCL2L11;METTL7A;ANAPC2;ENOSF1;DEPTOR;ITIH5;ARL14EP;FAM48B1,Nonseminomatous germ cell tumor;Cryptorchidism;Genetic Loci,"Cryptorchidism; Nonseminomatous germ cell tumor; Cryptorchidism (unilateral or bilateral); Cryptorchidism, Unilateral Or Bilateral; Cryptorchism; IDT - Imperfectly descended testis"
ELLIPSE Prostate Cancer Meta-Analysis and Genotyping,"The ELLIPSE Consortium is an international effort to discover risk loci for prostate cancer. It includes the meta-analysis of existing GWAS data as well as novel GWAS, exome, and iCOGS  genotyping. The GWAS meta-analysis includes the following cases and controls from studies of European ancestry: UK GWAS stage 1 (Illumina Infinium",phs001120.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001120,"Chris Haiman, ScD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),33398198,U19 CA 148537,2021-04-14,HMB-PUB;DS-PC;DS-PC-MDS;DS-CA-PUB,Array_SNP,Case-Control,Prostatic Neoplasms,12947.0,12947.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
ELLIPSE Prostate Cancer Genotyping,The Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium is an international effort to discover risk loci for prostate cancer. The following de novo genotyping was performed. The OMNI  2.5M genotyping was conducted for 977 prostate cancer cases from UKGPCS. The Exome SNP array genotyping was conducted for 4741 subjects from UKGPCS.,phs001125.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001125,"Chris Haiman, ScD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,U19 CA 148537,2021-04-14,HMB-PUB;DS-PC;DS-PC-MDS;DS-CA-PUB,Array_SNP,Case-Control,Prostatic Neoplasms,12947.0,12947.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
ELLIPSE Prostate Cancer Meta-Analysis,The Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium is an international effort to discover risk loci for prostate cancer. It includes the meta-analysis of existing GWAS data. The  GWAS meta-analysis includes the following cases and controls from studies of European ancestry: UK GWAS stage 1 (Illumina Infinium HumanHap 550,phs001081.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001081,"Chris Haiman, ScD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25217961,U19 CA 148537,2021-04-14,,,Case-Control,Prostatic Neoplasms,,,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Inherited Genetic Variation and Predisposition to Testicular Germ Cell    Tumor: UPenn Local TGCT Study,"Testicular germ cell tumors (TGCT) are the most common cancer in men ages 20-40. The incidence of TGCT has more than doubled over the past forty years, without clear etiology.  Both genetic effects and environmental exposures, specifically during the pre-natal period, are likely to play an important role in determining TGCT",phs001307.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001307,"Katherine Nathanson, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),24943593;24008901;23666239;23547758;23462292;23248619;21551455;19483682,R01-CA-114478,2021-04-13,DS-CA-MDS,Array_SNP,Case-Control,Testicular Germ Cell Tumor,1397.0,1400.0,,,Seminoma,Seminoma
Derivation and Investigation of The First Human Cell-Based Model of    Beckwith-Wiedemann Syndrome,"Beckwith-Wiedemann Syndrome (BWS) is the most common human imprinting disorder, and phenotypes include hepatomegaly and hepatoblastoma development. In approximately 20% of patients, this syndrome is caused by uniparental isodisomy of  the paternal allele across chromosome 11p15 (pUPD11). From fibroblasts cultured from 2 BWS patients with pUPD11, we derived induced pluripotent stem",phs002365.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002365,"Jennifer Kalish, MD,PHD",Mariam Eljanne,Center for Cancer Training (CCT),33300436,K08 CA193915,2021-04-07,GRU,RNA-Seq,Cohort,Beckwith-Wiedemann Syndrome,4.0,18.0,,,,BWS; Beckwith Wiedemann Syndrome; Beckwith's syndrome; Beckwith-Wiedemann syndrome chromosome region; EMG SYNDROME; EMG Syndromes
Whole Genome Sequencing to Discover Familial Myeloma Risk Genes,"We identified germline KDM1A truncating mutations in patients with multiple myeloma (MM), and loss of heterozygosity (LOH) in tumors. KDM1A mutation burden is higher in sporadic MM patients than in  controls, and mRNA levels are lower in MM compared with normal plasma cells. KDM1A pharmacological inhibition in vitro promotes myeloma cell",phs001819.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001819,"Steven M. Lipkin, MD, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),30967618;29559475;28404951;22699452;27330041,CA167824,2021-03-31,DS-CA-MDS;GRU,Seq_DNA_SNP,Case Set,Multiple Myeloma,39.0,39.0,,KDM1A,,"Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma; Kahler Disease"
Integrative Analysis of Lung Adenocarcinoma in Never Smokers,"We performed whole genome sequencing of lung cancers from never smoker subjects from Institut universitaire de cardiologie et de pneumologie de Qu&#x000e9;bec - Universit&#x000e9; Laval (IUCPQ-UL) (N 125), Universit&#x000e9; C&#x000f4;te  d'Azur (Nice) (N 47), the Environment And Genetics in Lung cancer Etiology (EAGLE) study (N 27), Yale University (N 22), and Moffitt Cancer Cente (N",phs001697.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001697,"Maria Teresa Landi, MD, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,"Intramural program, NCI, DCEG",2021-03-31,DS-LD;GRU-IRB;DS-LDS-MDS;GRU,WGS,Case Set,Lung Neoplasms,232.0,464.0,http://dceg.cancer.gov/eagle,,Smoking,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
Copy-Number Analysis of Understudied Black Women Ovarian Cancers,"Two general types of genetic alterations drive cancer progression: mutations and copy number alterations (CNAs). With the exception of p53, single nucleotide variant mutations (here, simply ""mutations"") are not drivers  of 80% of tumors within the most frequent and deadly histotype of ovarian cancer: serous ovarian cancer (SOC). Rather, CNAs are more prevalent in SOC",phs002313.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002313,"Joe Delaney, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,2021-03-23,GRU,WXS;Seq_DNA_CNV,Case Set;Copy Number Variation (CNV);Exome Sequencing;Tumor,Neoplasms,20.0,21.0,,,Ovarian Neoplasms,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Dynamics of Genomic and Immune Responses During Primary Immunotherapy    Resistance in Mismatch Repair Deficient Tumors,"We study a patient with dMMR lung cancer refractory to immunotherapy. Post-treatment tumor demonstrated compound heterozygous frameshift deletions located upstream of the kinase domain in the gene encoding JAK1 protein,  downregulation of JAK1 and mediators of its signal transduction, and total loss of JAK1 phosphorylation. Importantly, one of the JAK1 mutations,",phs002089.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002089,Anish Thomas,Kathleen Calzone,Center for Cancer Research (CCR),33028646,,2021-03-23,GRU,RNA-Seq;WXS;WGS,Case Set,Small Cell Lung Carcinoma,1.0,6.0,,JAK1,Turcot syndrome,"Turcot syndrome; Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer"
Analysis of Recurrently Protected Genomic Regions in Urine Cell-Free DNA,"This study investigated fragmentation patterns in urine and plasma cell-free DNA and evaluated the relevance of such analysis for cancer diagnostics using urine samples. Specifically, we performed whole-genome sequencing at  variable depths and evaluated genome-wide coverage in urine and plasma samples, relative to known genome annotation features. Tumor/germline exome",phs002273.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002273,Muhammed Murtaza,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),33597261,Ben and Catherine Ivy Foundation;1U01CA243078-01A1;1R01CA223481-01;BSP-0542-13,2021-03-22,HMB-PUB-MDS,WXS;WGS,Methods Development,Cell-Free Nucleic Acids,60.0,89.0,,,"Circulating Tumor DNA;Biomarkers, Tumor",Not Provided
A Super-Enhancer Associated with CD47 in Breast Cancer,"CD47 is a cell surface molecule that inhibits phagocytosis of cells that express it by binding to its receptor, SIRP&#x003b1;, on macrophages and other immune cells. CD47 is expressed at  different levels in normal cells, however, in cancer cells, CD47 transcript and protein expression is aberrantly increased. Here we sought to uncover",phs001264.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001264,"Irv L. Weissman, MD",Ian Fingerman,Division of Cancer Biology (DCB),28378740,P01 CA139490,2021-03-17,DS-BRCA-MDS;GRU,ChIP-Seq,Xenograft;Case Set,Breast Neoplasms,4.0,4.0,,CD47;NFKB1,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
VA APOLLO Project - Research for Precision Oncology (RePOP),"The Research for Precision Oncology Program (RePOP) is a research activity that establishes a cohort of Veterans diagnosed with cancer and who have had genomic analyses performed on their tumor  tissue as part of standard of care. All data relevant to a patient's cancer and cancer care will be collected under RePOP, including patient",phs001374.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001374,"Louis Fiore, MD",Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),,Research for Precision Oncology (RePOP),2021-03-15,GRU,,Longitudinal Cohort,Neoplasms,170.0,170.0,,,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Cross-site Concordance Evaluation of Tumor DNA and RNA Sequencing    Platforms of CIMAC-CIDC Network,"The Cancer Immune Monitoring and Analysis Centers (CIMACs) and the Cancer Immunologic Data Commons (CIDC)&#x000a0; has engaged in efforts to harmonize Whole-exome (WES) and RNA-sequencing (RNA-seq) data from three different  experimental platforms (MD Anderson, NCI MoCha lab, and Broad Institute) and are using a series of developed pipelines to process the early trial",phs002295.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002295,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2021-03-11,GRU,Seq_DNA_SNP_MAF_Ind;Seq_RNA_Expression,Case Set,"Carcinoma, Non-Small-Cell Lung",8.0,234.0,https://cimac-network.org/,TP53,,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER"
Cellular and Molecular Characterization of Renal Cell Carcinoma,We are performing a comprehensive cellular and molecular characterization of renal cell carcinoma. This work includes an initial cohort of patients whose tumors (and adjacent normal tissue) underwent single cell  analysis. Single-cell RNA sequencing (scRNA-seq) and TCR sequencing (scTCR-seq) analysis of untreated clear cell renal cell carcinoma tumor and,phs002252.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002252,"Catherine J. Wu, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,P50 CA101942-14,2021-03-11,DS-RCCA-MDS,WXS;OTHER,Cohort;Tumor vs. Matched-Normal,"Carcinoma, Renal Cell",13.0,53.0,,,Kidney Neoplasms,"Kidney Neoplasms; ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell"
Optimized Polyepitope Neoantigen DNA Vaccines Elicit Neoantigen-Specific    Immune Responses in Preclinical Models and in Clinical Translation,"A patient with Lynch syndrome and a neuroendocrine tumor sequenced with exome, whole genome, and bulk RNAseq. Sequence data was used to create a personalized cancer vaccine. Principal Investigator: William  Gillanders, MD, Washington University School of Medicine, St Louis, MO, USA",phs002342.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002342,"William Gillanders, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2021-03-09,GRU,RNA-Seq;WXS;WGS,Individual-Level Genomic Data,"Carcinoma, Neuroendocrine",1.0,5.0,,,Cancer Vaccines,
Dana-Farber Cancer Institute (DFCI) Wu Lab/Avicenne CLL RNA-Seq Study,"Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy characterized by accumulation of CD5+ B cells in peripheral lymphoid organs, bone marrow and blood. Recently, the advent of large-scale whole-exome sequencing  of hundreds of CLL samples has led to gain a comprehensive understanding of the mutational landscape of this clonal B cell malignancy, but the",phs002335.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002335,Catherine J. Wu,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2021-03-09,HMB-NPU-MDS,RNA-Seq,Cohort,Leukemia,12.0,14.0,,IKZF3,Lymphocytic;Chronic;B-Cell,Blood (Leukemia); Blood cancer; Leucocythaemia; Leucocythaemias; Leucocythemia; Leucocythemias
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic    Response In Vivo,"Oncogenic alterations in EGFR frequently co-occur with additional genetic alterations in EGFR-driven lung adenocarcinoma (LUAD), but how specific combinations of mutations affect tumor phenotypes and responses to targeted therapy is  yet unknown. We leveraged a genetically engineered mouse model of EGFR mutant/Trp53-deficient LUAD to study the consequences of inactivating 10",phs002334.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002334,"Katerina Politi,
  PhD;Monte Winslow, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),33707235,P50 CA196530;R01 CA231253;R01 CA234349;R01 CA120247;F31 CA203488;F32 CA210516,2021-03-09,DS-LCTC-MDS,WXS,Cohort,Adenocarcinoma of Lung,29.0,78.0,,EGFR;KEAP1,,"ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma"
Comprehensive Analysis of Structural Variants in Breast Cancer Genomes    Using Single Molecule Sequencing,"This study used the SKBR3 breast cell line and tumor/normal organoids derived from breast tissue to explore the utility of long read sequencing for detecting structural variants in complex samples.  Three technologies were used to characterize the samples: Illumina/10X, Pacific Biosciences, and Oxford Nanopore. Methylation results were derived",phs002210.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002210,Michael Schatz,Brandon Wright,Office of Data Sharing (ODS),32887686,DBI-135004;R01- HG006677;R21-CA220411;5P30CA045508;1R01HG009190;Bill and Melinda Gates Foundation,2021-03-05,GRU-IRB,Seq_DNA_SV;WGS,Case Set,Breast Neoplasms,2.0,7.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Integrative Somatic and Germline Molecular Characterization of    Genitourinary Cancers,"We have performed integrative bulk (whole exome sequencing of tumor and normal paired and whole transcriptome sequencing) and single cell analysis of primary and metastatic non-prostate genitourinary cancer specimens, such  as renal and bladder tumors. Principal Investigator: Eliezer M. Van Allen, MD, Dana-Farber Cancer Institute, Boston, MA, USA Funding Sources: R37",phs002065.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002065,"Eliezer M. Van Allen, MD",,,,R37 CA222574;R01 CA227388,2021-03-05,HMB,RNA-Seq;WXS,Case-Control;Tumor vs. Matched-Normal,Urinary Bladder Neoplasms,8.0,18.0,,,Kidney Neoplasms,Bladder Neoplasms; Kidney Neoplasms; Bladder Cancer; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder
Evolution of Core Archetypal Phenotypes in High-Grade Serous Ovarian    Cancer (HGSOC),"The evolution of resistance in high-grade serous ovarian cancer (HGSOC) cells in response to chemotherapy is only partially understood. To uncover phenotypic changes associated with chemotherapy resistance, we performed single-cell  RNA-sequencing (scRNA-seq) or whole-genome sequencing of 23 total patients, with longitudinal samples collected from 9, treatment-na&#x000ef;ve",phs002294.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002294,"Andrea Bild, PhD",Shannon Hughes,Division of Cancer Biology (DCB),,U54CA209978;US Army Medical Research and Development Command grant DAMD17-01-1-0729,2021-03-04,GRU,OTHER;WGS,Longitudinal,Ovarian Neoplasms,23.0,72.0,,,"Carcinoma, Ovarian Epithelial;Drug Resistance, Neoplasm","Carcinoma, Ovarian Epithelial; Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian"
National Cancer Institute Clinical and Laboratory Analysis of Familial    Cancer,"The purpose of this study is to continue the analysis begun on 09C0079 which was focused on identification of the genetic mutation associated with a new gastric polyposis syndrome, Gastric  Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS). GAPPS, first described in 2012, is an autosomal dominant gastric polyposis syndrome",phs001935.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001935,"Kathleen Calzone, PhD, RN, AGN-BC, FAAN",Kathleen Calzone,Center for Cancer Research (CCR),27087319,,2021-03-03,NRUP;GRU,WXS,Case Set,Stomach Neoplasms,12.0,12.0,,,"Adenocarcinoma;Polyposis, Gastric","Adenocarcinoma; Polyposis, Gastric; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant"
Yale SPORE in Skin Cancer Project 2,"Understanding the relationship between tumor and peripheral immune environments could allow longitudinal immune monitoring in cancer. Here, we examined whether T cells that share the same TCRab and are found  in both tumor and blood can be interrogated to gain insight into the ongoing tumor T cell response. Paired transcriptome and TCRab repertoire of",phs002289.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002289,David A. Hafler;Harriet M. Kluger,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),33651881,,2021-02-26,HMB,RNA-Seq;Seq_RNA_Expression,Single Cell Analysis,Single-Cell Analysis,13.0,50989.0,https://doi.org/10.1101/2020.09.30.321240,CD8A;CD74;GZMB;GZMK;IFNG;KLRD1;LAG3;LGALS1;CD99;PDCD1;HAVCR2,"Tumor-infiltrating Lymphocytes;Receptors, Antigen, T Cell, alpha beta;Liquid biopsy",Not Provided
Therapeutic Targeting of ATR Yields Durable Regressions in High    Replication Stress Tumors,"Patients with relapsed or recurrent small cell lung cancer or extra-pulmonary small cell cancers were enrolled on an investigator-initiated, single-arm, phase 2 trial (NCT02487095) combining an ATR inhibitor M6620 (VX-970,  berzosertib) administered at 210 mg/m2 intravenously over 60 minutes on day 2 and day 5, and topotecan 1.25 mg/m2 intravenously over 30 minutes every",phs002327.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002327,Anish Thomas,Kathleen Calzone,Center for Cancer Research (CCR),,,2021-02-22,GRU,Seq_DNA_SNP_MAF_Ind;Seq_RNA_SNP_MAF_Ind;RNA-Seq;WXS;Seq_RNA_Expression,Clinical Trial,Small Cell Lung Carcinoma,24.0,24.0,https://clinicaltrials.gov/ct2/show/NCT02487095,RNASEH2;ASCL1;RAD54L;CCNE1;INSM1;MYC;SOX2;SOX4;ARID1A;BEX1,,"Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL"
ALCHEMIST Study,"The ALCHEMIST study will accrue patients that are potentially eligible for the Intergroup adjuvant studies and perform central EGFR and ALK genotyping using a central reference laboratory certified by the  Clinical Laboratory Improvement Amendments of 1988 (CLIA). Patients may either present prior to surgery with resectable NSCLC, may present following",phs001140.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001140,"David E. Kozono, MD, PhD",,,,,2021-02-17,GRU,,Case Set,"Carcinoma, Non-Small-Cell Lung",5731.0,5731.0,,,,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER"
Methylation Biomarker Study of Magnesium Deficiency and Colorectal Cancer,"Five US studies using the Mg tolerance test, the ""gold standard"" test of Mg status, indicated that 50% participants had Mg deficiency. In our ongoing US trial, we have found  a similar result. In growing recognition of the importance of Mg in human health, very recently, Mg was selected by the US Federal Dietary Reference",phs002037.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002037,"Qi Dai, MD PhD",Natalie Abrams,Division of Cancer Prevention (DCP),30541089;29607802;28501704;29263344;32280092,R01CA202936,2021-02-10,NRUP;GRU,Array_DNA_Methylation,Randomized;Clinical Trial,Magnesium Deficiency,240.0,476.0,,,DNA Methylation,"DNA Methylation; Deficiencies, Magnesium; Deficiency, Magnesium; Magnesium Deficiencies"
Tumor Fraction Guided Cell-Free DNA Profiling in Metastatic Cancer    Patients,"Cell-free DNA (cfDNA) profiling is increasingly used to guide cancer care, yet mutations are not always identified. The ability to detect somatic mutations in plasma depends on both assay sensitivity  and the fraction of circulating DNA in plasma that is tumor-derived (i.e cfDNA tumor fraction). We hypothesized that cfDNA tumor fraction could",phs002290.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002290,David B. Solit,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2021-02-05,DS-CA,WXS;WGS,Sequencing;Whole Genome Sequencing,Cell-Free Nucleic Acids,118.0,131.0,https://cbioportal.org/study/summary?id=mixed_cfdna_msk_2020,,DNA Mutational Analysis,Not Provided
Role of Tobacco Smoke in Clear Cell Renal Cell Carcinoma,"Background. Clear cell renal cell carcinoma (ccRCC) is the most common histologically defined renal cancer. However, it is not a uniform disease and includes several genetic subtypes with different prognoses.  ccRCC is also characterized by distinguished metabolic reprogramming. Tobacco smoking (TS) is an established risk factor for ccRCC with unknown",phs002083.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002083,Maria Czyzyk-Krzeska,Ian Fingerman,Division of Cancer Biology (DCB),32970633,,2021-02-05,GRU,RNA-Seq,Cohort,"Carcinoma, Renal Cell",32.0,50.0,,ATP5MC1 (ATP5G1);ATP5MC3 (ATP5G3);ATP5PF (ATP5J);ATP5PO (ATP5O);MRPL49;ECI1;ETFB;MDH1;NDUFA7;SDHC;UQCRC1;MICU1;ATP5PD (ATP5H);MPC2;NDUFA13;MPC1;OGDHL;COQ9,normal kidney tissue;Tobacco Smoking,"ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell"
Molecular Genetics of Histiocytic Sarcoma,"This is a comprehensive genomic analysis of a rare set of histiocytic sarcomas from the consult service of the Hematopathology section of the Laboratory of Pathology, NCI, NIH. The study  identifies two distinct groupings of these tumors based on the site of disease, their mutational spectrum, and proliferation signature. All archived",phs001748.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001748,"Elaine S. Jaffe, MD",Kathleen Calzone,Center for Cancer Research (CCR),,,2021-02-05,GRU,RNA-Seq;Seq_DNA_SNP_MAF_Ind;Seq_RNA_Expression;WXS,Case Set,Histiocytic Sarcoma,25.0,54.0,,,,"Histiocytic Lymphoma, True; Histiocytic Lymphomas, True; Histiocytic Sarcomas; Histiocytoses, True Malignant; Histiocytosis, True Malignant; Lymphoma, True Histiocytic"
Genetics of Mammographic Density in Ashkenazi Jews,"Mammographic density (MD) is a strong risk factor for breast cancer and is also a highly heritable trait with 60-70% of the variance due to genetic factors, based on twin  studies. MD is also higher in families with a strong history of breast cancer. Genome-wide association studies (GWAS), which focus on common genetic",phs001857.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001857,Elad Ziv,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),23668689;23887672;24461459,R21CA179442,2021-02-03,DS-MDBRCA-MDS;NRUP,Array_SNP,Cross-Sectional,Breast Density,2028.0,677.0,,,,"Mammographic Breast Density; Breast Densities, Mammographic; Breast Density, Mammographic; Density, Mammographic; Mammographic Breast Densities; Mammographic Densities"
Polygenic Risk Score for the Prediction of Breast Cancer Is Related to    Lesser Terminal Duct Lobular Unit Involution of the Breast,"The Susan G. Komen Tissue Bank (KTB) at the Indiana University Simon Cancer Center is an annotated biobank, which has recruited healthy women who provided demographic, lifestyle, and cancer-related information  via self-administered questionnaire, blood samples and normal breast tissues. H&E slides of the normal breast tissues were scanned for image analysis",phs002062.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002062,"Gretchen Gierach, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),32964115,,2021-01-28,DS-BRCA,,Control Set;Cross-Sectional,Breast Neoplasms,1089.0,1089.0,https://virtualtissuebank.iu.edu/,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Genomic Profiling of Peripheral T-cell Lymphoma,"Peripheral T-cell lymphomas (PTCLs) are malignant and highly aggressive hematologic tumors arising from mature post-thymic T cells. The diagnosis of PTCL includes diverse lymphoma subgroups, altogether accounting for about 15%  of all non-Hodgkin lymphomas. Despite recent advances in uncovering the mutational landscape of PTCLs, the prognoses of most PTCLs remain poor. To",phs001962.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001962,Teresa Palomero,,,28062691,R01CA197945;U01CA243073,2021-01-28,HMB-PUB,RNA-Seq,Cohort,"Lymphoma, T-Cell, Peripheral",20.0,20.0,,FYN;VAV1;TRAF3IP2,"Lymphoma, Non-Hodgkin","Lymphoma, Non-Hodgkin; Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology"
Genome-Wide Association Study of HCC in Non-Asian USA Population,This GWAS of HCC relied on existing biological and data resources from 7 USA sites and one Canadian site which allows for the integration of genetic and environmental data. Total  of 2199 case patients and 1103 non cancer controls were genotyped. Case patients are defined as patients with pathological or radiological diagnosis,phs001744.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001744,Manal M Hassan (Contact);Chris Amos;Donghui Li;Lewis Roberts,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),19070394;18688864;20166205;15329910;15643599;17659576;28833342,Center for Inherited Disease Research (CIDR),2021-01-27,DS-LCCLD-MDS;NRUP;DS-HCC-IRB,Imputation_SNP_CNV;Array_SNP,Case-Control,Liver Neoplasms,3260.0,3352.0,,,"Carcinoma, Hepatocellular;Neoplasms","Carcinoma, Hepatocellular; Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells"
Evolution of Resistance in ER+ Breast Cancer,"While the combination of endocrine therapy and CDK4/CDK6 inhibitors has been shown to be effective in the metastatic ER+ breast cancer setting, to test whether it is effective in an  earlier stage neoadjuvant setting, the FELINE trial (NCT02712723) was established to test the efficacy of letrozole and ribociclib in a ER-positive,",phs002287.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002287,Andrea H. Bild;Qamar J. Khan,Shannon Hughes,Division of Cancer Biology (DCB),,,2021-01-15,GRU,WXS,Case-Control;Clinical Trial;Exome Sequencing;Individual-Level Genomic Data;Randomized Controlled Clinical Trial;Tumor vs. Matched-Normal,Breast Neoplasms,24.0,72.0,,CDK4;CDK6;ERBB4;ESR1;ERK;JNK,Drug Resistance;Antineoplastic Agents;Letrozole;Cyclin-Dependent Kinase 4,Drug Resistance; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors
Pharmacogenomic Analysis of Microtubule Targeting Agent Response and    Toxicity,"Microtubule targeting agents are commonly prescribed for early and metastatic breast cancer and other solid tumors. However, interindividual variability in microtubule targeting drug response and toxicity can cause limited therapeutic  benefit and impact quality of life. In the present study, genome-wide analyses were performed to investigate how genetic factors can be used to",phs002060.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002060,"Deanna L. Kroetz, PhD;Hope S. Rugo, MD;Kouros Owzar, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26056183;30260474;32562552;28620884;31802506,"R01CA192156;U10CA180821;U10CA180882;U24CA196171;UG1CA233320;UG1CA233327;T32GM007175;F31GM113350;P01CA142538;Breast Cancer Research Foundation, New York, NY, USA;Give Breast Cancer the Boot",2020-12-22,NRUP;HMB,Seq_DNA_SNP_CNV;Array_SNP,Cohort,Peripheral Nervous System Diseases,628.0,624.0,,CALU;S1PR1;CX3CL1;SCUBE1;FGD4,Progression-Free Survival;Breast Neoplasms,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Discovery of Colorectal Cancer Susceptibility Genes in High-Risk Families,"Colorectal cancer remains one of the most common cancers in the US with 146,970 new diagnoses and 49,920 deaths estimated for 2009. Colon cancer is also one of the most  familial of cancers. Individuals with a first-degree relative with colon cancer have a 2- to 3-fold increased risk, and those with more than one",phs001787.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001787,"Sean Vahram Tavtigian, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),2841598;12761718;10891514;21970370;19781682;21244692;21700766;22464251,R01CA164138,2020-12-22,DS-CA-MDS;NRUP,WXS;Array_SNP,Case Set,"Colorectal Neoplasms, Hereditary Nonpolyposis",242.0,206.0,,,,Familial Nonpolyposis Colon Cancer
Kids First: The Intersection of Childhood Cancer and Birth Defects,Birth defects and childhood cancer share biological pathways that are important for cell growth and division. We propose that sequencing pediatric patients suffering both conditions will allow us to discover  the underlying genes and in turn advance our understanding of the causes of these devastating diseases. 1806 samples were selected for whole genome,phs001846.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001846,"Hakon Hakonarson, MD, PhD;Patrick Sleiman, PhD",,,,X01 HL140544-01,2020-12-21,GRU,,Cohort;Parent-Offspring Trios,Neoplasms,1805.0,1805.0,https://commonfund.nih.gov/kidsfirst/X01Projects,,Congenital Abnormalities,"Congenital Abnormalities; Abnormalities, Congenital; Abnormality, Congenital; Birth Defect; Birth Defects; CM - Congenital malformation"
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7    for HPV-Associated Cancers,This is a phase I clinical trial testing the safety and efficacy of gene-engineered T cells expressing a T-cell receptor targeting an HLA-A 02:01-restricted epitope of HPV-16 E7 (E7 TCR  T cells) in patients with metastatic HPV-16+ epithelial cancers. A total of 12 patients were treated. The maximum tested dose was tolerated. Side,phs002286.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002286,Christian Hinrichs,Kathleen Calzone,Center for Cancer Research (CCR),29669936,Intramural Research Program (IRP) IZIABC011479,2020-12-16,GRU,RNA-Seq;WXS,Clinical Trial;Copy Number Variation (CNV);Exome Sequencing;Full Transcriptome Sequencing;Individual-Level Genomic Data;Metastasis;RNA Sequencing;Sequencing;Tumor vs. Matched-Normal,Neoplasms,6.0,17.0,https://clinicaltrials.gov/ct2/show/NCT02858310?term=Hinrichs&draw=7&rank=13,B2M;CALR;CANX;PDIA3;HLA-A;IFNAR1;IFNAR2;IFNGR1;IFNGR2;JAK1;JAK2;PSMB5;PSMB8;PSMB9;PTPN2;STAT1;STAT2;TAP1;TAP2;TAPBP;TYK2;PIAS1;SOCS1;MED14;IRF9;NLRC5,Virus Diseases;Otorhinolaryngologic Diseases;Male Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications,"Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Otorhinolaryngologic Diseases; Virus Diseases; Genitourinary Disease, Male; Genitourinary Diseases, Male"
Kids First: Genomic Analysis of Esophageal Atresia and Tracheoesophageal    Fistulas and Associated Congenital Anomalies,The Gabriella Miller Kids First Pediatric Research Program (Kids First) is a trans-NIH effort initiated in response to the 2014 Gabriella Miller Kids First Research Act and supported by the  NIH Common Fund. This program focuses on gene discovery in pediatric cancers and structural birth defects and the development of the Gabriella Miller,phs002161.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002161,"Wendy Chung, MD, PhD",,,28878607;28003020;26294094,X01 HL145692-01,2020-12-16,GRU,,Cohort;Parent-Offspring Trios,Tracheoesophageal Fistula,410.0,410.0,https://commonfund.nih.gov/kidsfirst/X01Projects,FANCA;FANCB,Esophageal Atresia,Abnormal connection between trachea and esophagus; Abnormal connection between trachea and oesophagus; Esophageal Atresia and/or Tracheoesophageal Fistula; Esophageal Atresia/Tracheoesophageal Fistula; Esophageal atresia with or without tracheoesophageal fistula; Esophagotracheal Fistula
Multimodal Mapping of the Immune Landscape in Human Pancreatic Cancer,"Pancreatic ductal adenocarcinoma (PDA) is characterized by an immune-suppressive tumor microenvironment that has rendered it largely refractory to immunotherapy. We used single-cell RNA sequencing on patient tumors and matched blood,  and we uncovered a previously unappreciated, complex environment of immune-suppressive cellular interactions. These experiments reveal immune",phs002071.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002071,"Marina Pasca di Magliano, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,R01CA151588;R01CA198074;U01CA224145,2020-12-14,HMB,RNA-Seq,Cohort,"Carcinoma, Pancreatic Ductal",25.0,41.0,,TIGIT,,"Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas; Duct Cell Carcinoma, Pancreas"
Identification of Rare Germline Variants in Familial Patients with    Non-medullary Thyroid Cancer,"As the most common malignancy of the endocrine system, thyroid cancer is classified into two major categories, non-medullary thyroid cancer (NMTC) and medullary thyroid cancer (MTC) according to the origins  and clinical features. NMTC includes papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), and anaplastic thyroid cancer (ATC). Sporadic",phs001758.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001758,"Albert de la Chapelle, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,P01CA124570,2020-12-14,GRU,WGS,Case Set,"Thyroid Cancer, Papillary",10.0,10.0,,,"Thyroid cancer, papillary","Cancer, Papillary Thyroid; Cancers, Papillary Thyroid; Carcinoma, Papillary Thyroid; Carcinomas, Papillary Thyroid; Familial Papillary Thyroid Carcinoma; NONMEDULLARY THYROID CARCINOMA, PAPILLARY"
Elucidating Transcription Regulation by Epigenetics in Neuroblastoma,"PURPOSE Whole-genome profiles of the epigenetic modification 5-hydroxymethylcytosine (5-hmC) are robust diagnostic biomarkers in adult patients with cancer. We investigated if 5-hmC profiles would serve as novel prognostic markers in  neuroblastoma, a clinically heterogeneous pediatric cancer. Because this DNA modification facilitates active gene expression, we hypothesized that",phs001831.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001831,Mark Applebaum MD,Mariam Eljanne,Center for Cancer Training (CCT),31179414,K08CA226237,2020-12-09,GRU,RNA-Seq;OTHER,Cohort,Neuroblastoma,189.0,287.0,,,"5-hydroxymethylcytosine;Sequence Analysis, RNA",Not Provided
WES and RNA-Seq Analysis in Paired Sun-Exposed Epidermis and SCCIS    Samples,"Squamous cell carcinoma in situ (SCCIS) is a prevalent precancerous lesion that can progress to cutaneous squamous cell carcinoma (cSCC). Although SCCIS is common, its pathogenesis remains poorly understood. To  better understand SCCIS development, we performed laser-captured microdissection of human SCCIS and adjacent epidermis to isolate genomic DNA and RNA",phs002019.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002019,"John Seykora, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,RO1-CA165836;RO1-ES02811;P30-AR069589;Abramson Cancer Center CCSG P30 CA016520,2020-12-04,HMB,RNA-Seq;Seq_DNA_SNP;WXS,Case Set,Carcinoma in Situ,11.0,22.0,,LAMC1;NOTCH1;NOTCH2;NOTCH3;RYR1;TP53;NEURL1;DNAH1;SLFN5,carcinoma in situ,"Cancer in situ; Carcinoma, Intraepithelial; Carcinoma, Preinvasive; Intraepithelial Carcinoma; Non-invasive Carcinoma; Preinvasive Carcinoma"
A Model for Predicting Response to PD-1 Inhibitors in NSCLC,"Whole exome sequencing was used to examine the impact of human leukocyte antigen B44 in a non-small cell lung cancer cohort treated with single agent pembrolizumab with over five years  of follow-up. Study participants were treated on clinical trials with single-agent pembrolizumab at the University of California, Los Angeles who",phs002244.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002244,"Edward Garon, MD MS",Brandon Wright,Office of Data Sharing (ODS),31113840;35121931,R01 CA208403,2020-11-19,DS-CA-IRB-PUB-NPU,WXS,Cohort,"Carcinoma, Non-Small-Cell Lung",33.0,66.0,,,,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER"
Gabriella Miller Kids First Pediatric Research Program in Craniofacial    Microsomia,"Craniofacial microsomia (CFM), also termed hemifacial microsomia or oculo-auricular-vertebral spectrum, is the third most common congenital craniofacial condition. CFM comprises a variable phenotype and the most common features include malformations  of the ear (i.e. microtia) and lower jaw (i.e. mandibular hypoplasia) on one or both sides. Microtia in the absence of other anomalies is believed to",phs002130.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002130,"Daniela V Luquetti, MD, PhD",,,,X01 HL140518;R00 DC011282;R01 DE022438;RC1 DE020270,2020-11-13,DS-CFD,,Cohort;Parent-Offspring Trios,Goldenhar Syndrome,278.0,278.0,https://commonfund.nih.gov/kidsfirst/X01Projects,,Congenital Microtia;Microtia-Anotia;Hemifacial Microsomia,Congenital Microtia; Hemifacial Microsomia; Microtia-Anotia; Bilateral microtia; Hypoplasia of the external ear; Hypoplastic ears
Genomic Characteristics of MPNs in IR-Exposed Patients,"The study ""Genomic Characteristics of Myeloproliferative Neoplasms in Patients Exposed to Ionizing Radiation following the Chernobyl Nuclear Accident"" was designed as case-control study. We studied genomic characteristics of chronic Philadelphia  chromosome-negative myeloproliferative neoplasm (MPNs) in Ukrainian patients who were previously exposed to Ionizing Radiation (IR) due to Chernobyl",phs001761.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001761,"Steven Balk, MD, PhD;Paula Fraenkel, MD",Ian Fingerman,Division of Cancer Biology (DCB),30295334,"CA150529 (SB, PF);W9111NF-09-001 (EF)",2020-11-05,GRU,WXS;Seq_DNA_SNP_MAF_Ind;Targeted-Capture,Case-Control,Primary Myelofibrosis,155.0,155.0,,ABL2;ACVR2A;BIRC3;ARNT;ATM;ATRX;CCND1;BCL7A;BCL9;BRAF;BRCA2;CALR;RUNX1;RUNX1T1;CBL;CBLB;CCND2;CD79B;CDK4;CDK6;CDKN1B;CDKN2A;CDKN2C;CEBPA;CHD4;COL1A1;COX6C;CSF3R;CSK;CUX1;DAXX;DDIT3;DDX5;DDX6;DDX10;DKC1;DNMT3A;RBP3;EBF1;ELANE;ELK4;ELN;HLF;EPS15;ERBB2;ETV6;EWSR1;EXT1;EZH2;FANCA;FANCC;FANCD2;FANCE;FANCG;FCGR2B;FGFR1;FHIT;FOXO1;FOXO3;FLI1;FLT3;FLT3LG;FLT4;GATA2;GNAS;FH;HIP1;MNX1;IDH1;IDH2;IKBKB;IRF1;ITK;JAK1;JAK2;JAK3;JARID2;JUN;KIT;KRAS;LASP1;LCK;LCP1;LIFR;LYL1;MDM4;MAP3K1;MEN1;MET;KITLG;GAS7;MLLT1;MLLT3;MLLT6;MN1;MPL;MUC1;MUTYH;MYC;NBN;NF1;NF2;NFIB;NOTCH1;NPM1;NUMA1;PAFAH1B2;PAX5;PAX7;PBX1;PCM1;PDGFRB;PEG3;PER1;PIGA;PIK3R1;PLAG1;PML;PRRX1;POU2AF1;PRCC;PRF1;PRKAR1A;PRKACA;PTPN11;RAD21;RAP1A;RAP1B;RAP1GAP;RAP1GDS1;RARA;RB1;RBBP4;RBBP5;RBBP6;RBBP7;RBBP8;RBL1;RBL2;RBP1;RBP4;ROS1;RPL5;RPL22;SDHB;SDHC;SDHD;MAP2K4;SFPQ;SRSF2;SMARCA4;SMO;SRC;SRP72;STK11;STRN;TAL1;TCEA1;TCF3;TERF2;TERT;TRB;TOP1;TP53;TP53BP1;TP53BP2;TPM4;TPR;U2AF1;KDM6A;WHSC1;WRN;WT1;XIST;TAF15;ZRSR2;RBM10;TRRAP;PICALM;AXIN2;PPM1D;PPFIBP1;TNFRSF14;TRIM24;BCL10;GPRC5A;USP6;SMC3;PCSK7;RECQL4;TP53I3;RBM39;NCOR2;RBM19;MAFB;THRAP3;SH2B3;RBM12;RBM7;RBM6;RBM5;LHFP;RBM14;NCOA2;PRPF8;RBCK1;STAG2;SEPT9;DIDO1;CHEK2;RBPJL;LAMB4;DIS3;RBM34;ERC1;ARHGAP26;RAP1GAP2;CAMTA1;ATMIN;ACSL6;ARHGEF12;CRTC1;SF3B1;SUZ12;RBFOX2;CBLC;POT1;SS18L1;SETBP1;TINF2;AFF4;RBMS3;RBMX;RBM15B;TLX3;SBDS;WT1-AS;DDX41;WWOX;RTEL1;RBM11;TERF2IP;RBM47;RBFOX1;TET2;WHSC1L1;RBM28;RBM23;RBM41;FBXW7;RBM38;RBM22;GOPC;RNF213;RBAK;TP53INP2;RBM25;BCORL1;TP53AIP1;PRDM16;CDH23;RBKS;NSD1;CSMD1;CREB3L2;RBM15;RANBP17;ZSWIM4;ASPSCR1;CHCHD7;CDC73;NEIL1;RBFA;FCRL4;RBP5;RBM4B;BRIP1;RBM48;MAML2;RBM17;SLC45A3;UMODL1;TP53INP1;TP53RK;DIS3L;RBP7;AEBP2;MSI2;CALR3;DIS3L2;RBMXL3;CBLN4;CTCFL;RBFOX3;RBM33;ZNF384;ASXL1;U2AF1L4;FLCN;RBM24;MDS2;RBM20;RBM43;RBM44;MALAT1;RBM12B;RBMXL1;RAD21L1;RAD21-AS1,"Thrombocythemia, Essential;Polycythemia Vera","Acquired primary erythrocytosis; Disease, Osler-Vaquez; Erythremia; Erythremias; Osler Vaquez Disease; Osler-Vaquez Disease"
A New Pipeline to Predict and Confirm Tumor Neoantigens Predicts Better    Response to Checkpoint Blockade,Mutations that drive oncogenesis in cancer can generate neoantigens that may be recognized by the immune system. Identification of these neoantigens remains challenging due to the complexity of the major  histocompatibility complex (MHC) antigen and T-cell receptor interaction. Here we describe the development of a systematic approach to efficiently,phs002269.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002269,Nicholas Durham,Ian Fingerman,Division of Cancer Biology (DCB),,,2020-11-04,GRU,WXS,Case Set,"Antigens, Neoplasm",37.0,37.0,,,,Not Provided
Characterization of Clonal Evolution in Microsatellite Unstable    Metastatic Cancers through Multi-Regional Tumor Sequencing,"Whole exome sequencing was performed on blood and multiple tumor samples from six patients with known microsatellite unstable tumors. Subclones within each tumor site were identified and within each subclone,  differing microsatellite instability was characterized. Inclusion Criteria: 1) A histologically or cytologically confirmed diagnosis of cancer 2)",phs001925.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001925,Sameek Roychowdhury,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),33229401,"American Cancer Society MRSG-12-194-01-TBG;Prostate Cancer Foundation;NHGRI UM1HG006508;NCI UH2CA202971;NCI UH2CA216432;American Lung Association;Pelotonia;NIGMS T32GM068412;Pelotonia Graduate Research Fellowship;Pelotonia Post-Doctoral Research Fellowship;NIH TL1TR002735;American Society of Clinical Oncology
  Young Investigator Award;NCI K08CA241309",2020-11-04,DS-CA,WXS,Case Set,Microsatellite Instability,6.0,38.0,,,Clonal Evolution,"Clonal Evolution; Evolution, Clonal; Error Phenotype, Replication; Error Phenotypes, Replication; Phenotype, Replication Error; Phenotypes, Replication Error"
SU2C GEMM Trial,The goal of the GEMM Trial is to ascertain if comprehensive and systematic interrogation of a patient's tumor molecular profile improves outcomes compared to the current practice of physician's choice  for metastatic melanoma patients who have progressed following first line therapy. The data shared here includes tumor/normal exome and tumor RNAseq,phs001786.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001786,Jeffrey Trent,Ian Fingerman,Division of Cancer Biology (DCB),,Stand Up To Cancer (SU2C) - Melanoma Research Alliance Melanoma Dream Team Translational Cancer Research Grant (#SU2C-AACR-DT0612),2020-11-03,HMB-PUB-MDS,Seq_DNA_SV,Case Set;Longitudinal,Melanoma,36.0,137.0,,BRAF,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Somatic Genome Dynamics of Barrett's Esophagus Patients with Non-Cancer    and Cancer Outcomes,"A case-control study was designed with 80 participants diagnosed with Barrett's Esophagus (BE) selected from a larger case-cohort study (Li et al., 2014, PMID: 24253313) within the Seattle Barrett's Esophagus  Program (SBEP) at the Fred Hutchinson Cancer Research Center. The study included 40 cases with BE with non-cancer outcomes, ""NCO"", who did not",phs001912.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001912,"Brian J. Reid, MD, PhD;Xiaohong Li, PhD",Claire Zhu,Division of Cancer Prevention (DCP),24253313;30541069;33007263,P01 CA91955 Barrett's Esophagus: Predictors of Progression;P30 CA015704 Cancer Center Support Grant;U54 CA217376 Arizona Cancer and Evolution Center (ACE);U2C CA233254 Breast Pre-Cancer Atlas Center;R01 CA140657 Modeling Neoplastic Progression in Barrett's Esophagus;BC 132057 Genomic Diversity and the Microenvironment as Drivers of Progressions in DCIS;U24 CA15020 Genomic Data Network Visualization Genomic Data Center;F31 CA 232465 Graduate Research Fellowship;Burroughs Wellcome Fund Career Award for Medical Scientists;Doris Duke Clinical Foundation Clinical Scientist Career Development Award,2020-10-19,DS-BE-EA,WGS;Array_SNP,Case-Control;Longitudinal,Barrett Esophagus,80.0,427.0,,,,BARRETT METAPLASIA; BE; Barret syndrome; Barrett Metaplasias; Barrett Syndrome; Barrett esophagus/esophageal adenocarcinoma
RNA Sequence-Based Analysis Used to Compare Breast Primary and Metastatic    Tumor Pairs,The goal of this study is to capture the transcriptome landscape of luminal and basal-like metastatic breast tumors. We will aim to show the importance of using the most up-to-date  cancer biopsy for detecting cancer drivers that were often not present in the primary tumor. RNA-Seq data are available through dbGaP's Authorized,phs001866.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001866,"Charles Perou, PhD",Ian Fingerman,Division of Cancer Biology (DCB),32573490;23000897;28249905;24414130,RO1-CA148761,2020-10-19,GRU,RNA-Seq,Cohort,Breast Neoplasms,166.0,166.0,,ESR1;FGFR4;PGR,Metastases;RNA Sequence Analyses,Metastases; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors
Neoadjuvant Pazopanib in Renal Cell Carcinoma,"This study examined the tissue of patients who received oral pazopanib prior to nephrectomy. Patients were consented and underwent a pre-treatment biopsy. Pretreatment samples for analysis were preserved as available.  Subjects underwent a proscribed course of treatment with pazopanib. At the completion of treatment, subjects underwent a planned nephrectomy, and",phs002053.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002053,"W. Kimryn Rathmell, MD, PhD",Mariam Eljanne,Center for Cancer Training (CCT),,Novartis,2020-10-13,DS-KD-IRB,RNA-Seq;OTHER,Prospective;Clinical Trial,"Carcinoma, Renal Cell",22.0,36.0,,,,"ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell"
CIDR: NCI Genome Wide Predictors of Survival in Colorectal Cancer,CIDR/Molecular Correlates: This study genotyped archived blood samples from colorectal cancer cases participating in clinical trials. The goals of this project were to identify genetic variants associated with survival outcomes  treatment and treatment-related severe adverse events among patients with colorectal cancer. Another goal was to examine the impact of adding,phs001290.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001290,"Andrew Chan, MD, MPH;Polly Newcomb, PhD, MPH;Eva Martinez-Balibrea, PhD;Eva Martinez-Balibrea, PhD;Eva Martinez-Balibrea, PhD;Eva Martinez-Balibrea, PhD;Steve Alberts;Dan Sargent;Steve Alberts;Dan Sargent",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26527776;20628391;18448328;15175436;19451431;18718892;17548839;22474202;14665611;16849748;20940184,R01 CA176272;Multiple;Multiple;Multiple;Multiple;CA-25224;CA-37404;CA-35103;CA-35113;CA-35272;CA-114740;CA-32102;CA-14028;CA49957;CA21115;CA31946;CA12027;CA37377;CA25224;CA32102;CA38926;CA21115;CA77202;Pharmacia Corporation (now Pfizer);Sanofi-Synthelabo (now sanofi-aventis);U10-CA-012027;U10-CA-069651;U10-CA-037377;U10-CA-069974,2020-10-07,GRU-PUB;NRUP;GRU-COL-NPU;GRU-COL,Imputation_SNP;Array_SNP,Clinical Trial,Colorectal Neoplasms,6107.0,6371.0,https://clinicaltrials.gov/ct2/show/NCT00202774;https://clinicaltrials.gov/ct2/show/NCT00202787;https://clinicaltrials.gov/ct2/show/NCT00079274;https://clinicaltrials.gov/ct2/show/NCT00003594;http://www.nsabp.pitt.edu/C-08.asp;https://www.clinicaltrials.gov/ct2/show/NCT00275210,,Survival Analysis;toxicity;Prognosis,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Follow-up of Ovarian Cancer Genetic Association and Interaction Studies    (FOCI),"(Excerpted/paraphrased from original grant application): FOCI seeks to expand our understanding of epithelial ovarian cancer through a coordinated and comprehensive approach. Project 1 will focus on discovery, expansion, and replication.  By pooling GWAS, we expect to identify new associations and achieve independent replication, explore whether there are risk variants specific for",phs001133.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001133,"Thomas A. Sellers, PhD, MPH",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),23535648;23382860;23591404;23513043;26091520;25528498;24764580;24272484;24740199;26399219;25940428;25581431;26075790;26424751;26430965;26319099;26138067;26391404;26209509;27594614;23535730;28346442;26152742;26747452;22891074,U19-CA148112,2020-09-24,DS-CA;DS-OVCA-NPU;DS-OVCA;DS-OVTU;DS-OVCA-NPU-MDS;DS-OVCA-MDS-GSO;GRU-COL;GRU;DS-OVCA-MDS;OVCARES;HMB-PUB-NPU;DS-BRCA-MDS;DS-BOED-MDS,Imputation_SNP;Array_SNP_CNV;Array_CNV;Array_SNP,Case-Control,Ovarian Neoplasms,14796.0,16783.0,,,,"Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian"
FOCI Mayo 2.5M,This sub-study phs001150 Mayo 2 5M contains genotype data generated using 2.5M genotyping array and selected phenotype of subjects available from the phs001150 study. Summary level phenotypes for the NCI  FOCI Cohort study participants can be viewed at the top-level study page phs001133 FOCI Cohort. Individual level phenotype data and molecular data,phs001150.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001150,"Ellen L. Goode, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),23535730;28346442;26075790;25581431,U19-CA148112,2020-09-24,DS-CA;DS-OVCA-NPU;DS-OVCA;DS-OVTU;DS-OVCA-NPU-MDS;DS-OVCA-MDS-GSO;GRU-COL;GRU;DS-OVCA-MDS;OVCARES;HMB-PUB-NPU;DS-BRCA-MDS;DS-BOED-MDS,Array_SNP_CNV,Case-Control,Ovarian Neoplasms,1000.0,1021.0,,,,"Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian"
FOCI Mayo OmniExpress,This sub-study phs001142 Mayo Omni Express contains genotype data and selected phenotype of subjects available from the phs001142 study. Summary level phenotypes for the NCI FOCI Cohort study participants can  be viewed at the top-level study page phs001133 FOCI Cohort. Individual level phenotype data and molecular data for all FOCI Cohort top-level study,phs001142.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001142,"Ellen L. Goode, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26152742,U19-CA148112,2020-09-24,DS-CA;DS-OVCA-NPU;DS-OVCA;DS-OVTU;DS-OVCA-NPU-MDS;DS-OVCA-MDS-GSO;GRU-COL;GRU;DS-OVCA-MDS;OVCARES;HMB-PUB-NPU;DS-BRCA-MDS;DS-BOED-MDS,Imputation_SNP,Case Set,Ovarian Neoplasms,171.0,171.0,,,,"Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian"
FOCI GWAS Meta-Analysis,This sub-study phs001132 GWAS Meta Analysis contains genotype data pulled from several GWAS studies and selected phenotype of subjects available from the phs001132 study. Summary level phenotypes for the NCI  FOCI Cohort study participants can be viewed at the top-level study page phs001133 FOCI Cohort. Individual level phenotype data and molecular data,phs001132.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001132,"Thomas A. Sellers, PhD, MPH",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),23535730;28346442;26075790;25581431;26152742;23382860,U19-CA148112,2020-09-24,DS-CA;DS-OVCA-NPU;DS-OVCA;DS-OVTU;DS-OVCA-NPU-MDS;DS-OVCA-MDS-GSO;GRU-COL;GRU;DS-OVCA-MDS;OVCARES;HMB-PUB-NPU;DS-BRCA-MDS;DS-BOED-MDS,Array_CNV,Case-Control,Ovarian Neoplasms,2818.0,2818.0,,,,"Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian"
FOCI Affymetrix Exome Chip,This sub-study phs001131&#x000a0;Affymetrix Exome Chip contains genotype data generated using exome genotyping array and selected phenotype of subjects available from the phs001131 study. Summary level phenotypes for the NCI FOCI  Cohort study participants can be viewed at the top-level study page phs001133 FOCI Cohort. Individual level phenotype data and molecular data for all,phs001131.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001131,"Thomas A. Sellers, PhD, MPH",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),27378695;26848776;26747452,U19-CA148112,2020-09-24,DS-CA;DS-OVCA-NPU;DS-OVCA;DS-OVTU;DS-OVCA-NPU-MDS;DS-OVCA-MDS-GSO;GRU-COL;GRU;DS-OVCA-MDS;OVCARES;HMB-PUB-NPU;DS-BRCA-MDS;DS-BOED-MDS,Array_SNP,Case-Control,Ovarian Neoplasms,12773.0,12773.0,,,,"Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian"
Memorial Sloan Kettering (MSKCC) Single Cell Mutational Profiling in    Myeloid Malignancies,"Myeloid malignancies have previously been characterized by large scale bulk molecular profiling studies on patient samples. These studies, while clinically informative, are unable to delineate mutation order as well as  clonal architecture and complexity. To investigate the clonal framework of myeloid malignancies, the Single Cell Mutational Profiling in Myeloid",phs002049.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002049,Ross L. Levine;Linde A. Miles;Robert L. Bowman,Ian Fingerman,Division of Cancer Biology (DCB),"No PMID: Single cell mutational profiling delineates clonal trajectories in myeloid malignancies | Miles LA, Bowman RL, et al.;27276561;25426838;22932223;23634996;30087104;25834112;22417203;25516983;25426827;16434490;25326804;20068184;28803919",R35 CA197594;R01 CA173636,2020-09-23,HMB,Seq_DNA_SNP_CNV;AMPLICON,Cohort,"Leukemia, Myeloid, Acute",117.0,148.0,,ATM;BRAF;CALR;RUNX1;CBL;DNMT3A;EZH2;FLT3;GATA2;IDH1;IDH2;JAK2;KIT;KRAS;MPL;NPM1;NRAS;PTPN11;RAD21;SRSF2;TP53;U2AF1;WT1;PPM1D;STAG2;CHEK2;SF3B1;SETBP1;TET2;PHF6;ASXL1,Myeloproliferative Disorders,AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL
Kids First: Pediatric Research Project on the Genomic Analysis of    Congenital Diaphragmatic Hernia,The Gabriella Miller Kids First Pediatric Research Program (Kids First) is a trans-NIH effort initiated in response to the 2014 Gabriella Miller Kids First Research Act and supported by the  NIH Common Fund. This program focuses on gene discovery in pediatric cancers and structural birth defects and the development of the Gabriella Miller,phs001110.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001110,"Wendy Chung, MD, PhD;Yufeng Shen, PhD",,,26034137;24385578;24094947;23138528;23375362;23054247;30532227,X01 HL132366;X01 HL136998;X01 HL140543;R01 HD057036,2020-09-16,GRU,Seq_DNA_SNP;Seq_DNA_CNV;WGS,Parent-Offspring Trios,"Hernias, Diaphragmatic, Congenital",2312.0,2358.0,http://www.cdhgenetics.com/;https://commonfund.nih.gov/kidsfirst/overview,,,Agenesis of Hemidiaphragm; CDH; CDH - Congenital diaphragmatic hernia; Congenital Diaphragmatic Defect; Congenital Diaphragmatic Defects; Congenital Diaphragmatic Hernia
"WES, RNASeq and CNV Analysis of NF1-Associated Atypical Neurofibromas","Neurofibromatosis type 1 (NF1) is a tumor-predisposition disorder caused by germline mutations in NF1. NF1 patients have an 8-16% lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST),  a highly aggressive soft-tissue sarcoma, often arising from pre-existing benign plexiform neurofibromas (PN) and atypical neurofibromas (ANF). ANF",phs001993.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001993,"Douglas R. Stewart, MD",Kathleen Calzone,Center for Cancer Research (CCR),30722027,,2020-09-15,GRU,RNA-Seq;WXS;Seq_DNA_CNV,Cohort,Neurofibromatosis 1,69.0,74.0,,CCND1;CCND2;CCND3;CDK4;CDK6;CDKN2A;CDKN2B;EZH2;MDM2;NF1;NRAS;SMARCA2;EED;SUZ12,Neurofibroma,"Molluscum Fibrosum; Multiple non-ossifying fibromatosis; NEUROFIBROMATOSIS TYPE 1; NEUROFIBROMATOSIS, PERIPHERAL TYPE; NEUROFIBROMATOSIS, TYPE I; NEUROFIBROMATOSIS, TYPE I, SOMATIC"
dbGaP submission of CORECT OncoArray GWAS data,"This analysis represents the genome-wide association study results of several international case-control studies of colorectal cancer. Inclusion Criteria In general, for cases: (1) age 18 years (some studies capped age  at 69, and others did not), (2) newly-diagnosed CC (stages I-III), (3) English or German or Spanish speaking dependent on study locale, and (4)",phs001903.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001903,"Stephen B. Gruber, MD, PhD, MPH",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),29917119,"HHSN268201200008I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2020-09-15,CHRONIC-MDS;DS-CA-PUB;DS-CA-IRB-PUB-NPU-MDS;HMB-IRB-COL;DS-BCEMOPCA-NPU-MDS;CRCSTATS;HMB;DS-COC-IRB-COL;CADM;DS-CC-MDS;DS-CA-GSO;DS-COC-PUB-NPU;HMB-PUB-NPU;DS-CC-PUB;DS-CC;DS-COC-MDS;DS-CA-NPU-GSO;DS-CA-MDS;GRU;DS-CC-COL-NPU;EPIMEDCA-MDS;GRU-PUB,Array_SNP,Case-Control,Colorectal Neoplasms,37437.0,37437.0,,NR3C2,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Determinants of Venetoclax Resistance,"The study aimed to identify genetic determinants of resistance to Venetoclax, a recently approved BCL-2 inhibitor for patients with chronic lymphocytic leukemia (CLL). Whole exome sequencing of tumor samples from  6 CLL patients relapsing on Venetoclax revealed clonal evolution when comparing pre- and post-Venetoclax samples. Genetic screens for genes involved",phs001875.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001875,"Catherine J Wu, MD",Ian Fingerman,Division of Cancer Biology (DCB),,PO1CA206978,2020-09-10,NRUP;GRU,WXS,Longitudinal,"Leukemia, Lymphocytic, Chronic, B-Cell",8.0,19.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128563,BCL2;ID3;MCL1;PRKAA2;PRKAR2B,"Lymphoma, Large B-Cell, Diffuse","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic"
Genomic Changes in Breast Cancer Among Chinese Women in Hong Kong,"Recently, tumor sequencing and profiling analyses have improved molecular classification and refined existing breast cancer subtypes. However, epidemiologic data are absent in most somatic profiling studies even in extensively studied  Western populations. The expansion of genomic studies to understudied populations with the integration of etiologic factors will allow the capture of",phs001870.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001870,"Rose Yang, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),17903304;39810;15781015,Intramural research,2020-09-10,DS-BRCA-MDS,Array_DNA_Methylation;WXS;RNA-Seq,Case Set,Breast Neoplasms,92.0,340.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Whole Exome Predictors Immune Checkpoint Therapy Response in Renal Cell    Carcinoma,"Immune checkpoint therapies, including monoclonal antibodies to programmed cell death-1 (PD-1) and cytotoxic % lymphocyte associated protein-4 (CTLA-4), yield durable clinical responses across many tumor types, including metastatic melanoma, non-small  cell lung cancer (NSCLC), and renal cell carcinoma (RCC). However, predictors of response to these therapies in RCC are still unknown. Genomic",phs001493.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001493,"Eliezer Van Allen, MD",Ian Fingerman,Division of Cancer Biology (DCB),,,2020-08-26,DS-CA-MDS;GRU,RNA-Seq;WXS,Cohort,"Carcinoma, Renal Cell",71.0,143.0,,,,"ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell"
Integrative Analysis of Lung Adenocarcinoma (Version 2),"We performed a comprehensive analysis of intratumor heterogeneity of somatic mutations in cancer driver genes, copy number aberrations and DNA methylation in 292 tumor samples from 84 lung adenocarcinoma (LUAD)  patients from the Environment And Genetics in Lung cancer Etiology (EAGLE) study. SNVs of 37 established lung cancer driver genes were profiled by",phs001169.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001169,"Maria Teresa Landi, MD, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,"Intramural program, NCI, DCEG",2020-08-24,DS-LDS-MDS,RNA-Seq;WXS;Seq_DNA_Methylation;Targeted-Capture;Array_SNP,Case Set,Adenocarcinoma of Lung,132.0,1114.0,http://dceg.cancer.gov/eagle,,Adenocarcinoma of Lung,"ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma"
The Genomic Landscape of Mongolian Hepatocellular Carcinoma,"Background and Hypotheses: Mongolia has the highest reported incidence of - and mortality from - hepatocellular carcinoma (HCC) in the world, which is between three and seven times higher than  that observed in other high-incidence populations, such as South Korea, Thailand, and China. Although its causative factors and underlying tumor",phs002000.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002000,"Xin Wei Wang, PhD",Kathleen Calzone,Center for Cancer Research (CCR),,,2020-08-19,GRU,Targeted-Capture,Case Set,"Carcinoma, Hepatocellular",76.0,142.0,,AK2;PCDH7;SPTA1;FKBP9;VPS13A;PCLO;PNRC2;DYNC2H1;SMC6;CSMD2;GTF2IRD2B,,"Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells"
Genomic Analysis of Primary Plasma Cell Leukemia,Primary plasma cell leukemia (pPCL) is a rare and aggressive form of multiple myeloma (MM) that is characterized by poor overall survival despite advances in anti-MM therapy. The disease biology  as well as molecular mechanisms that distinguish pPCL from non-pPCL MM remain poorly understood. In an attempt to identify key biological mechanisms,phs002022.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002022,"Carolina Schinke, MD",Ian Fingerman,Division of Cancer Biology (DCB),23288300;22508408;26046463;23599371,KL2TR000063,2020-08-18,GRU,WXS,Cohort,"Leukemia, Plasma Cell",23.0,46.0,,ACTG1;PRDM1;ZFP36L1;CKS1B;CYLD;DUSP2;EGR1;EP300;H1.4;KRAS;LTB;MAF;MYC;NF1;NFKBIA;NRAS;PIK3CA;RB1;TP53;TRAF2;FUBP1;HUWE1;DIS3;ZNF292;SF3B1;SAMHD1;TET2;FAM46C;KMT2C,Multiple Myeloma,"Leukemia Plasmacytic; Leukemia, Plasmacytic; Leukemias, Plasma Cell; Leukemias, Plasmacytic; PCL; Plasma Cell Leukemia"
DNA Methylation in Rhabdomyosarcoma PDX and PDX-Derived Primary Cells,"Conditions to maintain primary tumor cells in culture are largely unknown for most tumor entities including rhabdomyosarcoma. In this collaborative study with Dr. Beat Sch&#x000e4;fer's laboratory, we performed DNA methylation  profiles of rhabdomyosarcoma patient-derived xenograft (PDX) and their matching PDX-derived primary cells (PPC), where the PPCs were developed and",phs002051.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002051,"Frederic G. Barr, MD, PhD",Kathleen Calzone,Center for Cancer Research (CCR),,,2020-08-17,GRU,Array_DNA_Methylation;WXS;Array_CNV,Case Set,Rhabdomyosarcoma,39.0,99.0,,FOXO1;PAX3;PAX7,,Not Provided
Chemotherapy and Unrelated Donor SCT for Blood and Immune System Cancers,"Background: Major problems with stem cell transplantation (SCT) for cancer treatment are a lack of suitable donors for patients without an HLA tissue-matched sibling and graft-versus-host disease (GVHD), a serious  side effects of immune-suppressing chemotherapy that is given to bring the cancer under control before SCT. In GVHD, the patient's immune system",phs002021.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002021,"Steven Z. Pavletic, MD",Kathleen Calzone,Center for Cancer Research (CCR),23689118;16980994;16503494,NIH Intramural funding,2020-08-14,GRU,RNA-Seq,Clinical Trial,Graft vs Host Disease,2.0,2.0,https://clinicalstudies.info.nih.gov/ProtocolDetails.aspx?B_2007-C-0195.html,,"Lymphoma;Leukemia;Multiple Myeloma;Preleukemia;Myelodysplastic Syndromes;Neoplasms by Histologic Type;Neoplasms;Lymphoproliferative Disorders;Lymphatic Diseases;Immunoproliferative Disorders;Immune System Diseases;Neoplasms, Plasma Cell;Hemostatic Disorders;Vascular Diseases;Cardiovascular Diseases;Paraproteinemia;Blood Protein Disorders;Hematologic Diseases;Hemorrhagic Disorders;Bone Marrow Diseases;Precancerous Conditions;Cytarabine;Cyclosporine;Sirolimus;Rituximab;Alemtuzumab;Fludarabine;Fludarabine phosphate;Tacrolimus;Cyclosporins",Blood Protein Disorders; Bone Marrow Diseases; Cardiovascular Diseases; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders
Gabriella Miller Kids First Pediatric Research Program: An Integrated    Clinical and Genomic Analysis of Treatment Failure in Pediatric    Osteosarcoma,"Although the survival of children with relapsed osteosarcoma is very poor, little is known about the etiology of treatment failure in this disease. The purpose of this project is to  perform whole genome sequencing on serial samples from patients with osteosarcoma obtained before treatment, after treatment, and at",phs001714.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001714,"Kenan Onel, MD, PhD",,,,X01 HL132378,2020-08-14,GRU,,Tumor vs. Matched-Normal,Osteosarcoma,84.0,311.0,https://commonfund.nih.gov/kidsfirst/x01projects#Onel,,,Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma
Intraductal Transplantation Models of PDAC Reveal Progression of Subtypes,"Pancreatic ductal adenocarcinoma (PDAC) is the most lethal common malignancy, with little improvement in patient outcomes over the past few decades. Recently, subtypes of pancreatic cancer with different prognoses have  been elaborated. However, the inability to model these subtypes has precluded mechanistic investigation of their origins. Here, we present an",phs002045.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002045,"David A. Tuveson, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,The Lustgarten Foundation;5P30CA045508;5U01CA224013;5R01CA188134;5U01CA210240;5R01CA190092;5U10CA180944;5P20CA192996;1R01CA229699;Simons Foundation (552716);The V Foundation for Cancer Research;Cold Spring Harbor Laboratory Association;Northwell Health Affiliation (Project Lazarus);Northwell Health Tissue Donation Program,2020-08-10,GRU,RNA-Seq;Seq_RNA_Expression;Seq_DNA_CNV;WGS,Case Set,"Carcinoma, Pancreatic Ductal",15.0,70.0,,KRAS,Pancreatic Intraductal Neoplasms;Neoplasm Transplantation,"Pancreatic Intraductal Neoplasms; Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas"
CORECT: Affymetrix Axiom GWAS Data,"This study is part 1 of 2 for Schumacher et al, Nat Commun. 2015 Jul 7;6:7138. Part 1 is the original GWAS data for 9,259 participants on the Affymetrix Axiom  platform of the studies listed below in the Inclusion Criteria. Inclusion Criteria The CORECT consortium coordinated the analysis of six",phs001856.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001856,Stephen B. Gruber,,,26151821;26498495,,2020-08-10,DS-CC;DS-CC-MDS;DS-CA-MDS;GRU;DS-CA-IRB-PUB-NPU-MDS;HMB;DS-COC-IRB-COL;HMB-IRB-COL,Array_SNP,Case-Control,Colorectal Neoplasms,9924.0,9924.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Pharmacogenomic Interactions in Glioblastoma Cell Line Models,"Glioblastoma (GBM) is a lethal disease without effective treatments. To advance toward effective therapeutic approaches that are biomarker-driven, there is a need for new targeted agents and to develop accurate  preclinical models that encompass its cellular and molecular diversity. Historical cell line models poorly represent molecular diversity of GBMs, so",phs001793.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001793,"Keith L. Ligon, MD, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),24120142;18184972;22460905,R01 CA188228,2020-08-06,HMB,WXS,Case Set,Glioma,33.0,34.0,,,Glioblastoma,"Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme"
Genomic Characterization of Metastatic Castration Resistant Prostate    Cancer,"Biopsies of castration resistant prostate cancer metastases were subjected to whole genome sequencing (WGS), along with RNA-sequencing (RNA-Seq). The overarching goal of the study is to illuminate molecular mechanisms of  acquired resistance to therapeutic agents, and particularly androgen signaling inhibitors, in the treatment of metastatic castration resistant",phs001648.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001648,Eric Small,,,,Prostate Cancer Foundation,2020-07-28,GRU,Bisulfite-Seq,Cohort,"Prostatic Neoplasms, Castration-Resistant",101.0,311.0,,AR;BRCA1;BRCA2;PTEN;RB1;TP53,Neoplasm Metastasis,"Neoplasm Metastasis; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize"
Whole-Exome Sequencing and Targeted DNA Sequencing of Matched Ocular    Melanocytosis and Uveal Melanoma,"Ocular melanocytosis is the most important predisposing condition for the eye cancer uveal melanoma (UM). Here we used whole-exome and deep targeted sequencing to identify for the first time a  clonal Gq pathway mutation in ocular melanocytosis, which gave rise to UM. Additionally, we elucidated the order in which canonical genetic",phs001835.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001835,"J. William Harbour, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,R01 CA125970;Core Grant P30EY014801,2020-07-21,HMB-PUB,WXS,Case Set,Uveal melanoma,1.0,3.0,,PLCB4;BAP1,,Not Provided
Familial Breast Cancer Study (FBCS),"Breast cancer has a significant genetic component. The strongest epidemiologic risk factor is family history of the disease. Familial studies have identified a number of genes contributing to increased risk.  Of these, the highly penetrant BRCA1 and BRCA2 genes account for the majority of families in whom disease-causal mutations have been identified.",phs000480.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000480,"Fergus J. Couch, PhD;Csilla Szabo, PhD;Jeffrey N. Weitzel, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,X01 HG006197-01;HHSN268201100011I,2020-07-21,DS-BRCA;NRUP,WXS;Seq_DNA_SNP_CNV,Family,Breast Neoplasms,367.0,129.0,,,Breast Cancer,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Intra-Tumor Heterogeneity and Clonal Evolution of Papillary Renal Cell    Carcinoma,"Limited knowledge of intratumor heterogeneity (ITH), and clonal evolution of papillary renal cell carcinoma (pRCC) and rare kidney tumor subtypes hinders understanding of tumorigenesis and therapeutic efficacy. We conducted an  integrative genomic and epigenomic ITH analysis and studied clonal evolutionary history of pRCC and rare kidney tumor subtypes. We dissected multiple",phs001573.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001573,Maria Teresa Landi,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),24390350;32555180,Intramural DCEG/NCI Funding,2020-07-14,GRU,Array_DNA_Methylation;WGS;Targeted-Capture;Array_SNP,Case Set,"Carcinoma, Renal Cell",39.0,502.0,,,Collecting Duct Carcinoma (Kidney);Sarcoma,"Sarcoma; ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell"
Sequencing of Cervical Cancer,Precision mapping of genetic alterations in cancer can enable better selection of therapies and improved outcomes when combined with new sequencing diagnostics. We describe whole-exome sequences from cervical adenocarcinomas and  paired normal samples in Hong Kong Chinese women. These data uncover a heterogeneous genomic landscape but identify commonly aberrant loci including,phs000723.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000723,Yick Fu Wong,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),24037752;23791828;24390348;25626421,Departmental private funds,2020-07-14,GRU-NPU-MDS,Targeted-Capture,Case-Control,Uterine Cervical Neoplasms,15.0,29.0,,,,"Cervical Neoplasm, Uterine; Cervical Neoplasms; Cervical Tumor; Cervical neoplasm; Cervix Neoplasm; Cervix Neoplasms"
Smoking and Tumor Immune Microenvironment in HNSCC,"This study was designed to measure immune cell differences between HNSCC patients according to smoking history. We measured CD3, CD8, FoxP3, PD-1 and PD-L1 for immune markers and Pancytokeratin to  distinguish between tumor and surrounding tissue. We observed that current smokers have significantly lower numbers of immune cells surrounding the",phs001994.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001994,"Christine Chung, MD",Ian Fingerman,Division of Cancer Biology (DCB),31848186,7JK02;P30-CA076292,2020-07-09,GRU-NPU,RNA-Seq;WXS,Cohort,Squamous Cell Carcinoma of Head and Neck,61.0,120.0,,,,Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx
Drug Screening of Patient-Derived Organoids from Colorectal Peritoneal    Metastases,Colorectal cancer (CRC) patients with peritoneal metastases (CRPM) have limited treatment options and the lowest CRC survival rates. We trialed the possibility of organoid directed precision treatment for CRPM patients.  CRPM organoids (peritonoids) isolated from patients underwent next-generation sequencing and medium-throughput drug panel testing ex vivo to identify,phs002023.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002023,Susan L Woods;Robert G Ramsay;Vignesh Narasimhan;Daniel L Worthley,Ian Fingerman,Division of Cancer Biology (DCB),30620402;28721098;22162570;27743922;24783222;20737420;15383792;24756812;27780675;32027455;30554404;27110915;31197820;29526367;28964609;11248153;21639808;12637609;28886003;28481359;21889923;26460009;31171691;30726695;29472484;31591597;31597751;31761724;29853643;31053628;29224780;28331002;29921838;29599409;16646834;26457759;29316426;22810696;20049735;20944090;18946069;18946061;31566309;39161961,,2020-07-08,GRU,WXS,Cohort,Peritoneal Neoplasms,14.0,30.0,,,Colorectal Neoplasms,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Whole Exome Sequencing of DNA in Breast Cancers Enrolled in the S0800    Trial,Purpose: The purpose of this study was to assess the somatic mutation landscape of breast tumors before and after neoadjuvant chemotherapy. The data includes whole exome sequencing of pre- and  post- tissues that were collected in the context of an already published clinical trial SWOG S0800 (ZA Nahleh et al. Breast Cancer Research and,phs001883.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001883,"Lajos Pusztai, MD, DPhil",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),27393622,"CA180888;CA180819;CA180826;Genentech (Roche);Abraxis BioScience (Celgene);Pittsburgh, PA, USA;The HOPE Foundation;Susan Komen Foundation Leadership Award;Breast Cancer Research Foundation",2020-07-08,GRU-COL,WXS,Clinical Trial;Cohort,Breast Neoplasms,29.0,45.0,https://clinicaltrials.gov/ct2/show/NCT00856492?term=NCT00856492,,Neoadjuvant Therapy;Drug Therapy,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Molecular Characterization of Response to Rectal Chemoradiation,"Pre-operative chemoradiation (CRT) followed by resection is the standard of care option for patients with locally advanced rectal adenocarcinoma. Pathologic downstaging after CRT is associated with improved outcomes, but molecular  predictors of response are poorly understood. We performed whole exome sequencing, gene expression profiling, and immune infiltrate analysis on",phs001829.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001829,"Eliezer Van Allen, MD;Theodore Hong, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,R01CA227388,2020-07-06,DS-GID-MDS,RNA-Seq;WXS,Case Set,Rectal Neoplasms,17.0,48.0,,KRAS;TP53,,"CA - Cancer of rectum; Cancer of Rectum; Cancer of the Rectum; Cancer, Rectal; Cancer, Rectum; Carcinoma of Rectum"
Genomic Landscape of Human Skin at a Single-Cell Resolution,"Every cell in the human body has a unique set of somatic mutations, yet it remains difficult to comprehensively genotype an individual cell. Here, we developed solutions to overcome this  obstacle in the context of normal human skin, thus offering the first glimpse into the genomic landscapes of melanocytes at single-cell resolution.",phs001979.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001979,"A. Hunter Shain, PhD",Mariam Eljanne,Center for Cancer Training (CCT),33469220,K22 CA217997,2020-07-01,GRU,RNA-Seq;Seq_RNA_Expression;WXS;Targeted-Capture,Cross-Sectional,Melanoma,7.0,355.0,,,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Cellular Origins and Genetic Landscape of Cutaneous GD T Cell Lymphoma,"Cutaneous gamma-delta T cell lymphomas are a rare and aggressive subtype of cutaneous lymphoma. In the present study, we analyzed these cancers by DNA and RNA sequencing in order to  illuminate the genetic landscape for this rare disease. We obtained tumor samples from multiple institutions, including Northwestern University",phs001969.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001969,"Jaehyuk Choi, MD PhD",Mariam Eljanne,Center for Cancer Training (CCT),32286303,K08-CA191019-01A1,2020-06-24,GRU,OTHER;WGS;RNA-Seq;WXS;Targeted-Capture,Case Set,"Lymphoma, T-Cell, Cutaneous",20.0,37.0,,,,"Granulomatous Slack Skin; Slack Skin, Granulomatous"
Kids First Pediatric Research Study in Familial Predisposition to    Hematopoietic Malignancies (SJFAMILY-HM),"Acute lymphoblastic leukemia (ALL) is the commonest childhood tumor and a leading cause of cancer death in children, adolescents and young adults. Hodgkin and non-Hodgkin lymphoma are also important hematologic  malignancies (HM) that occur in children. Each are genetic diseases with growing evidence for a germline predisposition of both familial and sporadic",phs001738.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001738,Charles G. Mullighan,,,,1  X01 HL136999-01,2020-06-18,GRU,,Cohort;Parent-Offspring Trios,Precursor Cell Lymphoblastic Leukemia-Lymphoma,366.0,373.0,https://commonfund.nih.gov/kidsfirst/X01Projects,,"Hodgkin Disease;Lymphoma, Non-Hodgkin","Hodgkin Disease; Lymphoma, Non-Hodgkin; CHL; Classic Hodgkin disease; Disease, Hodgkin; Disease, Hodgkin's"
Beckwith-Wiedemann Syndrome (BWS) Study,"miRNA data from Beckwith-Wiedemann syndrome patients was compared with samples from large overgrowth syndrome animals (GSE117015). Tongue samples from patients with Beckwith-Wiedemann Syndrome were included. Principal Investigator: Jennifer Kalish, MD,  PhD, Children's Hospital of Philadelphia, Philadelphia, PA, USA Funding Sources: K08 CA193915, National Institutes of Health, Bethesda, MD, USA",phs001794.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001794,"Jennifer Kalish, MD, PhD",,,,K08 CA193915,2020-06-16,GRU,miRNA-Seq,Cohort,Beckwith-Wiedemann Syndrome,12.0,12.0,,,Macroglossia,Macroglossia; BWS; Beckwith Wiedemann Syndrome; Beckwith's syndrome; Beckwith-Wiedemann syndrome chromosome region; EMG SYNDROME
DNA Methylation in Rhabdomyosarcoma,"Rhabdomyosacoma (RMS) is a common pediatric soft tissue tumor that is associated with the skeletal muscle lineage. RMS comprises two major subtypes: fusion-positive (FP, most commonly PAX3- FOXO1 or PAX7-FOXO1)  and fusion-negative (FN, frequently associated with mutations in RAS pathway). Our previous study demonstrated that FP and FN tumors exhibit distinct",phs001970.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001970,"Frederic G. Barr, MD, PhD",Kathleen Calzone,Center for Cancer Research (CCR),30565669,,2020-06-12,GRU,Array_DNA_Methylation,Case Set,Rhabdomyosarcoma,134.0,134.0,,FOXO1;HRAS;KRAS;NRAS;PAX3;PAX7,,Not Provided
Kids First: Genomics of African and Asian Orofacial Clefts Triads,The focus of this study is to identify novel risk variants for OFC in Africa and Asian OFC case-parent triads through analysis of Whole Genome Sequencing data. About 300 Case-parent  trio samples were selected for this whole genome sequencing as part of the Gabriella Miller Kids First Orofacial Clefts Projects. Samples of,phs001997.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001997,"Azeez Butali, DDS, PhD;Terri Beaty, PhD",,,27033726;27018472;21740177;27369588;28116324,X01 HL140516,2020-05-22,DS-OC-PUB-MDS;GRU,,Cohort;Parent-Offspring Trios,Cleft Lip,791.0,791.0,https://commonfund.nih.gov/kidsfirst/X01Projects,,Cleft Palate,Cleft Palate; CL - Cleft lip; Cheiloschisis; Cheiloschisis of upper lip; Cleft Lips; Cleft of upper lip
Early Stage Lung Adenocarcinoma,"Lung cancer in East Asia is characterized by high percentage of never-smokers, early-onset and predominant EGFR mutations. To provide an insight into the molecular phenotype of this demographically distinct disease,  we have performed a proteogenomics study on a prospectively collected cohort representing early stage lung adenocarcinomas in Taiwan. The distinct",phs001954.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001954,"""Hsuan Yu Chen, PhD""",,,,,2020-05-19,GRU-NPU,RNA-Seq;WXS,Case Set,Adenocarcinoma of Lung,89.0,356.0,,,"Carcinoma, Non-Small-Cell Lung","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma"
Single Molecule Molecular Inversion Probe Capture Developed Using CIViC,This study evaluated the use of the Clinical Interpretations of Variants in Cancer database (CIViC) to develop an Open-sourced CIViC Annotation Pipeline (OpenCAP). OpenCAP is a resource that allows users  to develop a clinical capture panel that can be linked back to clinical summaries within the CIViC database. This method for capture panel,phs001890.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001890,"Obi L. Griffith, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2020-05-07,DS-CA;GRU-IRB;DS-LC-IRB;GRU,AMPLICON,Tumor vs. Matched-Normal,Database Management Systems,17.0,31.0,https://civicdb.org;http://opencap.org/,,,Not Provided
SEER Remote Access Pilot Test Data (2018),"This is a limited use Surveillance, Epidemiology, and End Results (SEER) file for use in a pilot test of remote data access. The SEER Program of the National Cancer Institute  (NCI) is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer",phs002012.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002012,,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2020-05-05,,,Methods Development,SEER Program,,,https://seer.cancer.gov/,,,Not Provided
Hereditary Cancer Predisposition Syndromes and Uveal Melanoma,"Uveal melanoma (UM) is a subtype of melanoma characterized by the strong contribution of genetic rather than environmental factors in the pathogenesis of the disease, making it an ideal model  disease to study the genetic basis of cancer. The long-term goal of our laboratory is to determine the genes and mechanisms responsible for",phs001943.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001943,Mohamed Abdel-Rahman,Ian Fingerman,Division of Cancer Biology (DCB),32081490,R21CA191943,2020-05-01,DS-CA-PUB-NPU-MDS-GSO,WXS,Cohort,Uveal melanoma,34.0,34.0,,BAP1,Hereditary Cancer Syndrome,"Cancer Syndrome, Hereditary; Cancer Syndromes, Hereditary; Cancer predisposition; Familial Neoplastic Syndrome; Familial Tumor Syndrome; Germline Neoplastic Syndrome"
Genetic Architecture of Susceptibility to Melanoma,"Most genetic susceptibility to cutaneous melanoma (CM) remains to be discovered. Meta-analysis genome-wide association study (GWAS) of 36,760 melanoma cases (67% newly-genotyped) and 375,188 controls identified 54 significant loci with  68 independent SNPs. Analysis of risk estimates across geographical regions and host factors suggests the acral melanoma subtype is uniquely",phs001868.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001868,Maria Teresa Landi,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,DCEG intraraural funding,2020-04-24,GRU,Array_SNP,Case-Control,Melanoma,11234.0,11234.0,,,Nevus;Pigmentation,"Nevus; Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant"
Contribution of Systemic and Somatic Factors to Clinical Response and    Resistance in Urothelial Cancer,Patients with metastatic urothelial cancer (n 29) were treated with atezolizumab (anti-PD-L1). All 29 patients had T-cell receptor sequencing (TCR-seq) of the pre-treatment blood; 24 also had TCR-seq on at  least one post-treatment blood sample. 24 patients had TCR-seq of their pre-treatment tumors. TCR-seq data can be found at,phs001743.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001743,"Dean F. Bajorin, MD",Ian Fingerman,Division of Cancer Biology (DCB),28552987;29642008,"Ludwig Institute for Cancer Research, New York, NY, USA;P30CA008748",2020-04-24,DS-BLADDERCA-GSO,RNA-Seq;WXS;Seq_DNA_SNP_CNV,Longitudinal Cohort,Urologic Neoplasms,29.0,78.0,,,,"Neoplasm of Urinary System; Neoplasm of the Urinary System; Neoplasm, Urinary Tract; Neoplasm, Urologic; Neoplasm, Urological; Neoplasms, Urinary Tract"
PLCO - Limited Use Pilot Test Data,"This is a sample of Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial data for limited use in a pilot test for remote data access. The PLCO is a  randomized, controlled trial of screening tests for prostate, lung, colorectal and ovarian cancers. Approximately 155,000 participants were enrolled",phs002011.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002011,,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2020-04-21,,,Longitudinal,Early Detection of Cancer,,,https://cdas.cancer.gov/plco/,,,Not Provided
Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma    Evaluated After Starting Hu14.18-IL2 Predicts Outcome,"Background: We analyzed whole transcriptome sequencing in tumors from 23 patients with stage III or IV melanoma from a pilot trial of the anti-GD2 immunocytokine, hu14.18-IL2, to identify predictive immune  and/or tumor biomarkers in melanoma patients at high risk for recurrence. Methods: Patients were randomized to receive the first of 3 monthly-courses",phs001947.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001947,"Javed Khan, MD",Kathleen Calzone,Center for Cancer Research (CCR),,,2020-04-21,GRU,,Cohort,Melanoma,23.0,23.0,,,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Genomic Determinants of Response to Immunotherapy,"This study evaluates integrated genomic models of response to immune checkpoint blockade for lung cancer patients. A computationally adjusted tumor mutation burden was combined with HLA class I genetic variation,  mutational smoking signature and activating mutations in receptor tyrosine kinase genes to generate a prognostic classifier that outperforms tumor",phs001940.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001940,"Anagnostou, Valsamo;Velculescu, Victor",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),32984843;30541742;28031159,R01 CA121113,2020-04-17,HMB-IRB,WXS,Cohort,"Carcinoma, Non-Small-Cell Lung",36.0,72.0,,,Whole Exome Sequencing;Immunotherapy,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER"
Transdisciplinary Research Into Cancer of the Lung (TRICL),"The study was conducted under the auspices of the Transdisciplinary Research In Cancer of the Lung (TRICL) Research Team, which is a part of the Genetic Associations and MEchanisms in  ONcology (GAME-ON) consortium, and associated with the International Lung Cancer Consortium (ILCCO). Ethics All participants provided written",phs000876.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000876,Christopher Amos,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),24880342;22899653;24681604;16273220;18385738;18978790;17108128;16243968;24081945;24113142;22941188;24174329;24670920;18087271;22910935;24441672;21317179;23972816;25208072,U19 CA148127,2020-04-10,DS-CA;DS-LCS-RD;LCRF;HMB-PUB;HMB-MDS;DS-CA-MDS;GRU-COL;DS-CA-PUB;GRU;NRUP;CADM,WXS;Seq_DNA_SNP_CNV;Array_SNP,Case-Control,Lung Neoplasms,12200.0,12225.0,,,"Adenocarcinoma;Neoplasms, Squamous Cell","Adenocarcinoma; Neoplasms, Squamous Cell; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant"
Transdisciplinary Research Into Cancer of the Lung (TRICL) - Affymetrix,"This sub-study phs001681 Affy Axiom Array contains genotype, sequence data, and selected phenotype of subjects available from the phs001681 study. Summary level phenotypes for the NCI Lung Cancer Transdisciplinary Research  Cohort study participants can be viewed at the top-level study page phs000876 Lung Cancer Transdisciplinary Research Cohort. Individual level",phs001681.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001681,Christopher Amos,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26590902,U19 CA148127,2020-04-10,DS-CA;DS-LCS-RD;LCRF;HMB-PUB;HMB-MDS;DS-CA-MDS;GRU-COL;DS-CA-PUB;GRU;CADM,Array_SNP,Case-Control,Lung Neoplasms,10195.0,10195.0,http://www.u19tricl.org/,BRCA2;CHRNA3;CHRNA5;MSH5;RAD52;TERT;BAT3;TP63;CHEK2;CLPTM1L,"Adenocarcinoma;Neoplasms, Squamous Cell","Adenocarcinoma; Neoplasms, Squamous Cell; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant"
Transdisciplinary Research Into Cancer of the Lung (TRICL) - Exome Plus    Targeted Sequencing,"This sub-study phs000878 CIDR Lung Cancer contains genotype, sequence data, and selected phenotype of subjects available from the phs000878 study. Summary level phenotypes for the NCI Lung Cancer Transdisciplinary Research  Cohort study participants can be viewed at the top-level study page phs000876 Lung Cancer Transdisciplinary Research Cohort. Individual level",phs000878.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000878,Christopher Amos,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),24880342;22899653;24681604;16273220;18385738;18978790;17108128;16243968;24081945;24113142;22941188;24174329;24670920;18087271;22910935;24441672;21317179;23972816;25208072,"U19 CA148127;HHSN268201200008I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2020-04-10,DS-CA;DS-LCS-RD;LCRF;HMB-PUB;HMB-MDS;DS-CA-MDS;GRU-COL;DS-CA-PUB;GRU;NRUP;CADM,WXS;Seq_DNA_SNP_CNV,Case-Control,Lung Neoplasms,1964.0,2030.0,,,"Adenocarcinoma;Neoplasms, Squamous Cell","Adenocarcinoma; Neoplasms, Squamous Cell; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant"
Transdisciplinary Research Into Cancer of the Lung (TRICL) - Meta    Analysis,"This sub-study phs000877 Meta Analysis contains genotype, sequence data, and selected phenotype of subjects available from the phs000877 study. Summary level phenotypes for the NCI Lung Cancer Transdisciplinary Research Cohort  study participants can be viewed at the top-level study page phs000876 Lung Cancer Transdisciplinary Research Cohort. Individual level phenotype data",phs000877.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000877,Christopher Amos,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),24880342;22899653;24681604,U19 CA148127,2020-04-10,,,Case-Control,Lung Neoplasms,,,,BRCA2;CHRNA3;CHRNA5;MSH5;RAD52;TERT;BAG6;TP63;CHEK2;CLPTM1L,"Adenocarcinoma;Neoplasms, Squamous Cell","Adenocarcinoma; Neoplasms, Squamous Cell; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant"
Women's Health Study Accelerometry Dataset,"Background The Women's Health Study (WHS) was a randomized trial testing low-dose aspirin and vitamin E for preventing cancer and CVD among 39,876 women aged &#x02265;45 years throughout the US  from 1992-2004. When the trial ended as planned, women who were willing to participate continued in an observational follow-up study. Participants in",phs001964.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001964,"I-Min Lee, MBBS, ScD;Julie E. Buring, ScD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),30666321;29109088;31141585,CA154647;CA182913,2020-03-19,GRU,,Longitudinal,Exercise,17062.0,0.0,http://whs.bwh.harvard.edu/,,Sedentary Behavior,"Sedentary Behavior; Behavior, Sedentary; Lifestyle, Sedentary; Sedentary Behaviors; Sedentary Lifestyle; Sedentary life style"
Understanding the Progression of Metastatic Colorectal Cancer,This study is to understand (1) the clonal evolution of metastatic colorectal cancer using DNA sequencing and (2) long non-coding RNAs associated with metastatic colon cancer using RNA sequencing. Our  goal is to better understand the progression of aggressive colorectal cancer. All metastatic colon cancer patients coming in for surgery were,phs001722.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001722,"Ryan Fields, MD",Ian Fingerman,Division of Cancer Biology (DCB),,Siteman Team Science Award,2020-03-17,GRU,RNA-Seq;WXS;Targeted-Capture;WGS,Cohort,Neoplasms,20.0,219.0,,,Colorectal Neoplasms;Neoplasm Metastasis,Neoplasm Metastasis; CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine
PAK4 Inhibition Improves PD-1 Blockade Immunotherapy,"Introduction with rationale and aims for study Immune checkpoint blockade therapies have significantly altered the current landscape of cancer treatment. However, this immunotherapy still fails more often than it succeeds.  There are now evidences that the lack of tumour infiltration by immune cells is the main mechanism of primary resistance to PD&#x02010;1 blockade",phs001919.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001919,"Antoni Ribas, MD PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),25970248;25428505,P01 CA168585,2020-03-13,HMB-PUB-NPU-MDS,RNA-Seq,Cohort,Melanoma,39.0,60.0,,PAK4,Immunotherapy,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate    Cancer,"A genome-wide association study (GWAS) of prostate cancer (PCa) was conducted in Kaiser Permanente (KP) Northern California health plan members (7,783 cases, 38,595 controls; 80.3% non-Hispanic white, 4.9% African-American, 7.0%  East Asian, and 7.8% Latino) [PMID: 26034056]. The data for these members were drawn from three KP cohort studies: Research Program in Genes,",phs001221.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001221,"John S. Witte, PhD;Stephen K. Van Den Eeden, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),"26034056;26092718;21565264;21903159;22138821;22384356;26544944;21949389;30305743;33398198;No PMID: Association Study of Over 200,000 Subjects Detects Novel Rare Variants, Functional Elements, and Polygenic Architecture of Prostate Cancer Susceptibility | Emami NC, Cavazos TB, Rashkin SR, Cario CL, Graff RE, Tai CG, Mefford JA, Kachuri L, Wan E, Wong S, Aaronson DS, 			Presti J, Habel LA, Shan J, Ranatunga DK, Chao CR, Ghai NR, Jorgenson E, Sakoda LC, Kvale MN, Kwok P-Y, Schaefer C, 			Risch N, Hoffmann TJ, Van Den Eeden SK, Witte JS.",CA127298;CA088164;CA112355,2020-03-12,DS-PC-IRB-NPU-MDS;NRUP,Array_SNP_CNV;Imputation_SNP_CNV,Cohort,Prostatic Neoplasms,35405.0,34736.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Single Cell Analysis Reveals New Evolutionary Complexity in Uveal    Melanoma,"Uveal melanoma (UM) is a rare eye cancer that is highly aggressive and leads to metastatic death in up to half of patients. Here, we conduct droplet-based single-cell RNA sequencing  of 59,915 neoplastic and non-neoplastic cells from 8 primary and 3 metastatic UMs. Single-cell VDJ sequencing of RNA is conducted to determine",phs001861.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001861,"J. William Harbour, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,R01 CA125970;Core Grant P30EY014801;Core Grant P30CA240139,2020-03-11,HMB-PUB,RNA-Seq;WGA,Case Set,Uveal melanoma,11.0,24.0,,EIF1AX;GNA11;GNAQ;BAP1;SF3B1,,Not Provided
Rare Germline Variations in Familial Melanoma,"Although a number of high-risk melanoma genes have been identified, they account for melanoma risk in less than 40% of melanoma-prone families. The major goals of our research are to  identify novel high-penetrance genes for familial melanoma in melanoma-prone families without known mutations and to identify modifier factors,",phs001177.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001177,"Rose Yang, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),27476724,Intramural Research,2020-03-09,HMB-MDS,RNA-Seq;WXS;Targeted-Capture;Array_SNP,Family,"Melanoma, Cutaneous Malignant",3357.0,3495.0,,,,"CMM; Cutaneous Malignant Melanoma; Cutaneous Malignant Melanomas; Cutaneous melanoma; MELANOMA, MALIGNANT; MM (malignant melanoma) of skin"
Genome Sequencing of Lung Cancer in European Americans and African    Americans,"The goal of this study is to compare the somatic mutation landscape between European Americans and African Americans. It includes various histological forms of lung cancer. In LUAD, we find  increased prevalence of PTPRT and JAK2 mutations among African Americans. These proteins function in the same pathway and as such, this may be a new",phs001895.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001895,"Brid Ryan, PhD MPH",Kathleen Calzone,Center for Cancer Research (CCR),"No PMID: Recurrent PTPRT/JAK2 Mutations in Lung Adenocarcinomas in African Americans | Mitchell K, Nichols N, Tang W, Walling J, Stevenson H, Pineda M, Stefanescu R, 		         Edelman D, Girvin A, Zingone A, Sinha S, Bowman E, Rossi E, Arauz R, Zhu YL, 				 Lack J, Weingartner E, Waterfall J, Pine S, Simmons J, Paul M, Ryan BM;35121843",BC011554-05,2020-03-05,GRU,Targeted-Capture;Array_CNV,Case-Control,Lung Neoplasms,286.0,578.0,,JAK2;PTPRT,"Carcinoma, Non-Small-Cell Lung","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell"
Germline Variants of Clinical Cancer Specimens,"These clinical specimens represent solid tumors and matched blood controls that were collected as part of patients' routine care at Memorial Sloan Kettering Cancer Center. They were sequenced on the  targeted platform MSK-IMPACT. Here, we performed germline variant calling on the normal blood specimens and assessed their zygosity in the",phs001858.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001858,Michael F. Berger,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),34741162;31292550,R01 CA227534;U54 OD020355;P01 CA221757;R01 CA207244;P50 CA092629,2020-02-25,DS-CA-PUB-MDS,Seq_DNA_SNP_MAF_Ind,Case Set,Neoplasms,17152.0,34304.0,,,Genomics,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Temporal and Clonal Progression in Pediatric Ependymoma,"Whole genome and exome-based DNA sequencing of germline and tumor specimens from serial samples of a single patient's ependymoma. The findings reveal the extent to which treatment with radiation and  chemotherapies resulted in the diversification of the tumor subclonal architecture and shaped the neo-antigen landscape, and provide new insights",phs001461.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001461,"Joshua Rubin, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),29440180,McDonnell Genome Institute endowment;Robert E. and Louise F. Dunn Distinguished Professorship endowment,2020-02-24,DS-BT-PUB-NPU-MDS,RNA-Seq;WGS,Longitudinal,Ependymoma,1.0,11.0,,,Supratentorial Neoplasms,"Supratentorial Neoplasms; Cellular Ependymoma; Clear Cell Ependymoma; Brain Neoplasms, Supratentorial; Neoplasm, Supratentorial; Neoplasms, Supratentorial"
MGH Gastrointestinal Malignancies Resistance Initiative,"Tumor heterogeneity can drive the evolution of multiple tumor subclones harboring unique molecular resistance alterations in different metastatic lesions in an individual patient, under the selective pressure of therapy1-3. Studies  have suggested that liquid biopsy may better capture the heterogeneity of acquired resistance, but systematic, direct comparisons of post-progression",phs001853.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001853,"Ryan Corcoran MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,IBM,2020-02-21,DS-GICA-MDS,WXS,Longitudinal Cohort,Colorectal Neoplasms,15.0,44.0,,,Cholangiocarcinoma;Stomach Neoplasms;Esophageal Neoplasms,"Esophageal Neoplasms; Bile duct cancer; CC; CCA; Carcinoma, Cholangiocellular; Carcinomas, Cholangiocellular"
Genomic Profiling of Metastatic Uveal Melanoma,"Up to 50% of patients with uveal melanoma (UM) develop metastatic disease, for which there is no effective systemic treatment. This study aimed to evaluate the safety and efficacy of  the orally available protein kinase C inhibitor, AEB071, in patients with metastatic UM, and to perform genomic profiling of metastatic tumor",phs001953.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001953,Sophie Piperno-Neumann,Ian Fingerman,Division of Cancer Biology (DCB),,Novartis Pharmaceuticals Corporation,2020-02-14,DS-UM-GSO,WXS,Clinical Trial,Uveal Neoplasms,89.0,89.0,,ALK;APC;ATM;ATR;ATRX;BACH1;PRDM1;BRCA1;BRAF;BRCA2;RUNX1;RUNX1T1;CCND3;CD79B;CDH1;CDKN2A;CDKN2B;CDKN2C;CTNNB1;DAXX;DNMT3A;ERG;FANCE;FGFR3;GNA11;GNAQ;GRIN2A;HLA-A;IRF4;MRE11;MYC;NBN;NF1;NFKBIA;NOTCH4;NRAS;PIK3C2G;PPP2R1A;PRKAR1A;PRKDC;PTCH1;SMARCA4;TP53;WT1;KMT2D;BAP1;GNA13;SF3B1;LRP1B;PBRM1;PAK5;BCORL1;BRIP1;FAT3;RICTOR,Neoplasm Metastasis;Eye Neoplasms,"Eye Neoplasms; Neoplasm Metastasis; Cancer of Eye; Cancer of the Eye; Cancer, Eye; Cancers, Eye"
Count Me In: Angiosarcoma Project (CMI-ASCproject),Count Me In - The Angiosarcoma Project: A Patient-Partnered Research Initiative to Accelerate Research in a Rare Sarcoma The Angiosarcoma Project (ASCproject) is a research study that directly engages angiosarcoma  patients online and empowers them to accelerate cancer research by sharing medical information and clinical samples. Angiosarcoma is an exceedingly,phs001931.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001931,"Nikhil Wagle, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),32042194,Institutional Funding,2020-02-14,GRU,,Cohort,Sarcoma,36.0,84.0,http://ascproject.org/data-release,,Hemangiosarcoma;Neoplasms,Angiosarcoma; Angiosarcomas; Hemangioendothelial sarcoma; Hemangiosarcomas; Malignant hemangioendothelioma; angiosarcoma (disease)
Molecular Determinants of Tumor Behavior in Early Lung Adenocarcinoma,"Lung adenocarcinoma is the leading cause of cancer death worldwide and a heterogeneous disease with poor survival in the advanced stage. Given that the frequency of early diagnosis is increasing,  the investigation of the molecular determinants of disease progression is paramount. Prediction of whether the tumor is indolent or aggressive has",phs001811.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001811,"Pierre Massion, MD;Charles A. Powell, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),31747302,CA196405;CA163772,2020-02-12,DS-LC-NPU,Targeted-Capture,Cohort,Adenocarcinoma of Lung,102.0,102.0,,,Adenocarcinoma in Situ,"Adenocarcinoma in Situ; AIS; AIS - Adenocarcinoma in situ; Adenocarcinoma in Situs; Adenocarcinoma, Intraepithelial; Adenocarcinoma, Preinvasive"
"Genome, Exome, and Transcriptome Sequencing of Gastric Cancer","The integration of exogenous DNA into the human genome can cause somatic mutations associated with oncogenesis. For example, the insertion of HPV DNA into human chromosomes is the single most  important event leading to tumorigenesis in cervical cancer. It is also now preventable with vaccines against HPV. In contrast to viral DNA",phs001936.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001936,"Julie Dunning Hotopp, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,1R01CA206188-01,2020-01-30,DS-GICA-PUB-NPU-MDS,RNA-Seq;WXS;WGS,Case Set,Gastrointestinal Neoplasms,9.0,19.0,,,,"Cancer of Gastrointestinal Tract; Cancer of the Gastrointestinal Tract; Cancer, Gastrointestinal; Cancers, Gastrointestinal; Gastrointestinal Cancer; Gastrointestinal Cancers"
Endometrial Cancer Association Consortium - OncoArray Genotypes,The data come from 9 studies participating in the Endometrial Cancer Association Consortium (ECAC). ECAC data included in this dbGaP submission include OncoArray data from 4486 endometrial cancer cases genotyped  at the Center for Inherited Disease Research (CIDR). Samples were genotyped using the Illumina OncoArray beadchip 500K SNP custom array. Details of,phs001885.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001885,Thomas Sellers,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),30093612;27697780,U19-CA148112;HHSN268201200008I,2020-01-27,GRU-NPU;DS-BCEMOPCA-NPU-MDS;ENDTU-MDS;GRU,Array_SNP,Case Set,Endometrial Neoplasms,4486.0,4486.0,,,Neoplasms,Endometrial Tumor; Endometrial neoplasm; Endometrium Neoplasm; Endometrium Tumor; Neoplasm of Endometrium; Neoplasm of the Endometrium
MGH/Broad Hurthle Cell Carcinoma Whole Exome Sequencing Study,"In this study, we performed whole-exome sequencing of 41 patients with Hurthle cell carcinoma, a thyroid cancer variant with abundant mitochondria. We were able to identify recurrent somatic mutations in  both the nuclear and mitochondrial genomes of Hurthle cell carcinoma. Our study identifies mutations in DAXX (GeneID: 1616), TP53 ( GeneID:7157),",phs001580.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001580,"David McFadden, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,,2020-01-15,HMB-MDS,WXS,Cohort,"Thyroid cancer, Hurthle cell",41.0,111.0,,CDKN1A;DAXX;ARHGAP35;MT-ND1;MT-ND2;MT-ND4;MT-ND5;NF1;NRAS;TERT;TP53,"DNA, Mitochondrial;Neoplasm Metastasis","Neoplasm Metastasis; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize"
DNA Methylation Markers and Pancreatic Cancer Risk,"Pancreatic cancer is the 4th leading cause of cancer deaths in the US. Due to the lack of early symptoms, pancreatic cancer is difficult to identify at early stages and  no screening is available for the general population. Identifying pancreatic cancer at earlier stages could significantly improve survival with",phs001917.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001917,"Dominique S. Michaud, ScD;Karl T. Kelsey, MD, MOH",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,R01 CA207110,2020-01-08,HMB-PUB-MDS,Array_DNA_Methylation,Nested Case-Control,Pancreatic Neoplasms,824.0,824.0,,,"Carcinoma, Pancreatic Ductal","Carcinoma, Pancreatic Ductal; Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas"
DNA Methylation and Prostate Cancer,"The study cohort includes 525 Caucasian and African American prostate cancer (PCa) patients who underwent radical prostatectomy (RP) as primary therapy for clinically localized adenocarcinoma of the prostate. These patients  were previously enrolled in one of two population-based studies: 1) men 40-64 years of age, diagnosed between January 1993 and December 1996; and, 2)",phs001921.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001921,Janet L. Stanford,Ian Fingerman,Division of Cancer Biology (DCB),27358489;29956356;26902887;32226005,,2019-12-27,DS-PRD-PUB-NPU-MDS,Array_DNA_Methylation,Cohort,Prostatic Neoplasms,525.0,525.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
CPTAC: Microscaled Proteogenomic Methods for Precision Oncology,"Cancer proteogenomics combines genomics, transcriptomics and mass spectrometry-based proteomics to gain insights into cancer biology and treatment outcomes. To promote clinical investigation, we developed a ""microscaled"" proteogenomics approach for tumor-rich  frozen core needle biopsies. Tissue-sparing specimen processing (""Biopsy Trifecta EXTraction"", BioTExt) and microscaled proteomics (MiProt) generated",phs001907.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001907,Matthew J Ellis,Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),,U01 CA214125,2019-12-27,HMB-NPU,RNA-Seq;Seq_DNA_SNP_MAF_Ind;WXS,Cohort,Breast Neoplasms,14.0,58.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
"Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer, including    KRAS and Her2","Neoantigen-specific T cell responses were characterized in 4 patients with non-small cell lung cancer. Candidate neoantigens were identified by sequencing tumor and normal DNA from each patient, and ranking single  nucleotide variants by expression. Multiple T cell responses were isolated, and in two patients with lung adenocarcinoma, CD4+ T cell responses to",phs001805.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001805,"Stanley Riddell, MD",Ian Fingerman,Division of Cancer Biology (DCB),31043415,T32 T32CA009515;K12 CA076930-16A1;EU-FP7-PEOPLE-2012-IOF 331255,2019-12-26,GRU-NPU,RNA-Seq;WXS,Case Set,Adenocarcinoma of Lung,4.0,10.0,,ERBB2;KRAS,"Carcinoma, Squamous Cell","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma"
LCCC 1108 (UNCseqTM),"The primary objective of this specimen correlative study was two-fold: to provide a mechanism for the association of known molecular alterations with clinical outcomes, and to provide rapid genetic profiling  of alterations with known clinical utility using tumor and germline specimens to support treatment decisions. Inclusion Criteria: 1.Current or",phs001713.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001713,"H. Shelton Earp, MD",Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),26076459;26371432;29158372;27083775;24628946;25642706;24907369;30009279;30662871;30102605;29866652;32913973,"University Cancer Research Fund (UCRF), Chapel Hill, NC, USA;National Cancer Institute (NCI), Bethesda, MD, USA",2019-12-26,GRU,Targeted-Capture,Cohort,Neoplasms,2074.0,3558.0,,,"Sequence Analysis, DNA;Humans",Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
The Cancer Genome Atlas (TCGA),"The Cancer Genome Atlas (TCGA) is a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale  genome sequencing. TCGA is a joint effort of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), which are",phs000178.v11.p8,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000178,,,,18772890;17348159;21720365;29925955;32669708,,2019-12-18,GRU,Seq_DNA_SNP_MAF_Sum,Tumor vs. Matched-Normal,Neoplasms,11429.0,11467.0,http://cancergenome.nih.gov,,"Adenocarcinoma;Brain Neoplasms;Carcinoma, Endometrioid;Carcinoma, Hepatocellular;Carcinoma, Squamous Cell;Carcinoma, Thyroid;Carcinoma, Transitional Cell;Carcinoma, squamous cell of head and neck;Chronic Lymphocytic Leukemia;Clear Cell Renal Cell Carcinoma;Colonic Neoplasms;Cystadenocarcinoma, Serous;Esophageal Neoplasms;Glioblastoma;Glioma;Invasive Ductal Carcinoma, Breast;Leukemia, Myeloid, Acute;Lung Neoplasms;Adenocarcinoma of Lung;Lymphoma, Large B-Cell, Diffuse;Lymphoma, Non-Hodgkin;Melanoma;Pancreatic Neoplasms;Papillary Renal Cell Carcinoma;Prostatic Neoplasms;Rectal Neoplasms;Sarcoma;Skin Neoplasms;Squamous Cell Carcinoma;Stomach Neoplasms;Urinary Bladder Neoplasms;Uterine Cervical Neoplasms","Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Transitional Cell; Cystadenocarcinoma, Serous; Esophageal Neoplasms; Invasive Ductal Carcinoma, Breast"
Genome-Wide Analysis of Noncoding Regulatory Mutations in Cancer,"Large-scale sequencing of human tumor samples has transformed the identification of somatic genetic alterations that drive the cancer phenotype. However, most efforts have focused on the protein-coding exome, which comprises  less than 2% of the human genome. Here, we analyzed whole genome sequences from The Cancer Genome Atlas with a focus on recurrently mutated",phs000854.v3.p8,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000854,William Lee,,,25261935,,2019-12-18,GRU,Seq_DNA_SNP_MAF_Sum,Tumor vs. Matched-Normal,Neoplasms,356.0,356.0,http://cancergenome.nih.gov,SDHD;TERT;WDR74;PLEKHS1,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Altered topology drives oncogenic programs in SDH-deficient GIST,"Metabolic lesions with pleiotropic effects on epigenetic regulation and other cellular processes are widely implicated in cancer, yet their oncogenic mechanisms remain poorly understood. Succinate dehydrogenase (SDH) deficiency causes a  subset of gastrointestinal stromal tumors (GISTs) with DNA hyper-methylation. Here we associate this hyper-methylation with changes in chromosome",phs001906.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001906,"Bradley E. Bernstein, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),31666694,DP1 CA216873;Ludwig Center at Harvard,2019-12-17,DS-CA-MDS;HMB,RNA-Seq;ChIP-Seq;Bisulfite-Seq,Case Set,Gastrointestinal Stromal Tumors,22.0,84.0,,FGF3;FGF4;KIT,,GI stroma tumor; GI stroma tumour; GIST; GIST - Gastrointestinal stromal tumor; Gastrointestinal Stromal Neoplasm; Gastrointestinal Stromal Neoplasms
Genetics of Cutaneous T-Cell Lymphoma,"Mycosis fungoides (MF) is a common extranodal T-cell lymphoma primarily arising in the skin. In early disease stages, MF presents as skin patches and plaques that in some cases may  progress to tumor and disperse to lymph nodes and other internal organs. The 10-year overall survival is 50% in advanced stages. Early diagnosis is",phs001877.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001877,Robert Gniadecki,Ian Fingerman,Division of Cancer Biology (DCB),,CDF RES0035718;Unrestricted Research Grant;R124-A7592 Rp12350,2019-12-16,GRU-IRB,WXS,Case-Control;Longitudinal,Mycosis Fungoides,31.0,82.0,,,"Lymphoma, T-Cell, Cutaneous","Lymphoma, T-Cell, Cutaneous; Granulomatous Slack Skin; Slack Skin, Granulomatous"
AACR Project GENIE,AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) is an international pancancer registry of real-world data assembled through data sharing between 19 leading international cancer centers with the goal of  improving clinical decision-making. The registry leverages ongoing clinical sequencing efforts (CLIA/ISO-certified) at participating cancer centers,phs001337.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001337,,,,28572459;30652542,"American Association for Cancer Research, Philadelphia, PA, USA;Genentech, CA, USA;Boehringer-Ingelheim, Ingelheim am Rhein, Germany",2019-12-09,GRU-PUB,,Case Set,Neoplasms,46510.0,48447.0,http://www.cbioportal.org/genie/login.jsp;https://www.synapse.org/genie;www.aacr.org/Research/Research/Pages/aacr-project-genie.aspx,,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Human Pilocytic Astrocytoma Single Cell RNA Sequencing,"Pilocytic astrocytoma (PA), the most common childhood brain tumor, is a low-grade glioma with a single driver BRAF rearrangement. Here, we perform scRNAseq in six PAs using methods that enabled  detection of the rearrangement. When compared to higher-grade gliomas, a strikingly higher proportion of the PA cancer cells exhibit a",phs001854.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001854,"Rameen Beroukhim, MD, PhD;Pratiti Bandopadhayay, MBBS, PhD;Keith L. Ligon, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),31427603,R01 CA215489,2019-12-03,DS-NDR-MDS,RNA-Seq,Case Set,Astrocytoma,6.0,1234.0,,BRAF,,ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm; Astrocytoma (excluding glioblastoma); Astrocytomas
Non-coding RNAs Activated in Hepatoblastoma,"Hepatoblastoma (HB) is the most common pediatric liver tumor, affecting mostly children under 3 years of age. This rare tumor represents 1% of all pediatric cancers. Genetic studies have shown  that HB is characterized by high frequency mutations of the CTNNB1 gene encoding beta-catenin (around 75%) and relative genomic stability. Here we",phs001433.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001433,Marie Annick Buendia;Piero Carninci;Jamila Faivre,Ian Fingerman,Division of Cancer Biology (DCB),26510915,Modhep (259743),2019-11-27,HMB,RNA-Seq,Case-Control,Hepatoblastoma,21.0,42.0,http://www.modhep.eu/,,,
Enhancer Signatures of Neuroendocrine Tumors,"Most pancreatic neuroendocrine tumors (PNETs) do not produce symptoms of hormonal excess and are hence considered &#x0201c;non-functional&#x0201d;. Their clinical behaviors vary widely, emphasizing the need for a robust classification with  prognostic power. Using enhancer maps to infer regulatory programs, we find that the large majority of non-functional PNETs fall into two major",phs001910.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001910,"Bradley E. Bernstein, MD PhD;Ramesh A. Shivdasani, MD PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),31263286,P50CA127003;Neuroendocrine Tumor Research Foundation,2019-11-25,HMB;DS-PACA-MDS;DS-PACA-NPU-MDS,RNA-Seq;ChIP-Seq,Case Set,Neuroendocrine Tumors,46.0,62.0,,PDX1;ARX,Neuroendocrine tumors,
UW TAN Study of Metastatic Urothelial Carcinoma,"Patients with metastatic urothelial carcinoma treated at our institution, who elected to undergo rapid autopsy at the time of death, are included in this study. These patients agreed to submit  their tissue (normal samples for germline analysis [kidney or liver] as well as primary and metastatic tumor sites [urothelial carcinoma]) and the",phs001797.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001797,"Andrew Hsieh, MD",Ian Fingerman,Division of Cancer Biology (DCB),,Howard Cohen Bladder Cancer Foundation;Johns Hopkins Greenburg Bladder Cancer Institute,2019-11-21,HMB-PUB-MDS,WXS,Case Set,Urogenital Neoplasms,7.0,46.0,,,,Genito-urinary Neoplasm; Genito-urinary Neoplasms; Genitourinary Neoplasm; Genitourinary tract neoplasia; Genitourinary tract neoplasm; Genitourinary tract tumors
99 Cases of Small Cell Lung Cancer Study,"Small cell lung cancer (SCLC) is an aggressive disease with poor survival. A few sequencing studies performed on limited number of samples have revealed potential disease-driving genes in SCLC, however,  much still remains unknown, particularly in the Asian patient population. Here we conducted whole exome sequencing (WES) and transcriptomic",phs001083.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001083,"Dong Shen, MD PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,"Medimmune research fund, Gaithersburg, MD, USA",2019-11-21,GRU-PUB-MDS,WXS,Case Set,Small Cell Lung Carcinoma,99.0,99.0,,,,"Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL"
Molecular Epidemiology of Colorectal Cancer (MECC) Metastasis Study,"This study compared Ashkenazi Jewish individuals with Stage IV metastatic colon cancer to those with non-metastatic Stage I or II colon cancers. A genome-wide association study, using a 2-stage design,  identified a significant association with rs60745952. Inclusion Criteria Cases Diagnosis with a primary colorectal cancer Stage IV, Stage I, Stage II",phs001045.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001045,Stephen B. Gruber;Gad Rennert;Sanford D. Markowitz,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26751797,R01 CA144040 (S.D.M.);P50 CA150964 (S.D.M.);P30 CA043703;U19 CA148107 (S.B.G.);P30 CA014089 (S.B.G.);K07 CA129162 (N.L.N.);T32 ES013678 (S.L.S.);R01CA136726 (L.L);the Leonard and Joan Horvitz Foundation (S.D.M);the Richard Horvitz and Erica Hartman-Horvitz Foundation (S.D.M.);the Anton B. Burg Foundation at USC Norris;the Sharon Levine Corzine Research Fund;the Robert and Kate Niehaus Clinical Genetics Initiative at MSKCC,2019-11-21,DS-CC,Array_SNP,Case Set,Colorectal Neoplasms,323.0,323.0,,NR3C2,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Case Study of Acquired Resistance to FGFR Inhibition in    Cholangiocarcinoma,"Targeted sequencing was performed on blood, tumor, and cell free DNA samples from an FGFR2-fusion positive cholangiocarcinoma patient before and after treatment with an FGFR targeted therapy. Inclusion Criteria: 1.  A histologically or cytologically confirmed diagnosis of cancer 2. Patients with any malignancy 3. Patients must have tumor suitable for research",phs001924.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001924,Sameek Roychowdhury,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),31911531,American Cancer Society MRSG-12-194-01-TBG;Prostate Cancer Foundation;NHGRI UM1HG006508;NCI UH2CA202971;NCI UH2CA216432;American Lung Association;Pelotonia;NIH T32 5T32CA009338;NIH TL1TR002735;Pelotonia Undergraduate Research Fellowship;Alex&#39;s Lemonade Stand Young Investigator Award;Children&#39;s Cancer Research Fund Emerging Scientist Grant;NIH 2K12HD052892-11A1;Pelotonia Post-Doctoral Research Fellowship;American Society of Clinical Oncology Young Investigator Award,2019-11-15,DS-CA,Targeted-Capture,Case Set,Cholangiocarcinoma,1.0,8.0,,FGFR2;KIAA1598,"Receptor, Fibroblast Growth Factor, Type 2;Gene Fusion;Polymorphism, Single Nucleotide","Bile duct cancer; CC; CCA; Carcinoma, Cholangiocellular; Carcinomas, Cholangiocellular; Cholangiocar.- intra/extrahepatic"
Clonal Mapping of Multi-Organ Metastasis and Chemoresistance in Triple    Negative Breast cancer,Clonal dynamics during metastasis were studied in two patient-derived xenograft (PDX) models established from treatment-naive primary breast tumors from TNBC patients diagnosed with concurrent metastatic disease. Genomic sequencing and barcode-mediated  clonal tracking revealed robust alterations in clonal architecture between primary tumors and metastases. Polyclonal seeding and maintenance of,phs001742.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001742,"Helen Piwnica-Worms, PhD",Ian Fingerman,Division of Cancer Biology (DCB),30498242;30996079,,2019-11-15,GRU,RNA-Seq;WXS;Targeted-Capture,Case-Control;Longitudinal,Triple Negative Breast Neoplasms,4.0,113.0,,,Neoplasm Metastasis;Drug Therapy,"Neoplasm Metastasis; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize"
High-Risk Breast Cancer GWAS,"The GWAS includes High Risk Women from the following epidemiological studies of breast cancer, comprising a total of 3,719 cases and 3,642 controls (cases/controls: MEC, 0/200; ABCFR, 326/418; FCCC, 56/3;  BCFR-UT, 66/32; CNIO-BC, 87/92; GESBC, 65/0; LIFE, 164/0; MARIE, 41/105; MAYO, 208/210; MNYR, 293/409; MSKCC, 310/0; NC-BCFR, 234/233; OFBCR,",phs000929.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000929,Chris Haiman;John Hopper,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,"R01 CA165038;HHSN268201200008I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease"";HHSN26800080, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2019-11-13,DS-BROC-GSO;DS-BRD;DS-BRCA-PUB-MDS;HMB-PUB;DS-CA-MDS;DS-CA-GSO;GRU;DS-CA-PUB;DS-CA-IRB-PUB-COL-NPU-MDS-GSO;NRUP;DS-BRCA-MDS;CABNHD-MDS,Imputation_SNP_CNV;Array_SNP,Case-Control,Breast Neoplasms,7295.0,7369.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Genomic Analysis of Hepatocellular Carcinoma,"Fibrolamellar hepatocellular carcinoma (FL-HCC) is a very rare and distinct subtype of hepatocellular carcinoma that occurs in the previously healthy livers of adolescents and young adults. The low incidence rate  has kept FL-HCC an understudied cancer, thus the list of FL-HCC markers is limited and the genetic alterations driving its growth have remained",phs000828.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000828,"Julien Sage, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25122662,CA114102;UL1 RR025744,2019-11-13,DS-PLC-GSO,RNA-Seq;Seq_DNA_SNP;WXS;WGS,Case Set,Fibrolamellar hepatocellular carcinoma,1.0,5.0,,,"Carcinoma, Hepatocellular","Carcinoma, Hepatocellular; Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells"
Genomic Variation in Diffuse Large B Cell Lymphomas,"Integrative analysis of genetic lesions in 574 diffuse large B cell lymphomas (DLBCL). The study investigates genomic structural variation, genetic alteration and its effect on the development and biology of  lymphomas by using high throughput sequencing, gene expression, and methylation status. Clinically diagnosed as DLBCL Note: Controlled datasets at",phs001444.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001444,Louis M. Staudt,Kathleen Calzone,Center for Cancer Research (CCR),29641966;29925955,NCI Intramural Research,2019-11-08,GRU,,Case Set,"Lymphoma, Large B-Cell, Diffuse",489.0,1916.0,,KRAS,,Centroblastic diffuse large B-cell malignant lymphoma; Centroblastic diffuse malignant lymphoma; Centroblastic malignant lymphoma; DLBCL; DLBCL - diffuse large B cell lymphoma; Diffuse Histiocytic Lymphoma
Multiregion Sequencing of Localized Prostate Cancer,"Ten patients with treatment-na&#x000ef;ve, locally advanced or localized prostate cancer underwent radical prostatectomy. Pathological stage ranged from T2aN0 to T3bN1, and Gleason scores from 3+4 to 4+5. Tumor foci were  mapped, and DNA was extracted from multiple (5-9) regions from a single, contiguous index focus. Whole exome sequencing was performed to identify",phs001465.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001465,David VanderWeele,Kathleen Calzone,Center for Cancer Research (CCR),,W81XWH-13-1-0451,2019-11-04,DS-CA-IRB-NPU,WXS;Seq_DNA_SNP_MAF_Ind;WGS,Case Set,Prostatic Neoplasms,10.0,153.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
CORECT: Meta-analysis,"This study is part 2 of 2 for Schumacher et al, Nat Communication. 2015 Jul 7;6:7138. Part 2 is the pooled meta-analysis of 29 different studies of 37,955 European (18,299  Cases/19,656 Controls) participants using eight different genotyping platforms/variations. Study Name Participants Platform CFR-1 2976 Illumina 1M,",phs001499.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001499,Stephen B. Gruber,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26151821;26498495,"The authors wish to acknowledge the CORECT study which was supported by the National Cancer Institute, 			National Institute of Health under RFA #CA-09-002, NIH/NCI U19 CA148107, and NIH/NCI P30 CA014089",2019-10-25,,,Case-Control,Colorectal Neoplasms,,,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Pathways Study,"The Pathways Study (NCI R01 CA105274, PI: Kushi), is a prospective cohort study of a diverse population of recently diagnosed breast cancer survivors in KPNC. The aims are to examine  the effect on recurrence and survival of 1) lifestyle factors such as diet, physical activity, and use of complementary and alternative therapies and",phs001534.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001534,"Lawrence H. Kushi, ScD;Christine Ambrosone, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),18478338;19184414;19463150;20140494;20686660;20937633;20803066;21079093;21476003;21953007;22912069;23657404;23715629;24521998;24521995;24604094;24884705;25354083;25921910;25990554;26467773;27217451;27449493;27488523;27794123;27832250;27915435;28154107;28176174;28295245;28349440;28864455;29249058;18478338,"U01 CA195565;X01HG008335;HHSN268201200008I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2019-10-18,DS-BRCA-IRB-PUB-NPU-MDS;NRUP,Imputation_SNP;Array_SNP,Longitudinal,Breast Neoplasms,4429.0,4576.0,http://pathways.kaiser.org,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Mayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC)    Study,"Twenty five patients with early stage carcinoma (Stage I and II) of the ovary were consented for this study. As part of a collaborative agreement with Illumina Inc, Tumor-DNA and  patient matched normal DNA from blood underwent whole genome sequencing and microarray genotyping and RNA underwent RNASeq. Tissue also underwent IHC",phs000897.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000897,Ellen L. Goode,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),25916844,P50-CA136393;R01-CA122443;P30-CA15083;Fred C. and Katherine B. Andersen Foundation;Mayo Clinic Center for Individualized Medicine;Wallace and Evelyn Simmers&#39;s Career Development award;Jim and Marcia Guzy Career Development Award;Minnesota Cancer Alliance (MOCA);W81XWH-10-1-0386;National Cancer Institute,2019-10-18,GRU-MDS,RNA-Seq;WGS;Array_SNP,Case Set,"Cystadenocarcinoma, Serous",16.0,142.0,,BRCA1;BRCA2;POLE;PRIM2;RAD51C;RAD51D;TP53;CHEK2;CSMD3,Ovarian Neoplasms,"Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian"
Understanding RNA Biology and Therapeutics in Hematopoiesis and Leukemia,"Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and is expected to increase in frequency as the population ages. Most subtypes of AML are  difficult to treat, in part due to a lack of understanding of possible molecular targets. Furthermore, the peak incidence of AML is in the sixth",phs001847.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001847,Melissa Jane Fullwood,Ian Fingerman,Division of Cancer Biology (DCB),,"Singapore Ministry of Education AcRF Tier 3 grant;  			National Research Foundation, the Singapore Ministry of Education under its Centres of Excellence initiative",2019-10-17,GRU,WGS,Cohort,"Leukemia, Myeloid, Acute",2.0,4.0,,,RNA;DNA,AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL
Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis,"Chronic neutrophilic leukemia (CNL), atypical chronic myeloid leukemia (aCML), and unclassified myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN-U) are a group of rare, heterogeneous myeloid disorders. There is strong morphologic resemblance amongst these  distinct diagnostic entities as well as lack of specific molecular markers and limited understanding of disease pathogenesis, which has made their",phs001799.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001799,"Jeffrey W. Tyner, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2019-10-17,DS-LEU,,Cohort,Leukemia,176.0,238.0,http://www.vizome.org,,,Blood (Leukemia); Blood cancer; Leucocythaemia; Leucocythaemias; Leucocythemia; Leucocythemias
MAP Kinase-Mutant Hematologic Malignancies and Their Therapeutic    Resistance,"The Mitogen-Activated Protein Kinase (MAPK) signaling pathway has been critically important in understanding pathology and developing targeted therapy for many cancers, but high frequency mutations in this pathway in hematopoietic  malignancies were unknown until a series of sequencing studies from our group and others revealed a high frequency of activating mutations in BRAF",phs001864.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001864,"Omar Abdel-Wahab, MD",Ian Fingerman,Division of Cancer Biology (DCB),30867592;26566875;20519626;25202140;26287849;10606898;11756160;28854169;22153499;23478061;26235028;22902366;17292918;23076159;25801821;28801450;28566492;31028088;23153540;22237106,R01 CA201247-01,2019-10-08,DS-HIST-MDS,WXS,Cohort,Histiocytosis,22.0,22.0,,ALK;ARAF;BRAF;CSF1R;KRAS;NRAS;NTRK1;MAP2K1;MAP2K2;RAF1;RET,"Histiocytosis, Langerhans-Cell;Histiocytosis, Non-Langerhans-Cell;Erdheim-Chester Disease;Xanthogranuloma, Juvenile;Rosai-Dorfman Disease;Histiocytic Sarcoma;Dendritic Cell Sarcoma, Interdigitating;Twins, Monozygotic;Leukemia, Hairy Cell","Dendritic Cell Sarcoma, Interdigitating; Erdheim-Chester Disease; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Histiocytosis, Non-Langerhans-Cell; Leukemia, Hairy Cell"
Genomic Analysis of Bevacizumab-induced Hypertension,"Bevacizumab use in the treatment of cancer can lead to the development of hypertension in some patients, and high-grade toxicity can limit therapy or lead to cardiovascular complications. The factors  that contribute to interindividual variability in blood pressure rise during bevacizumab treatment are not well understood. In the present study,",phs001597.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001597,"Deanna L. Kroetz, PhD;Kouros Owzar, PhD;Alan P. Venook, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),28632865;28882537;29871907,U10CA180821;U10CA180882;T32GM007175;F31GM113350,2019-10-08,DS-CA-COL,Seq_DNA_SNP,Case-Control,Hypertension,62.0,62.0,,SLC29A1;HSP90AB1,,"Arterial hypertension; BP - High blood pressure; BP+ - Hypertension; Blood Pressure, High; Blood Pressures, High; HBP - High blood pressure"
Count Me In: Metastatic Breast Cancer Project (CMI-MBCproject),Count Me In - The Metastatic Breast Cancer Project: A Patient-Driven Research Initiative to Accelerate Metastatic Breast Cancer Research The Metastatic Breast Cancer Project (MBCproject; mbcproject.org) is a research study  that directly engages patients with metastatic breast cancer via social media and advocacy groups and empowers them to accelerate cancer research by,phs001709.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001709,"Nikhil Wagle, MD",,,,Institutional Funding,2019-10-04,GRU,RNA-Seq;WXS,Cohort,Breast Neoplasms,200.0,478.0,https://www.mbcproject.org/data-release,,Neoplasm Metastasis;Carcinoma,Neoplasm Metastasis; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors
Deep Sequencing of 3 Cancer Cell Lines on 2 Sequencing Platforms,"To test the performance of a new sequencing platform, develop an updated somatic calling pipeline and establish a reference for future benchmarking experiments, we performed whole-genome sequencing of 3 common  cancer cell lines (COLO-829, HCC-1143 and HCC-1187) along with their matched normal cell lines to great sequencing depths (up to 278X coverage) on",phs001839.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001839,"Nicolas Robine, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,Internal,2019-09-27,GRU,WGS,Case Set,Neoplasms,3.0,12.0,https://www.nygenome.org/bioinformatics/3-cancer-cell-lines-on-2-sequencers/,,"Melanoma;Breast Neoplasms;Cell Line, Tumor",Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Discovering the Genetic Basis of Human Neuroblastoma: A Gabriella Miller    Kids First Pediatric Research Program (Kids First) Project,"Children with disseminated neuroblastoma have a very high risk of treatment failure and death despite receiving intensified chemotherapy, radiation therapy and immunotherapy. The long-term goal of our research program is  to ultimately improve neuroblastoma cure rates by first comprehensively defining the genetic basis of the disease. The central hypothesis to be",phs001436.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001436,John M. Maris,,,31474320,GMKF X01: HL136997-01,2019-09-25,GRU,,Dyads;Parent-Offspring Trios;Tumor vs. Matched-Normal,Neuroblastoma,1694.0,2281.0,,ALK;BARD1;MYCN;TP53;PHOX2B,,Not Provided
African American Multiple Myeloma GWAS,"The case set is from a case-control study designed to identify common genetic risk factors for multiple myeloma in African Americans, the population with the highest risk for this cancer.  We conducted two GWAS and combined each of these with convenience controls consisting of unaffected African American participants in cohorts with",phs001632.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001632,"Wendy Cozen, DO, MPH;Christopher A. Haiman, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),27587788,5R01CA134786,2019-09-06,DS-CA;GRU-NPU;HMB-PUB;HMB-IRB-NPU;GRU;DS-CA-PUB;DS-MM-MDS;DS-CA-IRB-GSO;GRU-PUB-NPU,Array_SNP,Case Set,Multiple Myeloma,1408.0,1408.0,,,Smoldering Multiple Myeloma,"Smoldering Multiple Myeloma; Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma"
West Africa Breast Cancer Study (WABCS),Differences in breast cancer incidence and mortality rates between North American Caucasian and African American women are well-described and transcend socioeconomic issues. Black women are diagnosed with breast cancer at  a younger median age; have more clinically aggressive disease and stage-for-stage; and have higher mortality rates than age-matched Caucasian women.,phs001687.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001687,"Olufunmilayo I. Olopade, MD, FACP;Kevin P. White, PhD;Dezheng Huo, MD, PhD;Jordi Barretina, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,U01-CA161032;SAC110026;Breast Cancer Research Foundation;Novartis Institutes for BioMedical Research,2019-08-29,GRU-PUB,,Case-Control,Breast Neoplasms,294.0,722.0,,,African Continental Ancestry Group;Nigeria,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
NCI-Epidemiology of Burkitt Lymphoma in East African Children and Minors    (EMBLEM),"A genome-wide analysis of genetic structure, gene flow, and natural selection was conducted in populations in the endemic Burkitt lymphoma (eBL) belt in Ghana and Northern Uganda, both subject to  a high incidence of falciparum malaria and eBL. These populations have different ethnolinguistic ancestries and are located 2400 miles apart in",phs001705.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001705,"Sam M. Mbulaiteye, MD",,,28320389;29925378;29033373;22885699;18767045,"Intramural Research Program, DCEG, NCI: HHSN261201100063C;Intramural Research Program, DCEG, NCI: HHSN261201100007I",2019-08-15,GRU-IRB,Array_SNP,Case-Control,Burkitt Lymphoma,568.0,568.0,https://www.emblem.cancer.gov/,ALDH1A1;ATP2B4;CDK6;EIF2S1;ESRRB;FYN;HCK;HDAC2;ROCK1;SATB1;STIM1;TLR5;TOP2B;TRH;TRPV1;CCR9;RIMS1;GPR160;USP46,Malaria,Malaria; BL; BL - Burkitt's lymphoma; Burkitt Tumor; Burkitt lymphoma/leukemia; Burkitt's Lymphoma
Proteogenomic Landscape of Squamous Cell Lung Cancer,"To provide a detailed analysis on how genomic and transcriptomic alterations related to proteome level changes in squamous cell lung cancer (SCC), we performed an integrated analysis incorporating DNA copy  number, somatic mutations, expression RNA-sequencing, and expression proteomics in 108 SCC nested within clinical outcome, tumor pathology, and other",phs001781.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001781,"Eric Haura, MD",Freddie Pruitt,Center for Cancer Genomics (CCG),31395880,P30-CA076292,2019-08-14,HMB-MDS,RNA-Seq;Targeted-Capture,Cohort,"Carcinoma, Non-Small-Cell Lung",108.0,108.0,,,,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER"
GWAS for Breast Cancer Chemotherapy Toxicities in S0221,"When undergoing treatment for breast cancer, many women experience severe side effects, some of which result in treatment-related death and some that can persist for years. Little is understood regarding  factors that may predict drug toxicities. Pharmacogenetics, the investigation of variants in candidate genes in drug metabolism pathways, has been",phs001428.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001428,"Christine Ambrosone, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,R01CA139426,2019-08-13,DS-BRCATOX-COL-MDS-GSO,Array_SNP,Clinical Trial;Cohort,Peripheral Nervous System Diseases,1847.0,1847.0,,,Breast Neoplasms,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Genetic Epidemiology of CLL,"Chronic lymphocytic leukemia (CLL) is a subtype of B-cell lymphoproliferative disorders (LPD), and is the most common form of adult leukemia in Caucasians in the United States. Small lymphocytic lymphoma  (SLL) is also a B-cell LPD and is typically considered to be the same disease as CLL, based on pathology. We consider CLL and SLL as the same disease",phs001568.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001568,"Nicola J Camp, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26956414;27008888;28165464;23770605;23025533,R01CA134674,2019-08-12,DS-HM-GSO,Array_SNP,Case-Control,"Leukemia, Lymphoid",715.0,715.0,,,"Lymphoma, Non-Hodgkin","Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic; Leukemias, Lymphocytic; Leukemias, Lymphoid; Lymphatic leukemia; Lymphocytic Leukemia"
Genome and Transcriptome Analysis of Lung Cancer Cell Lines,"We have used a ""chemistry first"" approach to discover druggable acquired vulnerabilities that arised in the pathogenesis of non-small cell lung cancer (NSCLC). We screened chemical libraries ( 200,000 compounds)  for chemical toxins that killed subsets of NSCLC but not normal human lung epithelial cells (HBECs). We first screened a panel of 12 NSCLC lines that",phs001823.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001823,"John D. Minna, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),29681454,P50 CA70907;U01 CA176284;T32GM8203,2019-08-09,DS-LC-IRB,RNA-Seq;Seq_DNA_SNP_MAF_Ind;Seq_RNA_Expression;WXS,Cohort,"Carcinoma, Non-Small-Cell Lung",279.0,813.0,,,Small Cell Lung Carcinoma,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER"
NCI Waldenstrom Macroglobulinemia Genome-Wide Association Study,"A discovery GWAS is performed, consisting of genotyping 221 Waldenstrom macroglobulinemia (WM) cases on the Illumina Omni Express 12v1.1 platform and analyzing the genotypes together with those of 3798 previously  genotyped controls in a model taking into account gender, age, and principal components of ancestry (i.e., significant eigenvectors). Directly",phs001284.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001284,"Neil E Caporaso, MD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),30305637,Intramural Research Program,2019-08-09,DS-CA-MDS;GRU,Imputation_SNP;Array_SNP,Case-Control,Waldenstrom Macroglobulinemia,217.0,217.0,,EXOC2,Lymphoplasmacytoid Lymphoma,"Lymphoplasmacytoid Lymphoma; Lymphoma, Lymphocytic, Plasmacytoid; Lymphoma, Lymphoplasmacytoid; Lymphomas, Lymphoplasmacytoid; Lymphoplasmacytoid Lymphomas; Macroglobulinaemia, Waldenstrom's"
Tumor Heterogeneity and Drug Resistance in FGFR2-Fusion    Cholangiocarcinoma,Whole exome sequencing was performed on blood and tumor specimens (collected from biopsy or rapid research autopsy) from a patient with FGFR2 fusion positive cholangiocarcinoma. Inclusion Criteria: 1) A histologically  or cytologically confirmed diagnosis of cancer 2) Patients with any malignancy 3) Patients must have tumor suitable for research tumor biopsy (as,phs001830.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001830,"Sameek Roychowdhury, MD, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),31371345,American Cancer Society MRSG-12-194-01-TBG;Prostate Cancer Foundation;NIH NCI UH2CA202971;NIH NCI UH2CA216432;American Lung Association;Pelotonia;NIH T32 5T32CA009338;NIH TL1TR002735;NIH T32 T32GM068412;Pelotonia Graduate Fellowship;Pelotonia Post-Doctoral Fellowship;ASCO Conquer Cancer Foundation Young Investigator Award;Helene Fuld Health Trust Nursing Scholarship,2019-08-06,DS-CA,WXS;Seq_DNA_CNV,Case Set,Cholangiocarcinoma,1.0,12.0,,FGFR2;CLIP1,"Receptor, Fibroblast Growth Factor, Type 2;Gene Fusion;Clonal Evolution","Clonal Evolution; Bile duct cancer; CC; CCA; Carcinoma, Cholangiocellular; Carcinomas, Cholangiocellular"
T Cell States Associated with Response to Checkpoint Blockade in Melanoma,"Checkpoint blockade therapy using antibodies targeting CTLA4, PD1 or PDL1 have changed the way cancer patients with advanced disease are being treated, as evident by their FDA approval in a  wide variety of malignancies, and their ability to induce high response rates when compared to conventional therapies (e.g. chemotherapy). However,",phs001680.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001680,"Nir Hacohen, PhD",Ian Fingerman,Division of Cancer Biology (DCB),27192570;27501248;26167163;28397821;26997480;26027431;28514453;24056875;25891173;29070816;27533016;17950003;20727791;29066514;27301722;28487385;26359337,NCI,2019-07-23,DS-MSC-MDS;DS-CA-IRB-PUB,RNA-Seq;WXS;ATAC-seq,Cohort,Immunotherapy,32.0,98.0,,TCF7,Melanoma;T-Lymphocytes,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma; Melanoma, Malignant"
Single-Cell Analysis of Human Pancreatic Ductal Adenocarcinoma,"Cancer-associated fibroblasts (CAFs) are major players in the progression and drug resistance of pancreatic ductal adenocarcinoma (PDAC). CAFs constitute a diverse cell population consisting of several recently described subtypes, although  the extent of CAF heterogeneity has remained undefined. Here we employ single-cell RNA-sequencing to thoroughly characterize the neoplastic and tumor",phs001840.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001840,"David Tuveson, MD, PhD;Paul Robson, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,The Lustgarten Foundation;P30CA045508;R01CA190092;U01CA224013;P30CA034196,2019-07-17,GRU,RNA-Seq;Seq_RNA_Expression,Cohort,"Carcinoma, Pancreatic Ductal",6.0,9.0,,,Cancer-Associated Fibroblasts;Tumor Microenvironment,"Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas; Duct Cell Carcinoma, Pancreas"
Functional Genomics and Molecular Imaging of Liver Disease and Cancer,"Molecular imaging with 18F-fluorocholine PET/CT reveals two distinct imaging phenotypes for hepatocellular carcinoma (HCC) as a potential source of non-invasive insight into its molecular heterogeneity. Using gene set enrichment analyses,  we found 18F-fluorocholine-avid tumors to be significantly enriched by genes comprising a subset of previously published HCC-related gene signatures.",phs001784.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001784,"Sandi Kwee, MD, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),30760520;27787742;27928466;29315063;29376136,R01CA161209-6,2019-07-15,DS-LCCLD-COL,Array_mRNA_Expression,Control Set,"Carcinoma, Hepatocellular",41.0,41.0,,,,"Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells"
NCI LTG Human Pancreas QTL Study,We created a human histologically normal pancreas eQTL resource using 91 fresh frozen tissue samples from patients diagnosed with pancreatic cancer (Mayo Clinic and Memorial Sloan Kettering Cancer Center) or  from organ donors without a history of pancreatic cancer (Penn State University) by RNA-Sequencing. Genome wide genotyping was done using blood,phs001776.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001776,"Laufey Amundadottir, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),"28634199;31917448;No PMID: Abstract 1591: Large-scale transcriptome-wide association study (TWAS) identifies novel candidate 			susceptibility genes for pancreatic cancer | Jun Zhong, Ashley Jermusyk, Lang Wu, Jason W. Hoskins, Irene Collins, Mingfeng Zhang, Song Lei, 			Charles C. Chung, Tongwu Zhang, Wenming Xiao, Rachael Stolzenberg-Solomon, Alison P. Klein, Brian M. 			Wolpin, Xiao-Ou Shu, Stephen J. Chanock, Sara Olson, Nilanjan Chatterjee, Jill Smith, Jianxin Shi, 			Peter Kraft, Gloria M. Petersen, Wei Zheng and Laufey T. Amundadottir","National Cancer Institute Intramural Research Program, National Institutes of Health, Bethesda, MD, USA",2019-07-12,DS-PACA-IRB-MDS;GRU-IRB-PUB-NPU,RNA-Seq;Array_SNP,Genotype/Expression,Pancreas,91.0,182.0,,,,Not Provided
Whole Genome Sequencing of Waldenstrom's Macroglobulinemia,Whole genome sequencing was conducted on 10 tumor/germline paired samples along with 20 additional unpaired tumor samples from patients with Waldesntrom's macroglobulinemia. Tumor lymphoplasmacytic lymphoma cells were obtained from CD19+  selected bone marrow mononuclear cells. Germline tissue was obtained from CD19 depleted peripheral blood mononuclear cells. High molecular weight DNA,phs000740.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000740,"Steven Treon, MD, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),24366360;22931316,Peter Bing;Foundation Grant,2019-07-11,GRU-MDS,WGS,Case-Control,Waldenstrom Macroglobulinemia,30.0,40.0,,,,"Lymphoma, Lymphocytic, Plasmacytoid; Lymphoma, Lymphoplasmacytoid; Lymphomas, Lymphoplasmacytoid; Lymphoplasmacytoid Lymphoma; Lymphoplasmacytoid Lymphomas; Macroglobulinaemia, Waldenstrom's"
RNASeq of Plasmacytoid Dendritic Cells in Head and Neck Squamous Cell    Cancer,"Plasmacytoid dendritic cells (pDC) are a subset of dendritic cells with unique immunophenotypic properties and functions. While their role in antiviral immunity through production of type I interferons is well-established,  their contributions to anti-tumor immunity are less clear. While some evidence demonstrates that pDC in the tumor microenvironment (TME) may drive",phs001824.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001824,"Bin Zhang, MD, PhD;Kate O. Poropatich, MD, MHS",Ian Fingerman,Division of Cancer Biology (DCB),,United-4 A Cure Award,2019-06-28,GRU,RNA-Seq,Longitudinal Cohort,Dendritic Cells,7.0,19.0,,,Squamous Cell Carcinoma of Head and Neck,Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx
Pancreas Cancer Organoid Profiling,"We generated a collection of patient-derived pancreatic normal and cancer organoids. We performed whole genome sequencing, targeted exome sequencing, and RNA sequencing on organoids as well as matched tumor and  normal tissue if available. This dataset is a valuable resource for pancreas cancer researchers, and those looking to compare primary tissue to",phs001611.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001611,"David Tuveson, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),29853643,Lustgarten Foundation,2019-06-21,GRU,,Cohort,Neoplasms,71.0,188.0,,,"Carcinoma, Pancreatic Ductal","Carcinoma, Pancreatic Ductal; Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas"
Kids First: Genomics of Orofacial Cleft Birth Defects in Latin American    Families,"The Kids First study of nonsyndromic orofacial cleft (OFC) birth defects in Latin American families is a whole genome sequencing study of 283 Latin-American parent-case trios drawn from ongoing collaborations  led by Dr. Mary L. Marazita of the University of Pittsburgh Center for Craniofacial and Dental Genetics, and including a collaboration with Dr. Lina",phs001420.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001420,"Mary L. Marazita, PhD;Eleanor Feingold, PhD",,,27033726;27018472;22703175;22750566;14981713,X01-HL136465;R01-DE016148;R01-DE015667;U24-HD090743,2019-06-14,DS-OBDR-RD,,Parent-Offspring Trios,Cleft Lip,828.0,828.0,https://www.commonfund.nih.gov/KidsFirst,,Cleft Palate,Cleft Palate; CL - Cleft lip; Cheiloschisis; Cheiloschisis of upper lip; Cleft Lips; Cleft of upper lip
Rapid Autopsy in Thoracic Malignancy Cancer Patients to Investigate Tumor    Heterogeneity,"Integrated proteo-genomics studies to characterize tumor heterogeneity of metastatic lung adenocarcinoma and thymic carcinoma are lacking. We carried out whole exome sequencing, RNA sequencing, copy number estimation and mass spectrometry-based  proteomics of 40 tumors from five rapid/warm autopsy patients. We found highly variable mutational heterogeneity that was largely driven by",phs001432.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001432,"Udayan Guha, MD, PhD",Kathleen Calzone,Center for Cancer Research (CCR),30840888,Intramural Research Program ZIA BC 011259 (U.G),2019-05-28,HMB-PUB,RNA-Seq;Seq_RNA_Expression;WXS;Seq_DNA_SNP_CNV,Case Set,Adenocarcinoma of Lung,6.0,86.0,,EGFR;HRAS;KRAS;TP53;APOBEC3B;CD274;APOBEC3A_B,Adenocarcinoma of Lung;Thymoma;Mesothelioma,"Mesothelioma; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung"
Acral Melanoma Targeted Sequencing Study (UCSF),"Acral melanoma affects world populations irrespective of skin color. It has comparatively few single nucleotide mutations, but exhibits genomic instability characterized by structural rearrangements and amplifications. As acral melanoma harbors  BRAF (GeneID:673) mutations at low frequencies, we searched for alternative therapeutic targets. We performed targeted deep sequencing of",phs001596.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001596,Boris C. Bastian,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),30657954,R35 CA220481,2019-05-22,DS-M-NPU,Targeted-Capture,Case Set,Melanoma,37.0,37.0,,ALK;BRAF;EP300;NF1;NTRK3;PRKCA;SPRED1,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Next Generation Sequencing of Diffuse Intrinsic Pontine Glioma Samples,"Diffuse intrinsic pontine glioma (DIPG) is an extremely rare ( 350 cases/year) and universally fatal childhood brain cancer. Standard clinical strategies such as chemotherapy and radiotherapy show only transient improvement  in patient condition and result in negligible change in survival, DIPG remains at below 1% survival after 5 years. Prioritization of panobinostat",phs001526.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001526,"Charles Keller, MD",,,29621254,Lyla Nsouli Foundation grant;With Purpose Foundation grant,2019-05-06,GRU-COL-NPU;GRU-COL;GRU,RNA-Seq;Seq_RNA_Expression;WXS,Sequencing;Cohort,Glioma,14.0,52.0,http://www.cc-tdi.org/,IL4;IL4R;IL13;IL13RA1;IL13RA2,,Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia
DRIVE Breast Cancer Whole Genome Sequencing,"This study consists of whole genome sequencing (target: average 30x coverage) of 110 European-ancestry (EA), early-onset, family-history-positive breast cancer cases, 21 Asian cases, 25 African-American cases, and 24 controls from  six studies participating in the Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) consortium, part of the NCI's Genetic",phs001483.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001483,David J. Hunter,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,U19CA148065,2019-05-01,DS-BRD;HMB-PUB;GRU;DS-CA-PUB;DS-COBC-NPU-MDS;HMB-PUB-NPU;DS-BRD-MDS,Seq_DNA_SNP_CNV;WGS,Case Set,Breast Neoplasms,180.0,180.0,http://gameon.dfci.harvard.edu,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Castration    Resistant and Neuroendocrine Prostate Cancer,"Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may develop de novo or as a mechanism of treatment resistance. N-myc is capable of driving NEPC progression.  Alisertib inhibits the interaction between N-myc and its stabilizing factor Aurora-A, inhibiting N-myc signaling, and suppressing tumor growth. In",phs001666.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001666,Himisha Beltran,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2019-04-25,HMB-PUB,RNA-Seq;WXS,Case Set,Adenocarcinoma,49.0,64.0,,,Prostatic Neoplasms;Neuroendocrine tumors,"Neuroendocrine Tumors; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant; Malignant Adenoma"
Kids First: Genomic Studies of Orofacial Cleft Birth Defects,The Gabriella Miller Kids First Pediatric Research Program (Kids First) is a trans-NIH effort initiated in response to the 2014 Gabriella Miller Kids First Research Act and supported by the  NIH Common Fund. This program focuses on gene discovery in pediatric cancers and structural birth defects and the development of the Gabriella Miller,phs001168.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001168,"Mary L. Marazita, PhD;Eleanor Feingold, PhD",,,27033726;27018472;22703175,X01-HL132363;R01-DE016148;R01-DE014581;R01-DD000295,2019-04-05,HMB-MDS;GRU;DS-OBDR-MDS;DS-OBD-MDS;DS-OC-PUB-MDS,WGS,Parent-Offspring Trios,Cleft Lip,1378.0,1311.0,https://www.commonfund.nih.gov/KidsFirst,,Cleft Palate,Cleft Palate; CL - Cleft lip; Cheiloschisis; Cheiloschisis of upper lip; Cleft Lips; Cleft of upper lip
Clinical Crenolanib Resistance in AML,"FLT3 mutations are commonly detected in Acute Myeloid Leukemia (AML) patients and are associated with poor prognosis. Crenolanib, a potent type I pan-FLT3 (GeneID:2322) inhibitor, is effective against both internal  tandem duplications (ITD) and resistance-conferring tyrosine kinase domain (TKD) mutations. While crenolanib monotherapy has demonstrated significant",phs001628.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001628,"Jeffrey W. Tyner, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,"The Leukemia &#38; Lymphoma Society, Beat AML;NIH/NCI, 1U54CA224019;NIH/NCI, 1U01CA217862;NIH/NCI, 3P30CA069533-18S5",2019-03-29,DS-LEU,,Longitudinal;Cohort,"Leukemia, Myeloid, Acute",56.0,119.0,http://www.vizome.org/,FLT3;IDH1;IDH2;NRAS;TET2,,AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL
Uncovering the Genetic Architecture of Colorectal Cancer with Focus of    Rare and Less Frequent Variants,The Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) is a collaborative effort comprised of a coordinating center and scientific researchers from well-characterized cohort and case-control studies conducted in North  America and Europe. This international consortium aims to accelerate the discovery of common and rare genetic risk variants for colorectal cancer by,phs001415.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001415,"Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),30510241,"X01 HG008596;U01 CA164930;HHSN268201200008I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2019-03-27,DS-BOCA;GRU-GSO;HMB-IRB;DS-CA-IRB;RCV-CRC-MDS;HMB-IRB-NPU;HMB-PUB;HMB-COL-GSO;GRU;DS-CEC-IRB;NRUP;HMB;HMB-PUB-NPU-GSO;CADM,Imputation_SNP;Array_SNP,Case-Control;Cohort;Nested Case-Control,Colorectal Neoplasms,29778.0,30487.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Multiple Myeloma CoMMpass Study,"The Multiple Myeloma Research Foundation (MMRF) CoMMpass (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) trial (NCT01454297) is a longitudinal observation study of 1000 newly diagnosed myeloma  patients receiving various standard approved treatments that aim at collecting tissue samples, genetic information, Quality of Life (QoL) and various",phs000748.v7.p4,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000748,"Sagar Lonial, MD;Fiona An, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),"No PMID: Interim Analysis Of The MMRF CoMMpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles | Keats JJ, Craig DW, Liang W, Venkata Y, Kurdoglu A, Aldrich J, Auclair D, Allen K, Harrison B, Jewell S, Kidd PG, Correll M, Jagannath S, Siegel DS, Vij R, Orloff G, Zimmerman TM, MMRF CoMMpass Network, Capone W, Carpten J, Lonial S.","Multiple Myeloma Research Foundation (MMRF), Norwalk, CT, USA",2019-03-20,DS-MCRD-MDS;GRU-MDS,RNA-Seq;WXS;WGS,Longitudinal,Multiple Myeloma,1014.0,5118.0,http://www.themmrf.org/research-programs/commpass-study/,,"Neoplasms, Plasma Cell","Neoplasms, Plasma Cell; Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma"
Mucosal Melanoma Targeted Sequencing Study (UCSF),"Mucosal melanoma is a deadly disease that carries the worst prognosis amongst subtypes of melanoma. Like all melanomas, mucosal melanomas are frequently driven by activating mutations in the MAPK and/or  PI3K pathways; however, unlike melanomas that arise on sun-exposed skin, mucosal melanomas harbor few point mutations. Instead, most somatic",phs001594.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001594,Boris C. Bastian,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),30385465,R35 CA220481,2019-03-19,DS-M-NPU,Targeted-Capture,Case Set,Melanoma,38.0,43.0,,BRAF;KIT;NF1;NF2;NRAS;SF3B1;SPRED1,Mucous Membrane,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
UCLA/Gabriella Miller Kids First Disorders of Sex Development Study,The Gabriella Miller Kids First Pediatric Research Program (Kids First) is a trans-NIH effort initiated in response to the 2014 Gabriella Miller Kids First Research Act and supported by the  NIH Common Fund. This program focuses on gene discovery in pediatric cancers and structural birth defects and the development of the Gabriella Miller,phs001178.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001178,"Eric VILAIN, MD, PhD",,,1717;25970709;20301589,X01HL132384,2019-03-19,GRU,Seq_DNA_SNP_CNV;WGS,Parent-Offspring Trios,Disorders of Sex Development,300.0,300.0,https://commonfund.nih.gov/kidsfirst/X01Projects#Vilain,NR0B1;AMH;AMHR2;AR;ATRX;BBS1;BBS2;BBS4;FOXL2;AKR1C4;CYP11A1;CYP17A1;CYP19A1;CYP21A2;AKR1C2;DHCR7;DMRT1;EMX2;FGF8;FGFR1;FGFR2;NR5A1;GATA4;GNRH1;GNRHR;HFE;HSD3B2;HSD17B3;ANOS1;LEP;LEPR;LHCGR;MAP3K1;PCSK1;POR;PROP1;SOX3;SOX9;SRD5A2;SRY;STAR;VAMP7;TAC3;TACR3;WT1;LHX3;MKKS;HESX1;MAMLD1;DMRT2;TRIM32;ZFPM2;BBS9;DHH;WWOX;WNT4;BBS7;CHD7;HHAT;PROK2;BBS10;ARL6;KISS1R;CBX2;TTC8;PROKR2;BBS5;BBS12;ARX;RSPO1,"Disorders of sex development;46, XY Disorders of Sex Development;Sex Chromosome Disorders of Sex Development;Ovotesticular Disorders of Sex Development;46, XX Testicular Disorders of Sex Development;Hypospadias;Cloaca;Gonadal Dysgenesis;Urogenital Abnormalities;Mullerian aplasia;Omphalocele exstrophy imperforate anus;Sexual Development","46, XX Testicular Disorders of Sex Development; 46, XY Disorders of Sex Development; Hypospadias; Mullerian aplasia; Omphalocele exstrophy imperforate anus; Ovotesticular Disorders of Sex Development"
Breast Cancer Family Registry Early-onset Breast Cancer GWAS,"In order to enhance our understanding of the genetic etiology of breast cancer, this study analyzed 1,265,548 Hapmap3 single-nucleotide polymorphisms (SNP) among a discovery set of 3,523 EOBC incident cases  and 2,702 age-matched population control women, all of whom were age 50 or younger at enrollment. Subjects were recruited from the eight sites, some",phs001589.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001589,Habibul Ahsan,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),28503721,"R01CA122171, RC1CA145506, U01CA122171, RC1CA145506, R01CA094069, UM1CA164920, RFA-CA-95-011, UO1CA66572, U19CA148065, R25-CA057699 2T32, and       CA057699-26",2019-03-07,,,Case-Control,Breast Neoplasms,,,http://www.bcfamilyregistry.org/,BRCA1;BRCA2,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
DAXX Suppression of ALT,"Many tumors maintain chromosome ends through a telomerase-independent, homologous recombination based mechanism called alternative lengthening of telomeres (ALT). While ALT occurs in only a subset of tumors, it is strongly  associated with mutations in the genes encoding components of the histone H3.3 chaperone complex, ATRX and DAXX. To date the mechanistic role of ATRX",phs001495.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001495,Paul Metzer,Kathleen Calzone,Center for Cancer Research (CCR),,,2019-03-06,GRU,RNA-Seq;OTHER,Case Set,Osteosarcoma,5.0,14.0,,ATRX;DAXX;KIFC3,,Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma
Genomic Characterization of Parathyroid Cancer,"Here we performed genomic characterization of twenty-nine sporadic parathyroid cancers using next generation whole exome sequencing. Thirty-three novel candidate driver genes for sporadic parathyroid cancer were proposed, in addition to  previously known driver genes CDC73 and MEN1. All patients undergoing surgical resection for sporadic parathyroid cancer at a tertiary cancer center",phs001765.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001765,"Nancy Dugal Perrier, MD, FACS",Mariam Eljanne,Center for Cancer Training (CCT),30788456,T32CA009599-24,2019-02-27,GRU,WXS,Cohort,Parathyroid Neoplasms,41.0,41.0,,MEN1;TP53;CDC73,,"Neoplasm of Parathyroid; Neoplasm of Parathyroid Gland; Neoplasm of the Parathyroid; Neoplasm of the Parathyroid Gland; Neoplasm, Parathyroid; Neoplasms, Parathyroid"
Lung Cancer Pharmacogenomics (LUPG),"Lung cancer is frequently treated with paclitaxel in combination with several other agents; however, paclitaxel treatment is often ineffective or limited by treatment-related toxicities. Heritable variants in genes associated with  absorption, distribution, metabolism, and elimination may predict paclitaxel clinical outcome and toxicity. We designed a prospective",phs001660.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001660,"Giuseppe Giaccone, MD, PhD;Gideon M. Blumenthal, MD",Kathleen Calzone,Center for Cancer Research (CCR),30817750,Intramural Research Program of the National Cancer Institute,2019-02-22,GRU-IRB;HMB-IRB;DS-CA-IRB,Array_SNP,Case Set,Paclitaxel,103.0,103.0,https://clinicaltrials.gov/ct2/show/NCT00923884,,Progression-Free Survival;Lung Neoplasms,Lung Neoplasms; Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung
Genomic Landscape of Cutaneous Diffuse Large B Cell Lymphoma,"Cutaneous diffuse large B cell lymphomas (DLBCL) are aggressive lymphomas with a poor prognosis. To elucidate their genetic bases, we performed whole exome capture and massively parallel sequencing on 19  tumor samples of diffuse large B cell lymphoma, leg type (DLBCL-LT) and 6 samples of secondary cutaneous diffuse large B cell lymphoma, not otherwise",phs001645.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001645,"Jaehyuk Choi, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),29857068,,2019-02-19,HMB-NPU,WXS,Case Set,"Lymphoma, Large B-Cell, Diffuse",25.0,25.0,,MYD88;CD274;PDCD1LG2,"Lymphoma, B-Cell","Lymphoma, B-Cell; Centroblastic diffuse large B-cell malignant lymphoma; Centroblastic diffuse malignant lymphoma; Centroblastic malignant lymphoma; DLBCL; DLBCL - diffuse large B cell lymphoma"
Integrative Clinical Sequencing Analysis of Metastatic Castration    Resistant Prostate Cancer Reveals a High Frequency of Clinical    Actionability,"Most prostate cancer deaths are caused by metastatic, castration resistant disease (mCRPC). To develop a precision medicine framework for mCRPC, we established a multi-institutional, international clinical sequencing infrastructure to enroll  and carry out prospective whole exome and transcriptome sequencing of tumors from a cohort of mCRPC patients. We obtained high quality DNA and RNA",phs000915.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000915,Arul Chinnaiyan,,,,Stand up to Cancer,2019-02-08,HMB-PUB-NPU;DS-CA-MDS;DS-PC-MDS;GRU,RNA-Seq;Seq_DNA_SNP_MAF_Ind;WXS,Case Set;Longitudinal,Prostatic Neoplasms,274.0,763.0,http://www.standup2cancer.org/,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
CTSP: Clinical Trial Sequencing Project,"For the Clinical Trials Sequencing Project (CTSP), National Cancer Institute (NCI) will utilize whole genome sequencing and/or whole exome sequencing in conjunction with transcriptome sequencing to try to identify recurrent  genetic alterations (mutations, deletions, amplifications, rearrangements) and/or gene expression signatures that would be important to the",phs001175.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001175,"Jean Claude Zenklusen, PhD",,,29925955,,2019-01-29,GRU,,Case Set,Breast,366.0,366.0,,,"Carcinoma, Renal Cell;Lymphoma, Large B-Cell, Diffuse","ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell"
CTSP Diffuse Large B-Cell Lymphoma (DLBCL) CALGB 50303,"For the CTSP-DLBCL sub-project, National Cancer Institute (NCI) will utilize whole genome sequencing and/or whole exome sequencing in conjunction with transcriptome sequencing to try to identify recurrent genetic alterations (mutations,  deletions, amplifications, rearrangements) and/or gene expression signatures that would be important to the hypothesis(es) submitted by the",phs001184.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001184,"Jean Claude Zenklusen, PhD",,,29925955,,2019-01-29,GRU,,Case Set,"Lymphoma, Large B-Cell, Diffuse",366.0,366.0,,,,Centroblastic diffuse large B-cell malignant lymphoma; Centroblastic diffuse malignant lymphoma; Centroblastic malignant lymphoma; DLBCL; DLBCL - diffuse large B cell lymphoma; Diffuse Histiocytic Lymphoma
Hispanic Colorectal Cancer Study,"Genome-wide association studies (GWAS) of colorectal cancer (CRC) have been instrumental in identifying a number of common susceptibility loci in Non Hispanic (NH)-White populations, and a NCI priority is to  extend GWAS findings to other populations to address racial/ethnic disparities in cancer susceptibility. Currently, GWA studies of CRC in NH-Whites,",phs001193.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001193,"Jane Figueiredo, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),27207650,R01 CA155101-01,2018-12-27,DS-CA;HMB-MDS;GRU,Array_SNP,GWAS,Colorectal Neoplasms,1597.0,1597.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
The Platinum Study,"The Platinum Study is an R01-funded, multicenter study of testicular cancer survivors that characterizes both long-term cisplatin-induced peripheral neuropathy (CisIPN) and cisplatin-associated ototoxicity, i.e., permanent, bilateral hearing loss. We collected  data abstracted from medical records (e.g., cumulative cisplatin dose), conducted audiometric examinations, and administered self-report",phs001621.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001621,"Travis, Lois MD, ScD",,,28611204;28039263,5R01CA157823,2018-12-21,GRU,Imputation_SNP;Array_SNP,Longitudinal;Cross-Sectional,Cisplatin,680.0,680.0,,,,Not Provided
Enhancer Mapping in Chronic Lymphocytic Leukemia,"In this study we profile the epigenomic enhancer landscapes of CLL B cells (CD19+/CD5+) harvested from peripheral blood of patients from our Center. Included are results of ChIPseq profiling using  chromatin immunoprecipitation of the enhancer histone mark H3K27ac (acetylated lysine 27 on histone H3), and open chromatin profiles using ATAC-seq",phs001704.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001704,"Christopher Ott, PhD;Jennifer Brown, MD, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,P01-CA81534;K99CA190861,2018-12-18,DS-CLL,RNA-Seq;ChIP-Seq;ATAC-seq,Case-Control,"Leukemia, Lymphocytic, Chronic, B-Cell",28.0,66.0,,,,"B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic"
Tumor Heterogeneity in Metastatic Adrenocortical Tumors,We have analyzed 33 human metastatic adrenocortical tumors from 14 patients with advanced metastases and performed whole exome sequencing to identify novel signatures in these tumors. We observed tumor heterogeneity  in these tumors coming from the same metastatic tissue site across different patients while the different metastatic tumor sites coming from the same,phs001658.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001658,"Electron Kebebew, MD",Kathleen Calzone,Center for Cancer Research (CCR),,Intramural Grant,2018-12-04,GRU,WXS;Seq_DNA_SNP_MAF_Ind,Cohort,Adrenocortical Carcinoma,14.0,33.0,,,,ACC; Adenoid Cystic Carcinoma; Adrenal Cortex Adenocarcinoma; Adrenal Cortex Cancer; Adrenal Cortex Carcinoma; Adrenal Cortical Adenocarcinoma
NSAIDS and Somatic Mutations in Barrett's Esophagus,"Background: Use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been shown to protect against tetraploidy, aneuploidy, and chromosomal alterations in the metaplastic condition Barrett's esophagus (BE) and to  lower the incidence and mortality of esophageal adenocarcinoma (EA). The esophagus is exposed to both intrinsic and extrinsic mutagens resulting from",phs001654.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001654,"Xiaohong Li, PhD;Brian J. Reid, MD, PhD",Claire Zhu,Division of Cancer Prevention (DCP),29486792;23785299;17326708;16321762;12163328,"R01CA179949 (PQA1) Aspirin and Inflammation: Mutations, Genes, Pathways and Prevention,;P01CA91955 Barrett&#39;s Esophagus: Predictors of Progression;P30 CA015704 Cancer Center Support Grant",2018-11-28,DS-BE,Seq_DNA_SNP_CNV;OTHER,Case-Control,Barrett Esophagus,82.0,164.0,,,,BARRETT METAPLASIA; BE; Barret syndrome; Barrett Metaplasias; Barrett Syndrome; Barrett esophagus/esophageal adenocarcinoma
Genomic Studies for Understanding Etiology of Esophageal Adenocarcinoma    (EsophagealAdenocarcinoma_Chinese),"While the incidence of esophageal adenocarcinoma (EAC) has risen drastically in Western countries over the last 40 years, a similar trend has not been observed for EAC in China. Here  we analyzed mutational spectrum, copy number alterations, and structural variants from whole-genome sequencing of ten Chinese EAC tumor samples and",phs001696.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001696,"James Dai, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,R21 CA197502,2018-11-27,DS-E-C-NPU,Seq_DNA_SNP;WGS,Case Set,Esophageal Neoplasms,10.0,20.0,,,,"Esophageal Neoplasms, Benign and Malignant; Esophageal Tumor; Esophageal Tumors; Esophageal neoplasm; Esophageal tumour; Esophagus Neoplasm"
"Common Variant GWAS, GECCO","Genetics & Epidemiology of Colorectal Cancer Consortium (GECCO) is a collaborative effort which aims to accelerate the discovery of colorectal cancer-related variants by discovering, replicating and fine-mapping Genome Wide Association  Study (GWAS) findings, conducting a meta-analysis of GWAS data, and investigating how genetic variants are modified by environmental risk factors.",phs001078.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001078,"Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),23266556,U01 CA137088;R01 CA059045,2018-11-27,HMB-PUB-NPU-MDS-GSO;HMB-IRB;HMB-IRB-NPU;DS-CC-MDS;HMB-PUB;GRU;DS-CA-PUB;DS-CC-NPU-GSO;CADM,Array_SNP,Case-Control;Cohort;Nested Case-Control,Colorectal Neoplasms,17766.0,18509.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Multiethnic Cohort Study (MEC),This study phs001171 MEC Colorectal Cancer contains genotype and phenotype of subjects available from the phs001171 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed  at the top-level study page phs001078 GECCO Consortioum. Individual level phenotype data and molecular data for all GECCO Consortium top-level study,phs001171.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001171,"Loic Le Marchand, MD, MPH;Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),10695593;23266556,R37 CA54281;P01 CA033619;R01 CA63464;U01 CA137088,2018-11-27,HMB-PUB-NPU-MDS-GSO;HMB-IRB;DS-CC;HMB-IRB-NPU;HMB-PUB;GRU;DS-CA-PUB;DS-CC-NPU-GSO;CADM,Array_SNP,Case-Control,Colorectal Neoplasms,722.0,735.0,http://www.crch.org/multiethniccohort/,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Hawai'i Colorectal Cancer Studies 2&3 (Colo2&3),This study phs001170 Colo2and3 contains genotype and phenotype of subjects available from the phs001170 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortioum. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and,phs001170.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001170,"Loic Le Marchand, MD, PhD;Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),11751443;23266556,R01 CA60987;U01 CA137088;R01 CA059045,2018-11-27,HMB-PUB-NPU-MDS-GSO;HMB-IRB;HMB-IRB-NPU;DS-CC-MDS;HMB-PUB;GRU;DS-CA-PUB;DS-CC-NPU-GSO;CADM,Array_SNP,Case-Control,Colorectal Neoplasms,225.0,232.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Nurses' Health Study (NHS),This study phs001129 NHS contains genotype and phenotype of subjects available from the phs001129 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and,phs001129.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001129,"Andrew Chan, MD, MPH;Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),248266;23266556,UM1 CA186107;R01 CA137178;P01 CA87969;R01 CA151993;P50 CA127003;U01 CA137088;R01 CA059045,2018-11-27,HMB-PUB-NPU-MDS-GSO;HMB-IRB;HMB-IRB-NPU;DS-CC-MDS;HMB-PUB;GRU;DS-CA-PUB;DS-CC-NPU-GSO;CADM,Array_SNP,Nested Case-Control;Longitudinal Cohort,Colorectal Neoplasms,2606.0,2660.0,http://www.channing.harvard.edu/nhs/,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Physicians' Health Study (PHS),This study phs001128 PHS contains genotype and phenotype of subjects available from the phs001128 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and,phs001128.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001128,"Andrew Chan, MD, MPH;Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),2664509;23266556,R01 CA137178;U01 CA137088;R01 CA059045;R01 CA042182;P50 CA127003,2018-11-27,HMB-PUB-NPU-MDS-GSO;HMB-IRB;HMB-IRB-NPU;DS-CC-MDS;HMB-PUB;GRU;DS-CA-PUB;DS-CC-NPU-GSO;CADM,Array_SNP,Nested Case-Control;Longitudinal Cohort,Colorectal Neoplasms,806.0,817.0,http://phs.bwh.harvard.edu/,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Health Professionals Follow-up Study (HPFS),This study phs001114 HPFS contains genotype and phenotype of subjects available from the phs001114 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and,phs001114.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001114,"Andrew Chan, MD, MPH;Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),2090285;23266556,P01 CA 055075;UM1 CA167552;R01 137178;P50 CA127003;U01 CA137088;R01 CA059045,2018-11-27,HMB-PUB-NPU-MDS-GSO;HMB-IRB;HMB-IRB-NPU;DS-CC-MDS;HMB-PUB;GRU;DS-CA-PUB;DS-CC-NPU-GSO;CADM,Array_SNP,Nested Case-Control,Colorectal Neoplasms,1497.0,1539.0,https://content.sph.harvard.edu/hpfs/,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Darmkrebs: Chancen der Verhutung durch Screening (DACHS),This study phs001113 DACHS contains genotype and phenotype of subjects available from the phs001113 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and,phs001113.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001113,"Jenny Chang-Claude, PhD;Hermann Brenner, MD, MPH;Michael Hoffmeister, PhD;Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),21200035;16434594;23266556,BR 1704/6-1;BR 1704/6-3;BR 1704/6-4;CH 117/1-1;Deutsche Forschungsgemeinschaft;01KH0404;01ER0814;U01 CA137088;R01 CA059045,2018-11-27,HMB-PUB-NPU-MDS-GSO;HMB-IRB;DS-CC;HMB-IRB-NPU;HMB-PUB;GRU;DS-CA-PUB;DS-CC-NPU-GSO;CADM,Array_SNP,Case-Control,Colorectal Neoplasms,4686.0,5125.0,http://dachs.dkfz.org/dachs/ziel.html,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
French Association STudy Evaluating RISK for Sporadic Colorectal Cancer    (ASTERISK),This study phs001104 ASTERISK contains genotype and phenotype of subjects available from the phs001104 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortioum. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and,phs001104.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001104,"Stephane Bezieau, PharmD, PhD;Sebastien Kury, DVM, PhD;Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),17627011;23266556,"Hospital Clinical Research Program (PHRC) and supported by the Regional Council of Pays de la Loire, 			the Groupement des Entreprises Francaises dans la Lutte contre le Cancer (GEFLUC), the Association Anne de Bretagne 			Genetique and the Ligue Regionale Contre le Cancer (LRCC);U01 CA137088;R01 CA059045",2018-11-27,HMB-PUB-NPU-MDS-GSO;HMB-IRB;HMB-IRB-NPU;DS-CC-MDS;HMB-PUB;GRU;DS-CA-PUB;DS-CC-NPU-GSO;CADM,Array_SNP,Case-Control,Colorectal Neoplasms,1937.0,2005.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
"Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)",This study phs001094 PLCO contains genotype and phenotype of subjects available from the phs001094 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and,phs001094.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001094,"Robert Schoen, MD, MPH;Richard Hayes, DDS, PhD;Sonja Berndt, PharmD, PhD;Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),11189687;11189684;11189683;23266556,"Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported 			by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS;U01 CA137088;R01 CA059045;Intramural Research Program",2018-11-27,HMB-PUB-NPU-MDS-GSO;HMB-IRB;HMB-IRB-NPU;DS-CC-MDS;HMB-PUB;GRU;DS-CA-PUB;DS-CC-NPU-GSO;CADM,Array_SNP,Case-Control;Longitudinal Cohort,Colorectal Neoplasms,1123.0,1189.0,http://prevention.cancer.gov/plco,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Postmenopausal Hormones Supplementary Study to the Colon Cancer Family    Registry (PMH-CCFR),This study phs001092 PMH CCFR contains genotype and phenotype of subjects available from the phs001092 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at  the top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and,phs001092.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001092,"Polly Newcomb, PhD, MPH;Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),17671225;23266556,R01 CA076366;U01 CA137088;R01 CA059045;P30 CA015704,2018-11-27,HMB-PUB-NPU-MDS-GSO;HMB-IRB;HMB-IRB-NPU;DS-CC-MDS;HMB-PUB;GRU;DS-CA-PUB;DS-CC-NPU-GSO;CADM,Array_SNP,Case-Control,Colorectal Neoplasms,450.0,463.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Women's Health Initiative (WHI),This study phs001077 WHI Colorectal Cancer contains genotype and phenotype of subjects available from the phs001077 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed  at the top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study,phs001077.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001077,"Garnet Anderson, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),14575939;9492970;23266556,HHSN268201600018C;HHSN268201600003C;HHSN268201600002C;HHSN268201100004C;HHSN268201600001C,2018-11-27,HMB-PUB-NPU-MDS-GSO;HMB-IRB;HMB-IRB-NPU;DS-CC-MDS;HMB-PUB;GRU;DS-CA-PUB;DS-CC-NPU-GSO;CADM,Array_SNP,Case-Control;Longitudinal,Colorectal Neoplasms,2191.0,2191.0,https://www.whi.org/,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
"Diet, Activity, and Lifestyle Study (DALS)",This study phs001056 DALS contains genotype and phenotype of subjects available from the phs001056 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and,phs001056.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001056,"Martha Slattery, PhD, MPH;Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),8988044;23266556,R01 CA48998;U01 CA137088;R01 CA059045,2018-11-27,HMB-PUB-NPU-MDS-GSO;HMB-IRB;HMB-IRB-NPU;DS-CC-MDS;HMB-PUB;GRU;DS-CA-PUB;DS-CC-NPU-GSO;CADM,Array_SNP,Case-Control,Colorectal Neoplasms,880.0,916.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
VITamins And Lifestyle (VITAL),This study phs000965 VITAL contains genotype and phenotype of subjects available from the phs000965 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and,phs000965.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000965,"Emily White,  PhD;Ulrike Peters, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),14693663;23266556,K05 CA154337;U01 CA137088;R01 CA059045,2018-11-27,HMB-PUB-NPU-MDS-GSO;HMB-IRB;HMB-IRB-NPU;DS-CC-MDS;HMB-PUB;GRU;DS-CA-PUB;DS-CC-NPU-GSO;CADM,Array_SNP,Nested Case-Control;Longitudinal Cohort,Colorectal Neoplasms,607.0,637.0,http://www.fredhutch.org/en/labs/phs/projects/cancer-prevention/projects/vital.html,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
High-Throughput Determination of the Antigen Specificities of T cell    Receptors in Single Cells,"High-throughput linking of T cell receptor (TCR) sequences to their binding antigens is vital for immune profiling, yet challenging. We present Tetramer associated TCR Sequencing (TetTCR-Seq) to address this challenge.  Binding is determined using a library of DNA-barcoded antigen tetramers that are rapidly and inexpensively generated using an in vitro",phs001678.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001678,Ning Jiang;Weiping Jia,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),30418433,"NIH Grants R00AG040149, S10OD020072, R33CA225539, and NSF CAREER Award 1653866;Welch Foundation Grant F1785;Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation;National Natural Science Foundation of China Major International (Regional) Joint Research Project 81220108006, NSFC-NHMRC Joint Research Grant 81561128016",2018-11-23,HMB-IRB-NPU,RNA-Seq,Single Cell Analysis,Humans,10.0,144.0,,TRA;TRB,Cytomegalovirus,Not Provided
"Single Patient BRAF Mutant Brain Tumor, Pre- and Post-dabrafenib WES.","A single adolescent patient with a BRAF V600E mutated brain tumor was treated with dabrafenib and had a complete response, followed by progression. The pre-treatment and post-progression tumors were both  sequenced in order to identify potential drivers of resistance. The patient had both pre-treatment and post-progression specimens available for",phs001629.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001629,Christine Pratilas,Mariam Eljanne,Center for Cancer Training (CCT),29880583,K08 CA127350,2018-11-08,GRU-IRB-PUB,WXS;Seq_DNA_SNP_MAF_Ind,Case Set,Ganglioglioma,1.0,2.0,,BRAF,Astrocytoma,ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm; Astrocytoma (excluding glioblastoma); Astrocytomas
The Genomic Landscape of Endocrine Resistant Advanced Breast Cancers.,"The genomic evolution of breast cancers exposed to systemic therapy and its effects on clinical outcome have not been broadly characterized. We integrated the genomic sequencing of 1918 breast cancers,  including 1501 hormone receptor-positive tumors, with detailed clinical information and treatment outcomes. Functional mutations in ERBB2 and",phs001674.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001674,"Jose Baselga, MD, PhD;Barry S. Taylor, PhD;David B. Solit, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),30205045,R01CA190642 (J.B.);R01CA207244 (B.S.T.);R01CA204749 (B.S.T.);P30 CA008748;U54 OD202355,2018-11-05,HMB,WXS,Case Set;Longitudinal,Breast Neoplasms,30.0,95.0,,BRAF;EGFR;ERBB2;ERBB3;FOXA1;KRAS;NF1;MAP2K1;ARID1A;CTCF;ARID2,"Antineoplastic Agents, Hormonal;Neoplasm Metastasis;Drug Resistance, Neoplasm;Estrogen Receptor Antagonists;Estrogen Antagonists;Aromatase Inhibitors",Neoplasm Metastasis; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors
Integrated Single-Cell Analysis in Chronic Lymphocytic Leukemia,"Intratumoral genetic heterogeneity has been characterized across cancers by genome sequencing of bulk tumors, including chronic lymphocytic leukemia (CLL). In order to more accurately identify subclones, define phylogenetic relationships, and  probe genotype-phenotype relationships, we developed methods for targeted mutation detection in DNA and RNA isolated from thousands of single cells",phs001372.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001372,Catherine Wu,Ian Fingerman,Division of Cancer Biology (DCB),28679620,R01CA182461,2018-10-18,GRU,Seq_DNA_SNP;Seq_RNA_Expression,Case Set,"Leukemia, Lymphoid",5.0,1567.0,,,,"Leukemia, Lymphocytic; Leukemias, Lymphocytic; Leukemias, Lymphoid; Lymphatic leukemia; Lymphocytic Leukemia; Lymphocytic Leukemias"
Sequence of Primary ER+ Breast Tumors Treated with 5 Years of Tamoxifen,"Targeted massively parallel sequencing analysis was conducted on DNA extracted from archived 22-28 year old, formalin-fixed primary breast tumors from 625 patents from British Columbia treated with five years of  adjuvant tamoxifen monotherapy and followed for over 10 years. Genes were selected for targeted sequencing by review of existing large-scale breast",phs001234.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001234,"Matthew J. Ellis, MD, PhD;Elaine Mardis, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),30181556;30429476,Susan G. Komen Promise grant PG12220321 and Komen CCR award CCR16380599 (Matthew J. Ellis),2018-10-16,DS-CA-IRB,WXS,Case Set,Breast Neoplasms,625.0,625.0,,AGTR2;AKT1;ATR;BRAF;DDR1;RUNX1;CBFB;CDH1;CDKN1B;CSF1R;ERBB2;ERBB3;ERBB4;ESR1;MTOR;GATA3;FOXA1;INSRR;JAK1;JAK2;KIT;KRAS;LTK;LYN;MDM2;MDM4;MAP3K1;MAP3K4;MET;MYB;NF1;PDGFRA;PIK3CA;PIK3R1;PTEN;RB1;MAP2K4;TBX3;TP53;KMT2D;NCOR1;CTCF;SMG1;SF3B1;BIRC6;KMT2C;FRG1B;MALAT1,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
NCI Biospecimen Pre-analytical Variables (BPV) Analysis,The Biospecimen Pre-analytical Variables (BPV) Program is a National Cancer Institute-sponsored study to systematically assess the effects of pre-analytical factors on the molecular profile of biospecimens. A robust biospecimen collection  infrastructure was established to prospectively collect biospecimens using rigorous standard operating procedures to control for most variables while,phs001304.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001304,Ping Guan,,,,National Cancer Institute (BPV),2018-10-12,GRU-PUB,RNA-Seq;WXS;Legacy_Genotype;miRNA-Seq,Case Set,"Carcinoma, Renal Cell",153.0,1554.0,https://biospecimens.cancer.gov/programs/bpv/default.asp,,"Ovarian Neoplasms;Fallopian Tube Neoplasms;Adenocarcinoma of Lung;Carcinoma, Squamous Cell;Colorectal Neoplasms","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung"
TumorStorage,This study phs001640 Tumor Storage contains molecular data and phenotype of subjects available from the phs001640 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can be  viewed at the top-level study page phs001304 Biospecimen PV cohort. Individual level phenotype data and molecular data for all Biospecimen PV cohort,phs001640.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001640,Ping Guan,,,,National Cancer Institute (BPV),2018-10-12,GRU-PUB,Legacy_Genotype,Case Set,"Carcinoma, Renal Cell",53.0,340.0,https://biospecimens.cancer.gov/programs/bpv/default.asp,,"Ovarian Neoplasms;Fallopian Tube Neoplasms;Adenocarcinoma of Lung;Carcinoma, Squamous Cell;Colorectal Neoplasms","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung"
NGS,This study phs001639 NGS contains molecular data and phenotype of subjects available from the phs001639 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can be viewed  at the top-level study page phs001304 Biospecimen PV cohort. Individual level phenotype data and molecular data for all Biospecimen PV cohort,phs001639.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001639,Ping Guan,,,,National Cancer Institute (BPV),2018-10-12,GRU-PUB,RNA-Seq;WXS;miRNA-Seq,Case Set,"Carcinoma, Renal Cell",35.0,341.0,https://biospecimens.cancer.gov/programs/bpv/default.asp,,"Ovarian Neoplasms;Fallopian Tube Neoplasms;Adenocarcinoma of Lung;Carcinoma, Squamous Cell;Colorectal Neoplasms","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung"
mRNA_TaqMan,This study phs001638 mRNA TaqMan contains molecular data and phenotype of subjects available from the phs001638 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can be  viewed at the top-level study page phs001304 Biospecimen PV cohort. Individual level phenotype data and molecular data for all Biospecimen PV cohort,phs001638.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001638,Ping Guan,,,,National Cancer Institute (BPV),2018-10-12,GRU-PUB,Legacy_Genotype,Case Set,"Carcinoma, Renal Cell",20.0,100.0,https://biospecimens.cancer.gov/programs/bpv/default.asp,,"Ovarian Neoplasms;Fallopian Tube Neoplasms;Adenocarcinoma of Lung;Carcinoma, Squamous Cell;Colorectal Neoplasms","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung"
GlobalMetaboliteProfiling,This study phs001637 Global Metabolite Profiling contains molecular data and phenotype of subjects available from the phs001637 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can  be viewed at the top-level study page phs001304 Biospecimen PV cohort. Individual level phenotype data and molecular data for all Biospecimen PV,phs001637.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001637,Ping Guan,,,,National Cancer Institute (BPV),2018-10-12,GRU-PUB,Legacy_Genotype,Case Set,"Carcinoma, Renal Cell",40.0,240.0,https://biospecimens.cancer.gov/programs/bpv/default.asp,,"Ovarian Neoplasms;Fallopian Tube Neoplasms;Adenocarcinoma of Lung;Carcinoma, Squamous Cell;Colorectal Neoplasms","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung"
FixationDelay,This study phs001636 Fixation Delay contains molecular data and phenotype of subjects available from the phs001636 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can be  viewed at the top-level study page phs001304 Biospecimen PV cohort. Individual level phenotype data and molecular data for all Biospecimen PV cohort,phs001636.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001636,Ping Guan,,,,National Cancer Institute (BPV),2018-10-12,GRU-PUB,Legacy_Genotype,Case Set,"Carcinoma, Renal Cell",20.0,95.0,https://biospecimens.cancer.gov/programs/bpv/default.asp,,"Ovarian Neoplasms;Fallopian Tube Neoplasms;Adenocarcinoma of Lung;Carcinoma, Squamous Cell;Colorectal Neoplasms","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung"
CNV_aCGH,This study phs001635 CNV aCGH contains molecular data and phenotype of subjects available from the phs001635 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can be  viewed at the top-level study page phs001304 Biospecimen PV cohort. Individual level phenotype data and molecular data for all Biospecimen PV cohort,phs001635.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001635,Ping Guan,,,,National Cancer Institute (BPV),2018-10-12,GRU-PUB,Legacy_Genotype,Case Set,"Carcinoma, Renal Cell",38.0,229.0,https://biospecimens.cancer.gov/programs/bpv/default.asp,,"Ovarian Neoplasms;Fallopian Tube Neoplasms;Adenocarcinoma of Lung;Carcinoma, Squamous Cell;Colorectal Neoplasms","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung"
CIT_mRNA,This study phs001634 CIT mRNA contains molecular data and phenotype of subjects available from the phs001634 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can be  viewed at the top-level study page phs001304 Biospecimen PV study. Individual level phenotype data and molecular data for all Biospecimen PV cohort,phs001634.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001634,Ping Guan,,,,National Cancer Institute (BPV),2018-10-12,GRU-PUB,Legacy_Genotype,Case Set,"Carcinoma, Renal Cell",40.0,209.0,https://biospecimens.cancer.gov/programs/bpv/default.asp,,"Ovarian Neoplasms;Fallopian Tube Neoplasms;Adenocarcinoma of Lung;Carcinoma, Squamous Cell;Colorectal Neoplasms","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung"
Pan-Tumor Genomic Biomarkers for PD-1 Based Immunotherapy,Tumor mutation burden (TMB) and a T-cell-inflamed gene expression profile (GEP) independently predict clinical outcome in pembrolizumab-treated patients in 22 indications and stratify distinct targets of resistance biology. TMB was  evaluated by whole exome sequencing (WES) of germline and tumor DNA from formalin-fixed paraffin-embedded (FFPE) pre-treatment samples in multiple,phs001572.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001572,Razvan Cristescu,Ian Fingerman,Division of Cancer Biology (DCB),30309915,,2018-10-11,DS-CA-IRB,WXS,Case Set,Neoplasms,312.0,624.0,,,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Oral Microbiome in Esophageal Adenocarcinoma,The purpose of our study was to assess the influence of oral microbiota on the development of esophageal cancer. Our preliminary case-control studies reported a global alteration of foregut microbiome  in esophageal adenocarcinoma with the strongest changes found in the oral microbiome. We hypothesise that commensal oral bacteria are capable of,phs001527.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001527,"Zhiheng Pei, MD, PhD (Contact);Jiyoung Ahn, PhD",Claire Zhu,Division of Cancer Prevention (DCP),,5U01CA182370-03,2018-09-28,HMB-IRB-PUB-COL,WGS,Case-Control;Prospective,Esophageal Neoplasms,219.0,219.0,,,,"Esophageal Neoplasms, Benign and Malignant; Esophageal Tumor; Esophageal Tumors; Esophageal neoplasm; Esophageal tumour; Esophagus Neoplasm"
Chordoma Genomics,"In this study, we performed paired tumor/normal whole exome and shallow long insert whole genome sequencing, as well as tumor RNAseq, from archival chordoma specimens collected from four patients at  the Barrow Neurological Institute in Phoenix, AZ. The purpose of this analysis was to identify potential therapeutic targets. In three patients, we",phs001643.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001643,Winnie Liang,Ian Fingerman,Division of Cancer Biology (DCB),,"Barrow Neurological Foundation,  Phoenix, AZ, USA",2018-09-25,HMB-PUB,RNA-Seq;WXS;WGS,Case Set,Chordoma,4.0,8.0,,,High-Throughput Nucleotide Sequencing,"CHDM; Chordomas; Notochordal sarcoma; chordoma (disease); chordoma, malignant; chordoma, susceptibility to"
Intra-Lesion Heterogeneity and Clonality of Lobular Carcinomas In Situ,"This study comprises prospectively accrued, microdissected fresh frozen samples of multifocal lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), invasive lobular carcinoma and invasive ductal carcinoma from patients  undergoing prophylactic or therapeutic mastectomies after a diagnosis on LCIS diagnosed and managed at Memorial Sloan Kettering Cancer Center",phs001006.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001006,"Tari A King, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),30185420,Philanthropy,2018-09-13,GRU,WXS,Prospective,"Carcinoma, Lobular",24.0,94.0,,,carcinoma in situ,"Carcinoma in Situ; Cancer in situ; Carcinoma, Intraepithelial; Carcinoma, Preinvasive; Intraepithelial Carcinoma; Non-invasive Carcinoma"
Structural Alterations in Castration-Resistant Prostate Cancer,Adapted from manuscript in review: Nearly all prostate cancer deaths are from metastatic castration-resistant prostate cancer (mCRPC) but there have been few whole genome sequencing (WGS) studies of this disease  state. We performed linked-read WGS on 23 mCRPC biopsy specimens and analyzed cell-free DNA sequencing data from 86 patients with mCRPC. In addition,phs001577.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001577,Matthew Meyerson,,,29610475;28843286,,2018-09-12,DS-PC-MDS;DS-MDS,WGS,Cohort,"Prostatic Neoplasms, Castration-Resistant",20.0,43.0,,AR;MYC;ZBTB16;NCOR1;NCOR2;CDK12,Prostatic Neoplasms,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Inherited Bone Marrow Failure Syndromes Study,Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Mutations in IBMFS genes are relevant to  carcinogenesis in sporadic cancers. Patients with IBMFS who develop cancer differ in their genetic and/or environmental features from patients with,phs001481.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001481,Blanche P. Alter,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),27824607;27028275;26810774;27468421,,2018-09-06,GRU,WXS,Prospective;Family;Cohort,Bone Marrow Failure Disorders,456.0,456.0,https://www.marrowfailure.cancer.gov/,BACH1;BRCA1;BRCA2;CR;DKC1;XPF;FANCA;FANCC;FANCD2;FANCE;FANCB;FANCF;XRCC9;FA;GATA1;PARN;RAD51;RAD51C;RPL5;RPL11;RPL15;RPL18;RPL26;RPL27;RPL31;RPL35A;RPS7;RPS10;RPS17;RPS19;RPS24;RPS26;RPS27;RPS28;RPS29;TERC;TERT;XRCC2;NAF1;MAD2L2;RPL35;POT1;TINF2;UBE2T;SBDS;RTEL1;POG;WRAP53;KIAA1794;NOLA3;NOLA2;FANCM;BRIP1;ACD;NORD;PALB2;OBFC1;CTC1;FANCJ;SLX4;TSR2;DNAJC21;HSP40,"Anemia, Fanconi;Dyskeratosis Congenita","Bone Marrow Failure Syndromes; Dyskeratosis Congenita; Anemia, Fanconi; Anemia, Fanconi's; Anemias, Fanconi; FA"
Genome-Wide Association Study and Meta-Analysis of Ewing Sarcoma,"We combined a set of 122 French Ewing sarcoma (EWS) cases from the Institut Curie, 19 EWS cases from the National Cancer Institute (NCI) Center for Cancer Research (CCR), and  29 EWS cases from the NCI Bone Disease and Injury Study. All EWS cases were confirmed by medical record review and the presence of a specific",phs001549.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001549,Stephen Chanock;Olivier Delattre;Javed Khan;Robert Hoover;Mitchell Machiela,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),"No PMID: Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility 			Nature Communications, submitted | Mitchell J. Machiela, Thomas G. P. Gr&#252;newald, Didier Surdez, et al.",,2018-08-31,DS-ES;DS-BONE;GRU,Imputation_SNP;Array_SNP,Case-Control,"Sarcoma, Ewing",170.0,170.0,,,,ES; Ewing Sarcoma; Ewing Tumor; Ewing tumour; Ewing's Sarcoma; Ewing's Tumor
GMKF: Kids First Pediatric Research Program on Congenital Cranial    Dysinnervation Disorders and Related Birth Defects,"Goals of this ongoing study are to identify novel ""congenital cranial dysinnervation disorder"" (CCDD) genes and define the role of the wildtype and mutant genes in normal and aberrant development.  The umbrella term (CCDD) refers to congenital birth defects with malformation of one or more cranial nerves, typically resulting in limitations of",phs001247.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001247,"Elizabeth Engle, MD",,,,X01: 1X01HL132377-01,2018-08-24,DS-EMD;DS-ELMD;DS-CCDD-RD,Seq_DNA_SNP_CNV;WGS,Cohort;Parent-Offspring Trios,Cranial Nerve Diseases,899.0,899.0,https://commonfund.nih.gov/kidsfirst/overview,,Oculomotor Nerve Diseases;Facial Nerve Diseases;Abducens Nerve Diseases;Trochlear Nerve Diseases,Abducens Nerve Diseases; Facial Nerve Diseases; Oculomotor Nerve Diseases; Trochlear Nerve Diseases; Abducens Nerve Disease; Abducens nerve weakness
Dormant TILs and Sensitivity to Immune Checkpoint Blockers in Lung Cancer,"The biological determinants of sensitivity and resistance to immune checkpoint inhibitors are not completely understood. To elucidate the role of intratumoral T-cells and its association with the tumor genomic landscape,  we perform paired whole exome DNA sequencing and multiplexed quantitative immunofluorescence (QIF) in pre-treatment samples from non-small cell lung",phs001618.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001618,"Kurt A. Schalper, MD, PhD;Scott Gettinger, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),30097571,"P50CA196530;P30CA016359;R01CA195720;Stand Up to Cancer - Lung Cancer Translational Lung Dream Team Grant;U.S. Department of Defense, Lung Cancer Research Program Career Development Award LC150383;Lung Cancer Research Foundation;The Diane and David Heller Foundation",2018-08-03,DS-LCTC-MDS;GRU,WXS;Seq_DNA_SNP,Cohort,Neoplasms,49.0,84.0,,EGFR;KRAS,"Carcinoma, Non-Small-Cell Lung","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell"
Mechanisms of Chemotherapy Resistance in T-ALL,"The goals of this study are to unravel the molecular mechanisms underlying leukemic transformation and chemotherapy resistance in T-cell acute lymphoblastic leukemia (T-ALL). Towards this end, a cohort of T-ALL  lymphoblast specimens was collected at the time of initial T-ALL diagnosis (prior to the start of therapy) from children enrolled on contemporary",phs001513.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001513,"Alejandro Gutierrez, MD",Ian Fingerman,Division of Cancer Biology (DCB),,Grant NIH/NCI R01 CA193651,2018-08-02,DS-LEU,RNA-Seq;Targeted-Capture,Cohort,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,109.0,109.0,,ABL1;ACVR1;NR0B1;AKT1;AKT2;ALK;ALOX12B;APC;FAS;AR;ARAF;RHOA;RHOH;ATM;ATR;ATRX;AXL;B2M;BARD1;CCND1;BCL2;BCL2L1;BCL6;PRDM1;BLM;BMPR1A;FOXL2;BRCA1;BRAF;BRCA2;BUB1B;CALR;CASP8;RUNX1;RUNX1T1;CBFA2T3;CBFB;CBL;CBLB;CCND2;CCND3;CCNE1;CD58;CD79B;CDK1;CDH1;CDH4;CDK2;CDK4;CDK5;CDK6;CDK8;CDK9;CDKN1A;CDKN1B;CDKN1C;CDKN2A;CDKN2B;CDKN2C;CEBPA;CHEK1;COL7A1;CREBBP;CRKL;CSF3R;CTLA4;CTNNA1;CTNNB1;CUX1;CYLD;DAXX;DDB1;DDB2;DKC1;DMD;DNMT3A;EGFR;ELANE;ENG;EP300;EPHA3;EPHA5;EPHA7;ERBB2;ERBB3;ERBB4;ERCC1;ERCC2;ERCC3;ERCC4;ERCC5;ERCC6;ERG;ESR1;ETV1;ETV4;ETV5;ETV6;MECOM;EWSR1;EXT1;EXT2;EZH2;FANCA;FANCC;FANCD2;FANCE;FAH;PTK2B;FANCB;FANCF;FANCG;FAT1;FGFR1;FGFR3;FGFR2;FGFR4;FLT1;FLT3;FLT4;MTOR;SF1;FUS;XRCC6;GATA2;GATA3;GATA4;GATA6;GBA;GPC3;GLI1;GLI2;GLI3;GNA11;GNAQ;GNAS;ARHGAP35;GSTM5;MSH6;H3F3A;H3F3B;HABP2;FH;HFE;NRG1;HMBS;FOXA1;HRAS;ID3;ID4;IDH1;IDH2;IGF1R;IGF2;IL7R;ITK;JAK1;JAK2;JAK3;KCNQ1;KDR;KIT;KRAS;LIG4;LMO1;LMO2;SH2D1A;EPCAM;SMAD2;SMAD4;MAF;MAX;MCL1;MDM2;MDM4;MAP3K1;MEN1;MET;CIITA;MITF;MLH1;KMT2A;MPL;MRE11;MSH2;MTAP;TRIM37;MUTYH;MYB;MYBL1;MYC;MYCL;MYCN;MYD88;NBN;NF1;NF2;NFE2L2;NFKBIA;NFKBIE;NKX3-1;NOTCH1;NOTCH2;NOTCH3;NPM1;NRAS;NTHL1;NTRK1;NTRK2;NTRK3;DDR2;OGG1;PARK2;PAX5;PDGFRA;PDGFRB;SERPINA1;PIK3C2B;PIK3CA;PIM1;PIK3R1;PML;PMS1;PMS2;POLB;POLD1;POLE;POLH;PPARG;PPP2R1A;PRF1;PRKAR1A;PRKCI;PRKCZ;PRKDC;MAPK1;MAP2K1;MAP2K2;PRSS1;PSMD13;PTCH1;PTEN;PTK2;PTPN11;PTPN14;RAC1;RAD21;RAD51;RAD51C;RAD51D;RAD52;RAF1;RARA;RASA1;RB1;KDM5A;RBBP8;RBL2;REL;RELA;RET;RHEB;RIT1;ROS1;RPA1;RPL26;SDHA;SDHB;SDHC;SDHD;MAP2K4;SRSF2;SMARCA4;SMARCB1;SMARCE1;SMO;SOS1;SOX2;SOX9;SRC;SRY;SS18;STAT3;STAT6;AURKA;STK11;SYK;TAL1;TAL2;TAZ;TCEB1;HNF1A;TCF3;TCF7L2;TDG;TERT;TFE3;NKX2-1;TMPRSS2;TNFAIP3;TP53;TP53BP1;TRAF3;TSC1;TSC2;TSHR;U2AF1;UROD;KDM6A;VEGFA;VHL;WAS;WHSC1;WRN;WT1;XPA;XPC;XPO1;XRCC1;XRCC2;XRCC3;XRCC4;XRCC5;ZNF708;ZNF217;CXCR4;KAT6A;BRD3;KMT2D;ZRSR2;RBM10;KDM5C;SMC1A;ARID1A;AXIN2;BAP1;HIST1H3C;HIST1H3B;SPOP;PPM1D;PTCH2;ABCB11;SOCS1;EED;PHOX2B;MBD4;RNF8;USP8;MTA1;SMC3;EXO1;AURKB;KLF4;RECQL4;QKI;BRE;KEAP1;MAFB;MED12;AKT3;SH2B3;RAD50;SLC25A13;STAG1;IKZF1;KLF2;YAP1;HOXB13;SLC34A2;PRPF8;CTCF;POLQ;STAG2;PNRC1;TOPBP1;DMC1;CHEK2;PNKP;FKBP9;IKZF3;DIS3;FAN1;PAXIP1;NT5C2;KIF1B;KDM6B;CIC;MGA;ARHGEF12;CRTC1;DICER1;SF3B1;BRD4;SUZ12;KAT6B;PRAME;PRPF40B;RAD54B;POT1;SETBP1;GREM1;MLH3;SETD2;BABAM1;UBE2T;CD274;TLX3;SBDS;LEF1;SUFU;UIMC1;CDK12;EGLN1;TET2;FAM46C;BCOR;RNF43;WHSC1L1;SDHAF2;FANCL;RIF1;PBRM1;FANCI;NEIL3;RHOT1;FBXW7;TMEM127;LMO3;ARID1B;RPTOR;USP28;FANCM;RINT1;BCORL1;CRLF2;NSD1;RFWD2;NFKBIZ;DCLRE1C;BCL11B;SLX1B;BRCC3;CDC73;RHBDF2;NEIL1;GALNT12;PALB2;MUS81;TET1;PDCD1LG2;NECTIN4;DOCK8;TCF7L1;BCL2L12;BRIP1;ZNRF3;FAM175A;TRAF7;PHF6;CARD11;SLX4;MCM8;RSPO3;RHPN2;HELQ;DIS3L2;EME1;ASXL1;ARID2;CRTC2;FLCN;JAZF1;NEIL2;RICTOR;RSPO2;GEN1;SLX1A;KLLN;MEF2B,,Acute T Cell Leukemia; Acute T Cell Lymphoblastic Leukemia; Acute T-Cell Leukemia; Acute T-Cell Leukemias; Acute T-Cell Lymphoblastic Leukemia; Acute T-Lymphocytic Leukemia
Mutations in Breast Cancer Patient with Neurofibromatosis,"Targeted genetic sequencing was performed on a 41-year-old female with metaplastic breast cancer (MBC) and neurofibromatosis type I (NF1). A custom panel capturing 279 cancer related genes was used to  identify a germline pathogenic SNV in NF1, as well several other somatic alterations. Single case report Related Genes: NF1 Principal Investigator:",phs001566.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001566,"Sameek Roychowdhury, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),29449315,Institutional funds,2018-07-25,GRU,Seq_DNA_SNP,Case Set,Neurofibromatosis 1,1.0,2.0,,NF1,Breast Neoplasms,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Pre-treatment Molecular Characterizations of Tumors from Patients Who    Receive Immune Checkpoint Therapies,"Immune checkpoint inhibitors yield clinical benefit in many cancer types, but molecular predictors of response have not yet been robustly characterized. In this study, we pursued whole exome sequencing (WES)  of pre-treatment tumors from patients treated with immune checkpoint therapies - including monoclonal antibodies targeting programmed cell death-1",phs001565.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001565,"Eliezer Van Allen, MD",Ian Fingerman,Division of Cancer Biology (DCB),,,2018-07-03,DS-CATHLU-MDS;DS-CA-MDS;DS-BLADDERCA-MDS;GRU,WXS,Case Set,Neoplasms,71.0,142.0,,,"Carcinoma, squamous cell of head and neck;Lung Neoplasms;Carcinoma, Transitional Cell;Urinary Bladder Neoplasms","Carcinoma, Transitional Cell; Lung Neoplasms; Urinary Bladder Neoplasms; Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma"
Gut Microbiome and Types of Colorectal Polyps,Colorectal cancer is a heterogeneous disease arising from at least two precursors-the conventional adenoma and the serrated polyp. This dataset was used to test the relationship of the gut microbiota  to specific colorectal polyp types. We included samples from two independent study populations based at colonoscopy clinics: the Centers for Disease,phs001381.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001381,"Jiyoung Ahn, PhD",Claire Zhu,Division of Cancer Prevention (DCP),28038683,R21CA183887,2018-06-15,GRU,AMPLICON,Cross-Sectional,Colonic Polyps,667.0,667.0,,,Adenomatous Polyps,Adenomatous Polyps
Development of Precision Neoadjuvant-Adjuvant Therapies,"In clinical trials assessing neoadjuvant androgen deprivation therapy plus next-generation androgen receptor axis inhibitors, a subset of patients fail to demonstrate a complete pathologic response following treatment and radical prostatectomy.  We performed exome and transcriptome analyses on laser capture microdissected foci of residual tumor from these patients. Patients with residual",phs001399.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001399,Steven Balk;Mary-Ellen Taplin;Adam Sowalsky,Kathleen Calzone,Center for Cancer Research (CCR),25311217;29921690,PC150635P1;PC150635P2;PC150635P3;P50 CA090381;P01 CA163227;COU-AA-201;ZIA BC011679,2018-05-31,DS-CA-NPU,WXS,Case Set,Prostatic Neoplasms,19.0,69.0,,,"Receptors, Androgen;Abiraterone Acetate","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
GECCO: Detecting Common and Rare Genetic Loci and GxE Interactions in    Colorectal Cancer,"COLON, Colorectal Cancer: Longitudinal Observational study on Nutritional and lifestyle factors that influence colorectal tumor recurrence, survival and quality of life: The COLON study is a multi-center prospective cohort study  to assess the role of diet and other lifestyle factors in cancer recurrence and survival among incident colorectal cancer patients in the",phs001315.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001315,"Ulrike Peters, PhD, MPH;Ellen Kampman, PhD;Franzel van Duijnhoven, PhD;Brenner Hermann, MD, PMH;Jenny Chang-Claude, PhD;Michael Hoffmeister, PhD;Marc J. Gunter, PhD;Andrew T. Chan, MD, MPH;Andrew T. Chan, MD, PMH;Edith Feskens, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),23266556,"X01 HG007585-01, U01 CA164930;HHSN268201200008I, NIH contract High throughput genotyping for studying the genetic contributions to human disease",2018-05-23,DS-CC-PUB-NPU;HMB-PUB;GRU;DS-CC-NPU-GSO;NRUP,Imputation_SNP;Array_SNP,Case-Control;Cohort;Nested Case-Control,Colorectal Neoplasms,8803.0,9101.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Genetics of Pigmentation in Eastern and Southern African Populations    Study,"The goal of this study was to identify genes and loci associated with pigmentation in African populations. It comprises 1,593 participants from Ethiopia, Tanzania, and Botswana. Sexes are evenly represented  (768 males and 825 females) and self reported ages ranged from 18 to 103. Mean age was used for individuals without ages. For each participant, a DSM",phs001396.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001396,"Sarah Tishkoff, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),29025994,1R01DK104339-01;1R01GM113657-01,2018-05-15,GRU-NPU,Seq_DNA_SNP;WGS;Array_SNP,Cohort,Skin Pigmentation,1573.0,1573.0,,DDB1;OCA2;HERC2;TMEM138;MFSD12;SLC24A5,Age Factors;Sex,Not Provided
Detection of Genes Predisposing to Hematologic Malignancies,"We have been conducting genetic studies on families at high risk of different hematologic malignancies, in order to define the related tumors in the families, define precursor and other related  conditions, and map and identify susceptibility genes. We have focused mainly on four types of lymphoid malignancies: chronic lymphocytic leukemia",phs001219.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001219,"Neil E. Caporaso, MD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),25939664;26721895;27365461,National Cancer Institute Intramural,2018-05-10,DS-CA-MDS,WXS,Family,"Leukemia, Lymphocytic, Chronic, B-Cell",475.0,475.0,https://clinicalstudies.info.nih.gov/cgi/wais/bold032001.pl?A_02-C-0210.html,,"Hodgkin Disease;Lymphoma, Non-Hodgkin;Waldenstrom Macroglobulinemia;Leukemia, Hairy Cell;Leukemia, Myeloid, Acute;Leukemia, Myelomonocytic, Juvenile","Hodgkin Disease; Leukemia, Hairy Cell; Leukemia, Myelomonocytic, Juvenile; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; CHL"
OncoArray: Prostate Cancer,"Original description of the study: From ELLIPSE (linked to the PRACTICAL consortium), we contributed 78,000 SNPs to the OncoArray. A large fraction of the content was derived from the GWAS  meta-analyses in European ancestry populations (overall and aggressive disease; 27K SNPs). We also selected just over 10,000 SNPs from the",phs001391.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391,Christopher Haiman,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),33398198,"U19 CA148537;HHSN268201200008I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2018-03-21,DS-CA-NPU;GRU-NPU;PC-RITPC;DS-CA-PUB;DS-CA-MDS-GSO;PC-MDS-NOCTRL;DS-PC-MDS-GSO;DS-CA;HMB-NPU;DS-BCEMOPCA-NPU-MDS;HMB;DS-CHDSAD-MDS;DS-PC-PUB-MDS;DS-PCP;CADM;CHRONIC;EPIMEDCA;HMB-PUB-NPU;GRU-IRB;DS-PC;HMB-PUB;DS-CA-NPU-GSO;DS-CA-MDS;GRU;MHNSI-MDS;DS-PC-MDS,Array_SNP,Case-Control,Prostatic Neoplasms,99622.0,99622.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Whole Exome Sequencing of Signet Ring/Plasmacytoid Variant Bladder Cancer,"In this study, six plasmacytoid bladder cancers were analyzed by whole exome sequencing. The results show loss of the CDH1 gene in every sample and correlate with E-cadherin loss of  expression by immunohistochemistry. A separate validation cohort of plasmacytoid samples showed loss of E-cadherin expression by CDH1 mutation or",phs001064.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001064,"David Solit, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),24582117;20019984;7585573,P30CA008748,2018-03-12,DS-BLADDERCA,WXS;Seq_DNA_SNP_MAF_Sum,Cohort,"Carcinoma, Signet Ring Cell",6.0,12.0,,CDH1,Urinary Bladder Neoplasms,Urinary Bladder Neoplasms; Signet Ring Cell Adenocarcinoma; Signet Ring Cell Carcinoma; Signet cell adenocarcinoma; Signet ring carcinoma; Signet-Ring Cell Carcinoma
Metastatic Castrate-Resistant Prostate Cancer Study (MCRPCS),"We examined genetic resistance to second generation androgen targeting therapies (abiraterone acetate or enzalutamide) by analyzing whole exome sequencing of patient-matched pre-treatment and post-resistance tumors from a series of castrate-resistant  prostate cancer (CRPC) patients. Abiraterone resistant tumors harbored alterations in AR and MYC, whereas patients treated with enzalutamide had",phs001447.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001447,Eliezer M. Van Allen;Mary-Ellen Taplin,Mariam Eljanne,Center for Cancer Training (CCT),,,2018-03-07,DS-CA-MDS;DS-PC-MDS,WXS,Cohort,Prostatic Neoplasms,7.0,21.0,,AR;CDK6;CDKN2A;MYC,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,"In this study the investigators looked at adaptive reprogramming impact on the kinome when a MEK inhibitor called GSK1120212 (trametinib) was administered in a ""window of opportunity"" trial. GSK1120212 is  not yet approved by the FDA for use in breast cancer patients. The investigators gave GSK1120212 for a short period of time (one week) to examine MEK",phs001405.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001405,"Lisa A. Carey, MD;Shelton Earp, MD;Kristalyn Gallagher, DO",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),28108460;28287892;22500798;22310242;24664307;25109955,IIR12-225201;Supplied trametinib;GM101141;CA058223,2018-03-07,HMB-PUB-MDS,RNA-Seq,Clinical Trial,Triple Negative Breast Neoplasms,12.0,28.0,,,Breast Neoplasms;Neoplasms;Neoplasms by Site;Breast Diseases;Skin Diseases;trametinib;Antineoplastic Agents;Protein Kinase Inhibitors;Enzyme Inhibitors;Molecular Mechanisms of Pharmacological Action,"Breast Diseases; Molecular Mechanisms of Pharmacological Action; Neoplasms by Site; Skin Diseases; Breast Disease, Endocrine; Breast Diseases, Endocrine"
Gene Expression and Histone Modification Profiles in GBM Tumors,"The primary goal of this study was to collect and analyze genomic data from primary glioblastoma multiforme tumors. Our collaborators at St David's Medical Center (SDMC) obtained informed consent from  patients undergoing surgery to remove a tumor in the brain. After consent was obtained, specimens were removed from the operating suite and flash",phs001389.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001389,"Vishwanath R. Iyer, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,HG004563;CA130075;RP120194,2018-03-06,HMB,RNA-Seq;ChIP-Seq,Case Set,Glioblastoma,13.0,109.0,,,Astrocytoma;Neoplasms,ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm; Astrocytoma (excluding glioblastoma); Astrocytomas
High Response Rate to Anti PD-1 Therapy in Desmoplastic Melanoma,"Desmoplastic melanoma (DM) is a rare subtype of melanoma characterized by dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations, but is highly associated with ultraviolet  light DNA damage. We analysed 60 patients with advanced DM treated with programmed cell death 1 (PD-1) or PD-1 ligand (PD-L1) blocking antibody",phs001469.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001469,"Antoni Ribas, MD, PhD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),29320474,R35 CA197633;P01 CA168585;5P50CA168536;GM08042,2018-03-01,HMB-PUB-NPU-MDS,WXS;Seq_DNA_SNP_MAF_Ind,Cohort,Immunotherapy,17.0,34.0,,,Melanoma,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma; Melanoma, Malignant"
Sequence-Based Analysis of Human Breast Tumors,"The goal of this study is to study gene expression patterns in tumors, normal tissues, and cell lines. Principal Investigator: Charles Perou, PhD, Lineberger Comprehensive Cancer Center, University of North  Carolina at Chapel Hill,Chapel Hill, NC, USA Funding Source: P50-CA058223, P50-CA058223",phs000676.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000676,"Charles Perou, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),23000897,P50-CA058223,2018-02-28,DS-CA-MDS;GRU-MDS,RNA-Seq;WXS,Tumor vs. Matched-Normal;RNA Sequencing,Breast Neoplasms,28.0,232.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Differential Mutations in Matched Primary and Metastatic Colorectal    Cancers,"This study compares DNA mutations detected in matched primary and metastatic colorectal cancer samples from 18 individuals across 1,321 genes. We found many more mutations were shared between tumor pairs  (avg. 33.3 mutations/tumor) than were discordant (avg. 2.3 mutations / tumor). Nearly all tumors showed at least one discordance, and these were",phs001084.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001084,Timothy Yeatman,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),25974029,U01CA157960,2018-02-20,GRU,Targeted-Capture,Case Set;Metastasis;Tumor,Colorectal Neoplasms,18.0,38.0,,KRAS;TP53,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Whole Exome Sequencing and Methylation Profiling of Uveal Melanoma,"Uveal melanoma (UM) is the most common primary cancer of the eye and frequently leads to metastatic death. Metastatic risk can be stratified into low, intermediate and high based on  the presence of mutually exclusive mutations in EIF1AX, SF3B1 and BAP1, respectively. The purpose of this study was to comprehensively profile the",phs001421.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001421,JW Harbour,Shannon Hughes,Division of Cancer Biology (DCB),,"R01 CA125970;R01 CA161870;F30 CA206430;Research to Prevent Blindness, Inc. Senior Scientific Investigator Award;Melanoma Research Foundation;Melanoma Research Alliance;Ocular Melanoma Foundation;The 2015 RRF/Kayser Global Pan-American Award;The Alcon Research Institute;AACR-Ocular Melanoma Foundation Fellowship in honor of Robert C. Allen, MD;NIH Core Grant P30EY014801;Department of Defense Grant #W81XWH-13-1-0048;Research to Prevent Blindness Unrestricted Grant;Generous gift from Dr. Mark J. Daily",2018-01-25,HMB-PUB,Array_DNA_Methylation;WXS,Cohort,Uveal melanoma,37.0,64.0,,EIF1AX;BAP1;SF3B1,Exome;Methylation,Methylation
NCI SEER Formalin Fixed Paraffin Embedded (FFPE) Tissue Feasibility Study,"Next Generation Sequencing (NGS) technologies are being used for detection of somatic mutations in tumors and studies of germline variation. However, most NGS studies used DNA isolated either from whole  blood or fresh frozen tissue specimens. Meanwhile, the tissue specimens available from most National Cancer Institute (NCI) funded cohorts and the",phs000950.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000950,"Wendy Cozen, DO, MPH;Brenda Hernandez, PhD, MPH;Charles F. Lynch, MD, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),16084952;26222067,Division of Cancer Control and Population Sciences,2018-01-04,HMB-MDS;GRU,RNA-Seq;Seq_DNA_SNP;WXS,Case Set,Neoplasms,59.0,129.0,http://seer.cancer.gov/biospecimen/,,Ovarian Neoplasms;Adenocarcinoma,"Adenocarcinoma; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant; Malignant Adenoma"
Ancestry Admixture among Chileans,"The purpose of this study is to investigate ancestry admixture among Chileans with and without gallbladder cancer. All cases from the Chile Gallbladder Cancer Pilot and Expansion studies with available  genotype data. Principal Investigator: Jill Koshiol, PhD, National Institutes of Health, Bethesda, MD, USA Funding Source: Z01 CP010218, National",phs001385.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001385,"Jill Koshiol, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),28542165,Z01 CP010218,2017-12-28,GRU,Array_SNP,Case-Control,Gallbladder Neoplasms,189.0,204.0,,,,"Bladder Cancer, Gall; Bladder Cancers, Gall; Cancer of Gallbladder; Cancer of the Gallbladder; Cancer, Gall Bladder; Cancer, Gallbladder"
Genetic Analysis to Interrogate Tumor Heterogeneity in Lung    Adenocarcinoma,"We employed next-generation sequencing to identify somatic alterations in multiple metastatic sites from an ""exceptional responder"" lung adenocarcinoma patient during his seven year course of ERBB2-directed therapies. The degree of  heterogeneity was unprecedented, with 1% similarity between somatic alterations of the lung and lymph nodes. One novel translocation, PLAG1-ACTA2,",phs001159.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001159,"Udayan Guha, MD, PhD",Kathleen Calzone,Center for Cancer Research (CCR),,,2017-12-12,HMB-IRB-PUB,WXS;Seq_DNA_SNP_CNV;WGS,Case Set,Adenocarcinoma of Lung,1.0,4.0,,ACTA2;ERBB2;PLAG1;TP53;CDK12,Adenocarcinoma of Lung,"ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma"
WES and CNV analysis of NF1-Associated Plexiform Neurofibromas,"Neurofibromatosis type 1 (NF1) is a common tumor-predisposition disorder due to germline mutations in the tumor suppressor gene NF1. A virtually pathognomonic finding of NF1 is the plexiform neurofibroma (PN),  a benign, likely congenital tumor that arises from biallelic inactivation of NF1. PN can undergo transformation to a malignant peripheral nerve",phs001403.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001403,"Douglas Stewart, MD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),28068329,"National Institutes of Health, Bethesda, MD, USA",2017-11-30,GRU,WXS;Array_SNP,Case-Control,Neurofibromatosis 1,21.0,44.0,,NF1,,"Neurofibromatosis Type I; Molluscum Fibrosum; Multiple non-ossifying fibromatosis; NEUROFIBROMATOSIS TYPE 1; NEUROFIBROMATOSIS, PERIPHERAL TYPE; NEUROFIBROMATOSIS, TYPE I"
Clonal Architectures and Driver Mutations in Metastatic Melanomas,"This study contains sequence data from 15 patients with stage IV melanoma, including the whole genome sequence of 15 metastatic tumors and corresponding normal blood samples from 13 cases, and  targeted capture sequence of four synchronous metastatic samples from two additional cases. These data provide a comprehensive survey of the clonal",phs001241.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001241,"Jeffrey S. Weber, MD, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25393105,"Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, Tampa, Florida, USA;Our Mark on Melanoma Inc. Foundation;Come Out Swinging Inc. Foundation",2017-11-20,GRU-MDS,WXS;WGS,Case Set,Melanoma,15.0,36.0,,,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Shanghai Breast Cancer Genetics Study (SBCGS),"The Shanghai Breast Cancer Genetics Study (SBCGS) includes data from four population-based studies conducted among Chinese women in urban Shanghai: the Shanghai Breast Cancer Study (SBCS), the Shanghai Breast Cancer  Survival Study (SBCSS), the Shanghai Women's Health Study (SWHS), and the Shanghai Endometrial Cancer Study (SECS, contributing controls only).",phs001088.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001088,"Wei Zheng, MD, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),10861490;16236996,R01CA064277;R01CA118229;R37CA070867;UM1CA182910;U19CA148065;Ingram Professorship endowment and Anne Potter Wilson Chair endowment,2017-11-14,HMB-PUB-NPU,Array_SNP,Case-Control,Breast Neoplasms,2392.0,2392.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Sub-Saharan Sophageal Squamous Cell Carcinoma Molecular Analysis,"Esophageal squamous cell carcinoma (ESCC) occurs as much as 20x more frequently in sub-Saharan Africa than Western countries. Through the UNC-Malawi project collaboration we obtained whole-exome matched tumor/normal and RNA  sequencing of 59 ESCC from Malawi between 2011-2012. DNA analysis revealed similar mutations as other cohorts, while RNA analysis revealed three",phs001448.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001448,Ned Sharpless,Sean Hanlon,Center for Strategic Scientific Initiatives (CSSI),22374539;27734031,P30CA01608641,2017-10-27,DS-E-C,RNA-Seq;WXS,Cohort,Esophageal Neoplasms,59.0,177.0,,,"Carcinoma, Squamous Cell;High-Throughput Nucleotide Sequencing","Esophageal Neoplasm; Carcinoma, Epidermoid; Carcinoma, Planocellular; Carcinoma, Squamous; Carcinoma, Squamous Cell; Carcinomas, Epidermoid"
GWAS of Sporadic and Familial Testicular Germ Cell Tumors,"Case-Control Study: Testicular germ cell cancer has been increasing among men during most of the 20th century. Despite this increase, the etiology of testicular cancer is poorly understood. To better  understand the molecular epidemiology of testicular cancer, the National Cancer Institute and the Department of Defense are conducting a case-control",phs001303.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001303,Katherine McGlynn;Mark H. Greene,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),23666239;23462292;24943593;1285161;16407372;18086791;18841155;19549888;19162511;21617256;25303766;26265202;17110638,NIH Intramural Program,2017-10-26,DS-TGCT-COL-MDS;GRU,Array_SNP,Case-Control;Family,Germinoma,1509.0,1556.0,https://dceg.cancer.gov/research/cancer-types/testes/familial-testicular-cancer-study,RAD51C;UCK2;MAD1L1;PPM1E;HPGDS;RFWD3;TEX14,,
Mutational Landscape of Lethal Castrate Resistant Prostate Cancer,"Exome sequencing of matched pairs of tumor / normal genomic DNA was performed from high risk localized prostate cancer or lethal, metastatic, castrate resistant prostate cancer (CRPC). Exome libraries were  prepared using Illumina Paired_End Genome DNA Sample Prep Kit and captured using Agilent SureSelect Capture Library or Roche EZ Exome capture",phs000554.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000554,"Arul M. Chinnaiyan, MD, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),22722839,P50CA69568,2017-10-17,DS-CA-MDS,WXS,Tumor vs. Matched-Normal,Prostatic Neoplasms,59.0,120.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Genomic Analysis of Pre-Treatment and Autopsy Glioblastoma Specimens,"We performed whole exome sequencing data of pre-treatment glioblastoma specimens, matched to post-treatment recurrent intracranial autopsy samples and metastatic extracranial post-treatment autopsy samples. We identified early genetic events common to  the evolutionary ancestry of both pre-treatment glioblastoma and later recurrences. We demonstrated that there were no protein-coding mutations as",phs001424.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001424,Priscilla Brastianos;Tracy Batchelor;Gad Getz;Daniel Cahill,Ian Fingerman,Division of Cancer Biology (DCB),29872714,,2017-10-13,DS-NDC-MDS,WXS,Longitudinal,Glioblastoma,12.0,36.0,,,,"Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme"
Foregut Microbiome in Development of Esophageal Adenocarcinoma,"The distal esophagus is an important anatomical area where gastric acid reflux can cause reflux esophagitis (RE), Barrett's esophagus (BE) (intestinal metaplasia), and esophageal adenocarcinoma (EA). The incidence of EA  has increased 6-fold in the U.S. since the 1970s, parallel to a significant increase in the prevalence of gastroesophageal reflux diseases (GERD).",phs000260.v4.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000260,"Zhiheng Pei, MD, PhD;Karen Nelson, PhD",Ian Fingerman,Division of Cancer Biology (DCB),15657344;17142109;15545159;9827707;16221805;17106919;11352068;16112578;16497592;17183312;11123195;11959090;16437628;15016918;19394334,"National Institutes of Health, Bethesda, MD, USA",2017-10-13,HMP,WGS;AMPLICON,Case-Control,Adenocarcinoma Of Esphophagus,110.0,575.0,http://gerd.med.nyu.edu/,,Adenocarcinoma Of Esophagus;Barrett&#39;s Esophagus;GERD,Adenocarcinoma Of Esophagus; Barrett's Esophagus; GERD; Adenocarcinoma of the Esophagus; Esophageal adenocarcinoma; Esophagus Adenocarcinoma
Genomic Regions Associated with Susceptibility to Barrett's Esophagus and    Esophageal Adenocarcinoma in African Americans: The Cross BETRNet    Admixture Study,Differences in rates of diseases between different populations with similar environments are presumed to be secondary to variability in population frequencies of disease causing alleles. Recently admixed populations such as  African Americans (AAs) provide a natural opportunity to identify disease-causing variants by examining the ancestry of long chromosomal haplotypes.,phs001454.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001454,"Amitabh Chak, MD, MS",Natalie Abrams,Division of Cancer Prevention (DCP),,U54 CA163060,2017-10-10,GRU-IRB,Array_SNP,Case Set,Adenocarcinoma Of Esophagus,28.0,28.0,,,Esophageal Neoplasms;Barrett Esophagus,Barrett Esophagus; Esophageal Neoplasms; Adenocarcinoma of the Esophagus; Esophageal adenocarcinoma; Esophagus Adenocarcinoma; adenocarcinoma - esophagus
Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer,Mechanisms of acquired resistance to immune checkpoint inhibitors (ICIs) are poorly understood. The purpose of this study was to investigate whether alterations in genes encoding components of the HLA Class  I antigen processing and presentation machinery or interferon signaling pathways play a role in acquired resistance to PD-1 or PD-L1 antagonistic,phs001464.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001464,"Katerina Politi, PhD;Scott Gettinger, MD",Ian Fingerman,Division of Cancer Biology (DCB),29025772,"P50CA196530;P30CA016359;R01CA195720;F32CA210516;Stand Up to Cancer - Lung Cancer Translational Lung Dream Team Grant;U.S. Department of Defense, Lung Cancer Research Program Career Development Award: LC150383;Lung Cancer Research Foundation;Italian Association for Cancer Research;Leslie H. Warner Fellowship;The Diane and David Heller Foundation;The Beatrice Klienberg Neuwirth Research Program;Melissa Marottoli Hogan Foundation",2017-10-06,DS-LCTC-MDS,RNA-Seq;WXS,Cohort,"Carcinoma, Non-Small-Cell Lung",14.0,63.0,,B2M,,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER"
Post-Liver Transplant Recurrent Human Hepatocellular Carcinoma Study    (RHCCS),"The whole exome sequencing showed that HERC5 deletion and under-expression associates with shorter: time to tumor recurrence, progression-free, and overall survival in hepatocellular carcinoma (HCC) in two independent studies (p1  0.004, HR1 1.80; p2 0.018, HR2 3.31) totaling 286 HCC patients. Matched primary and recurrent tumors indicated a clonal selection advantage in",phs000782.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000782,"Brandon W. Higgs, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26653219,,2017-10-06,GRU-PUB-MDS,WXS;Seq_DNA_SNP_CNV,Longitudinal;Case-Control,"Carcinoma, Hepatocellular",16.0,46.0,,,Liver Transplantation;Organ Transplantation,"Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells"
WGS of a Malignant GCT with Metabolic Response to Pazopanib,"We report one case study of a malignant granular cell tumor patient with metabolic response to pazopanib. In this study, we used whole-genome sequencing of the tumor with the matched  blood to characterize the somatic mutation profile in this tumor. This is the first reported whole-genome sequencing study of the rare malignant",phs000978.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000978,"Carl Morrison, MD, DVM",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),27148567,The Roswell Park Alliance Foundation,2017-10-02,GRU-PUB-NPU,WGS,Case-Control,Granular Cell Tumor,1.0,2.0,,,,Abrikosoff's granulous cell tumor; Abrikosoff's granulous cell tumour; Abrikosoff's tumor; Abrikosoff's tumour; Abrikosovâs tumor; Abrikosovâs tumour
Head and Neck Cancer Genome-Wide Association Study,"Head and neck cancers have well-documented associations with tobacco and alcohol exposure, but the disease develops in only a small fraction of users, which implies an important role for genetic  susceptibility. Therefore, head and neck cancers are an excellent model for studying genetic susceptibility to environmental carcinogens. The primary",phs001173.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001173,"Sanjay Shete, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,R01CA131324,2017-09-27,GRU,Array_SNP,Case-Control,Squamous Cell Carcinoma of Head and Neck,3333.0,3333.0,,,,Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx
Time Lapse to Cancer-Defining the Transition from Polyp to Cancer,"In the US, CRC incidence has declined with uptake in colonoscopy for early detection and removal of polyps, the precursor lesion, can stop a cancer from developing but in spite  of this, CRC remains the second leading cause of cancer death in the United States. One third of people who undergo screening colonoscopy will have",phs001384.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001384,"Lisa Boardman, MD",Grace Mishkin,Division of Cancer Treatment and Diagnosis (DCTD),27584834;27567950,R01 CA170357,2017-09-20,HMB,RNA-Seq;Seq_DNA_SNP;Bisulfite-Seq;WGS,Case Set,Colorectal Neoplasms,31.0,268.0,,,Adenoma,"Adenoma; Adenoma, Microcystic; Adenomas, Microcystic; Microcystic Adenomas; microcystic adenoma; microcystic adenoma (morphologic abnormality)"
HNPCC-Sys: Molecular Characterization of Lynch Syndromes,"Lynch Syndrome (LS) tumors are characterized by constitutional mutations in DNA mismatch-repair genes. Colorectal cancers (CRCs) are the predominant tumor type in patients with LS. Here, we have used whole-genome  and transcriptome sequencing of LS- CRC to find similarities and differences of mutation and gene expression characteristics between LS-CRC and",phs001407.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001407,"Markus Loeffler, MD",Ian Fingerman,Division of Cancer Biology (DCB),22810696;28727142,,2017-09-18,DS-LYN-PUB-NPU,RNA-Seq;WGS,Tumor vs. Matched-Normal;Case Set,"Colorectal Neoplasms, Hereditary Nonpolyposis",11.0,46.0,,MSH6;MLH1;MSH2;PMS2,Colorectal Neoplasms;Neoplasms,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
DNA Inverted Repeats as an At-risk Motif for Palindromic Gene    Amplification,"DNA Inverted Repeats as an At-risk Motif for Palindromic Gene Amplification defines oncogene amplification that is configured as a series of inverted duplications (palindromic gene amplification). To study the impact  of palindromic gene amplification in cancer genomes, we developed an approach to enrich DNA palindromes from genomic DNA (Genome-wide Analysis of",phs001261.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001261,"Hisashi Tanaka, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),23181561;28211519;33290559,R01 CA149385;W81XWH1810058,2017-09-13,DS-BRCA-NPU-MDS,WGS;OTHER;Array_SNP,Case Set,Neoplasms by Site,8.0,17.0,,AR;CCND1;ERBB2,Breast Neoplasms;Prostate Neoplasms,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) - OncoArray    Genotypes,"The data come from 40 studies participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). CIMBA recruits individuals with pathogenic mutations in BRCA1 or BRCA2. The majority of  carriers were recruited through cancer genetics clinics offering genetic testing, and were enrolled into national or regional studies. The remainder",phs001321.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001321,"Christopher I Amos, PhD;Fergus J Couch, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),28346442;27697780,"X01HG007491 under contract number HHSN268201200008I;CA128978;HHSN268201200008I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2017-09-11,DS-BROC-MDS-GSO;GRU-NPU;DS-CA-MDS;GRU;DS-BROC-NPU;DS-CA-MDS-GSO;GRU-IRB;DS-BRCA-MDS;CABNHD-MDS,Array_SNP,Cohort,Breast Neoplasms,11841.0,11841.0,http://cimba.ccge.medschl.cam.ac.uk/,BRCA1;BRCA2,Ovarian Neoplasms,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Melanoma Sequential Immune Checkpoint Blockade Treatment Sequencing Study,"Blockade of T cell coinhibitory molecules such as CTLA-4 and PD-1, can activate T cell antitumor response. Although these immune checkpoint blockades (CTLA-4 blockade and PD-1 blockade) have shown durable  response, response rate is modest. Therefore, there is a need to find stable biomarkers predictive of response to immune checkpoint blockades and to",phs001425.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001425,"Andrew Futreal, PhD;Jennifer Wargo, MD",Shannon Hughes,Division of Cancer Biology (DCB),28251903,R1205 01;G-0040,2017-08-24,GRU-PUB-NPU,WXS,Case Set;Longitudinal,Melanoma,34.0,85.0,,,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Foundation Medicine Adult Cancer Clinical Dataset (FM-AD),"The Foundation Medicine adult cancer clinical dataset consists of 18,004 unique solid tumor samples that underwent genomic profiling on a single uniform platform as part of standard clinical care. The  dataset is derived from the FoundationOne&#x000ae; genomic profiling assay version 2 that interrogates exonic regions of 287 cancer-related genes and",phs001179.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001179,"Doron Lipson, PhD;Juliann Chmielecki, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),22981675;28235761,,2017-07-31,HMB-PUB,,Case Set,Neoplasms,18004.0,18004.0,http://foundationone.com/,,Thoracic Neoplasms;Digestive System Neoplasms;Breast Neoplasms;Urogenital Neoplasms;Endocrine Gland Neoplasms;Nervous System Neoplasms;Skin Neoplasms;Head and Neck Neoplasms;Abdominal Neoplasms,Abdominal Neoplasms; Digestive System Neoplasms; Endocrine Gland Neoplasms; Nervous System Neoplasms; Skin Neoplasms; Thoracic Neoplasms
TIGER-LC OncoVar Sequencing,Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are clinically disparate primary liver cancers with etiological and biological heterogeneity. We performed targeted sequencing of Thai ICC and HCC among the Thailand  Initiative in Genomics and Expression Research for Liver Cancer (TIGER-LC) cohort using the OncoVar platform. Incident cases residing in Thailand of,phs001199.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001199,"Xin Wei Wang, PhD;Mathuros Ruchirawat, PhD",,,28648284,,2017-07-03,GRU,WXS,Case Set,"Carcinoma, Hepatocellular",197.0,394.0,,,Cholangiocarcinoma,"Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells"
Genomic Sequencing of Ewing's Sarcoma,The Ewing sarcoma family of tumors (EFT) is a group of malignant small round blue cell tumors that arise in bone or soft tissue. Ewing sarcoma (ES) is the second  most common type of primary bone tumor to affect children and adolescents and accounts for 2.9% of all childhood cancers. This data set reports,phs000768.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000768,"Javed Khan, MD",Kathleen Calzone,Center for Cancer Research (CCR),25010205,National Cancer Institute,2017-06-29,GRU,RNA-Seq;WGS,Case Set,"Sarcoma, Ewing",93.0,99.0,https://ccr.cancer.gov/javed-khan,,"Neuroectodermal Tumors, Primitive, Peripheral","Neuroectodermal Tumors, Primitive, Peripheral; (pPNET) Peripheral Primitive Neuroectodermal Tumors; Ewing sarcoma / PNET; Extracranial Primitive Neuroectodermal Tumor; Neuroectodermal Neoplasm, Peripheral Primitive; Neuroectodermal Tumor, Peripheral"
DRIVE Breast Cancer OncoArray Genotypes,"Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) was one of five projects funded in 2010 as part of the NCI's Genetic Associations and Mechanisms in Oncology  (GAME-ON) initiative (http://epi.grants.cancer.gov/gameon/). GAME-ON's overall goal was to foster an intra-disciplinary and collaborative approach to",phs001265.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001265,"David J. Hunter, ScD",,,27697780,"HHSN268201200008I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease"";U19 CA148065;X01 HG007491",2017-06-12,DS-CA;HMB-PUB;DS-BROC;DS-CA-NPU-GSO;DS-BCEMOPCA-NPU-MDS;GRU;DS-BRCA-PUB;HMB-PUB-NPU;CADM;DS-BOED-MDS,Array_SNP,Case-Control;Family,Breast Neoplasms,60015.0,60015.0,http://epi.grants.cancer.gov/oncoarray/;http://bcac.ccge.medschl.cam.ac.uk/bcacdata/oncoarray/,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
CTLA4:CD28 in Sezary Syndrome,"We sequenced two tumor and one normal whole genome libraries for a Sezary syndrome patient and also sequenced RNA libraries for each tumor. We identified a novel, highly expressed CTLA4:CD28  gene fusion that is predicted to results in a leading to stimulatory T-cell signaling in the presence of an inhibitory signal. Principal",phs000773.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000773,"Winnie Liang, PhD;Aleksandar Sekulic, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2017-06-12,GRU-MDS,RNA-Seq;Seq_DNA_SNP_CNV;WGS,Case Set,Sezary Syndrome,3.0,7.0,,,High-Throughput Nucleotide Sequencing,"CTCL / Sezary syndrome; Erythroderma, Sezary; Lymphoma, Sezary's; SC)zary syndrome; SEZARY SYNDROME, SOMATIC; SS"
Molecular Evolution of Cancer,"Recently developed methods that utilize partitioning of long genomic DNA fragments, and barcoding of shorter fragments derived from them, have succeeded in retaining long-range information in short sequencing reads. These  so-called read cloud approaches represent a powerful, accurate, and cost-effective alternative to single-molecule long-read sequencing. We developed",phs001255.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001255,"Arend Sidow, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,R01CA183904,2017-06-09,DS-BRCA-MDS,WGS,Tumor vs. Matched-Normal,Liposarcoma,1.0,8.0,,,,"DDLPS; DDLS; Dedifferentiated Liposarcomas; Liposarcoma, Dedifferentiated; dedifferentiated liposarcoma"
Genetic Analysis of Tumor Samples,"Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-&#x003b3;, which  is a critical cytokine for host immune responses. However, the role of IFN-&#x003b3; signaling in tumor cells in the setting of anti-CTLA-4 therapy",phs001257.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001257,"Andy Futreal, PhD;Jennifer Wargo, MD",Ian Fingerman,Division of Cancer Biology (DCB),27667683,5U54CA163125-04,2017-04-12,DS-M-PUB-NPU,WXS,Case Set,Melanoma,22.0,44.0,,ADAR;CNTFR;CREB1;CSF2RA;CSF3R;F3;IFI6;IRF8;IFI16;IFI27;IFI35;IFIT2;IFIT1;IFIT3;IFNA1;IFNA2;IFNA4;IFNA5;IFNA6;IFNA8;IFNA14;IFNA21;IFNAR1;IFNAR2;IFNB1;IFNG;IFNGR1;IFNGR2;IFNW1;IFRD1;IL2RB;IL2RG;IL3RA;IL4R;IL5RA;IL6;IL6R;IL7R;IL9R;IL10RA;IL10RB;IL11RA;IL12A;IL12B;IL13RA1;IL15;CXCL10;IRF1;IRF2;IRF3;IRF4;IRF5;IRF6;IRF7;JAK1;JAK2;LEPR;MPL;MX1;OAS1;PIK3CA;SP110;PRKCD;PSME1;STAT1;STAT2;STAT3;STAT4;TYK2;IFRD2;IFITM1;PIAS1;SOCS1;SOCS3;ISG15;EBI3;IRF9;IFI30;CREB3;IFI44;IFITM2;IFI44L;IRF2BP1;TBX21;IL21R;PIAS4;IL20RA;IL20RB;IFNK;CRLF2;IFIH1;IL22RA2;IL31RA;PYHIN1;IL28RA;IL28A;IL29;IFNE;IRGM;IRF2BP2;IFIT1B,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Thoracic Patient-Derived Xenografts,"Targeted capture sequencing of 341 cancer associated genes in thoracic patient-derived xenografts. Principal Investigator: John Thomas Poirier, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA Funding Source: P01  CA129243-09, National Institutes of Health, Bethesda, MD, USA",phs001192.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001192,"John Thomas Poirier, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,P01 CA129243-09,2017-04-11,DS-LC-PUB-NPU,Targeted-Capture,Case Set,Lung Neoplasms,1.0,4.0,,,,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
Gastric Cancer Genetic Analysis of Metastasis,"To identify candidate drivers involved in oncogenesis and tumor evolution, we conducted an extensive genome sequencing analysis of metastatic progression in diffuse gastric cancer. This involved a comparison between a  primary tumor from a Hereditary Diffuse Gastric Cancer Syndrome proband and its subsequent recurrence as an ovarian metastasis. Principal",phs000795.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000795,"Hanlee Ji, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25315765,5R33CA174575,2017-04-11,NRUP;HMB-PUB-MDS,WXS;WGS,Case-Control,Stomach Neoplasms,17.0,6.0,,,Krukenberg Tumor,"Krukenberg Tumor; Carcinoma, Krukenberg; Krukenbergâs tumor; Krukenbergâs tumour; Krukenberg Carcinoma; Krukenberg Neoplasm"
NCI Lung Cancer and Smoking Phenotypes in African-American Subjects,"This is a two-stage case-control study designed to evaluate the association between common genetic variants and the risk of lung cancer. The stage 1 studies included 1737 cases and 3602  controls from the following studies: MD Anderson Lung Cancer Epidemiology Study, The Multiethnic Cohort Study (MEC), NCI-MD Lung Cancer-Case Control",phs001210.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001210,Curtis C. Harris;Stephen J. Chanock;Krista A. Zanetti;Zhaoming Wang,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),27393504,,2017-04-07,DS-CA;DS-CA-PUB-NPU-RD;DS-CA-MDS;GRU;GRU-IRB,Array_SNP,Case-Control;Longitudinal Cohort,Lung Neoplasms,5339.0,5644.0,,,,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
Chemosensitive Relapse in Small Cell Lung Cancer Patient-Derived    Xenografts,"Genetic and epigenetic analysis of patient-derived xenograft models of acquired chemoresistance in small cell lung cancer. Principal Investigator: John Thomas Poirier, PhD, Memorial Sloan Kettering Cancer Center, New York, NY,  USA Funding Source: R01 CA197936, National Institutes of Health, Bethesda, MD, USA",phs001249.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001249,"John Thomas Poirier, PhD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,R01 CA197936,2017-04-03,HMB-PUB,RNA-Seq;ChIP-Seq;WXS;WGS,Case Set,Lung Neoplasms,10.0,110.0,,,,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
Glioma International Case Control Study (GICC),"The main goals of the GICC Study were: 1) to identify novel genetic risk variants for glioma, as well as validate variants implicated by previous genome-wide association studies of glioma;  and 2) to explore biologically relevant gene-gene and gene-environment interactions in glioma susceptibility. The GICC Study includes participants",phs001319.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001319,"Melissa L. Bondy, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26656478;28346443,R01CA139020,2017-03-31,DS-CA;DS-GLRC;GRU-COL;DS-BT;GRU;DS-GL;DS-GL-PUB,Array_SNP,Case-Control,Glioma,7566.0,7566.0,,,,Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia
Single-Cell DNA and RNA Sequencing over A 29-Year Period of A CLL Patient,"Chronic lymphocytic leukemia (CLL) is a frequent B-cell malignancy characterized by recurrent somatic chromosome alterations and a low level of point mutations. Here we present single nucleotide polymorphism (SNP) microarray  analyses of a single CLL patient over 29-years of observation and treatment, and transcriptome and whole genome sequencing at selected timepoints. We",phs001181.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001181,"Michael Dean, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,HHSN261200800001E;CXZZ20150330171838997;ZDSYS20140509153457495;JSGG20140702161347218,2017-03-24,DS-CA-MDS,RNA-Seq;WGS;Array_SNP,Case Set,"Leukemia, Lymphocytic, Chronic, B-Cell",1.0,16.0,,FOS;JUN;KLF4,,"B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic"
Integrated Genetic and Pharmacologic Interrogation of Rare Cancers,"Due to the paucity of patient derived models in rare cancers, identification of therapeutic targets remains challenging. We developed a patient derived model, CLF-PED-015-T, from a patient with an undifferentiated  sarcoma. From this model, we performed pooled RNAi and CRISPR-Cas9 negative selection screens and integrated that with a small molecule screen.",phs001121.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001121,"William C. Hahn, MD, PhD;Jesse Boehm, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,U01 CA176058,2017-03-21,DS-CA-MDS,RNA-Seq;WXS;Seq_DNA_SNP_MAF_Sum,Cohort,Sarcoma,1.0,3.0,,AMFR;CDK4;DTNB;EMP1;FUS;GABRA3;GRID2;ITPR2;PRKCH;RPS24;VEGFA;XPA;XPO1;PDLIM1;IGF2BP2;TMED10;UBXN7;GALNT7;CLSTN2;FSD1;ALPK2;ZNF680,,"Sarcoma, Spindle Cell; Sarcomas, Spindle Cell; Spindle Cell Sarcomas; spindle cell sarcoma"
DRIVE Breast Cancer GWAS Meta-Analysis,"Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) was one of five projects funded in 2010 as part of the NCI's Genetic Associations and Mechanisms in Oncology  (GAME-ON) initiative (http://epi.grants.cancer.gov/gameon/). GAME-ON's overall goal was to foster an intra-disciplinary and collaborative approach to",phs001263.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001263,"David J. Hunter, MBBS, MPH, ScD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),27197191;22267197;23535729;22976474;23535733,U19CA148065,2017-03-09,,,Case-Control,Breast Neoplasms,,,http://gameon.dfci.harvard.edu,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Genomic Characterization of Acral Melanoma,"In this study, we performed paired tumor/normal long insert whole genome and exome sequencing and tumor RNA sequencing on primary or metastatic acral melanoma tumors collected from 34 patients. Patients  were enrolled from either Vanderbilt University or the Memorial Sloan-Kettering Cancer Center. We report an integrated analysis of DNA and RNA",phs001036.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001036,"Jeffrey Sosman, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,Acral Genomics Team Science Award,2017-03-01,GRU-PUB-NPU,RNA-Seq;WXS;Seq_DNA_SNP_MAF_Sum;WGS,Tumor vs. Matched-Normal,Melanoma,34.0,109.0,,,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Pooled Genome-Wide Analysis of Kidney Cancer Risk (KIDRISK),"Incidence rates of renal cell carcinoma (RCC) are rising and the latest estimates show that it accounts for over 300,000 cases and 120,000 deaths worldwide each year. Mechanisms underlying RCC  occurrence are not fully understood and a large part of the disease heritability remains unexplained. The study aimed at augmenting the size of",phs001271.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001271,"Ghislaine Sc&#233;lo, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,U01CA155309,2017-02-28,DS-CA-NPU-GSO;HMB-PUB-NPU-MDS;DS-RCC-MDS,Array_SNP,Case-Control;Case-Cohort,"Carcinoma, Renal Cell",5307.0,5307.0,,,Kidney Neoplasms,"Kidney Neoplasms; ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell"
Prostate Cancer Genome-Wide Association Study for Uncommon Susceptibility    Loci (PEGASUS),"This genome-wide association study was funded by the National Cancer Institute (NCI) to identify uncommon susceptibility loci for prostate cancer. A total of 4,600 prostate cancer cases and 2,840 controls  of European ancestry from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial were genotyped using the Illumina HumanOmni2.5",phs000882.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000882,Sonja Berndt;Stephen Chanock,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,Intramural Research Program,2017-01-24,CADM,Array_SNP,Case-Control,Prostatic Neoplasms,7440.0,7639.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Brain Metastases in Squamous Cell Lung Cancers,"Putative oncogenic pathways in squamous cell lung cancer have been recently characterized, although their biologic repercussions in patients is largely unknown. This study sought to discover potential clinical manifestations of  major pathways in squamous cell lung cancer, particularly the PI3K pathway. Two key findings emerged: patients with stage IV squamous cell lung",phs000907.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000907,"Paul K. Paik, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25929848,Conquer Cancer Foundation Awards,2016-12-22,DS-CA,WXS;Seq_DNA_SNP_MAF_Sum,Case Set,"Carcinoma, Squamous Cell",5.0,13.0,,,Nonsmall Cell Lung Cancer,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell"
The Genomic Landscape of Juvenile Myelomonocytic Leukemia,"This study analyzed samples from 29 patients with juvenile myelomonocytic leukemia (JMML) using whole exome sequencing. Each patient had a paired germline tissue along with a diagnostic leukemia sample. Germline  tissue types included buccal mucosa, cordblood, Epstein-Barr virus immortalized cell lines and fibroblasts from either skin or bone marrow. Leukemia",phs000973.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000973,"Mignon Loh, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26457647,6059-09;T32CA128583;R01CA173085,2016-12-21,DS-CA-NPU-MDS,WXS;Seq_DNA_SNP_MAF_Ind,Collection,"Leukemia, Myelomonocytic, Juvenile",29.0,65.0,,RUNX1;CBL;DNMT3A;EZH2;GATA2;JAK3;KRAS;NF1;NRAS;PTPN11;RRAS;ZRSR2;SH2B3;RRAS2;SETBP1;ASXL1,,JCML; JCML - Juvenile chronic myeloid leukemia; JMML; Juvenile Chronic Myelogenous Leukemia; Juvenile Myelomonocytic Leukemias; Juvenile chronic myelomonocytic leukemia
Genetic Basis of Breast Cancer Resistance in BRCA1 Mutation Carrier,"Our study addressed a specific question in NCI RFA-CA-12-022: ""What underlying causal events - e.g., genetic, epigenetic, biologic, behavioral, or environmental - allow certain individuals to survive beyond the expected  limits of otherwise highly lethal cancers?"". A germline mutation in BRCA1 (BRCA1+) is the most penetrant genetic predisposition for breast cancer.",phs001243.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001243,"San Ming Wang, MD",Ian Fingerman,Division of Cancer Biology (DCB),,R21 CA180008,2016-12-15,GRU-PUB,WXS,Case Set,Breast Neoplasms,54.0,54.0,,BRCA1,"Genes, BRCA1;Germ-Line Mutation",Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Genomic Sequencing of Ewing Sarcoma,"Pediatric Ewing sarcoma is a pediatric cancer that primarily arises from the bone. It is characterized by chimeric fusions of the EWS gene and an ETS family transcription factor. In  this study, we performed massively parallel sequencing of a larger collection of Ewing sarcoma tumors to define the genomic landscape of this",phs000804.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000804,Kimberly Stegmaier;Jaume Mora;Gad Getz,,,25186949,Slim Initiative for Genomic Medicine (SIGMA),2016-12-13,DS-CA-MDS;GRU,WXS;RNA-Seq;WGS;Array_SNP,Whole Genome Sequencing;Exome Sequencing;RNA Sequencing,"Sarcoma, Ewing",102.0,132.0,,,,ES; Ewing Sarcoma; Ewing Tumor; Ewing tumour; Ewing's Sarcoma; Ewing's Tumor
Genome-Wide Scan of Early-onset Prostate Cancer,This is a genome-wide association scan of 931 early-onset prostate cancer cases of European ancestry. The samples were selected from prostate cancer studies at the University of Michigan. Controls were  previously genotyped individuals selected from the Cancer Genetics Markers of Susceptibility (CGEMS) and Illumina's iControlDB database. All subjects,phs001185.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001185,Kathleen Cooney,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),24740154;26671023,CA136621,2016-11-03,DS-CA,Array_SNP,Case-Control,Prostatic Neoplasms,931.0,931.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Analysis of AR Gene Rearrangements in Prostate Cancer,"Molecularly-targeted therapies for advanced prostate cancer include castration modalities that suppress ligand-dependent transcriptional activity of the androgen receptor (AR). However, persistent AR signaling undermines therapeutic efficacy and promotes progression to  lethal castration-resistant prostate cancer (CRPC), even when patients are treated with potent second-generation AR-targeted therapies abiraterone",phs001223.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001223,"Scott M. Dehm, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,R01CA174777;U.S. Department of Defense Prostate Cancer Research Program Transformative Impact Award W81XWH-15-1-0430;Pacific Northwest Prostate Cancer SPORE (P50CA97186);PO1CA085859;PO1CA163227;Richard M. LUCAS Foundation;NIH Medical Scientist Training Program grant T32GM008244,2016-10-31,DS-CA-PUB-MDS,RNA-Seq;OTHER,Case Set,Prostatic Neoplasms,42.0,57.0,,AR,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Genome-Wide Association Study of Endometrial Cancer in E2C2,"Endometrial cancer, the most common gynecological malignancy in the United States, has both an environmental and genetic component. To this end, we conducted a genome-wide association study to identify genes  involved in endometrial cancer using studies from the NCI-supported Epidemiology of Endometrial Cancer Consortium (E2C2). For the discovery stage we",phs000893.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000893,"Immaculata De Vivo, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),19132539;24096698;24810602,R01 CA134958-01A1,2016-10-27,DS-CA;DS-ENDOMETRIAL-MDS;DS-EC-MDS;HMB-PUB-NPU-MDS-GSO;GRU-MDS;DS-CHRONIC;GRU-COL-MDS;CADM;DS-BOED-MDS,Array_SNP,Case-Control;Nested Case-Control,"Carcinoma, Endometrioid",8622.0,8622.0,http://epi.grants.cancer.gov/eecc/,,Endometrial Neoplasms;Uterine Neoplasms,Uterine Neoplasms; Endometrial Neoplasms; Endometrial Tumor; Endometrial neoplasm; Endometrium Neoplasm; Endometrium Tumor
AMBER Consortium,"The AMBER Consortium Study was formed to pool interview data, questionnaire data, and biological samples from epidemiological studies of breast cancer in African-American women to discover the potential causes of  early-onset and aggressive breast cancer in African-American women. AMBER is funded through a Program Project grant from the National Cancer",phs000669.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000669,Julie R. Palmer;Christine B. Ambrosone;Andrew F. Olshan,,,26743380;26577839;26650177;26458823,"P01 CA151135;HHSN268201200008I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2016-10-21,DS-BRCA-COL-MDS-GSO;NRUP,Imputation_SNP;Array_SNP,Case-Control,Breast Neoplasms,6900.0,7127.0,http://www.theamberproject.org/,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Genomic Analysis of Relapsed Pediatric Acute Lymphoblastic Leukemia,"Although multi-agent combination chemotherapy is curative in a significant fraction of childhood acute lymphoblastic leukemia (ALL) patients, 20% of cases relapse and most die due to chemo-refractory disease. Here we  used whole-exome and whole-genome sequencing to analyze the mutational landscape and pattern of clonal evolution at relapse in pediatric ALL cases.",phs001072.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001072,"Adolfo Ferrando, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),27655895,Translational Research Program (TRP) award,2016-10-11,DS-CA-PUB-MDS-GSO,WXS;WGS,Cohort,"Leukemia, Lymphoid",57.0,179.0,,KRAS;NRAS;PTPN11,"Lymphoblastic Leukemia, Acute, T-Cell;Precursor B-Cell Lymphoblastic Leukemia","Lymphoblastic Leukemia, Acute, T-Cell; Precursor B-Cell Lymphoblastic Leukemia; Leukemia, Lymphocytic; Leukemias, Lymphocytic; Leukemias, Lymphoid; Lymphatic leukemia"
NCI Non-Hodgkin Lymphoma GWAS,"Within the framework of the International Lymphoma Epidemiology Consortium (InterLymph) Consortium and NCI-sponsored Cohort Consortium, investigators from 22 studies came together to conduct a genome-wide association study (GWAS) of non-Hodgkin  lymphoma (NHL). The goal of the study was to identify common genetic variants associated with the risk of NHL. As described previously (Berndt SI et",phs000801.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000801,Sonja Berndt;Nathaniel Rothman;Stephen Chanock,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),23770605;25261932;25279986;25569183,Intramural Research Program,2016-09-22,DS-CA-IRB-NPU-GSO;DS-NHL-NPU-GSO;GRU-NPU-MDS,Array_SNP,Cohort;Case-Control;Case Set,"Lymphoma, Non-Hodgkin",10491.0,10791.0,,,"Leukemia, Lymphocytic, Chronic, B-Cell;Lymphoma, Large B-Cell, Diffuse;Lymphoma, Follicular","Lymphoma, Follicular; B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade"
NCI Non-Hodgkin Lymphoma GWAS: MZL,This sub-study phs000891 NCI Non-Hodgkin Lymphoma GWAS: MZL contains genotype and subject and sample phenotype of subjects available from the phs000891 study. Summary level phenotypes for the NCI Non-Hodgkin Lymphoma  GWAS study participants can be viewed at the top-level study page phs000801 NCI Non-Hodgkin Lymphoma GWAS. Marginal zone lymphoma (MZL) encompasses a,phs000891.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000891,Sonja Berndt;Nathaniel Rothman;Stephen Chanock,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),25569183,Intramural Research Program,2016-09-22,DS-CA-IRB-NPU-GSO;DS-NHL-NPU-GSO;GRU-NPU-MDS,Array_SNP,Case Set;Case-Control,"Lymphoma, Non-Hodgkin",825.0,839.0,,,"Lymphoma, B-Cell, Marginal Zone","Lymphoma, B-Cell, Marginal Zone; Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue; Extranodal marginal zone B-cell lymphoma; Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma); Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue; Immunocytoma"
NCI Non-Hodgkin Lymphoma GWAS: FL,This sub-study phs000890 NCI Non-Hodgkin Lymphoma GWAS: FL contains genotype and subject and sample phenotype of subjects available from the phs000890 study. Summary level phenotypes for the NCI Non-Hodgkin Lymphoma  GWAS study participants can be viewed at the top-level study page phs000801 NCI Non-Hodgkin Lymphoma GWAS. Genome-wide association studies (GWAS) of,phs000890.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000890,Sonja Berndt;Nathaniel Rothman;Stephen Chanock,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),25279986,Intramural Research Program,2016-09-22,DS-CA-IRB-NPU-GSO;DS-NHL-NPU-GSO;GRU-NPU-MDS,Array_SNP,Case-Control;Case Set;Longitudinal,"Lymphoma, Non-Hodgkin",2142.0,2186.0,,,"Lymphoma, Follicular","Lymphoma, Follicular; Non-Hodgkin Lymphoma; Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers"
NCI Non-Hodgkin Lymphoma GWAS: DLBCL,This sub-study phs000889 NCI Non-Hodgkin Lymphoma GWAS: DLBCL contain genotype and subject and sample phenotype of subjects available from the phs000889 study. Summary level phenotypes for the NCI Non-Hodgkin Lymphoma  GWAS study participants can be viewed at the top-level study page phs000801 NCI Non-Hodgkin Lymphoma GWAS. Diffuse large B-cell lymphoma (DLBCL) is a,phs000889.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000889,Sonja Berndt;Nathaniel Rothman;Stephen Chanock,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),25261932,Intramural Research Program,2016-09-22,DS-CA-IRB-NPU-GSO;DS-NHL-NPU-GSO;GRU-NPU-MDS,Array_SNP,Case-Control;Case Set;Cohort,"Lymphoma, Non-Hodgkin",2661.0,2706.0,,,"Lymphoma, Large B-Cell, Diffuse",Centroblastic diffuse large B-cell malignant lymphoma; Centroblastic diffuse malignant lymphoma; Centroblastic malignant lymphoma; DLBCL; DLBCL - diffuse large B cell lymphoma; Diffuse Histiocytic Lymphoma
NCI Non-Hodgkin Lymphoma GWAS: Controls,This sub-study phs000818 NCI Non-Hodgkin Lymphoma GWAS: Controls contains genotype and subject and sample phenotype of subjects available from the phs000818 study. Summary level phenotypes for the NCI Non-Hodgkin Lymphoma  GWAS study participants can be viewed at the top-level study page phs000801 NCI Non-Hodgkin Lymphoma GWAS. Within the framework of the International,phs000818.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000818,Sonja Berndt;Nathaniel Rothman;Stephen Chanock,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),23770605;25261932;25279986;25569183,Intramural Research Program,2016-09-22,DS-CA-IRB-NPU-GSO;DS-NHL-NPU-GSO;GRU-NPU-MDS,Array_SNP,Cohort;Case-Control;Case Set,"Lymphoma, Non-Hodgkin",2685.0,2835.0,,,,Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology; Reticulum-Cell Sarcoma
NCI Non-Hodgkin Lymphoma GWAS: CLL,This sub-study phs000802 NCI Non-Hodgkin Lymphoma GWAS: CLL contains genotype and subject and sample phenotype data from subjects available from the phs000802 study. Summary level phenotypes for the NCI Non-Hodgkin  Lymphoma GWAS study participants can be viewed at the top-level study page phs000801 NCI Non-Hodgkin Lymphoma GWAS. Individual level phenotype data,phs000802.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000802,Sonja Berndt;Nathaniel Rothman;Stephen Chanock,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),23770605,Intramural Research Program,2016-09-22,DS-CA-IRB-NPU-GSO;DS-NHL-NPU-GSO;GRU-NPU-MDS,Array_SNP,Case-Control;Case Set;Cohort,"Lymphoma, Non-Hodgkin",2178.0,2225.0,,,"Leukemia, Lymphocytic, Chronic, B-Cell","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic"
A Prognostic Role of APC in Colorectal Cancers,"Colorectal cancer (CRC) is a highly heterogeneous disease, for which prognosis has been relegated to clinic-pathologic staging for decades. There is a need to molecularly stratify subpopulations of CRC to  better predict outcome and assign therapies. Here we report targeted exome sequencing of 1,321 cancer-related genes on 468 tumor specimens, which",phs001111.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001111,"Timothy Yeatman, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),26446941;25974029;27302369,U01CA157960,2016-09-21,GRU,Targeted-Capture,Case Set,Colorectal Neoplasms,468.0,468.0,,APC;BRAF;GNAS;HLA-A;ITGB4;KRAS;SMAD4;MUC4;PIK3CA;TCF7L2;TP53;TTN;CBX4;SYNE1;LRP1B;FBXW7;OBSCN;MUC16;CSMD3;TAF1L;AMER1;ADAMTS18,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Breast Cancer Risk Pathways,We sought to identify genomic variants that differed between individuals who developed familial breast cancer and individuals who had a family history of breast cancer but who had not developed  breast cancer. We aggregated these data at the pathway level to identify pathways that play a role in familial breast cancer development. We profiled,phs001044.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001044,"Andrea H. Bild, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26969729,,2016-09-19,GRU,WXS;Seq_DNA_SNP_CNV,Case-Control,Breast Neoplasms,35.0,35.0,,BRCA1;BRCA2,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
The Landscape of Antisense Gene Expression in Human Cancers,"High throughput RNA Sequencing has revealed that the human genome is widely transcribed. However, the extent of natural antisense transcription, the molecular mechanisms by which natural antisense transcripts (NATs) might  affect their cognate sense genes, and the role of NATs in cancer are less well understood. Here, we use strand-specific paired-end RNA sequencing",phs000937.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000937,Arul M. Chinnaiyan,Natalie Abrams,Division of Cancer Prevention (DCP),,,2016-08-24,DS-CA-NPU-MDS;DS-LC-MDS,RNA-Seq,Cohort,Neoplasms,376.0,376.0,,,"Breast Neoplasms;Adenocarcinoma of Lung;Lung Neoplasms;Prostatic Neoplasms;Ovarian Neoplasms;Pancreatic Neoplasms;Meningioma;Cholangiocarcinoma;Carcinoma, Non-Small-Cell Lung;Carcinoma, Merkel Cell;Sarcoma;Osteosarcoma;Adrenocortical Carcinoma;Hodgkin Disease;Rhabdomyosarcoma","Carcinoma, Merkel Cell; Hodgkin Disease; Lung Neoplasms; Meningioma; Sarcoma; ADENOCARCINOMA OF LUNG"
Chromosome X Mosaicism Methylation Study,This study investigates methylation patterns in promoter regions on the X chromosomes of females with X chromosome mosaicism in an effort to phase mosaic events to either the active or  inactive X chromosome. Females with genotyping array detected X mosaic events greater than 2 Mb in size and with available DNA Principal,phs001112.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001112,Stephen Chanock,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),27291797,,2016-07-01,O-MDS_ONLY,Array_DNA_Methylation,Case Set,Neoplasms,33.0,33.0,,,Neoplasm,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Tissue Specimens from Patients with Melanoma for Genetic Analysis,"The purpose of this study was to obtain tissue specimens derived from patients with melanoma to generate research tools to advance our understanding of the genetics, pathogenesis, and therapeutics of  melanoma. Briefly, tissue was obtained from metastatic lesions and used to generate clonal primary cell lines from melanoma cells and fibroblasts",phs001115.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001115,"Carl D. Novina, PhD;Charles H. Yoon, MD, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,R01CA140986,2016-06-27,GRU,RNA-Seq,Case Set,"Melanoma, Cutaneous Malignant",3.0,6.0,,BRAF;NRAS,,"CMM; Cutaneous Malignant Melanoma; Cutaneous Malignant Melanomas; Cutaneous melanoma; MELANOMA, MALIGNANT; MM (malignant melanoma) of skin"
Somatic Reference Standard for Cancer Sequencing,"In this study, we separately performed PCR-free whole genome sequencing on the paired tumor/normal melanoma COLO-829 and lymphoblastoid COLO-829BL cell lines across three separate institutions (TGen, Illumina, Genome Sciences Centre  at the British Columbia Cancer Agency). We performed a meta-analysis of all data, in combination with the originally reported analysis of these cell",phs000932.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000932,"David Craig, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),20016485;27094764,Melanoma Research Alliance Melanoma Dream Team Translational Cancer Research Grant (#SU2C-AACR-DT0612),2016-06-15,GRU,Seq_DNA_SNP;WGA,Tumor vs. Matched-Normal,Melanoma,1.0,8.0,,,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma,"Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti-CTLA-4 treatment prolongs overall  survival in patients with melanoma. CTLA-4 blockade activates T cells and enables them to destroy tumor cells. We obtained tumor tissue from patients",phs001041.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001041,"Timothy Chan, MD, PhD, Vice Chair, Department of Radiation Oncology",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25409260;29132144,"Alexandra Snyder, MD",2016-06-10,HMB-PUB-NPU-MDS,WXS;Seq_DNA_SNP,Longitudinal Cohort,Melanoma,64.0,128.0,,,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Patient-Specific Factors Influence Somatic Variations in VHL Tumors,"Patients affected with von Hippel-Lindau disease are at risk of developing multiple independent clear cell renal carcinomas. This study performed whole genome sequencing on 40 tumors from 6 VHL patients  to compare somatic variation patterns within and between patients. Although tumors from the same patient showed many differences, within-patient",phs001107.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001107,"Paul Spellman, PhD;W. Marston Linehan, MD",Kathleen Calzone,Center for Cancer Research (CCR),27174753,"Intramural Research Program of the National Insititutes of Health;Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA",2016-06-08,DS-RCC-IRB,Seq_DNA_SNP;WGS,Tumor vs. Matched-Normal,von Hippel-Lindau Disease,6.0,51.0,,VHL,,"Angiomatoses, Familial Cerebello-Retinal; Angiomatoses, Familial Cerebelloretinal; Angiomatosis Retinae; Angiomatosis, Familial Cerebello-Retinal; Angiomatosis, Familial Cerebelloretinal; Cerebello-Retinal Angiomatoses, Familial"
DNA and RNA Sequence of an Acute Lymphoblastic Leukemia,"We used massively parallel sequencing technology to profile the genomic DNA and RNA of tumor cells (leukemic bone marrow) and normal cells (skin biopsy) obtained from a single patient with  Acute Lymphoblastic Leukemia (ALL), referred to throughout this study as 'ALL1'. Included in this study are samples obtained from a primary tumor,",phs001066.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001066,"Richard K. Wilson, PhD;Timothy Ley, MD",Ian Fingerman,Division of Cancer Biology (DCB),,P30 CA101937;U54 HG003079,2016-05-19,HMB,RNA-Seq;WXS;WGS,Case Set,Neoplasms,1.0,23.0,,,Leukemia,Leukemia; Blood (Leukemia); Blood cancer; Leucocythaemia; Leucocythaemias; Leucocythemia
Genomic Characterization of PDX Models for Breast Cancer Brain Metastases,"We have developed orthotopic patient-derived xenograft models of HER2 positive breast cancer metastasized into the brain of patients to test novel therapeutic strategies. In this study, we identified a novel  combinatorial therapeutic strategy that has resulted in a durable remission and markedly increased overall survival in majority of patient-derived",phs001063.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001063,"Jean J. Zhao, PhD;Keith L. Ligon, MD, PhD;Nancy U. Lin, MD;Eric P. Winer, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),27270588,,2016-05-12,GRU-IRB-PUB,WXS;Seq_DNA_SNP,Case Set,Breast Neoplasms,12.0,12.0,,AKT1;EIF4EBP1;ERBB2;MTOR;PIK3CA;RPS6,Neoplasm Metastasis;Brain Neoplasms;Neoplasm Transplantation;Molecular Targeted Therapy,Neoplasm Metastasis; Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour
Genomic Characterization of Pediatric Low-Grade Gliomas,"Pediatric low-grade gliomas (PLGGs) are the most common pediatric brain-tumor, with more than ten histologic subtypes recognized by the World Health Organization. We performed a genomic analysis of 230 PLGGs  of which 73 had whole genome/RNA sequencing performed and show that MYB-QKI fusions define the seizure associated tumor, Angiocentric Glioma (AG).",phs001054.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001054,"Adam Resnick, PhD;Rameen Beroukhim, MD, PhD;Keith L. Ligon, MD, PhD;Pratiti Bandopadhayay, MBBS, PhD;Lori Ramkissoon, PhD;Payal Jain;Guillaume Bergthold, MD;Azra Ligon, PhD;Mark Kieran, MD",,,26829751,,2016-04-06,DS-NTT;GRU,WXS;ChIP-Seq;RNA-Seq;WGS,Case Set,Glioma,80.0,93.0,,MYB;QKI,Astrocytoma,ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm; Astrocytoma (excluding glioblastoma); Astrocytomas
Use of WGS for Diagnosis and Discovery in the Cancer Genetics Clinic,"Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members  of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n 176) and those without (n 82). Initial analysis of potentially pathogenic",phs000942.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000942,"Theodora S. Ross, MD, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25099575;21677200;16021471;22344227;24941179;24941182;24251383;10213508;23460708;24055113;19892942;24896178;9322498;23788249;22703879;24487276;24733792;20719861;17942008;22699143;23035047;24319668;23622139;24510652;21173700;25318351;12645648;12545165;26023681,"Clinical Scientist Award ID# 1007448;Peter Bradley Carlson Charitable Trust, San Antonio, TX, USA;Jeanne Ann Plitt Professorship in Breast Cancer Research, Dallas, TX, USA;H. Ben and Isabelle T. Decherd Chair in Internal Medicine, Dallas, TX, USA;UL1TR001105",2016-03-03,NRUP;GRU-PUB-MDS,Seq_DNA_SNP_CNV;WGS,Cohort,Neoplasms,258.0,258.0,,NAT2;ACTA2;ACTC1;ACVRL1;ALAS2;APC;APOB;ASNS;SERPINC1;ATM;ATP7B;ATR;BARD1;BCHE;BLM;BMPR1A;BRCA1;BRCA2;CACNA1C;CACNA1S;CACNB2;CALCR;CASQ2;CD36;CDH1;CDK4;CDKN1A;CDKN2A;CDKN2B;CFTR;CHEK1;CHIT1;CLCN2;COL3A1;COL7A1;COL9A2;CPT2;CREBBP;CYP3A5;DMD;DMP1;DMPK;DPYD;DSC2;DSG2;DSP;EGFR;EMD;ENG;ERCC3;F5;FANCA;FBN1;FLG;FOLR1;FUT6;SLC37A4;GAA;GBE1;GCH1;GJA8;GLA;MSH6;GUCA1B;GYS2;HABP2;HAL;HEXA;FH;HFE;HIP1;HLA-G;HMBS;HOXB1;HRAS;IDUA;IGF2;INPP5B;JAK2;KCNE1;KCNH1;KCNH2;KCNJ2;KCNQ1;KDR;KIT;KRAS;KRT83;LAMB3;LDLR;LMNA;EPCAM;SMAD3;SMAD4;MEN1;MET;MGP;MITF;MLH1;MRE11A;MSH2;MUTYH;MYBPC3;MYH7;MYH11;MYL2;MYL3;MYLK;NBN;NF1;NF2;NME1;SLC11A2;NRAS;NTRK1;PAH;PCBD1;PCK2;PDGFRA;PEX6;SERPINA1;PKP2;PLN;PMS2;PRKAR1A;PRKCSH;PROC;PROS1;PRSS1;PTCH1;PTEN;PTPRQ;PTS;QDPR;RAD51;RAD51C;RAD51D;RB1;RBBP8;RET;RYR1;RYR2;SCN1B;SCN2A;SCN5A;SDHB;SDHC;SDHD;SGCD;HTT;SLC16A2;SMARCB1;SMO;STK11;AURKC;TGFB3;TGFBR1;TGFBR2;TNNI3;TNNT2;TNXB;TP53;TP53BP1;TPM1;TPMT;TSC1;TSC2;TTN;VHL;WNT10B;WRN;WT1;XRCC2;XRCC3;CNBP;ARID1A;DYSF;BAP1;DNAH11;RGS9;TNFRSF11A;HIP1R;PSTPIP1;H6PD;CEP135;CEP57;FIG4;MED12;KCNE2;KCNE3;HCN4;RAD50;SLC25A13;HOXB13;SEC23B;NPC2;PRPF8;GJB6;PNPLA6;SLC27A4;SLC7A9;LDB3;CHEK2;HPS5;ANKRD26;ICK;CEP164;GPD1L;SYNE1;GRIP1;TNFRSF13B;PIGN;PADI4;MMACHC;LDLRAP1;GREM1;HAVCR1;MLH3;COQ2;DMGDH;PDE11A;TMEM216;PRKAG2;NBAS;MYO3A;HYDIN;TRPM4;SAMD9;SDHAF2;ARMC4;CDK5RAP2;SCN3B;COQ9;RARS2;MIB1;FANCM;HAMP;ELAC2;CARD9;PINK1;C5orf42;FA2H;TMEM43;CDC73;TCTN1;GALNT12;PALB2;NHEJ1;BRIP1;FAM175A;MASTL;CCDC65;LRRK2;MTFMT;AGBL1;LOXHD1;OTOA;HFE2;TMPRSS6;ACSF3;FLCN;UNC13D;PCSK9;NPHP4;RBM20;CCDC39;OTOG;GEN1;KIF7;SLC26A5;SLC16A12,"Breast Neoplasms;Ovarian Neoplasms;Peritoneal Neoplasms;Skin Neoplasms;Esophageal Neoplasms;Thyroid Neoplasms;Urinary Bladder Neoplasms;Endometrial Neoplasms;Fallopian Tube Neoplasms;Melanoma;Testicular Neoplasms;Bile Duct Neoplasms;Lung Neoplasms;Colonic Neoplasms;Adrenocortical Carcinoma;Carcinoma, Renal Cell;Colonic Polyps;Adenomatous Polyposis Coli;Lymphoma, Large B-Cell, Diffuse;Pheochromocytoma;Paraganglioma;Leiomyoma;Hemangioblastoma;Hyperparathyroidism;Pancreatic Neoplasms;Vulvar Neoplasms;Brain Neoplasms;Liver Neoplasms;Kidney Neoplasms;Prostatic Neoplasms;Glioblastoma;Oncocytoma, renal",Adenomatous Polyposis Coli; Bile Duct Neoplasms; Colonic Polyps; Esophageal Neoplasms; Fallopian Tube Neoplasms; Hemangioblastoma
DNA Methylation Inhibitors in Immunotherapy,"We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway and re-expression of epigenetically silenced endogenous retrovirus. In melanoma patients treated with an  immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi",phs001038.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001038,"Timothy A. Chan, MD, PhD, Vice Chair, Department of Radiation Oncology;Stephen B. Baylin, MD;Jedd D. Wolchok, MD, PhD;Katherine B. Chiapinelli, PhD;Reiner Strick, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26317466,"CA058184;Epigenetic Dream Team;The Hodson Trust, MD, USA;The Samuel Waxman Cancer Research Foundation;Dr. Miriam and Sheldon G. Adelson Medical Research Foundation;Department of Defense (DOD) Teal Award BC031272;The Pershing Square Foundation and the Sohn Conference Foundation;STARR Cancer Consortium;The Ludwig Foundation;F32CA183214;The German Cancer Aid (Deutsche Krebshilfe 108215)",2016-03-02,HMB-PUB-NPU-MDS,RNA-Seq;Seq_RNA_Expression,Case Set,Melanoma,20.0,20.0,,BRAF;CTLA4;NRAS,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
The Mutational Landscape of CTCL and Sezary Syndrome.,Sezary syndrome is a leukemic and aggressive form of cutaneous T-cell lymphoma (CTCL) resulting from the malignant transformation of skin-homing central memory CD4+ T cells. To identify new genetic alterations  involved in Sezary syndrome and CTCL transformation we performed whole-exome sequencing of tumor-normal sample pairs from 26 Sezary syndrome and 16,phs000994.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000994,Teresa Palomero,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26551667,TRP award,2016-01-15,DS-CA-IRB-PUB,WXS,Longitudinal Cohort;Tumor vs. Matched-Normal,Sezary Syndrome,84.0,84.0,,,Mycosis Fungoides,"Mycosis Fungoides; CTCL / Sezary syndrome; Erythroderma, Sezary; Lymphoma, Sezary's; SC)zary syndrome; SEZARY SYNDROME, SOMATIC"
New England-Based Case-Control Study of Ovarian Cancer (NECC),"The case-control data provided to dbGaP were collected under NCI grant number CA54419 which had 3 enrollment phases: I (1992-1997), II (1998-2002) and III (2003-2008). Altogether, CA54419 funded 15 years  of data and specimen collection, resulting in one of the longest running population based case-control studies of ovarian cancer. The study goal was",phs001034.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001034,"Daniel W. Cramer, MD, ScD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),20852633;24190013;19648919;18973230;21415361;20056644;20628624;20559705;20719308;19127255;21636674;21482675;21385923;20142253;19276375;19858071;20817226;21532840;23050056;22749219;22961099;24740199;24272484;24764580;25940428;25528498;25940428;23650079;22267287;24551091;10667469;9439495;11668487;10209948;9718222;12146850;11821246;10667469;9439495;11668487;10209948;9718222;12146850;11821246;11237375;15894662;12946038;17389442;17666642;18057519;17220329;18632638;21277761;20943848;20850174;19117058;21953625;19902367;21471855;17194528;20576130;22361336;23925696;23456270;23339562;23364849;23404857;22740148;23315066;25189423;24473401;23307531;23535649;23569193;23761272;24503200;24462730;18768514;25066213;15718480;10904091,R01CA054419,2016-01-14,GRU-NPU,,Case-Control,Ovarian Neoplasms,4141.0,0.0,,,,"Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian"
The Genetic Landscape of Metastasis and Recurrence in HNSCC,Recurrence and/or metastasis occur in more than half of patients with head and neck squamous cell carcinoma (HNSCC) and pose the greatest threats to long-term survival. The genetic alterations underlying  recurrent/metastatic HNSCC are unknown. This study represents the first whole exome sequencing (WES) cohort study of patient-matched tumor pairs in,phs001007.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001007,"Jennifer Grandis, MD",Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,P50CA097190,2015-12-02,DS-CA-MDS,WXS,Case Set,Squamous Cell Carcinoma of Head and Neck,23.0,65.0,,ITPR3;DDR2;C17orf104,,Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx
Nurses' Health Study (NHS),"The Nurses' Health Study is an on-going prospective cohort study of women that was initiated in 1976. This specific study was part of a larger study to advance our knowledge  of breast cancer etiology, expand the current knowledge of mammographic density, and clarify the relationship between mammographic density and breast",phs000975.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000975,"Rulla Tamimi, ScD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25862352;25342443,R01CA131332,2015-12-02,GRU,Array_SNP,Case-Control,Breast Density,794.0,794.0,http://www.channing.harvard.edu/nhs/,,Breast Neoplasms,Mammographic Density; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors
Microdissected Pancreatic Cancer Whole Exome Sequencing,"109 micro-dissected pancreatic cancer cases and normal control tissue were subjected to whole-exome sequencing. Microdissection enriches tumor cellularity and enhances mutation calling. Inclusion: Diagnosis of pancreatic cancer with sufficient available  tumor tissue and normal control. Principal Investigator: Agnieszka Witkiewicz, University of Texas Southwestern Medical Center, Dallas, TX, USA",phs000953.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000953,Agnieszka Witkiewicz,Freddie Pruitt,Center for Cancer Genomics (CCG),25855536,,2015-11-30,DS-PACA-IRB-NPU-MDS,WXS,Longitudinal Cohort,Pancreatic Neoplasms,109.0,218.0,,,,"Cancer of the pancreas; Neoplasia of the pancreas; Neoplasm of Pancreas; Neoplasm of the Pancreas; Neoplasm, Pancreas; Neoplasm, Pancreatic"
PD-1 Blockade in Non-Small Cell Lung Cancer,"Patients with non-small cell lung cancer were treated with pembrolizumab. Their tumors and matched normal blood were sequenced. Inclusion: non-small cell lung cancer, treated with pembrolizumab Principal Investigators: Timothy Chan,  MD, PhD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA Principal Investigators: Matthew Hellmann, MD,",phs000980.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000980,"Timothy Chan, MD, PhD;Matthew Hellmann, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25765070;29132144,Geoffrey Beene Cancer Research Center;Society for Memorial Sloan Kettering Cancer Center;Frederick Adler Chair Fund;The STARR Foundation;Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant,2015-11-19,HMB-PUB-NPU,WXS;Seq_DNA_SNP_MAF_Sum,Cohort;Tumor vs. Matched-Normal,"Carcinoma, Non-Small-Cell Lung",34.0,68.0,,,,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER"
Sequencing of Targeted Genomic Regions Associated with Smoking,This study includes samples from two projects: Collaborative Genetic Study of Nicotine Dependence (COGEND; PI: Laura Bierut) and Genetic Study of Nicotine Dependence in African Americans (AAND; PI: Laura Bierut  and Eric Johnson). The majority of the COGEND subjects included in the current study overlap with the two datasets already available on dbGaP. GWAS,phs000813.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000813,"Laura J. Bierut, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),19207358;18482426;19596527;18519524;17716221;17158188;19760673;18583471;18065163;19172081;19280351;18629733;17644451;19184766;19706762;19259974;18759969;17135278;18565990;19381300;19298322;18783506;19029397;19706810;19443489;17210687;19896728;20700436;20584212;20700147;20061993;21079997;20840187;20624154;20871796;20663923;20202923;20091798;21173776;20585324;21102462;20718045;20300623;20844286;20531469,P01 CA089392;R01 DA025888;HHSN268201100011I,2015-10-23,HMB-MDS;NRUP,WXS;Seq_DNA_SNP;Array_SNP,Case-Control,Tobacco Use Disorder,2995.0,3098.0,https://zork5.wustl.edu/cogend/,,Smoking Cessation;Smoking,"Compulsive tobacco user syndrome; Dependence, Tobacco; Tobacco Dependence"
Genetic Analysis of Desmoplastic Melanoma,"Desmoplastic melanoma is an infrequent variant of melanoma with sarcomatous histology, distinct clinical behavior, and unknown pathogenesis. We performed low-coverage genome and high-coverage exome sequencing of 20 desmoplastic melanomas, followed  by targeted sequencing of 293 genes to validate candidate genes. A high mutation burden (median 62 mutations/Mb) ranked desmoplastic melanoma among",phs000977.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000977,"Boris C. Bastian, MD",Ian Fingerman,Division of Cancer Biology (DCB),24460190;26343386,P01 CA025874;R01 CA131524;Gerson and Barbara Bakar Distinguished Chair in Cancer Biology;Well Aging Research Center,2015-10-01,GRU;DS-M-MDS,WXS;WGS,Tumor vs. Matched-Normal,Melanoma,62.0,140.0,,NFKBIE,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Gut Microbiome Profiles and Risk of Colorectal Cancer,"Findings from recent studies suggest that the community of microbes residing in the human body is important in disease etiology; however, it remains unclear whether personal factors modulate human microbial  composition. Studies based on animal models indicate that differences in composition might be attributed to sex-mediated effects. We analyzed the",phs000884.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000884,"Jiyoung Ahn, PhD, MS, RD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),24316595,R03CA159414;R21CA183887;R01CA159036;UH3CA140233,2015-09-21,HMB-MDS,POOLCLONE,Control Set;Case-Control,Microbiota,240.0,240.0,,,Colorectal Neoplasms,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Phylogenetic Analyses Reveal Complex Patterns of Melanoma Metastasis,"Subpopulations of cells in a primary melanoma can disseminate and establish metastases. Still, the precise ancestral relationship between primary tumors and their metastases is not well understood. Using whole-exome sequencing  (for discovery) and targeted sequencing (for validation), we analyzed mutation patterns of primary melanomas and two or more metastases in each of 8",phs000941.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000941,Raymond J. Cho;Boris C. Bastian;Rajmohan Murali;Richard A. Scolyer,Mariam Eljanne,Center for Cancer Training (CCT),24265155;24265153,"Well Aging Research Center, Samsung Advanced Institute of Technology, under the auspices of Professor Sang Chul Park, 			the Dermatology Foundation, NIH, National Cancer Institute grants K08 CA169865 (R.J.C.), the Integrative Cancer Biology Program, 			U54 CA112970 and by the OHSU Knight Cancer Institute (J.W.G. and P.T.S.).",2015-09-18,GRU;DS-M-MDS,WXS,Tumor vs. Matched-Normal,Melanoma,8.0,39.0,,BRAF;CTNNB1;NF1,Neoplasm Metastasis;Phylogeny,"Neoplasm Metastasis; Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant"
Strong Activation of Retroviral LTRs in HCC,"The ncRNA transcriptome of human hepatocellular carcinoma (HCC) is largely unexplored. We used CAGE to characterize transcription start sites across different etiologies of human HCCs with emphasis on ncRNAs. Here  we report that retroviral LTR promoters, expressed in healthy tissues such as testis and placenta but not liver, are widely activated in HCC. Despite",phs000885.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000885,Piero Carninci;Jamila Faivre,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),23540693;24819516;26510915,Modhep (259743),2015-09-17,HMB-MDS,RNA-Seq;Seq_ncRNA_Expression,Case-Control,"Carcinoma, Hepatocellular",55.0,105.0,http://www.modhep.eu/,,,"Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells"
XPC and Non-XPC Cutaneous Squamous Cell Carcinoma Mutation Rate Study,"Base mutations occur at higher frequencies within heterochromatin and late-replicating DNA. In this study, we show that regional differences in mutation frequency are absent in portions of the genome that  are not transcribed within cutaneous squamous cell carcinomas (cSCCs) with an XPC-\- genetic background. The XPC-\- genetic background predicates a",phs000830.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000830,"Raymond J. Cho, MD, PhD",Mariam Eljanne,Center for Cancer Training (CCT),25456125,K08-CA169865;U54 CA112970,2015-09-16,DS-SKCA-MDS;DS-CA-MDS,WGS,Cohort,"Xeroderma Pigmentosum, Complementation Group C",13.0,26.0,,,"Carcinoma, Squamous Cell;Skin Neoplasms","Skin Neoplasms; Carcinoma, Epidermoid; Carcinoma, Planocellular; Carcinoma, Squamous; Carcinoma, Squamous Cell; Carcinomas, Epidermoid"
Genomic Analysis of Mycosis Fungoides and S&#x000e9;zary Syndrome,"Mycosis Fungoides (MF) and S&#x000e9;zary Syndrome (Sz) comprise the majority of Cutaneous T-Cell Lymphoma (CTCL) cases and are characterized by clinical heterogeneity. This array of symptoms includes skin patches, plaques  and tumors as well as blood involvement and erythroderma. Because the genetic basis of CTCL is still poorly understood, we performed whole-exome",phs000913.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000913,"Paul A. Khavari, MD, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),26258847,"Haas Family Foundation, San Francisco, CA, USA;Drs. Martin and Dorothy Spatz Charitable Foundation",2015-08-10,HMB,WXS;Array_SNP,Tumor vs. Matched-Normal;Case-Control,Mycosis Fungoides,93.0,170.0,,TNFRSF1B,Sezary Syndrome,"Sezary Syndrome; CTCL / Sezary syndrome; Erythroderma, Sezary; Lymphoma, Sezary's; SC)zary syndrome; SEZARY SYNDROME, SOMATIC"
Ghana Prostate Study,"Participants were recruited through the Ghana Prostate Study-a population-based component, and a clinical component. The population-based component was a probability sample designed using the 2000 Ghana Population and Housing Census  data in an attempt to recruit approximately 1,000 men aged 50-74 years in the Greater Accra region ( 3 million people), which successfully recruited",phs000838.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000838,"Michael B Cook, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),24185611;25217961;25027329;24747091;21912428;22111004;24783269;33398198,,2015-07-10,DS-UC-MDS,Array_SNP,Case-Control,Prostatic Neoplasms,932.0,932.0,http://dceg.cancer.gov/research/cancer-types/prostate/ghana-prostate-cancer-study,,Prostatic Hyperplasia,Prostatic Hyperplasia; BEP - Benign enlargement of prostate; BPH; BPH - benign prostatic hyperplasia; Benign Hyperplasia of Prostate; Benign Hyperplasia of the Prostate
NCI GWAS of Lung Cancer in Never Smokers,"A genomewide study of lung cancer in never smokers Abstract and specific aims In the United States, lung cancer incidence and mortality rates have been steadily declining over the past  decade, following decline in the prevalence of tobacco smoking. However, lung cancer remains the leading cause of cancer death, killing more patients",phs000634.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000634,"Olga Gorlova, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,R01 CA149462,2015-06-29,DS-CA;GRU-MDS,Array_SNP,Case-Control,Lung Neoplasms,2320.0,2320.0,,,,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
NCI GWAS of Renal Cell Carcinoma in African Americans,"The NCI GWAS of renal cell carcinoma (RCC) in African Americans was undertaken to provide insight into genetic loci affecting susceptibility to this malignancy in a racial group known to  be at elevated risk. We genotyped 1,136,723 single-nucleotide polymorphisms (SNPs) among 255 cases and 375 controls of African ancestry from the NCI",phs000863.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000863,"Jonathan Hofmann, PhD, MPH;Joanne Colt, MPH, MS",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),24220910;21881515,National Cancer Institute Intramural Research Program,2015-06-24,DS-RCC-NPU-MDS,Array_SNP,Case-Control,"Carcinoma, Renal Cell",630.0,650.0,,,,"ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell"
Pancreatic Cancer Case-Control Association Study,"Pancreatic cancer is the 4th leading cause of cancer death in the United States. This is in large part due to the rapidly fatal course of this disease, as the  vast majority of patients die within months of diagnosis and the five-year survival rate is less than 5. We have brought together over 8000",phs000648.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000648,Alison P. Klein,,,19318433;21251433;26098869,R01CA154823;HHSN268201200008I,2015-06-22,DS-PACA;NRUP,Array_SNP,Case-Control,Pancreatic Neoplasms,8093.0,8377.0,http://panc4.org/,,,"Cancer of the pancreas; Neoplasia of the pancreas; Neoplasm of Pancreas; Neoplasm of the Pancreas; Neoplasm, Pancreas; Neoplasm, Pancreatic"
Barrett's and Esophageal Adenocarcinoma Genetic Susceptibility Study    (BEAGESS),"BEAGESS is a genome-wide association study (GWAS) which takes advantage of the extensive data collected by investigators in the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON, http://beacon.tlvnet.net), representing many of the  high-quality population-based and other epidemiologic studies of BE and EA in the world. The overall goal of our research is to evaluate the",phs000869.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000869,"Thomas Vaughan, MD, MPH;David C. Whiteman, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),24121790;22961001;24168968;24943595;25269698;24530603;25280564;25447851,R01 CA136725,2015-06-19,NRUP;GRU-MDS,Array_SNP,Case-Control;Cohort,Esophageal Neoplasms,6931.0,6929.0,,,Barrett Esophagus,Barrett Esophagus; BARRETT METAPLASIA; BE; Barret syndrome; Barrett Metaplasias; Barrett Syndrome
Cancer Genetic Markers of Susceptibility for Bladder Cancer (CGEMS    Bladder),This study funded by the National Cancer Institute (NCI) involves conducting a genome-wide association study of common genetic variants to identify markers of susceptibility to bladder cancer. This bladder GWAS  has led to the discovery of three novel regions in the genome associated with bladder cancer risk. Cases were defined as individuals having,phs000346.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000346,Nathaniel Rothman;Montserrat Garcia-Closas;Debra Silverman;Stephen Chanock,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),20972438;21824976;24163127,Intramural program of NCI,2015-06-12,CADM,Array_SNP,Case-Control;Cohort,Urinary Bladder Neoplasms,11424.0,13060.0,,,Carcinoma,"Epithelial Carcinoma; Epithelial Neoplasm, Malignant; Epithelial Neoplasms, Malignant; Epithelial Tumor, Malignant; Epithelial Tumors, Malignant; Epithelioma"
San Francisco Bay Area Latina Breast Cancer Study,"The genome-wide association study (GWAS) includes participants enrolled into two different studies. The first study, the San Francisco Bay Area Cancer Study (SFBCS) is a population-based case-control study of breast  cancer conducted in the San Francisco Bay Area and included women ages 35-79 years from three racial/ethnic groups: Non-Hispanic whites, African",phs000912.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000912,"Elad Ziv, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),19047150;22228098;25327703,R01CA120120,2015-06-11,GRU-COL;DS-CABNHD-MDS,Imputation_SNP;Array_SNP,Case-Control,Breast Neoplasms,1165.0,1165.0,,,"Receptors, Estrogen;Receptors, Progesterone",Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
The Breast and Prostate Cancer Cohort Consortium (BPC3) GWAS of    Aggressive Prostate Cancer and ER- Breast Cancer,The Breast and Prostate Cancer Cohort Consortium (BPC3) was established in 2003 to pool data and biospecimens from nine large prospective cohorts to conduct research on gene-environment interactions in cancer  etiology. The BPC3 initially focused on the association of 70 candidate genes in the Steroid Hormone Metabolism and IGF pathways with risk of breast,phs000812.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000812,"David Hunter, ScD;Elio Riboli;Michael Thun;Susan Gapstur;Brian Henderson;Montserrat Garcia-Closas;Jonine D. Figueroa",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),22976474;21743057;16755295;33398198,U01 CA098233;U01 CA098216;U01 CA098710;U01 CA098758;Intramural Funds,2015-06-11,DS-BOED-MDS;HMB-PUB-MDS;CADM;GRU-MDS,Imputation_SNP;Array_SNP,Case-Control,Prostatic Neoplasms,12501.0,12501.0,http://epi.grants.cancer.gov/BPC3/,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Shanghai Breast Cancer Genetics Study (SBCGS),"The Shanghai Breast Cancer Genetics Study (SBCGS) includes data from four population-based studies conducted among Chinese women in urban Shanghai: the Shanghai Breast Cancer Study (SBCS), the Shanghai Breast Cancer  Survival Study (SBCSS), the Shanghai Women's Health Study (SWHS), and the Shanghai Endometrial Cancer Study (SECS, contributing controls only).",phs000799.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000799,"Wei Zheng, MD, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),19219042;10861490;16236996,R01CA124558;R01CA64277;R37CA70867;R01CA118229;UM1CA182910,2015-06-11,GRU-PUB-NPU,Seq_DNA_SNP;Imputation_SNP,Case-Control,Breast Neoplasms,5152.0,5152.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Multiethnic Cohort (MEC) Breast Cancer Genetics,"The Multiethnic Cohort Study is a population-based prospective cohort study (n 215,251) that was initiated between 1993 and 1996 and includes subjects from various ethnic groups - African Americans and  Latinos primarily from Californian (great Los Angeles area) and Native Hawaiians, Japanese-Americans, and European Americans primarily from Hawaii.",phs000517.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000517,"Chris Haiman, ScD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),10695593,R01 CA132839;W81XWH-08-1-0383,2015-06-11,DS-CA;HMB-MDS;GRU-MDS,Imputation_SNP;Array_SNP,Case-Control,Breast Neoplasms,3708.0,3790.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
CGEMS Breast Cancer GWAS,"The initial stage of the Cancer Genetic Markers of Susceptibility (CGEMS) breast cancer genome-wide association study (GWAS) included genotyping 528,173 SNPs (Illumina HumanHap550) in 1,145 postmenopausal women of European ancestry  with invasive breast cancer and 1,142 controls from the Nurses' Health Study (NHS). Subsequently, incident invasive breast cancer cases from the",phs000147.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000147,Stephen J. Chanock;David J. Hunter;Margaret Tucker;Daniela S. Gerhard;Joseph F. Fraumeni;Robert Hoover;Gilles Thomas,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),17529973;22976474;15864280;16489055,,2015-06-11,GRU,WXS;Imputation_SNP;Array_SNP,Case-Control,Breast Neoplasms,2576.0,2723.0,http://cgems.cancer.gov/;http://cgems.cancer.gov/ and http://www.channing.harvard.edu/nhs/,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Transcriptome Sequencing of Pediatric Neuroblastoma,"Neuroblastoma is the most common extra-cranial solid tumor in children. It represents 8% to 10% of all childhood cancers. Stage 4 Neuroblastoma is characterized by its clinical heterogeneous outcome. The  special category, stage 4S tumors (2-5% of all NB) are chemo-sensitive, and the patients show spontaneous regression. On the other hand, MYCN",phs000868.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000868,Javed Khan,Kathleen Calzone,Center for Cancer Research (CCR),,"National Cancer Institute, National Institutes of Health, Bethesda, MD, USA",2015-06-05,GRU,RNA-Seq,Case Set,Neuroblastoma,29.0,29.0,http://home.ccr.cancer.gov/oncology/oncogenomics/,MYCN,,Not Provided
Prediction of Trastuzumab Benefit in Adjuvant Breast Cancer: NSABP B31,"Background National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive  model for degree of benefit from trastuzumab using archived tumor blocks from B-31. Methods Case subjects with tumor blocks were randomly divided",phs000826.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000826,Soonmyung Paik,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),16236738;24262440,PA-Cure Grant;U10-CA-12027;U10-CA-69651;U10-CA-37377;U10-CA-69974,2015-05-12,DS-CA-IRB-MDS,Array_miRNA_Expression,Clinical Trial;Phase III,Breast Neoplasms,1579.0,1579.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Functionally-defined Therapeutic Targets in DIPG,"Diffuse Intrinsic Pontine Glioma (DIPG) is a universally fatal childhood cancer. Here, we performed a chemical screen in patient-derived DIPG cell cultures along with RNAseq expression analysis and integrated computational  modeling to identify potentially effective therapeutic strategies. Panobinostat, among the more promising agents identified, demonstrated efficacy in",phs000900.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000900,Charles Keller,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25939062,Lyla Nsouli Foundation,2015-05-01,GRU,RNA-Seq;WXS,Cohort,Glioma,22.0,75.0,,,,Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia
Longitudinal Genome-Wide Analysis of Patients with Chronic Lymphocytic    Leukemia,"Samples from two-center prospective phase 2 clinical trail conducted at Ohio State University (Columbus, OH) and Mayo Clinic (Rochester, MN) were analyzed in 12 cases. All patients had progressive CLL  as defined by National Cancer Institute (NCI) Working Group criteria. Patients provided written informed consent for correlative studies according to",phs000794.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000794,"Esteban Braggio, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),22261920;25377784,CA95241;Henry Predolin Foundation (Intramural Mayo Clinic Funding);The Marriott Specialized Workforce Development Awards in Individualized Medicine,2015-04-15,GRU-MDS,WXS,Longitudinal,"Leukemia, Lymphocytic, Chronic, B-Cell",12.0,42.0,,DDX3X;NOTCH1;SF3B1,,"B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic"
ICPCG Genome Wide Association Study of Familial Prostate Cancer,"Initially, the ICPCG focused largely on high-risk prostate cancer pedigrees using linkage analysis. However, association studies have also been informative to find prostate cancer susceptibility variants in the genome. We  hypothesize that genome-wide (GW) association studies of familial cases of prostate cancer will have the power to identify rarer and perhaps less",phs000733.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000733,"Lisa Cannon Albright, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),22712434;21748754;23064873,"R01 CA089600;HHSN268201200008I, NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2015-03-10,DS-PC;NRUP,Imputation_SNP;Array_SNP,Case-Control,"Prostate cancer, familial",4036.0,4181.0,http://www.icpcg.org/,,,Familial malignant neoplasm of prostate; Hereditary prostate cancer
Comparative Analysis of Primary and Metastatic Colorectal Cancer,"Molecular profiling for somatic mutations that predict response to anti-EGFR therapy in colorectal cancer (CRC) has become standard practice. However, abundant tissue from metastatic lesions is not always available from  patients with metastatic CRC. Concerns involving genetic heterogeneity between primary and metastatic lesions have called into question the",phs000790.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000790,"Michael Berger, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25164765,,2015-01-29,GRU-MDS,Seq_DNA_SNP_MAF_Ind;WGS,Cohort,Colorectal Neoplasms,4.0,12.0,,,Colonic Neoplasms,"CA - Cancer of colon; COLON CANCER; Cancer of Colon; Cancer of the Colon; Cancer, Colon; Cancer, Colonic"
Osteosarcoma Genomics,"In this study we attempt to elucidate the genomic characteristics of osteosarcoma. Clinical characteristics 58 tumor / normal pairs from 58 patients were included in the study. Median age at  diagnosis was 12 years. 49% of the patients were male and 47% had metastases at diagnosis. 5 year overall survival was 49% for the entire population,",phs000699.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000699,Todd Golub,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),25512523,,2015-01-07,DS-CA-NPU-MDS,RNA-Seq;Seq_DNA_SNP_MAF_Ind;WXS;WGS,Case Set,Osteosarcoma,58.0,116.0,,,,Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma
Towards a Genomic Understanding of Myeloma,This project was designed to describe genetic abnormalities in primary samples from patients with multiple myeloma by next generation sequencing. We generated sequence data from multiple myeloma (MM) patients analyzing  DNA both from tumor cells (purified from bone marrow using CD138 selection as a marker of plasma cells) and from normal peripheral blood cells,phs000348.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000348,Todd Golub,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,"Multiple Myeloma Research Foundation, Norwalk, CT, USA",2014-12-22,DS-CCRD-MDS;GRU-MDS,WXS;Seq_DNA_SNP_MAF_Sum;WGS,Tumor;Cohort,Multiple Myeloma,204.0,409.0,http://www.themmrf.org/,,,"Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma; Kahler Disease"
Characterization of a Metastatic Cervical Cancer Using NGS,"In this study, we used shallow whole genome, exome, and RNA sequencing to genomically and transcriptomically characterize a cervical squamous carcinoma lesion metastatic to the lung and to detect and  analyze HPV infection in the same sample. Principal Investigator: Winnie S. Liang, PhD, Translational Genomics Research Institute, Phoenix, AZ, USA",phs000628.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000628,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-12-16,GRU-MDS,RNA-Seq;Seq_DNA_SNP;WXS;WGS,,Uterine Cervical Neoplasms,3.0,7.0,,,,"Epithelial Carcinoma; Epithelial Neoplasm, Malignant; Epithelial Neoplasms, Malignant; Epithelial Tumor, Malignant; Epithelial Tumors, Malignant; Epithelioma"
Oncogenomics of Malignant Peripheral Nerve Sheath Tumors,"Malignant peripheral nerve sheath tumors (MPNSTs) are a group of highly aggressive soft tissue sarcomas that may occur sporadically, in association with neurofibromatosis type I (NF1-associated), or after radiotherapy (RT-associated).  We utilized comprehensive genomic approaches and identified recurrent loss-of-function somatic alterations in the Polycomb repressive complex 2",phs000792.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000792,Ping Chi,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-11-24,GRU-PUB-MDS,RNA-Seq;WXS;Array_SNP,Case Set,Neurilemmoma,18.0,46.0,,,Nerve Sheath Neoplasms;Neoplasms,Nerve Sheath Neoplasms; Blastoma; CA; CA - Cancer; Cancer; MT
Genomic Analysis of Peripheral T-Cell Lymphomas,"Peripheral T-cell lymphomas (PTCLs) are a heterogeneous and poorly understood group of non Hodgkin lymphomas. We aim to identify new genetic alterations in PTCL transformation by using a combination of  whole exome sequencing of tumor-normal DNA pairs, RNAseq analysis and targeted deep sequencing of candidate genes. Our data identified highly",phs000689.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000689,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-11-18,DS-CA-PUB-MDS,RNA-Seq;WXS,,"Lymphoma, T-Cell, Peripheral",59.0,55.0,,,,"Lymphoma, Non-Hodgkin; Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology"
Exome Sequencing of Pleuropulmonary Blastoma,"Pleuropulmonary blastoma (PPB) is a rare, aggressive pediatric cancer arising from the lung or pleural cavity. In this study, we sequenced and analyzed the exomes of 15 PPB matched tumor  and normal pairs. This study is part of a larger effort to characterize pediatric cancers as part of the Slim Initiative for Genomic Medicine (SIGMA)",phs000543.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000543,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-11-06,GRU-MDS,WXS;Seq_DNA_SNP_MAF_Ind,,Pleuropulmonary blastoma,15.0,30.0,,,,
Genetic Predictors of Adverse Radiotherapy Effects (Gene-PARE),"The goal of this study was to identify SNPs and CNPs that are associated with development of normal tissue toxicities resulting from radiotherapy for prostate cancer. The study population includes  approximately 1,400 men treated with brachytherapy, external beam radiation therapy, or a combination of the two treatments, and assessed for adverse",phs000772.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000772,"Barry S. Rosenstein, PhD;Harry Ostrer, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),23719583;23376709;23021708;24785509;24441285;24974847,R01CA134444,2014-10-17,NRUP;GRU-MDS,Array_SNP,Cohort,Prostatic Neoplasms,787.0,848.0,,,Proctitis;Urinary Tract Physiological Phenomena;Erectile Dysfunction,"Erectile Dysfunction; Proctitis; Abnormal erection; Dysfunction, Erectile; Erectile abnormalities; Failure of erection"
Genomics of Circulating Tumor Cells,"Comprehensive analyses of cancer genomes in clinical settings promise to inform prognoses and guide the deployment of precise cancer treatments. A major barrier, however, is the inaccessibility of adequate metastatic  tissue for accurate genomic analysis in prostate and other cancers. A potential solution is to characterize circulating tumor cells (CTCs), but this",phs000717.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000717,Christopher Love;Todd Golub;Jesse Bohem,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-10-17,DS-PC-MDS,WXS;Seq_DNA_SNP_MAF_Ind,Case Set,Prostatic Neoplasms,2.0,48.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
GWAS of Familial Lung Cancer,"Familial lung cancer cases were collected by the Genetic Epidemiology of Lung Cancer Consortium (GELCC) recruitment sites: University of Cincinnati, Karmanos Cancer Institute at Wayne State University, Louisiana State University  Health Sciences Center-New Orleans, Mayo Clinic, and Medical College of Ohio. Familial cases for this study came from three sources: 1) one case each",phs000629.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000629,"Ann G. Schwartz, PhD, MPH",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),15272417;20215501;19351763,"U01CA76293;HHSN268201100011I. NIH contract ""High throughput genotyping for studying the genetic contributions to human disease""",2014-10-16,NRUP;DS-LC-IRB-COL-MDS,Imputation_SNP;Array_SNP,Case-Control,Lung Neoplasms,1571.0,1620.0,,,,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
Spectrum of Mutations in Myeloid Neoplasms,Patients with myeloid malignancies bearing high-risk cytogenetic abnormalities lack effective therapies and have a poor overall survival. -7/del(7q) is identified in half of high-risk myeloid neoplasms. We recently identified CUX1  to be a haploinsufficient myeloid tumor suppressor gene located within the commonly deleted segment of 7q22. Here we identify the spectrum of somatic,phs000759.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000759,"Kevin White, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),24931631;25043302,"P01 CA040046;Leukemia and Lymphoma Society, White Plains, NY, USA;Cancer Research Foundation, Chicago, IL, USA;Chicago Cancer Genomes Project",2014-10-08,GRU-MDS,RNA-Seq;WXS,Tumor vs. Matched-Normal,"Leukemia, Myeloid, Acute",18.0,25.0,,,"Neoplasms, Therapy Related;Monosomy 7",Monosomy 7; AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult
High Density SNP Association Analysis of Lung Cancer,"This research builds upon an extensive resource of a case-control study that has been ongoing at the UT MD Anderson Cancer Center since 1991. To identify risk variants for lung  cancer, we conducted a genome-wide association study. Cases are newly diagnosed, histologically-confirmed patients presenting at MD Anderson Cancer",phs000753.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000753,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-09-30,GRU-MDS,Array_SNP,,Lung Neoplasms,2290.0,2290.0,,,,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
The UC San Diego Chronic Lymphocytic Leukemia (CLL) Study,"The UC San Diego Chronic Lymphocytic Leukemia Study is designed to identify genetic, epigenetic, and transcriptional changes important for CLL. This data release consists of samples collected to 1) identify  genomic changes associated with CLL progression using serially collected tumor samples; 2) characterize the transcriptional consequences of SF3B1",phs000767.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000767,Thomas J. Kipps,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,1R21CA152613;PO1-CA81534;DR1-01430,2014-07-11,DS-CLL,RNA-Seq;AMPLICON,Tumor vs. Matched-Normal,"Leukemia, Lymphocytic, Chronic, B-Cell",49.0,177.0,,,,"B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic"
Follicular Lymphoma 2013 - Malek,"A cohort of follicular lymphoma cases had tumor cells purified from tissue samples after informed consent using flow cytometry. DNA was extracted from the cells, and samples were subjected to  solution-based exome capture using the Illumina TruSeq Exome Enrichment Kit and the Illumina HiSeq 2000 platform. Patients were enrolled between 2008",phs000729.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000729,"Sami N. Malek, MD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),24435047,,2014-06-24,DS-LYM-MDS,WXS;Seq_DNA_SNP,Case Set,"Lymphoma, Follicular",9.0,18.0,,,"Lymphoma, Non-Hodgkin","Lymphoma, Non-Hodgkin; Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers; FOLLICULAR LYMPHOMA, SOMATIC"
RAD50 Hypomorphism as Basis for Response to Chemotherapy,"Outlier analyses represent a versatile method to identify predictive biomarkers of response to both targeted agents and chemotherapy. We performed whole genome sequencing (WGS) of tumor and germline blood from  a patient with metastatic small cell carcinoma of the ureter who experienced a durable complete response to a combination of irinotecan plus AZD7762,",phs000706.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000706,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-06-19,GRU-MDS,OTHER;WGS,,Ureteral Neoplasms,1.0,5.0,,,,"Neoplasia of the ureters; Neoplasm of Ureter; Neoplasm of the Ureter; Neoplasm, Ureteral; Neoplasms of Ureter; Neoplasms of the Ureter"
Osteosarcoma Genome-Wide Association Study,"This is a genome-wide association study (GWAS) of osteosarcoma, the most common primary bone malignancy. Osteosarcoma typically occurs in adolescents and young adults. It occurs at increased frequency in several  inherited cancer predisposition syndromes but the genetic contribution to sporadic osteosarcoma is largely unexplored. The objective of this study",phs000734.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000734,"Sharon A. Savage, MD;Lisa Mirabello, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),23727862,Intramural Research Program,2014-06-10,GRU,Array_SNP,Case Set,Osteosarcoma,694.0,717.0,,,,Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma
GWAS of Lung Cancer Susceptibility in Never-Smoking Women in Asia,"To learn about the etiology of lung cancer among never-smoking women in Asia, we formed the Female Lung Cancer Consortium in Asia (FLCCA), which includes studies of lung cancer in  Eastern Asia and conducted a GWAS. We analyzed a total of 5510 lung cancer cases and 4544 controls and identified 3 novel loci (Lan et al., 2012). Of",phs000716.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000716,,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,,2014-06-04,DS-LC-MDS,Array_SNP,,Lung Neoplasms,8881.0,9178.0,,,,"Adenocarcinoma; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant; Malignant Adenoma"
The Genome and Transcriptome of Fibrolamellar Hepatocellular Carcinoma,Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare liver tumor primarily affecting adolescents and young adults. Little is known of the molecular pathogenesis. To characterize the disease we performed RNA sequencing  and whole genome sequencing on FL-HCC tumors and adjacent normal tissue. The results demonstrate few consistent differences on the chromosomal level,phs000709.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000709,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-05-09,DS-CA-IRB-MDS,RNA-Seq,,Fibrolamellar hepatocellular carcinoma,11.0,29.0,,,,"Carcinoma, Hepatocellular; Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells"
Identification of Recurrent SMO and BRAF Mutations in Ameloblastomas,"RNA-seq data from two cases of ameloblastoma was analyzed for candidate gene fusions and point mutations. Recurrent point mutations identified in the RNA-seq data, as well as mutations identified with  limited panel targeted deep sequencing, were validated as somatic. Expanding to a larger cohort of 28, one of two activating mutations was found in",phs000739.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000739,"Robert West, MD, PhD;Jonathan Pollack, MD;Philip Beachy, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),13707265;24374844;15128061,Stanford Department of Pathology,2014-05-05,GRU-MDS,Seq_RNA_Expression;AMPLICON,Cohort,Ameloblastoma,7.0,7.0,,,"SMO protein, human;BRAF protein, human",
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma,This study was the first-known large-scale effort to uncover the mutational spectrum of head and neck cancers. We analyzed whole-exome sequence from 92 tumor-normal pairs and retained 74 of them  for significance analysis. The majority exhibited a mutational profile consistent with tobacco exposure; human papilloma virus sequence was,phs000370.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000370,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-04-17,DS-CA-MDS,WXS;Seq_DNA_SNP_MAF_Ind,,Head and Neck Neoplasms,92.0,184.0,,,,"Head Neoplasm; Head Neoplasms; Neoplasm, Head; Neoplasms, Head"
A Multiethnic Genome-wide Scan of Prostate Cancer,"Multiple GWA studies of prostate cancer conducted in European White populations are ongoing. These studies will continue to have a dramatic impact on our understanding of the contribution of common  genetic variation on inter-individual susceptibility to this common cancer. Important questions that will remain unanswered, however, are whether all",phs000306.v4.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000306,"Christopher Haiman, ScD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),10695593;17401364;33398198,U01 HG004726,2014-04-17,DS-PC;CHDSADM;GRU-MDS;HMB-PUB-MDS;NRUP;DS-CA-PUB-MDS,Imputation_SNP;Array_SNP,Cohort;Nested Case-Control,Prostatic Neoplasms,9482.0,11325.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Acquired Copy Number Alterations in Adult Acute Myeloid Leukemia Genomes,"We performed genome-wide copy number analysis with paired normal and tumor DNA obtained from 86 adult patients with de novo AML using the Affymetrix Genome-Wide Human SNP array 6.0 containing  1.85 million features. Acquired copy number alterations (CNA) were confirmed using an independent, higher resolution, custom array comparative",phs000201.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000201,,Ian Fingerman,Division of Cancer Biology (DCB),,,2014-04-17,DS-HEM-MDS-GSO,Array_SNP,,"Leukemia, Myeloid, Acute",86.0,172.0,,,,AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL
Identification of Targetable FGFR Gene Fusions in Diverse Cancers,"In this study, patients with advanced cancer across all histologies were enrolled in our IRB approved clinical sequencing program, called MI-ONCOSEQ, to go through an integrative sequencing which includes whole  exome sequencing of the tumor and matched normal, and transcriptome sequencing. Four index cases were identified which harbor gene rearrangements of",phs000602.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000602,,Natalie Abrams,Division of Cancer Prevention (DCP),,,2014-04-16,DS-CA-MDS,RNA-Seq,,Neoplasms,7.0,6.0,,,,Mouth Neoplasms; Urinary Bladder Neoplasms; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor
Temporal Dissection of Tumorigenesis in Primary Cancers,"The earliest genetic abnormalities in cancer represent a unique opportunity for timely clinical diagnosis. Classic deep sequencing of tumors identifies many aberrations acquired later in cancer progression. In this study,  data regarding simple mutation and chromosomal aberration were integrated to trace the evolution of cutaneous squamous cell carcinomas and ovarian",phs000418.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000418,,Ian Fingerman,Division of Cancer Biology (DCB),,,2014-04-16,DS-CA-IRB-MDS,WXS,,"Carcinoma, Squamous Cell",8.0,16.0,,,,"Carcinoma, Epidermoid; Carcinoma, Planocellular; Carcinoma, Squamous; Carcinomas, Epidermoid; Carcinomas, Planocellular; Carcinomas, Squamous"
Sequencing of ETP T-ALL,"CREST The accurate identification of structural variations using whole-genome DNA sequencing data generated by next-generation sequencing technology is extremely difficult. To address this challenge, we have developed CREST, an algorithm  that uses sequencing reads with partial alignments to the reference human genome (so-called soft-clipped reads) to directly map the breakpoints of",phs000340.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000340,,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2014-04-16,GRU-MDS,RNA-Seq;WXS;WGS;Array_SNP,,"Leukemia, T-Cell",106.0,196.0,,,,"Leukemia, Lymphocytic, T Cell; Leukemia, Lymphocytic, T-Cell; Leukemia, T Cell; Leukemia, T Lymphocytic; Leukemia, T-Cell Lymphocytic; Leukemia, T-Lymphocytic"
Genomic Characterization of Meningiomas,"Meningiomas are the most common primary brain tumor in the US. Although the tumor suppressor gene NF2 is disrupted in approximately half of meningiomas, the complete spectrum of genetic changes  in meningiomas remains poorly understood, particularly in the large subset of tumors without NF2 alterations. Therefore we performed whole-genome",phs000552.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000552,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-04-15,DS-BDBC-NPU-MDS,WXS;WGS;Seq_DNA_SNP_CNV;AMPLICON,,Meningioma,65.0,130.0,,,,"Diffuse meningiomatosis; Meningioma, Multiple; Meningiomas, Multiple; Meningiomatoses; Meningiomatosis; Multifocal meningiomata"
Genomic Sequencing of Pediatric Rhabdoid Cancers,"In this study, we sequenced the exomes of 35 rhabdoid tumors, highly aggressive cancers of early childhood. This study is part of a larger effort to characterize pediatric cancers as  part of the Slim Initiative for Genomic Medicine (SIGMA) project. Principal Investigator: Charles Roberts, MD, PhD, Dana Farber Cancer Institute,",phs000508.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000508,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-04-15,DS-CA-MDS;PCR,WXS;Seq_DNA_SNP_MAF_Sum,,Rhabdoid Tumor,35.0,70.0,,,,
Functionally Active Copy Number Variants Associated with Prostate Cancer    Risk,"Prostate cancer is a leading cause of cancer death in males throughout the world and has the largest estimated effect of heritability among the most common tumor types. Copy Number  Variants (CNVs) are a recently recognized class of human germline polymorphisms (Iafrate AJ, et al. (2004) Nat Genet 36, 949-951; Sebat J, et al.",phs000487.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000487,,Natalie Abrams,Division of Cancer Prevention (DCP),,,2014-04-15,DS-PC-NPU-MDS-GSO,Array_CNV,,Prostatic Neoplasms,1903.0,1903.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
FHCRC - Whole-Exome Sequencing of Hereditary Prostate Cancer Families,"The specific aim of this study is to identify hereditary prostate cancer (HPC) susceptibility genes using a novel study design, whereby whole-exome sequencing will be undertaken on multiple affected relatives  from 19 HPC families, in which &#x02265; 3 affected relatives were diagnosed with clinically aggressive and/or early onset prostate cancer (PC).",phs000350.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000350,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-04-01,NRUP;GRU-MDS,WXS,,Prostatic Neoplasms,283.0,96.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Genomic Sequencing of Cervical Cancers,"Cervical cancer is responsible for 10-15% of cancer related deaths in women worldwide. The etiological role of infection with high-risk human papilloma viruses (HPV) in carcinomas of the cervix is  well established. In general, the development of cervical carcinomas follows a progression from persistent HPV infection through precancerous lesions",phs000600.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000600,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-03-19,DS-CA-MDS,RNA-Seq;Seq_DNA_SNP_MAF_Ind;WXS;WGS,,Uterine Cervical Neoplasms,115.0,230.0,,,,"Cervical Neoplasm, Uterine; Cervical Neoplasms; Cervical Tumor; Cervical neoplasm; Cervix Neoplasm; Cervix Neoplasms"
UNC Hepatocellular Carcinoma Study by Exome Sequencing (HCCSES),"Genetic alterations in specific driver genes lead to disruption of cellular pathways and are critical events in the instigation and progression of hepatocellular carcinoma. As a prerequisite for individualized cancer  treatment, we sought to characterize the landscape of recurrent somatic mutations in hepatocellular carcinoma. We performed whole exome sequencing on",phs000627.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000627,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2014-03-14,GRU-MDS,WXS;Seq_DNA_SNP,,"Carcinoma, Hepatocellular",87.0,174.0,,,,"Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells"
Whole Exome Sequencing for Colorectal Cancer,This project was designed to use next generation sequencing technology to screen the protein coding regions of the genome for low frequency variants in a panel of high-risk colorectal adenocarcinoma  cases. Blood and cell-line DNA for colorectal cancer patients and a subset of quality control samples that had existing whole exome sequence data,phs000410.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000410,"Ulrike Peters, PhD",,,8859178;9427430;8988044;9492970;12117397;16467233,"U01 CA137088;R01 CA48998;N01 WH22110;N01 WH24152;N01 WH32100-2;N01 WH32105-6;N01 WH32108-9;N01 WH32111-13;N01 WH32115;N01 WH32118-32119;N01 WH32122;N01 WH42107-26;N01 WH42129-32;N01 WH44221;X01 HG006196-01;HHSN268200782096C ""High throughput genotyping for studying the genetic contributions to human disease"";HHSN268201100011I ""High throughput genotyping for studying the genetic contributions to human disease""",2014-03-14,GRU-NPU-MDS;GRU-MDS,WXS,Case-Control,Colorectal Neoplasms,165.0,174.0,http://www.whiscience.org/,,"Sequence Analysis, DNA","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Study of Melanoma Risk in Australia and the United Kingdom,"The results from a small number of melanoma GWAS have been published. Initial studies identified several pigmentation- and nevus-associated loci that mediate an effect on melanoma risk, however, these studies  were somewhat limited in that sample number (hence power) was low, they used first-generation low density SNP arrays, or used pools of DNA samples.",phs000519.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000519,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-03-12,DS-M-MDS;NRUP;GRU-MDS,Array_SNP,,Melanoma,3952.0,4079.0,,,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Genentech Lung Cancer Sequencing,"Version 1 Whole genome sequencing was applied to tumor and adjacent normal lung tissue in an individual non-small-cell lung cancer patient. We present an analysis of somatic changes identified throughout  the tumor genome, including single-nucleotide variants, copy number variants, and large-scale chromosomal rearrangements. Over 50,000 high-confidence",phs000299.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000299,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2014-02-28,HMB-MDS,RNA-Seq;WGS,,Lung Neoplasms,21.0,25.0,,,,"Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell"
An APOBEC Cytidine Deaminase Mutagenesis in Human Cancers,"Reprinted from Roberts et al. ""An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers"", Nature Genetics, 45:970-976, 2013, with permission of Nature Publishing Group: Recent studies indicate that  a subclass of APOBEC cytidine deaminases, which convert cytosine to uracil during RNA editing and retrovirus or retrotransposon restriction, may",phs000677.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000677,,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2013-12-20,GRU,Seq_DNA_SNP_MAF_Ind,,Neoplasms,5427.0,5427.0,,,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
Cohort-Based Genome-Wide Association Study of Glioma (GliomaScan),"We conducted a new independent GWAS of adult glioma using 1,856 cases and 4,955 controls from 14 cohort studies belonging to the Cohort Consortium, 3 case-control studies, and 1 population-based  case only study. Cases were newly diagnosed glioma [ICDO-3 codes 9380-9480 or equivalent], and controls were cancer-free at the time of glioma",phs000652.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000652,,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,,2013-12-17,DS-GAO-GSO;CADM,Array_SNP,,Glioma,6811.0,7072.0,,,,Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia
DNA Methylation Analysis of Prostate Cancer,Aberrant DNA methylation changes are known to occur during prostate cancer progression beginning with precursor lesions. Utilizing fifty nanograms of genomic DNA in Methylplex-Next Generation Sequencing (M-NGS) we mapped the  global DNA methylation patterns in prostate tissues (n 17) and cells (n 2). Peaks were located from mapped reads obtained in each sequencing run,phs000597.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000597,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2013-11-26,DS-CA-MDS,OTHER,,Prostatic Neoplasms,17.0,19.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
NGS in Advanced Cancers,"In this study, we used NGS to identify somatic events in advanced stage cancer patients to demonstrate the feasibility for using this approach to improve patient treatment. Principal Investigator: Glen  Weiss, MD, Translational Genomics Research Institute, Phoenix, AZ, USA Co-Investigator: Winnie Liang, PhD, Translational Genomics Research Institute,",phs000657.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000657,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2013-11-20,GRU-MDS,RNA-Seq;WXS;WGS,,Carcinoma,15.0,31.0,,,,"Epithelial Carcinoma; Epithelial Neoplasm, Malignant; Epithelial Neoplasms, Malignant; Epithelial Tumor, Malignant; Epithelial Tumors, Malignant; Epithelioma"
Genome-Wide Analysis of Chronic Lymphocytic Leukemia,"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation The pathogenesis of chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is still largely unknown  since the full spectrum of genetic lesions that are present in the CLL genome, and therefore the number and identity of dysregulated cellular",phs000364.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000364,,Ian Fingerman,Division of Cancer Biology (DCB),,,2013-11-15,DS-CA-PUB-MDS,WXS;Array_SNP,,"Leukemia, Lymphocytic, Chronic, B-Cell",43.0,61.0,,,,"B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic"
Somatic Mutations in Variant and IGHV4-34 Expressing Hairy Cell Leukemia,"To understand the genetic mechanisms driving variant and IGHV4-34 expressing hairy-cell leukemia, we performed whole exome sequencing of tumor/normal pairs from ten patients. All patients have either IGHV4-34 expressing classic  hairy cell leukemia, IGHV4-34 expressing variant hairy-cell leukemia, or IGHV4-34 non-expressing variant hairy-cell leukemia. Principal Investigator:",phs000671.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000671,,Kathleen Calzone,Center for Cancer Research (CCR),,,2013-11-14,HMB-MDS,WXS;Seq_DNA_SNP,,"Leukemia, Hairy Cell",10.0,20.0,,,,"HCL; HCL - Hairy cell leukemia; HCL-C; Hairy Cell Leukemias; LRE - Leukemic reticuloendotheliosis; Leukemias, Hairy Cell"
Small Intestine Neuroendocrine Tumors (Carcinoid Tumors),"The diagnosed incidence of small bowel neuroendocrine tumors (NETs) is increasing. While patients with localized disease can be treated surgically, those with metastatic disease currently have few treatment options. The  success of biologically targeted therapies in other malignancies has led to interest in the molecular alterations underlying the pathogenesis of",phs000579.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000579,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2013-11-06,DS-GI-MDS;DS-CA-MDS;GRU-MDS,WXS;Seq_DNA_SNP_MAF_Ind;WGS,,Intestinal Neoplasms,51.0,105.0,,,,Intestinal Tumor; Intestinal Tumors; Intestines Neoplasm; Intestines Neoplasms; Neoplasm of Intestines; Neoplasm of intestine
Identifying the Genetic Explanation for Heritable Breast Cancer,"The project developed a suite of new methods (FAVR) designed to assist the shortlisting of genetic variants under a rare variant-phenotype/disease model. The methods were designed to work with commonly  used massively parallel sequencing analysis pipelines, such as the GATK or ANNOVAR, and have been made publically available as a suite of software",phs000601.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000601,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2013-10-29,DS-CA-MDS;NRUP,WXS;Seq_DNA_SNP,,Breast Neoplasms,20.0,20.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Breakpoint Detection Using Long Insert Whole Genome Sequencing,"In this study, we hypothesize that shallow long insert whole genome sequencing (LI-WGS) increases our power for detecting breakpoints compared to shallow short insert WGS. We performed a priori analyses  to demonstrate the benefits of LI-WGS, developed a long insert library preparation protocol based off Illumina's protocol, and compared LI-WGS",phs000646.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000646,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2013-09-10,GRU-MDS,WGS,,Chromosome Breakpoints,3.0,6.0,,,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
The Effect of the Menstrual Cycle on the Normal Human Breast,"The Susan G. Komen for the Cure&#x000ae; Tissue Bank at the IU Simon Cancer Center [www.komentissuebank.iu.edu] (KTB) was established expressly for the prospective collection of normal, healthy breast tissue from  volunteer donors. Blood is also obtained from donors at the time of donation and is processed for serum, plasma and peripheral blood leukocyte DNA.",phs000644.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000644,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2013-09-10,DS-BRCA-PUB-MDS,RNA-Seq,,Menstrual Cycle,20.0,20.0,,,,Not Provided
Mapping Genes for Mammographic Density,"We recruited 1,521 women from the Old Order Amish (OOA) population of Lancaster County, Pennsylvania, with the primary goal of identifying genetic factors that influence mammographic density. All women were  between the ages of 40 and 88 years, with a mean of 54 years. Additional study design details, including eligibility criteria, are described",phs000604.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000604,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2013-08-22,,,,Neoplasms,,,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Gene Fusion Discovery through RNA Sequencing of Human Glioblastoma Stem    Cell Lines,"We used massively parallel, paired-end sequencing of expressed transcripts (RNA-seq) to detect novel gene fusions in short-term cultures of glioma stem-like cells freshly isolated from nine patients carrying primary glioblastoma  multiforme (GBM). The culture of primary GBM tumors under serum-free conditions selects cells that retain phenotypes and genotypes closely mirroring",phs000505.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000505,,Ian Fingerman,Division of Cancer Biology (DCB),,,2013-07-31,GRU-MDS,RNA-Seq,,Glioblastoma,24.0,24.0,,,,"Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme"
Genomic Analysis of Pediatric Low Grade Gliomas,"Pediatric low-grade gliomas (PLGGs) are among the most common solid tumors in children but, apart from mutations or duplications in the BRAF kinase in specific subclasses, few genetic driver events  are known. Diffuse PLGGs compose a set of uncommon subtypes that exhibit invasive growth and are therefore especially challenging clinically. These",phs000614.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000614,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2013-07-22,DS-PBDPBC-NPU-MDS,Seq_DNA_SNP;WGS,,Astrocytoma,1.0,2.0,,,,ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm; Astrocytoma (excluding glioblastoma); Astrocytomas
Genome Wide Association Studies in ECOG 2997 Trial,The ECOG 2997 trial was a randomized controlled trial for patients with previously untreated CLL comparing fludarabine monotherapy to the combination of fludarabine and cyclophosphamide. The initial clinical findings of  this study were published in the Journal of Clinical Oncology in 2007 (JCO 25:793-8). Additional laboratory studies have also published (JCO,phs000621.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000621,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2013-06-26,HMB-PUB-MDS,Array_SNP,,"Leukemia, Lymphoid",215.0,215.0,,,,"Leukemia, Lymphocytic; Leukemias, Lymphocytic; Leukemias, Lymphoid; Lymphatic leukemia; Lymphocytic Leukemia; Lymphocytic Leukemias"
The Genetic Basis of Hypodiploid ALL,"The genetic basis of hypodiploid acute lymphoblastic leukemia (ALL), a subtype of ALL characterized by aneuploidy and poor outcome, is unknown. Genomic profiling of 124 hypodiploid ALL cases, including whole-genome  and exome sequencing of 40 cases, identified two subtypes that differ in the severity of aneuploidy, transcriptional profiles and submicroscopic",phs000341.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000341,,Freddie Pruitt,Center for Cancer Genomics (CCG),,,2013-06-11,GRU,RNA-Seq;WXS;WGS;Array_SNP,,Precursor Cell Lymphoblastic Leukemia-Lymphoma,241.0,379.0,,,,"ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic; Leukemia, Lymphoblastic, Acute, L1"
Genetic Heterogeneity of Diffuse Large B Cell Lymphoma,"We sequenced exomes of 94 DLBCL tumors and cell lines. 34 of the tumors had paired normal tissue. Our work elucidates commonly occurring gene-coding mutations in DLBCL. Principal Investigator: Sandeep  Dave, MD, Duke University, Durham, NC, USA Funding Source: R21CA156168, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA",phs000573.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000573,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2013-04-02,GRU,WXS;Seq_DNA_SNP,,"Lymphoma, Large B-Cell, Diffuse",94.0,128.0,,,,"Lymphoma, Non-Hodgkin; Centroblastic diffuse large B-cell malignant lymphoma; Centroblastic diffuse malignant lymphoma; Centroblastic malignant lymphoma; DLBCL; DLBCL - diffuse large B cell lymphoma"
Expressed Pseudogenes in the Transcriptional Landscape of Human Cancers,"In this study, we describe a systematic analysis of pseudogene 'transcription' from an RNA-Seq resource of 293 samples, from 13 cancer and normal tissue types. We observed a highly prevalent,  genome-wide expression of pseudogenes that could be categorized as universally expressed or lineage- and/or cancer-specific. We also explored disease",phs000525.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000525,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2013-03-29,CRGM,RNA-Seq,,Neoplasms,293.0,293.0,,,,Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies
The Genetic Landscape of Mutations in Burkitt Lymphoma,"Burkitt lymphoma (BL) is characterized by deregulation of MYC, but the contribution of other genetic mutations to the disease is largely unknown. We sequenced exomes of 59 BL tumors, 14  of which had paired normal tissue. Our work elucidates commonly occurring gene-coding mutations in Burkitt lymphoma and implicates ID3 as a novel",phs000562.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000562,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2013-01-29,GRU,WXS,,Burkitt Lymphoma,59.0,72.0,,,,"Lymphoma, Non-Hodgkin; BL; BL - Burkitt's lymphoma; Burkitt Tumor; Burkitt lymphoma/leukemia; Burkitt's Lymphoma"
Characterization of Pancreatic Adenocarcinoma Patients Using NGS,"In this study, we whole genome sequenced tumor/normal pairs from three pancreatic adenocarcinoma patients to separately characterize each patient with respect to somatic alterations. For 2 patients for whom tumor  RNA was available, we also performed RNA sequencing to evaluate gene expression changes. While additional sequencing is needed to improve our",phs000550.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000550,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2013-01-29,GRU,RNA-Seq;WGS,,Pancreatic Neoplasms,4.0,9.0,,,,"Epithelial Carcinoma; Epithelial Neoplasm, Malignant; Epithelial Neoplasms, Malignant; Epithelial Tumor, Malignant; Epithelial Tumors, Malignant; Epithelioma"
Hyperdiploid Acute Lymphoblastic Leukemia RNA-Seq,"Few genetic drivers of children with hyperdiploid precursor B-cell acute lymphoblastic leukemia (ALL) have been identified to date. In an effort to detect novel genomic rearrangements that could be promoting  leukemogenesis in this subset of patients, we sequenced ribosomal RNA-depleted transcriptomes isolated from 5 hyperdiploid acute lymphoblastic",phs000522.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000522,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2013-01-16,PCRGM,RNA-Seq,,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma,5.0,5.0,,,,"Leukemia, Pre B Cell; Leukemia, Pre-B-Cell; Leukemias, Pre-B-Cell; Pre B ALL; Pre B Cell Leukemia; Pre B-ALL"
NAB2-STAT6 Gene Fusions in Solitary Fibrous Tumor by Integrative    Sequencing,"Transcriptome sequencing of solitary fibrous tumors / hemangiopericytomas from a variety of anatomic sites revealed recurrent gene fusions between two genes, NAB2 and STAT6. All SFTs examined exhibited an in-frame  fusion transcript encoding a fusion protein containing the EGR1 interaction domain of NAB2 with the transcriptional activation domain of STAT6.",phs000567.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000567,"Arul M. Chinnaiyan, MD, PhD",,,23313952,U01 CA111275,2013-01-11,CRM,RNA-Seq,Case Set,Solitary Fibrous Tumors,26.0,26.0,,,"Neoplasms, Connective and Soft Tissue","Neoplasms, Connective and Soft Tissue"
Genomic Sequencing of Solitary Fibrous Tumors,"Solitary fibrous tumors (SFTs) are rare mesenchymal tumors that can be benign or malignant. In this study, we sequenced and analyzed the exomes of 17 SFT matched tumor and normal  pairs. This study appertains to a large endeavor to characterize cancers as part of the Slim Initiative for Genomic Medicine in the Americas (SIGMA)",phs000568.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000568,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2013-01-10,GRU,WXS;Seq_DNA_SNP_MAF_Sum,,Sarcoma,17.0,34.0,,,,"Solitary Fibrous Tumors; Sarcoma, Spindle Cell; Sarcomas, Spindle Cell; Spindle Cell Sarcomas; spindle cell sarcoma"
GWAS of Breast Cancer in the African Diaspora,The paucity of data on the genetic epidemiology of breast cancer for racial/ethnic groups other than those of European ancestry hinders the development of innovative interventions to reduce health disparities.  Women in the African Diaspora experience a disproportionate burden of pre-menopausal breast cancer in comparison to all other races for reasons that,phs000383.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000383,Olufunmilyao I. Olopade,,,,R01 CA142996;HHSN268201100011I;HHSN268200782096C,2012-12-14,HRGM;NRUP,Imputation_SNP;Array_SNP,Case-Control,Breast Neoplasms,3827.0,4001.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Transcriptome Sequencing of Pediatric AML FAB-M7,"High resolution analysis of DNA copy number abnormalities and loss-of-heterozygosity on acute myeloblastic leukemia samples utilizing SNP arrays has demonstrated that in contrast to pediatric ALL, de novo AML is  characterized by a very low burden of genomic alterations (Radtke, et al., PNAS, 2009). Samples for this study represented a cross-section of the",phs000413.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000413,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2012-11-20,GRU,RNA-Seq;WXS;WGS;Array_SNP,,"Leukemia, Megakaryoblastic, Acute",15.0,85.0,,,,AMKL; AML M7; AMegL; Acute M7 Myeloid Leukemia; Acute Megakaryoblastic Leukemia (FAB Type M7); Acute Megakaryoblastic Leukemias
Genome and Targeted Sequencing of Bladder Cancer,"One primary bladder cancer and paired peripheral blood sample were subjected to whole genome sequencing on an Illumina HiSeq 2000 platform. This technology was utilized to investigate the genetic basis  of a durable remission of metastatic bladder cancer in a patient treated with everolimus, a drug that inhibits the mTOR (mammalian target of",phs000535.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000535,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2012-11-02,GRU,OTHER;WGS,,Urinary Bladder Neoplasms,14.0,16.0,,,,"Bladder Cancer; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder; Cancer, Urinary Bladder"
HIV-Resistant People with Hemophilia,"Rare individuals are highly resistant to infection with human immunodeficiency virus (HIV). Studies of candidate genes resulted in the discovery of a 32bp deletion in the CC-chemokine receptor 5 gene  (CCR5&#x00394;32), which rendered this critical co-receptor for primary HIV infection to be non-functional. Pharmacologic and vaccine-induced",phs000445.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000445,,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,,2012-10-16,HVI,OTHER;WGS,,HIV,20.0,21.0,,,,Hemophilia A; AHG deficiency disease; AUTOSOMAL HEMOPHILIA A; Classic Hemophilia; Classic Hemophilias; Classical hemophilia
Whole-Genome and Exome Sequencing in Clear-Cell Renal Cell Carcinoma,"Study to evaluate the molecular genetics of ccRCC through integrative analyses of tumors and tumorgrafts using multiple platforms in clinically annotated samples. Genome and exome data for patients giving consent  to have the information available on a public, secure, database is being submitted. Principal Investigator: James Brugarolas, MD, PhD, UT",phs000491.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000491,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2012-10-05,GRU,WXS,,"Carcinoma, Renal Cell",3.0,7.0,,,,"Urogenital Neoplasms; Urologic Diseases; ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal"
MAST Kinase and Notch Gene Families in Breast Cancer,Paired-end transcriptome sequencing was performed on a panel of breast cancer cell lines and tissues and a set of benign cell line and tissue controls. Analyses of the paired end  sequences were performed and chimeric transcripts derived from gene rearrangement events were identified. Sequencing was performed on Illumina GAII,phs000513.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000513,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2012-09-14,CRGM,RNA-Seq,,Breast Neoplasms,89.0,89.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Genome-Wide Analysis of Splenic Marginal Zone Lymphoma,"Splenic Marginal Zone Lymphoma (SMZL) is a B-cell malignancy of unknown pathogenesis and thus orphan of targeted therapies. By integrating whole-exome sequencing and copy-number analysis of 8 paired tumor-normal DNAs  from patients with SMZL, we show that the typical SMZL exome carries 30 genetic alterations. Targeted resequencing of selected candidates in an",phs000502.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000502,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2012-08-02,CRGM_PUB,WXS;Array_SNP,,"Lymphoma, Non-Hodgkin",8.0,16.0,,,,"Lymphoma, B-Cell; Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology"
Genentech Whole Genome Sequencing of Four Hepatocellular Carcinoma    Patients,Hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC). In this study we sequenced the whole genome ( 80X) and transcriptome of tumor and non-tumor  samples from four HCC patients and identified over two hundred HBV integration sites. We found significant clonal expansion of HBV-integrated,phs000384.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000384,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2012-07-30,GRU,RNA-Seq;WGS,,"Carcinoma, Hepatocellular",4.0,18.0,,,,Hepatitis B; Hepatocellular Carcinomas; HBV infection; Hepatitis B Virus Infection; Hepatitis B infection; Hepatitis B virus caused hepatitis
CPMCRI Breast Health Cohort,"Description of Cohort: The California Pacific Medical Center (CPMC) Breast Health Cohort is a cohort study based at CPMC and is linked to the San Francisco Mammography Registry, one of  the sites of the NCI-funded Breast Cancer Screening Consortium (U01CA063740). CPMC is a community hospital in San Francisco, which has one of the",phs000395.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000395,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2012-07-20,NRUP;GRU,Array_SNP,,Breast Neoplasms,1002.0,1014.0,,,,Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer
Whole Genome Sequencing of CBF-Leukemia,"Pediatric de novo acute myeloid leukemia (AML) is a heterogeneous disease that can be divided into clinically distinct subtypes based on the presence of specific chromosomal abnormalities or gene alterations.  One of the best characterized subtypes of AML involves leukemias with alterations of the core-binding factor (CBF)-complex, which comprises the FAB",phs000414.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000414,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2012-05-30,GRU,WGS,,"Leukemia, Myeloid, Acute",17.0,34.0,,,,AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL
Sequencing of Medulloblastoma,"Medulloblastoma is a heterogenous disease made up of at least four distinct subtypes of disease which appear to exploit and disrupt naturally occurring developmental pathways of cellular growth and hindbrain  development. To better understand the driver mutations of this disease, we performed whole genome sequencing of 37 medulloblastomas and the",phs000409.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000409,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2012-05-30,GRU,RNA-Seq;WGS;Array_SNP,,Medulloblastoma,93.0,306.0,,,,"Arachnoidal Cerebellar Sarcoma, Circumscribed; Circumscribed arachnoidal cerebellar sarcoma; Desmoplastic Medulloblastomas; Desmoplastic Nodular Medulloblastoma; Desmoplastic medulloblastoma; Medulloblastoma, Desmoplastic"
Molecular Profiling of Cancer,"Noncoding RNAs (ncRNAs) are emerging as key molecules in human cancer, with the potential to serve as novel markers of disease and to reveal uncharacterized aspects of tumor biology. Here  we discover 121 unannotated prostate cancer-associated ncRNA transcripts (PCATs) by ab initio assembly of high-throughput sequencing of polyA+ RNA",phs000443.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000443,,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,2012-05-08,CRGM,RNA-Seq,,Prostatic Neoplasms,72.0,144.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Sequence Analysis of Mutations and Translocations Across Breast Cancer    Subtypes,This study combined whole exome (103 samples) and whole genome (22 samples) sequencing over a total of 108 breast tumors and matched normal DNA to identify novel mutations and translocations.  Samples were subjected to paired-end Illumina sequencing with goal of 30x coverage of tumor/normal for whole genomes and 100x tumor/normal coverage,phs000369.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000369,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2012-04-19,CRGM;GRU,WXS;Array_mRNA_Expression;WGS;Array_SNP,,"Carcinoma, Ductal, Breast",108.0,216.0,,,,"BREAST CANCER, INVASIVE DUCTAL; Carcinoma, Infiltrating Duct; Carcinoma, Invasive Ductal, Breast; Carcinomas, Infiltrating Duct; Infiltrating Ductal Adenocarcinoma; Infiltrating Ductal Breast Carcinoma"
A Novel Recurrent Mutation in MITF Predisposes to Familial and Sporadic    Melanoma,"We conducted whole-genome sequencing of probands from several melanoma families, identifying one individual carrying a novel germline variant (c.G1075A, NM_000248.3; p.E318K, NP_000239.1; rs149617956) in the melanoma lineage-specific oncogene MITF. While  the variant cosegregated with melanoma in some, but not all cases in the family, linkage analysis of 31 families subsequently identified to carry the",phs000419.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000419,,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,,2012-02-03,CRO,WGS,,Melanoma,1.0,1.0,,,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Sequencing of Retinoblastoma,"Retinoblastoma is a pediatric cancer of the developing retina. All retinoblastomas are believed to initiate with biallelic inactivation of the RB1 gene. To identify subsequent genetic lesions in retinoblastoma, we  performed whole genome sequencing of tumor and normal DNA of 4 children with retinoblastoma and one matched orthotopic xenograft. Both alleles of RB1",phs000352.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000352,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2012-01-19,GRU,RNA-Seq;WGS;Array_SNP,,Retinoblastoma,46.0,93.0,,,,"Cancer, Retinoblastoma Eye; Cancers, Retinoblastoma Eye; Eye Cancer, Retinoblastoma; Eye Cancers, Retinoblastoma; RB; RB - retinoblastoma"
Epigenetic Profiling of Human Colorectal Cancer,"DNA methylation, together with chromatin modifications, constitute the epigenome that functions to regulate gene expression and genome integrity. DNA methylation alterations are ubiquitous in human cancers, as many genes acquire  DNA methylation in a cancer-specific manner. DNA methylation at these sites in the genome of cancer cells not only serves as a marker for tumor",phs000385.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000385,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2011-11-29,GRU,Bisulfite-Seq;Array_SNP,,Colorectal Neoplasms,100.0,104.0,,,,"CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal"
Genome-Wide Association Studies in Upper Gastrointestinal Cancers (Asian),"This project aims to conduct genome-wide association studies (GWAS) in two anatomically different upper gastrointestinal (UGI) cancer sites in two populations with distinctly different disease rates and genetic profiles. One  population has very high rates for both esophageal squamous cell carcinomas (ESCCs) and gastric cancers (GCs) and is comprised of Asians (the ""Asian",phs000361.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000361,,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,,2011-06-21,CODA;EGA,Array_SNP,,Intestinal Neoplasms,5623.0,5754.0,,,,"Esophageal Cancer; Esophageal Neoplasms, Benign and Malignant; Esophageal Tumor; Esophageal Tumors; Esophageal neoplasm; Esophageal tumour"
DCEG Lung Cancer Study,"Three genetic loci for lung cancer risk have been identified by genome-wide association studies (GWAS), but inherited susceptibility to specific histologic types of lung cancer is not well established. We  conducted a GWAS of lung cancer and its major histologic types genotyping 515,922 single nucleotide polymorphisms (SNPs) in 5,739 incident lung",phs000336.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000336,,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,,2011-05-27,SLD;CADM,Array_SNP,,Lung Neoplasms,11517.0,13073.0,,,,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
NCI Genome-Wide Association Study of Renal Cell Carcinoma,"The National Cancer Institute (NCI) genome-wide association study (GWAS) of renal cell carcinoma (RCC) was conducted to investigate common genetic variants associated with RCC risk. The GWAS includes 1,453 RCC  cases and 3,531 controls of European background from 4 studies (3 cohort, 1 case-control), scanned using the Illumina InfiniumHumanHap 550, 610 and",phs000351.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000351,,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,,2011-05-17,CADM,Array_SNP,,"Carcinoma, Renal Cell",4735.0,4909.0,,,,"Kidney Neoplasms; ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell"
DCEG Imputation Reference Dataset,"We have built a new resource for imputation of SNPs for existing and future genome-wide association studies (GWAS), known as the Division of Cancer Epidemiology and Genetics (DCEG) Reference Set.  The first build of the data set includes 728 cancer-free individuals of European descent from three large prospectively sampled studies, 98",phs000396.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000396,,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,,2011-05-07,EGC;CADM,Imputation_SNP,,National Program of Cancer Registries,1249.0,1249.0,,,,Not Provided
High Density SNP Association Analysis of Melanoma,This research builds upon an extensive resource of melanoma cases and hospital based controls collected over several years at the U.T. M.D. Anderson Cancer Center. The goal of this research  is to identify novel susceptibility and outcome-related genes for melanoma using a systematic genome-wide association-based approach. Our goal is to,phs000187.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000187,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,2010-05-18,NRUP;GRU,Imputation_SNP;Array_SNP,,Melanoma,3201.0,3311.0,,,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
CGEMS Prostate Cancer GWAS - Stage 1 - PLCO,"The Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer genome-wide association study (GWAS) included genotyping approximately 550,000 SNPs (Phase 1A with HumanHap300 and Phase 1B HumanHap240, both from Illumina, San  Diego, CA) in 1,172 prostate cancer patients and 1,157 controls of European ancestry from the Prostate, Lung, Colon and Ovarian (PLCO,",phs000207.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000207,,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,,2009-12-22,CADM,Array_SNP,,Prostatic Neoplasms,2252.0,2300.0,,,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
A Genome Wide Scan of Lung Cancer and Smoking,"The majority of cases of lung cancer are the culmination of a dynamic process that begins with smoking initiation, proceeds through dependency and smoking persistence, continues with lung cancer development  and ends with progression to disseminated disease or response to therapy and survival. We are conducting a whole genome study of lung cancer and",phs000093.v2.p2,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000093,,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,,2009-10-22,SLD;NRUP;CADM,Imputation_SNP;Array_SNP,,Lung Neoplasms,5678.0,11337.0,,,,Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung
"Clinical Outcomes and ctDNA Correlates for CAPOX BETR: A phase II trial    of Capecitabine, Oxaliplatin, Bevacizumab, Trastuzumab in Previously    Untreated Advanced HER2+ Gastroesophageal Adenocarcinoma","We performed circulating tumor DNA (ctDNA) analysis on plasma of patients with advanced HER2 positive gastroesophageal adenocarcinomas who were treated on a phase 2 clinical trial testing the addition of  bevacizumab to capecitabine, oxaliplatin, and trastuzumab. ctDNA was analyzed using panel based next generation sequencing assay (Predicine CARE),",phs003706.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003706,"Harshabad Singh, MBBS;Peter C. Enzinger, MD",Nathaniel Boyd,Office of Data Sharing (ODS),39122726,Funded by Genentech,,HMB,WGS,Clinical Trial,Esophageal Neoplasms,30.0,58.0,,ERBB2,"Stomach Neoplasms;Receptor, ErbB-2;Trastuzumab;Bevacizumab","Esophageal Neoplasms, Benign and Malignant; Esophageal Tumor; Esophageal Tumors; Esophageal neoplasm; Esophageal tumour; Esophagus Neoplasm"
"Somatic Mutations in 3,929 HPV-Positive Exfoliated Cervical Cell Samples","We investigated the detection, timing, and HPV type specificity of cervical somatic hotspot mutations (i.e., previously reported cancer driver mutations) in 3,929 HPV-positive exfoliated cervical cell samples from individuals undergoing  routine cervical screening in the U.S. using deep-targeted sequencing of 20 candidate genes. Our study included samples from 3,351 women with the",phs003691.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003691,"Lisa Mirabello, PhD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,Intramural Research Program,,GRU,AMPLICON,Case-Control;Longitudinal,Uterine Cervical Neoplasms,3351.0,3929.0,,,Human papillomavirus 16;Human papillomavirus 18;human papillomavirus 45,"Cervical Neoplasm, Uterine; Cervical Neoplasms; Cervical Tumor; Cervical neoplasm; Cervix Neoplasm; Cervix Neoplasms"
Phase 2 Study of Nivolumab and Entinostat in Unresectable or Metastatic    Cholangiocarcinoma and Pancreatic Adenocarcinoma,"The study was a single-center, open-label, phase II trial (registration no. NCT03250273) designed to evaluate the efficacy of entinostat in combination with nivolumab in patients with advanced pancreatic ductal adenocarcinoma  (PDAC). The aim was to assess the objective response rate using RECIST v1.1 criteria as the primary endpoint. A total of 27 patients with advanced",phs003615.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003615,Nilofer S. Azad;Marina Baretti;Elizabeth M. Jaffee,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),"No PMID: Immunomodulation of the tumor microenvironment of pancreatic
  ductal adenocarcinoma with histone deacetylase inhibition: results of a phase
  2 clinical trial of entinostat in combination with nivolumab | Baretti M, Danilova L, Durham JN, Betts CB,
  Cope L, Sidiropoulos DN, Tandurella JA, Charmsaz S, Gross N, Hernandez
  A, Ho WJ, Thoburn C, Walker R, Leatherman J, Mitchell S, Christmas B, Saeed A,
  Gaykalova DA, Yegnasubramanian S, Fertig EJ, Coussens LM, Yarchoan M, Jaffee
  E, Azad NS",P01CA247886,,HMB-IRB-NPU,RNA-Seq,Clinical Cohort,"Carcinoma, Pancreatic Ductal",30.0,53.0,https://clinicaltrials.gov/study/NCT03250273,,Histone Deacetylase Inhibitors;Immune Checkpoint Inhibitors;Nivolumab;entinostat,"Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas; Duct Cell Carcinoma, Pancreas"
The CHK1 Inhibitor Prexasertib in BRCA Wild-Type Platinum-Resistant    Recurrent High-Grade Serous Ovarian Carcinoma: a Phase 2 Trial,"Ovarian carcinoma, especially high-grade serous ovarian carcinoma (HGSOC), is the deadliest gynecologic malignancy in the USA. Despite initial treatment with surgery and platinum-based chemotherapy, around 80% of HGSOC patients experience  relapse. This is particularly challenging in platinum-resistant recurrent HGSOC, especially in cases where BRCA1/BRCA2 genes are wild-type (BRCAwt),",phs003588.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003588,"Jung-Min Lee, MD",Abid Al Reza,Center for Cancer Research (CCR),,,,GRU,WXS,Clinical Cohort;Sequencing,Ovarian Neoplasms,18.0,18.0,,RB1;RECQL4;PIK3CA;BRIP1;BCRA1;BCRA2,,"Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian"
National Cancer Institute Multi-Ancestry Genome-Wide Association Study of    Kidney Cancer (NCI-3),"The National Cancer Institute (NCI) multi-ancestral genome-wide association study (GWAS) of kidney cancer (""NCI-3"") was performed by NCI to further investigate common genetic variants associated with risk of kidney cancer  and its two major subtypes across individuals of different ancestries (European, African, East Asian, Latin American). The NCI-3 GWAS includes 12,315",phs003505.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003505,Mark Purdue,Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),,,,DS-RCC-IRB-PUB-NPU-GSO,Array_SNP_CNV;Seq_DNA_SNP_CNV,Case-Control;GWAS,Kidney Neoplasms,89808.0,89808.0,,,,Kidney Tumor; Kidney cancer; Kidney neoplasm; Neoplasia of the kidneys; Neoplasm of Kidney; Neoplasm of the Kidney
Circulating Tumor DNA Analyses of Breast Cancer Patients Paired and Over    Time,"Blood-based 'liquid biopsy' is increasingly utilized in clinical care of cancer patients and the fraction of tumor-derived DNA in circulation ('tumor fraction', TFx) has demonstrated clinical utility across multiple cancer  types. To determine TFx, shallow whole genome sequencing of cell-free DNA can be performed from a single blood sample, using an established",phs003500.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003500,Daniel G. Stover,Freddie Pruitt,Center for Cancer Genomics (CCG),,,,DS-CA,,Case Set;Case-Control;Longitudinal Cohort,Neoplasms,33.0,109.0,,,Neoplasm Metastasis,"Neoplasm Metastasis; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize"
Assessing Individual Head and Neck Squamous Cell Carcinoma Patient    Response to Therapy Through Integration of Functional and Genomic Data,"This study uses whole exome sequencing (WES) data, copy number variation (CNV) data, and a head and neck squamous cell carcinoma-specific inhibitor panel to characterize tumor cells from patients with  head and neck squamous cell carcinoma, in order to identify potential therapy targets on an individual patient basis. The data that will be available",phs003456.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003456,Molly Kulesz-Martin;Shannon McWeeney,Tamara Walton,Division of Cancer Treatment and Diagnosis (DCTD),,,,DS-SHNO-CA,RNA-Seq;WXS,Case Set;Clinical Cohort;Copy Number Variation (CNV);Exome Sequencing;Individual-Level Genomic Data;Sequencing;Tumor vs. Matched-Normal,Squamous Cell Carcinoma of Head and Neck,20.0,96.0,,,,Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx
The Genetic Evolution of Acral Melanoma,"Acral melanoma is a rare melanoma subtype arising on the sole, palm, or nail apparatus. We performed whole-exome sequencing (WES) for a cohort of 35 acral melanoma patients. For each  patient, we sequenced multiple tumor areas representing different tumor stages, including the in situ and invasive portions of the primary tumor and",phs003451.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003451,Boris C. Bastian,,,,1R35CA220481,,HMB,WXS;Targeted-Capture;WGS,Exome Sequencing;Sequencing;Tumor vs. Matched-Normal;Whole Genome Sequencing,Melanoma,35.0,208.0,,BRAF;NRAS;TERT,,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Patient-Derived Models of Prostate Cancer for Personalized Medicine,"The aim of this study was to develop a molecular dataset that reflects the heterogeneity of prostate cancer using patient-derived xenografts (PDX) grown in the subcutaneous flank of SCID (CB17/Icr-Prkdcscid/IcrIcoCrl)  mice. Whole-genome, targeted sequencing, and RNA sequencing were performed on tumors from 44 PDXs derived from 38 patients. The cohort included",phs003420.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003420,"Nora M. Navone, MD, PhD;Yu Chen, MD, PhD;Andrew Futreal, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,U01CA224044;P30CA016672;P50 CA140388,,DS-PC-PUB-COL-NPU,,Xenograft,Prostatic Neoplasms,38.0,44.0,,AR;PTEN;RB1;TP53;TMPRSS2;ERG;CDK12,,"NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate"
Targeted Genomic Sequencing in Large Human Genes to Detect Induced    Structural Variants,"Partial inhibition of DNA replication leads to de novo copy number variant (CNV) formation throughout the genome, especially at common fragile sites (CFSs). We previously showed that these hotspots for  genome instability reside in late-replicating domains associated with large, transcribed genes. In this study, we performed targeted, error-corrected",phs003121.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003121,Thomas E. Wilson;Thomas W. Glover,,,37181851,R01 CA200731;R01 GM147026,,GRU,Seq_DNA_SV;Targeted-Capture;WGS,Copy Number Variation (CNV);Methods Development;Resequencing;Sequencing;Whole Genome Sequencing,Chromosome Fragile Sites,1.0,32.0,,NEGR1;MAGI2;PRKG1;FHIT;WWOX,DNA Copy Number Variations;Genomic Instability;DNA Repair;DNA Replication;Cell Cycle,"Genomic Instability; Genome Instabilities; Genome Instability; Genomic Instabilities; Instabilities, Genome; Instabilities, Genomic"
Ipilimumab and Decitabine in Treating Patients With Relapsed or    Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia,The NCI Experimental Therapeutics Clinical Trials Network (ETCTN)/Cancer Therapy Evaluation Program (CTEP) 10026 study (NCT02890329) tested combined ipilimumab and decitabine treatment in two cohorts: Arm A consisted of patients with  relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation. Arm B consisted of patients with advanced,phs003015.v2.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003015,"Jacqueline Garcia, MD",,,36706355;36332187;39147891,P01CA229092,,HMB-COL,RNA-Seq;WXS;Targeted-Capture;ATAC-seq,Case Set;Clinical Trial;Interventional,"Leukemia, Myeloid, Acute",38.0,220.0,https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE223844,CTLA4;DNMT1,Hematopoietic Stem Cell Transplantation;Immune Checkpoint Inhibitors,AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL
Whole Transcriptome Analysis of Melanoma PDX Models,"This study reports bulk total RNA sequencing from melanoma patient-derived xenograft (PDX) tumors. The goal is to determine transcriptomic differences across melanomas of distinct subtypes including cutaneous, acral, mucosal, and  unknown primary. Fresh surgical specimens used for deriving PDX models were obtained from the University of Colorado Skin Cancer Biorepository under",phs002951.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002951,"Kasey Couts, PhD",Freddie Pruitt,Center for Cancer Genomics (CCG),,,,GRU,,Case Set;RNA Sequencing,Melanoma,65.0,65.0,,AACSP1;AAMDC;ABCA13;ABCA4;ABCB1;ABCC9;ABCG1;ABCG2;ABHD17B;ABHD17C;ABHD2;ABI1;ABI3BP;ABTB1;ACPP;ACSL1;ACSS3;ADA2;ADAM19;ADAM8;ADAMTS12;ADAMTS14;ADAMTS2;ADAMTS20;ADAMTS4;ADAMTS9;ADAMTSL3;ADCK2;ADCY3;ADGRA3;ADTRP;AGK;AGMO;AIM2;AK5;AKAP17A;AKR1B1;AKR1B1P1;AKR1C3;ALDH1A3;ALDH2;ALDH3B2;ALG8;AMIGO2;AMY2B;AMZ1;ANGPT1;ANK1;ANKRD30BP1;ANKRD45;ANO1;ANTXR2;ANXA3;AOX1;AP2S1;APC;APLNR;APOL1;APOL3;AQP1;AQP3;ARAF;AREG;ARHGAP18;ARHGAP24;ARHGAP39;ARHGEF28;ARL4C;ARMH4;ARNTL2;ARRDC3;ART3;ASAP1;ASNSP1;ATG4C;ATP12A;ATP5S;ATP6V0D2;ATP6V0E2;ATP7A;ATP8A2;AUP1;AVPR1A;AXL;AZIN1;B3GNT5;B4GALNT1;BARX1;BATF3;BCAP29;BCL7B;BDP1;BEX1;BHMT2;BIN3;BIRC3;BLOC1S5;BNC1;BPHL;BTBD8;BTBD9;BTF3P5;BTG3;C12orf45;C12orf76;C15orf48;C1QTNF1;C1QTNF3;C2orf40;C3;C3AR1;CA12;CA6;CA9;CACNA1B;CACNA2D2;CACNA2D4;CADM3;CALHM5;CALN1;CAMK1;CAMK1G;CAP2;CARD6;CASC19;CASK;CASP10;CATSPER1;CAVIN2;CAVIN3;CBFB;CBLN3;CBSL;CCDC127;CCDC188;CCDC43;CCL20;CCNG1;CCR1;CD109;CD14;CD33;CD96;CDC5L;CDCP1;CDH11;CDH12;CDH13;CDH18;CDH6;CDHR1;CDK15;CDK16;CDKAL1;CDS2;CDYL;CECR2;CEMIP;CENPX;CETP;CFAP54;CFH;CHAD;CHADL;CHN1;CHP1;CHPF2;CHRM1;CHRNA1;CHRNA6;CHST1;CHST2;CIT;CLASP2;CLCN6;CLDN11;CLEC2B;CLEC2L;CLIC2;CLIP2;CLMP;CLNS1A;CLU;CMPK2;CNIH3;CNKSR2;CNTF;CNTN1;CNTN5;COL12A1;COL13A1;COL1A1;COL20A1;COL24A1;COL3A1;COL4A4;COL5A2;COL6A2;COL6A3;COL7A1;COL8A1;CORO1A;COTL1;CPA4;CPM;CRABP1;CRABP2;CRKL;CRTAC1;CRYBG1;CSF2RA;CSMD3;CSPP1;CSRP2;CTLA4;CTNND1;CTSS;CXCL1;CXCL10;CXCL11;CXCL2;CXCL3;CXCL8;CYP26B1;CYP2E1;CYP4F11;CYSLTR2;CYTOR;DAB1;DCAF16;DCAF8L2;DCHS2;DCN;DDI1;DDIT4L;DDO;DGKB;DGKG;DHCR7;DHRS3;DIRC3;DKK1;DKK2;DKK3;DLG3;DLX1;DLX2;DMBT1;DMC1;DMXL1;DNAH5;DNAH9;DNAJB2;DNASE2B;DNM3OS;DNPEP;DOCK4;DOK1;DPP4;DPYD;DRAXIN;DRP2;DSCR4;DSE;DTX1;DTX3L;DUOX2;DUSP1;DUSP5;DYNLT3;DZIP1L;E2F3;E2F7;E2F8;EBAG9;EBF1;EDIL3;EDN3;EEF1D;EEPD1;EGF;EGFLAM;EGR3;EHF;EID2;EIF3H;EIF4B;EIF4BP2;ELFN1;ELFN2;ELK1;ELMO1;EMILIN3;EPB41L2;EPHA4;EPPK1;EPS15P1;ERCC6L2;ERRFI1;ESM1;ESPNL;ESRP1;ESRRG;ETV4;ETV7;EXOC2;EYA1;F2RL2;F3;FABP6;FABP7;FAM111A;FAM126A;FAM131B;FAM133A;FAM135B;FAM163A;FAM171B;FAM180A;FAM184B;FAM189A2;FAM20A;FAM219A;FAM238C;FAM84A;FAM87A;FAP;FBXL2;FCER1G;FCGR2C;FDCSP;FER1L6;FGD6;FGF12;FGF5;FGFR2;FGFR3;FGGY;FGL2;FHAD1;FHOD1;FKBP4;FKBP9P1;FLT1;FOLH1;FOSL1;FOSL2;FOXRED2;FRAT2;FRMD3;FSD1;FST;FTSJ1;FZD1;FZD7;G6PD;GAB2;GAB3;GABRR1;GAD1;GAGE1;GAP43;GBP1;GBP2;GCLC;GCNT3;GDF7;GEM;GFRA3;GJA5;GLB1L3;GLDC;GLIPR1;GLIS2;GLO1;GLRB;GLT8D2;GMFG;GNB2;GNG11;GPAM;GPKOW;GPR132;GPR37L1;GPR55;GRAMD1B;GRIA1;GRIA2;GRIA4;GRID2;GRPR;GSAP;GSG1L;GSS;GTDC1;GUCA1B;GUF1;GUK1;HACD3;HAO2;HAUS3;HCLS1;HDAC9;HECW2;HELZ;HEPH;HERC6;HEY2;HFE;HILPDA;HIST1H1D;HIST1H2AB;HIST1H2AE;HIST1H2AJ;HIST1H2BB;HIST1H2BG;HIST1H2BM;HIST1H4D;HIST2H2BA;HIST3H2BA;HIVEP3;HJURP;HLA-F-AS1;HLA-G;HLF;HOXD10;HPCAL1;HPRT1;HRASLS5;HS3ST3A1;HSPA7;HSPB6;HTN1;HTR7;HTRA1;ID1;ID3;IDS;IER3;IFI27;IFI35;IFI44;IFIH1;IFNAR2;IGFBP3;IGFBP6;IKBKG;IL11;IL12A;IL15;IL17RB;IL1A;IL1B;IL22RA1;IL31RA;IL4I1;IL6;IMPDH2;INHBA;INPP5D;INTS4;IRAK1;IRAK2;IRF1;IRF2;IRF5;IRF6;ISG15;ISG20;ISLR2;ITGA11;ITGA4;ITGA8;ITGAM;ITGBL1;ITIH5;ITM2A;ITPKA;ITPR1;JARID2;JRK;KANK4;KCNA3;KCNA4;KCNK3;KCNK9;KCNN4;KCNS1;KCNT2;KCTD11;KCTD21;KDM1B;KIAA1217;KIF13A;KIF1A;KIF5A;KITLG;KLHL31;KLHL34;KLHL4;KLHL41;KLK2;KMT2B;KRT8P46;KY;KYNU;LAMA2;LAPTM5;LARP1B;LAT2;LBH;LBR;LCNL1;LGALS12;LGI2;LHFPL4;LIF;LIMS2;LIN28A;LIVAR;LNP1;LOX;LOXL2;LOXL3;LPAR1;LPAR4;LPL;LPXN;LRFN5;LRIG1;LRP1B;LRRC17;LRRC49;LRRTM1;LTF;LUM;LUZP2;LYSMD4;LYZ;MAATS1;MAD2L2;MAGEA11;MAGEB2;MAN1A1;MAOA;MAP1A;MAP3K15;MAP3K7;MAPK14;MAPK4;MBLAC2;MCC;MCFD2;MCHR1;MCUB;MED14OS;MED20;MEG3;MEG8;MEIOC;MEIS1;MEOX1;MEOX2;MGAM2;MGAT4C;MICALL2;MICE;MILR1;MLC1;MMP1;MMP3;MMP8;MMP9;MOB3C;MPG;MRC2;MRPL44;MS4A7;MSH4;MT2A;MTCP1;MTMR10;MUC15;MUSK;MXRA5;MYO3B;MYO5A;MYOF;MYOM1;MYOZ1;MYOZ2;NAA11;NAALAD2;NCOA1;NDRG4;NDST3;NDUFAF6;NEURL1;NFATC2;NFYA;NGFR;NHS;NHSL2;NID1;NLRC5;NLRP3;NMU;NNMT;NOL7;NOL8;NOX4;NPR1;NPTX2;NR2E1;NR4A2;NRCAM;NRG1;NRP1;NRXN1;NT5E;NTS;NTSR1;NUCB2;OAF;OAS1;OAS2;OAS3;OASL;OCIAD2;OLFML3;OPHN1;OR10AD1;OR2H2;OR4F15;OSBPL6;OSMR;OVAAL;OVGP1;P2RX7;P4HA3;PABPC3;PAEP;PAGE5;PARP12;PARP4;PARP9;PARVG;PBRM1;PCAT1;PCDH18;PCDHB13;PCED1B;PCGF3;PCNX2;PCOLCE;PCSK1;PCSK2;PCYT1B;PDCD4;PDE1B;PDE1C;PDE3A;PDE4A;PDE7A;PDE7B;PDGFD;PDGFRB;PDGFRL;PDIA6;PDLIM2;PECAM1;PERM1;PEX5L;PGK1;PGM1;PHACTR1;PHF20L1;PHYHIP;PHYHIPL;PIGG;PIK3CG;PIK3R6;PIP4K2A;PIP5K1B;PKLR;PKM;PLA2G5;PLA2G7;PLA2R1;PLAU;PLAUR;PLD6;PLEKHA6;PLEKHG5;PLEKHS1;PLPPR4;PLXDC2;PLXNA3;PLXNB1;PMAIP1;PNLDC1;PODNL1;POLH;POLI;POLR2C;POP1;POU4F1;PPP1R1C;PRAF2;PRDM8;PRICKLE1;PROCR;PRPH;PRR5L;PRRG4;PRRX2;PRX;PSG4;PSG9;PSMB9;PSME2;PSORS1C1;PTGS2;PTH1R;PTHLH;PTN;PTPRB;PTPRE;PTPRK;PTPRN;PTPRR;PTX3;PURG;PXDNL;PYCARD;PYCR2;QRFPR;RAC2;RADIL;RAMP3;RAP2C;RAPGEF5;RASAL1;RASD1;RASGRF1;RASL12;RBFOX3;RCAN1;RDX;REEP1;RELB;RELN;REM1;RETREG1;REXO5;RFC2;RFX8;RGS13;RGS5;RHEB;RHOC;RILPL2;RNF166;RORC;RP1;RSAD2;RSF1;RTL1;RTN1;RTTN;RUNX2;RYR2;S100A16;SAMD9;SAMD9L;SAMHD1;SAMMSON;SATB1;SCG2;SCN2A;SCN3A;SCRT1;SCUBE2;SDCBPP2;SDCBPP3;SEC14L4;SELENOM;SEMA3A;SEMA3E;SEMA6B;SERPINB2;SERTM2;SFRP1;SFRP2;SFXN5;SGCE;SGIP1;SGK2;SH2B3;SHANK3;SHC1;SIGLEC9;SIRT5;SLAMF1;SLAMF9;SLC16A3;SLC18A1;SLC20A1;SLC25A37;SLC26A4;SLC26A7;SLC2A3;SLC2A4;SLC30A10;SLC30A8;SLC35G2;SLC38A5;SLC39A8;SLC45A1;SLC5A12;SLC7A11;SLC8A1;SLC9A7;SLCO2B1;SLIT3;SLITRK6;SMAGP;SMARCC1;SMC6;SNAI1;SNORA80B;SOAT2;SOCS6;SOX6;SP110;SP140;SP140L;SPAG1;SPAG16;SPAG17;SPATA13;SPHK1;SPN;SPOCD1;SPP1;SPRED3;SPRN;SRPX2;SSC5D;SSH2;ST20;ST6GALNAC4;ST8SIA4;ST8SIA5;STAC2;STAM;STC1;STK17A;STK17B;STK31;STK33;STX1B;SUSD5;SV2A;SVEP1;SYNGR3;SYNPO2;SYT1;SYT11;SYTL4;SYTL5;TAF2;TAF8;TAGLN3;TAS1R1;TBC1D22B;TBC1D31;TBX19;TCAIM;TCIRG1;TCN1;TEX14;TEX15;TFAP2A;TFAP2B;TFE3;TFPI2;TGFA;TGFBI;TGS1;THBD;THBS1;THSD4;THSD7A;THY1;TIMP1;TINAGL1;TLR2;TM4SF1;TM4SF18;TM4SF19;TMC7;TMEM100;TMEM154;TMEM158;TMEM163;TMEM236;TMEM26;TMEM59L;TMEM87B;TMIGD3;TMSB10;TMSB4X;TMSB4XP8;TNC;TNFAIP6;TNFRSF12A;TNFRSF1A;TNN;TOX2;TPCN2;TPMT;TRAC;TRAF1;TREM1;TRIM22;TRMT12;TRMT44;TSHZ3;TSNARE1;TSPAN13;TSPAN8;TTC3;TTC7A;TUBA4A;TWIST1;TWSG1;UBA1;UBA7;UBR2;UCHL1;UHRF1BP1;UHRF1BP1L;UNC5C;USP11;USP35;USP41;USP49;VAT1L;VGF;VIT;VPS37D;VXN;WDFY1;WDR54;WDR72;WFDC3;WIPF1;WISP3;WNT16;WNT5B;WNT7B;YES1P1;YTHDF3;ZBTB10;ZBTB32;ZC3H12A;ZFP2;ZFP41;ZHX1;ZNF141;ZNF16;ZNF24;ZNF250;ZNF251;ZNF326;ZNF33B;ZNF365;ZNF397;ZNF518A;ZNF57;ZNF587;ZNF587B;ZNF605;ZNF623;ZNF696;ZNF721;ZNF766;ZP1,High-Throughput Nucleotide Sequencing,"Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas"
Genomic Architecture of LGL Leukemia,"LGL leukemia results from a clonal expansion of cytotoxic T lymphocytes with a terminal effector memory (TEMRA) phenotype. LGL leukemia patients have multiple clinical phenotypes including chronic neutropenia, pure red  cell aplasia, and rheumatoid arthritis. The major focus of this project is to identify and understand how genomic changes contribute to the",phs002359.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002359,"Thomas P. Loughran, Jr., MD;Ross C. Hardison, PhD",Ian Fingerman,Division of Cancer Biology (DCB),33786584;33786584,R01CA178393;Bess Family Charitable Fund,,DS-LGL,,Aggregate Genomic Data;Case-Cohort;Epigenetics;Individual-Level Genomic Data;Sequencing;Tumor vs. Matched-Normal;Whole Genome Sequencing,"Leukemia, Large Granular Lymphocytic",7.0,20.0,,STAT3;TET2,"Killer Cells, Natural;Anemia;Neutropenia;Thrombocytopenia;Immunosuppressive Agents",Anemia; Neutropenia; Aggressive NK Cell Leukemia; Aggressive Natural Killer Cell Leukemia; LGL Leukemia; LGL Leukemias
National Cancer Institute Familial Burkitt Lymphoma in Shirati (FBiS),"In 1980, Dr. Glen Brubaker and colleagues reported 5 familial cases of Burkitt Lymphoma (BL) in Shirati in Tanzania and began collecting cryopreserved lymphocytes from affected and non-affected family members  to study the potential genetic basis of familial BL occurring in the malaria belt in Africa. This area is settled by the Luo tribe (85% of the",phs002223.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002223,"Sam M. Mbulaiteye, MD",Geoffrey Tobias,Division of Cancer Epidemiology and Genetics (DCEG),6937447;7141899,HHSN261201100063C;HHSN261201100007I;75N910D00024,,,,Case-Control;Parent-Offspring Trios,Burkitt Lymphoma,,,,TCF4;CHD8,Plasmodium falciparum;Epstein-Barr Virus Infections,Epstein-Barr Virus Infections; BL; BL - Burkitt's lymphoma; Burkitt Tumor; Burkitt lymphoma/leukemia; Burkitt's Lymphoma
Mayo Clinic - Fecal Microbiota and Colorectal Cancer Development,"Background: Adenomatous polyps are the most common precursor to colorectal cancer (CRC), the second leading cause of cancer death in the United States. We sought to learn more about early  events of carcinogenesis by investigating shifts in the gut microbiota of patients with adenomas. Methods: We analyzed 16S rRNA gene sequences from",phs001204.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001204,"Nicholas Chia, PhD",Ian Fingerman,Division of Cancer Biology (DCB),,R01 CA 179243,,GRU-COL;GRU,AMPLICON,Case-Control,Adenoma,819.0,819.0,,,Colorectal Neoplasms,"Adenoma, Microcystic; Adenomas, Microcystic; Microcystic Adenomas; microcystic adenoma; microcystic adenoma (morphologic abnormality); CRC"
Exome Sequencing of Craniopharyngiomas,Craniopharyngiomas are epithelial tumors of the brain that form in the suprasellar region. Patients experience a broad range of sequelae from growth of the tumors and from therapeutic interventions. We  used whole exome sequencing to investigate the genetic aberrations in both adamantinomatous and papillary craniopharyngiomas. We found mutations in,phs000696.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000696,,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),,,,,,,Craniopharyngioma,,,,,,Adamantinomatous tumor; Adamantinomatous tumour; Craniopharyngeal duct tumor; Craniopharyngioma (WHO Grade 1); Craniopharyngioma (WHO Grade I); Craniopharyngiomas
Evolution of Human BCR-ABL1 Lymphoblastic Leukemia-Initiating Cells,"Many tumour types are composed of genetically diverse cells, however little is known of how diversity evolves or the impact diversity has on functional properties. Here, using xenografting and DNA  copy number alteration (CNA) profiling of human BCR-ABL1 lymphoblastic leukaemia, we demonstrate that genetic diversity occurs in functionally",phs000329.v1.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000329,"John Dick, PhD",Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),18408710;21248843,,,,,Case Set;Tumor;Xenograft,Precursor Cell Lymphoblastic Leukemia-Lymphoma,,,,,Xenograft Model Antitumor Assays,"Acute Lymphoblastic Leukemia; ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic"
Neuroblastoma Genome-Wide Association Study (NBL-GWAS),Neuroblastoma is a malignancy of the developing sympathetic nervous system that most commonly affects young children and is often lethal. The etiology of this embryonal cancer is not fully understood.  We therefore initiated a genome-wide association study (GWAS) in 2007 focused on neuroblastoma patients identified through the Children's Oncology,phs000124.v3.p1,https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000124,John M. Maris,Emilie Charlisse Caga-Anan,Division of Cancer Control and Population Sciences (DCCPS),18463370;19412175;19536264;21124317;21436895;22328350;22350409;22941191;23222812;23243203;24634504;25312269;26100672;26481147;26560027;27541142;28033528;28545128;28924153;29117357;28667701;30132831,R01CA124709,,,,Case-Control,Neuroblastoma,,,,,,Not Provided
